Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.
Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts.
Leukemia induced experimentally in animals by exposure to leukemogenic agents, such as VIRUSES; RADIATION; or by TRANSPLANTATION of leukemic tissues.
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
Species of GAMMARETROVIRUS, containing many well-defined strains, producing leukemia in mice. Disease is commonly induced by injecting filtrates of propagable tumors into newborn mice.
A classification of B-lymphocytes based on structurally or functionally different populations of cells.
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
A malignant disease of the T-LYMPHOCYTES in the bone marrow, thymus, and/or blood.
A malignant disease of the B-LYMPHOCYTES in the bone marrow and/or blood.
An acute myeloid leukemia in which 80% or more of the leukemic cells are of monocytic lineage including monoblasts, promonocytes, and MONOCYTES.
A neoplastic disease of the lymphoreticular cells which is considered to be a rare type of chronic leukemia; it is characterized by an insidious onset, splenomegaly, anemia, granulocytopenia, thrombocytopenia, little or no lymphadenopathy, and the presence of "hairy" or "flagellated" cells in the blood and bone marrow.
A strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) arising during the propagation of S37 mouse sarcoma, and causing lymphoid leukemia in mice. It also infects rats and newborn hamsters. It is apparently transmitted to embryos in utero and to newborns through mother's milk.
Leukemia L1210 is a designation for a specific murine (mouse) leukemia cell line that was originally isolated from a female mouse with an induced acute myeloid leukemia, which is widely used as a model in cancer research, particularly for in vivo studies of drug efficacy and resistance.
The type species of DELTARETROVIRUS that causes a form of bovine lymphosarcoma (ENZOOTIC BOVINE LEUKOSIS) or persistent lymphocytosis.
A species of GAMMARETROVIRUS causing leukemia, lymphosarcoma, immune deficiency, or other degenerative diseases in cats. Several cellular oncogenes confer on FeLV the ability to induce sarcomas (see also SARCOMA VIRUSES, FELINE).
Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in leukemia.
An encapsulated lymphatic organ through which venous blood filters.
A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally being called a macroglobulin.
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
The activated center of a lymphoid follicle in secondary lymphoid tissue where B-LYMPHOCYTES are stimulated by antigens and helper T cells (T-LYMPHOCYTES, HELPER-INDUCER) are stimulated to generate memory cells.
Leukemia produced by exposure to IONIZING RADIATION or NON-IONIZING RADIATION.
Differentiation antigens expressed on B-lymphocytes and B-cell precursors. They are involved in regulation of B-cell proliferation.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Myeloid-lymphoid leukemia protein is a transcription factor that maintains high levels of HOMEOTIC GENE expression during development. The GENE for myeloid-lymphoid leukemia protein is commonly disrupted in LEUKEMIA and combines with over 40 partner genes to form FUSION ONCOGENE PROTEINS.
An immunoglobulin which accounts for less than 1% of plasma immunoglobulin. It is found on the membrane of many circulating B LYMPHOCYTES.
The largest of polypeptide chains comprising immunoglobulins. They contain 450 to 600 amino acid residues per chain, and have molecular weights of 51-72 kDa.
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
Inbred C57BL mice are a strain of laboratory mice that have been produced by many generations of brother-sister matings, resulting in a high degree of genetic uniformity and homozygosity, making them widely used for biomedical research, including studies on genetics, immunology, cancer, and neuroscience.
An acute leukemia exhibiting cell features characteristic of both the myeloid and lymphoid lineages and probably arising from MULTIPOTENT STEM CELLS.
Established cell cultures that have the potential to propagate indefinitely.
A strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) producing leukemia of the reticulum-cell type with massive infiltration of liver, spleen, and bone marrow. It infects DBA/2 and Swiss mice.
Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
A promyelocytic cell line derived from a patient with ACUTE PROMYELOCYTIC LEUKEMIA. HL-60 cells lack specific markers for LYMPHOID CELLS but express surface receptors for FC FRAGMENTS and COMPLEMENT SYSTEM PROTEINS. They also exhibit phagocytic activity and responsiveness to chemotactic stimuli. (From Hay et al., American Type Culture Collection, 7th ed, pp127-8)
Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.
Lymphocyte progenitor cells that are restricted in their differentiation potential to the B lymphocyte lineage. The pro-B cell stage of B lymphocyte development precedes the pre-B cell stage.
Aggressive T-Cell malignancy with adult onset, caused by HUMAN T-LYMPHOTROPIC VIRUS 1. It is endemic in Japan, the Caribbean basin, Southeastern United States, Hawaii, and parts of Central and South America and sub-Saharan Africa.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Glycoproteins expressed on all mature T-cells, thymocytes, and a subset of mature B-cells. Antibodies specific for CD5 can enhance T-cell receptor-mediated T-cell activation. The B-cell-specific molecule CD72 is a natural ligand for CD5. (From Abbas et al., Cellular and Molecular Immunology, 2d ed, p156)
Inbred BALB/c mice are a strain of laboratory mice that have been selectively bred to be genetically identical to each other, making them useful for scientific research and experiments due to their consistent genetic background and predictable responses to various stimuli or treatments.
That region of the immunoglobulin molecule that varies in its amino acid sequence and composition, and comprises the binding site for a specific antigen. It is located at the N-terminus of the Fab fragment of the immunoglobulin. It includes hypervariable regions (COMPLEMENTARITY DETERMINING REGIONS) and framework regions.
A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.
A tumor necrosis factor superfamily member that plays a role in the regulation of B-LYMPHOCYTE survival. It occurs as a membrane-bound protein that is cleaved to release an biologically active soluble form with specificity to TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR PROTEIN; B-CELL ACTIVATION FACTOR RECEPTOR; and B-CELL MATURATION ANTIGEN.
A strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) isolated from spontaneous leukemia in AKR strain mice.
An acute myeloid leukemia in which 20-30% of the bone marrow or peripheral blood cells are of megakaryocyte lineage. MYELOFIBROSIS or increased bone marrow RETICULIN is common.
Ordered rearrangement of B-lymphocyte variable gene regions coding for the IMMUNOGLOBULIN CHAINS, thereby contributing to antibody diversity. It occurs during the differentiation of the IMMATURE B-LYMPHOCYTES.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
Genes encoding the different subunits of the IMMUNOGLOBULINS, for example the IMMUNOGLOBULIN LIGHT CHAIN GENES and the IMMUNOGLOBULIN HEAVY CHAIN GENES. The heavy and light immunoglobulin genes are present as gene segments in the germline cells. The completed genes are created when the segments are shuffled and assembled (B-LYMPHOCYTE GENE REARRANGEMENT) during B-LYMPHOCYTE maturation. The gene segments of the human light and heavy chain germline genes are symbolized V (variable), J (joining) and C (constant). The heavy chain germline genes have an additional segment D (diversity).
T-cell enhancement of the B-cell response to thymic-dependent antigens.
A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.
Translation products of a fusion gene derived from CHROMOSOMAL TRANSLOCATION of C-ABL GENES to the genetic locus of the breakpoint cluster region gene on chromosome 22. Several different variants of the bcr-abl fusion proteins occur depending upon the precise location of the chromosomal breakpoint. These variants can be associated with distinct subtypes of leukemias such as PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; and NEUTROPHILIC LEUKEMIA, CHRONIC.
Antibodies produced by a single clone of cells.
Disease having a short and relatively severe course.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN.
Therapeutic act or process that initiates a response to a complete or partial remission level.
The initial phase of chronic myeloid leukemia consisting of an relatively indolent period lasting from 4 to 7 years. Patients range from asymptomatic to those exhibiting ANEMIA; SPLENOMEGALY; and increased cell turnover. There are 5% or fewer blast cells in the blood and bone marrow in this phase.
A member of the tumor necrosis factor receptor superfamily with specificity for CD40 LIGAND. It is found on mature B-LYMPHOCYTES and some EPITHELIAL CELLS, lymphoid DENDRITIC CELLS. Evidence suggests that CD40-dependent activation of B-cells is important for generation of memory B-cells within the germinal centers. Mutations of the gene for CD40 antigen result in HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 3. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
Multi-subunit proteins which function in IMMUNITY. They are produced by B LYMPHOCYTES from the IMMUNOGLOBULIN GENES. They are comprised of two heavy (IMMUNOGLOBULIN HEAVY CHAINS) and two light chains (IMMUNOGLOBULIN LIGHT CHAINS) with additional ancillary polypeptide chains depending on their isoforms. The variety of isoforms include monomeric or polymeric forms, and transmembrane forms (B-CELL ANTIGEN RECEPTORS) or secreted forms (ANTIBODIES). They are divided by the amino acid sequence of their heavy chains into five classes (IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M) and various subclasses.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
A general term for various neoplastic diseases of the lymphoid tissue.
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed)
Membrane antigens associated with maturation stages of B-lymphocytes, often expressed in tumors of B-cell origin.
Ordered rearrangement of B-lymphocyte variable gene regions of the IMMUNOGLOBULIN HEAVY CHAINS, thereby contributing to antibody diversity. It occurs during the first stage of differentiation of the IMMATURE B-LYMPHOCYTES.
A lectin and cell adhesion molecule found in B-LYMPHOCYTES. It interacts with SIALIC ACIDS and mediates signaling from B-CELL ANTIGEN RECEPTORS.
The altered state of immunologic responsiveness resulting from initial contact with antigen, which enables the individual to produce antibodies more rapidly and in greater quantity in response to secondary antigenic stimulus.
Mapping of the KARYOTYPE of a cell.
The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS.
A chronic leukemia characterized by a large number of circulating prolymphocytes. It can arise spontaneously or as a consequence of transformation of CHRONIC LYMPHOCYTIC LEUKEMIA.
A rare, aggressive variant of MULTIPLE MYELOMA characterized by the circulation of excessive PLASMA CELLS in the peripheral blood. It can be a primary manifestation of multiple myeloma or develop as a terminal complication during the disease.
Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes.
An ERYTHROLEUKEMIA cell line derived from a CHRONIC MYELOID LEUKEMIA patient in BLAST CRISIS.
A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.
A member of the tumor necrosis factor receptor superfamily that specifically binds B-CELL ACTIVATING FACTOR. It is found on B-LYMPHOCYTES and plays a role in maturation and survival of B-cells. Signaling by the activated receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
Progenitor cells from which all blood cells derive.
The phase of chronic myeloid leukemia following the chronic phase (LEUKEMIA, MYELOID, CHRONIC-PHASE), where there are increased systemic symptoms, worsening cytopenias, and refractory LEUKOCYTOSIS.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
The class of heavy chains found in IMMUNOGLOBULIN M. They have a molecular weight of approximately 72 kDa and they contain about 57 amino acid residues arranged in five domains and have more oligosaccharide branches and a higher carbohydrate content than the heavy chains of IMMUNOGLOBULIN G.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
A cell line derived from cultured tumor cells.
A member of the tumor necrosis factor receptor superfamily found on most T-LYMPHOCYTES. Activation of the receptor by CD70 ANTIGEN results in the increased proliferation of CD4-POSITIVE T-LYMPHOCYTES and CD8-POSITIVE T-LYMPHOCYTES. Signaling by the activated receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
A lymphoid leukemia characterized by a profound LYMPHOCYTOSIS with or without LYMPHADENOPATHY, hepatosplenomegaly, frequently rapid progression, and short survival. It was formerly called T-cell chronic lymphocytic leukemia.
Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases.
The ordered rearrangement of gene regions by DNA recombination such as that which occurs normally during development.
The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.
Molecular sites on or in B-lymphocytes, follicular dendritic cells, lymphoid cells, and epithelial cells that recognize and combine with COMPLEMENT C3D. Human complement receptor 2 (CR2) serves as a receptor for both C3dg and the gp350/220 glycoprotein of HERPESVIRUS 4, HUMAN, and binds the monoclonal antibody OKB7, which blocks binding of both ligands to the receptor.
Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process.
A strain of PRIMATE T-LYMPHOTROPIC VIRUS 1 isolated from mature T4 cells in patients with T-lymphoproliferation malignancies. It causes adult T-cell leukemia (LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED), T-cell lymphoma (LYMPHOMA, T-CELL), and is involved in mycosis fungoides, SEZARY SYNDROME and tropical spastic paraparesis (PARAPARESIS, TROPICAL SPASTIC).
A transcription factor that dimerizes with the cofactor CORE BINDING FACTOR BETA SUBUNIT to form core binding factor. It contains a highly conserved DNA-binding domain known as the runt domain. Runx1 is frequently mutated in human LEUKEMIAS.
A component of the B-cell antigen receptor that is involved in B-cell antigen receptor heavy chain transport to the PLASMA MEMBRANE. It is expressed almost exclusively in B-LYMPHOCYTES and serves as a useful marker for B-cell NEOPLASMS.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
A membrane glycoprotein and differentiation antigen expressed on the surface of T-cells that binds to CD40 ANTIGENS on B-LYMPHOCYTES and induces their proliferation. Mutation of the gene for CD40 ligand is a cause of HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 1.
Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
A programmed mutation process whereby changes are introduced to the nucleotide sequence of immunoglobulin gene DNA during development.
Antigenic determinants recognized and bound by the B-cell receptor. Epitopes recognized by the B-cell receptor are located on the surface of the antigen.
A leukemia/lymphoma found predominately in children and young adults and characterized LYMPHADENOPATHY and THYMUS GLAND involvement. It most frequently presents as a lymphoma, but a leukemic progression in the bone marrow is common.
One of the types of light chains of the immunoglobulins with a molecular weight of approximately 22 kDa.
Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
A pathologic change in leukemia in which leukemic cells permeate various organs at any stage of the disease. All types of leukemia show various degrees of infiltration, depending upon the type of leukemia. The degree of infiltration may vary from site to site. The liver and spleen are common sites of infiltration, the greatest appearing in myelocytic leukemia, but infiltration is seen also in the granulocytic and lymphocytic types. The kidney is also a common site and of the gastrointestinal system, the stomach and ileum are commonly involved. In lymphocytic leukemia the skin is often infiltrated. The central nervous system too is a common site.
A leukemia affecting young children characterized by SPLENOMEGALY, enlarged lymph nodes, rashes, and hemorrhages. Traditionally classed as a myeloproliferative disease, it is now considered a mixed myeloproliferative-mylelodysplastic disorder.
Glycoproteins found on the membrane or surface of cells.
A receptor tyrosine kinase that is involved in HEMATOPOIESIS. It is closely related to FMS PROTO-ONCOGENE PROTEIN and is commonly mutated in acute MYELOID LEUKEMIA.
CXCR receptors isolated initially from BURKITT LYMPHOMA cells. CXCR5 receptors are expressed on mature, recirculating B-LYMPHOCYTES and are specific for CHEMOKINE CXCL13.
A replication-defective strain of Murine leukemia virus (LEUKEMIA VIRUS, MURINE) capable of transforming lymphoid cells and producing a rapidly progressing lymphoid leukemia after superinfection with FRIEND MURINE LEUKEMIA VIRUS; MOLONEY MURINE LEUKEMIA VIRUS; or RAUSCHER VIRUS.
Ordered rearrangement of B-lymphocyte variable gene regions coding for the kappa or lambda IMMUNOGLOBULIN LIGHT CHAINS, thereby contributing to antibody diversity. It occurs during the second stage of differentiation of the IMMATURE B-LYMPHOCYTES.
White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
A rare acute myeloid leukemia in which the primary differentiation is to BASOPHILS. It is characterized by an extreme increase of immature basophilic granulated cells in the bone marrow and blood. Mature basophils are usually sparse.
Antibodies which react with the individual structural determinants (idiotopes) on the variable region of other antibodies.
Family of RNA viruses that infects birds and mammals and encodes the enzyme reverse transcriptase. The family contains seven genera: DELTARETROVIRUS; LENTIVIRUS; RETROVIRUSES TYPE B, MAMMALIAN; ALPHARETROVIRUS; GAMMARETROVIRUS; RETROVIRUSES TYPE D; and SPUMAVIRUS. A key feature of retrovirus biology is the synthesis of a DNA copy of the genome which is integrated into cellular DNA. After integration it is sometimes not expressed but maintained in a latent state (PROVIRUSES).
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
Cell separation is the process of isolating and distinguishing specific cell types or individual cells from a heterogeneous mixture, often through the use of physical or biological techniques.
Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations, or by parent x offspring matings carried out with certain restrictions. All animals within an inbred strain trace back to a common ancestor in the twentieth generation.
Abnormal number or structure of chromosomes. Chromosome aberrations may result in CHROMOSOME DISORDERS.
A hydrolase enzyme that converts L-asparagine and water to L-aspartate and NH3. EC 3.5.1.1.
Antigens which may directly stimulate B lymphocytes without the cooperation of T lymphocytes.
Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.
An aberrant form of human CHROMOSOME 22 characterized by translocation of the distal end of chromosome 9 from 9q34, to the long arm of chromosome 22 at 22q11. It is present in the bone marrow cells of 80 to 90 per cent of patients with chronic myelocytic leukemia (LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE).
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Specialized tissues that are components of the lymphatic system. They provide fixed locations within the body where a variety of LYMPHOCYTES can form, mature and multiply. The lymphoid tissues are connected by a network of LYMPHATIC VESSELS.
The number of LYMPHOCYTES per unit volume of BLOOD.
Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them.
Conditions in which the abnormalities in the peripheral blood or bone marrow represent the early manifestations of acute leukemia, but in which the changes are not of sufficient magnitude or specificity to permit a diagnosis of acute leukemia by the usual clinical criteria.
A myelodysplastic/myeloproliferative disorder characterized by myelodysplasia associated with bone marrow and peripheral blood patterns similar to CHRONIC MYELOID LEUKEMIA, but cytogenetically lacking a PHILADELPHIA CHROMOSOME or bcr/abl fusion gene (GENES, ABL).
Immunological rejection of leukemia cells following bone marrow transplantation.
The type species of LYMPHOCRYPTOVIRUS, subfamily GAMMAHERPESVIRINAE, infecting B-cells in humans. It is thought to be the causative agent of INFECTIOUS MONONUCLEOSIS and is strongly associated with oral hairy leukoplakia (LEUKOPLAKIA, HAIRY;), BURKITT LYMPHOMA; and other malignancies.
A soluble factor produced by activated T-LYMPHOCYTES that induces the expression of MHC CLASS II GENES and FC RECEPTORS on B-LYMPHOCYTES and causes their proliferation and differentiation. It also acts on T-lymphocytes, MAST CELLS, and several other hematopoietic lineage cells.
Process whereby the immune system reacts against the body's own tissues. Autoimmunity may produce or be caused by AUTOIMMUNE DISEASES.
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
Highly proliferative, self-renewing, and colony-forming stem cells which give rise to NEOPLASMS.
Virus diseases caused by the RETROVIRIDAE.
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors.
Remnant of a tumor or cancer after primary, potentially curative therapy. (Dr. Daniel Masys, written communication)
A receptor subunit that combines with CYTOKINE RECEPTOR GP130 to form the dual specificity receptor for LEUKEMIA INHIBITORY FACTOR and ONCOSTATIN M. The subunit is also a component of the CILIARY NEUROTROPHIC FACTOR RECEPTOR. Both membrane-bound and secreted isoforms of the receptor subunit exist due to ALTERNATIVE SPLICING of its mRNA. The secreted isoform is believed to act as an inhibitory receptor, while the membrane-bound form is a signaling receptor.
Elements of limited time intervals, contributing to particular results or situations.
The return of a sign, symptom, or disease after a remission.
Membrane proteins encoded by the BCL-2 GENES and serving as potent inhibitors of cell death by APOPTOSIS. The proteins are found on mitochondrial, microsomal, and NUCLEAR MEMBRANE sites within many cell types. Overexpression of bcl-2 proteins, due to a translocation of the gene, is associated with follicular lymphoma.
Cells of the lymphoid series that can react with antigen to produce specific cell products called antibodies. Various cell subpopulations, often B-lymphocytes, can be defined, based on the different classes of immunoglobulins that they synthesize.
DNA present in neoplastic tissue.
Endogenous or exogenous substances which inhibit the normal growth of human and animal cells or micro-organisms, as distinguished from those affecting plant growth (= PLANT GROWTH REGULATORS).
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
Polypeptide chains, consisting of 211 to 217 amino acid residues and having a molecular weight of approximately 22 kDa. There are two major types of light chains, kappa and lambda. Two Ig light chains and two Ig heavy chains (IMMUNOGLOBULIN HEAVY CHAINS) make one immunoglobulin molecule.
Examination of CHROMOSOMES to diagnose, classify, screen for, or manage genetic diseases and abnormalities. Following preparation of the sample, KARYOTYPING is performed and/or the specific chromosomes are analyzed.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
A transcription factor that is essential for CELL DIFFERENTIATION of B-LYMPHOCYTES. It functions both as a transcriptional activator and repressor to mediate B-cell commitment.
One of the types of light chain subunits of the immunoglobulins with a molecular weight of approximately 22 kDa.
A spectrum of disorders characterized by clonal expansions of the peripheral blood LYMPHOCYTE populations known as large granular lymphocytes which contain abundant cytoplasm and azurophilic granules. Subtypes develop from either CD3-negative NATURAL KILLER CELLS or CD3-positive T-CELLS. The clinical course of both subtypes can vary from spontaneous regression to progressive, malignant disease.
Formation of LYMPHOCYTES and PLASMA CELLS from the lymphoid stem cells which develop from the pluripotent HEMATOPOIETIC STEM CELLS in the BONE MARROW. These lymphoid stem cells differentiate into T-LYMPHOCYTES; B-LYMPHOCYTES; PLASMA CELLS; or NK-cells (KILLER CELLS, NATURAL) depending on the organ or tissues (LYMPHOID TISSUE) to which they migrate.
The classes of immunoglobulins found in any species of animal. In man there are nine classes that migrate in five different groups in electrophoresis; they each consist of two light and two heavy protein chains, and each group has distinguishing structural and functional properties.
A bifunctional enzyme that catalyzes the synthesis and HYDROLYSIS of CYCLIC ADP-RIBOSE (cADPR) from NAD+ to ADP-RIBOSE. It is a cell surface molecule which is predominantly expressed on LYMPHOID CELLS and MYELOID CELLS.
The biosynthesis of RNA carried out on a template of DNA. The biosynthesis of DNA from an RNA template is called REVERSE TRANSCRIPTION.
A member of the myeloid leukemia factor (MLF) protein family with multiple alternatively spliced transcript variants encoding different protein isoforms. In hematopoietic cells, it is located mainly in the nucleus, and in non-hematopoietic cells, primarily in the cytoplasm with a punctate nuclear localization. MLF1 plays a role in cell cycle differentiation.
Inbred AKR mice are a strain of laboratory mice that are homozygous at all gene loci and have a high incidence of developing certain diseases, such as leukemia and autoimmune disorders, making them useful for research purposes in biomedicine.
A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.
Proteins found in the nucleus of a cell. Do not confuse with NUCLEOPROTEINS which are proteins conjugated with nucleic acids, that are not necessarily present in the nucleus.
Substances that are recognized by the immune system and induce an immune reaction.
A CXC chemokine that is chemotactic for B-LYMPHOCYTES. It has specificity for CXCR5 RECEPTORS.
They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.
Non-hematopoietic cells, with extensive dendritic processes, found in the primary and secondary follicles of lymphoid tissue (the B cell zones). They are different from conventional DENDRITIC CELLS associated with T-CELLS. They are derived from MESENCHYMAL STEM CELLS and are negative for class II MHC antigen and do not process or present antigen like the conventional dendritic cells do. Instead, follicular dendritic cells have FC RECEPTORS and C3B RECEPTORS that hold antigen in the form of ANTIGEN-ANTIBODY COMPLEXES on their surfaces for long periods for recognition by B-CELLS.
Antibodies obtained from a single clone of cells grown in mice or rats.
Binary compounds of oxygen containing the anion O(2-). The anion combines with metals to form alkaline oxides and non-metals to form acidic oxides.
Inorganic or organic compounds that contain arsenic.
Transcriptional trans-acting proteins of the promoter elements found in the long terminal repeats (LTR) of HUMAN T-LYMPHOTROPIC VIRUS 1 and HUMAN T-LYMPHOTROPIC VIRUS 2. The tax (trans-activator x; x is undefined) proteins act by binding to enhancer elements in the LTR.
A species of GAMMARETROVIRUS causing leukemia in the gibbon ape. Natural transmission is by contact.
The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.
An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).
The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.
Eukaryotic cell line obtained in a quiescent or stationary phase which undergoes conversion to a state of unregulated growth in culture, resembling an in vitro tumor. It occurs spontaneously or through interaction with viruses, oncogenes, radiation, or drugs/chemicals.
The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc.
An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.
An inheritable change in cells manifested by changes in cell division and growth and alterations in cell surface properties. It is induced by infection with a transforming virus.
A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes.
Specific molecular sites on the surface of B- and T-lymphocytes which combine with IgEs. Two subclasses exist: low affinity receptors (Fc epsilon RII) and high affinity receptors (Fc epsilon RI).
Reduction in the number of lymphocytes.
Retrovirus-associated DNA sequences (abl) originally isolated from the Abelson murine leukemia virus (Ab-MuLV). The proto-oncogene abl (c-abl) codes for a protein that is a member of the tyrosine kinase family. The human c-abl gene is located at 9q34.1 on the long arm of chromosome 9. It is activated by translocation to bcr on chromosome 22 in chronic myelogenous leukemia.
A lymphoid neoplastic disease in cattle caused by the bovine leukemia virus. Enzootic bovine leukosis may take the form of lymphosarcoma, malignant lymphoma, or leukemia but the presence of malignant cells in the blood is not a consistent finding.
The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells.
A specific pair of GROUP G CHROMOSOMES of the human chromosome classification.
A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
An enzyme that catalyzes the deamination of cytidine, forming uridine. EC 3.5.4.5.
Normal cellular genes homologous to viral oncogenes. The products of proto-oncogenes are important regulators of biological processes and appear to be involved in the events that serve to maintain the ordered procession through the cell cycle. Proto-oncogenes have names of the form c-onc.
A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.
The developmental history of specific differentiated cell types as traced back to the original STEM CELLS in the embryo.

The role of alternative splicing of the adhesion molecule, CD44, in lymphoid malignancy. (1/2706)

AIM: To investigate the expression of CD44 isoforms containing variant exon 6 (v6) in a well characterised cohort of patients with non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukaemia (CLL), and to correlate this with phenotype and disease course. METHODS: Cryostat sections of OCT embedded diagnostic nodal material from NHL patients and cryopreserved mononuclear preparations from CLL patients were used as sources of RNA. After reverse transcription, PCR was carried out with amplimers positioned at either side of the variant exon insertion site to amplify all possible CD44 isoforms. Those isoforms containing v6 were identified after Southern blotting and hybridisation with a radiolabelled oligonucleotide. RESULTS: Of 32 NHL samples analysed, 16 did not express CD44 isoforms containing v6, six expressed an isoform containing exon v6 alone, and 10 expressed v6 long isoforms which contained exon v6 in addition to other variant exons. These data did not correlate with lymphoma classification, disease staging, or the presence or absence of extranodal disease. However, those patients expressing v6 long CD44 isoforms had a worse overall survival than those that did not. The plateau of the survival curves was 50% compared with 82%. No v6 long isoforms were detected in the 21 CLL samples investigated. CONCLUSIONS: The expression of v6 long CD44 isoforms is associated with aggressive disease in NHL, independent of grade, stage, or presence of extranodal disease.  (+info)

Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. (2/2706)

Chronic lymphocytic leukemia (CLL) shows a remarkably heterogeneous clinical outcome; survival ranges from several months in advanced stages to more than 10 years in early stages. The Binet and Rai staging systems distinguish three major prognostic subgroups, but do not accurately predict the individual risk of disease progression in early CLL (Binet stage A or Rai stage 0 to II). Because most newly diagnosed CLL patients present with early disease, it seems desirable to search for additional prognostic factors to identify early CLL patients at high risk of rapid progression. It has been shown that elevated serum thymidine kinase (s-TK) levels predict disease progression in CLL. Therefore, this study aimed to assess the prognostic value of s-TK in 122 previously untreated patients with Binet stage A CLL (mean age +/- SD, 58.7 +/- 8.5 years). In univariate analyses, 18 of the 22 parameters investigated predicted progression-free survival (PFS). In a stepwise multiple regression analysis, only three parameters provided independent prognostic information on PFS: s-TK greater than 7.1 U/L; presence of lymphadenopathy; and white blood cell (WBC) count greater than 75, 000/microL. When added to the classification of smoldering versus nonsmoldering CLL, s-TK levels separated two groups within the group of nonsmoldering stage A patients: patients with s-TK values greater than 7.1 U/L had a median PFS of 8 months, whereas patients with s-TK values +info)

CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells. (3/2706)

Although spontaneous remissions may rarely occur in B-cell chronic lymphocytic leukemia (B-CLL), T cells do generally not develop a clinically significant response against B-CLL cells. Because this T-cell anergy against B-CLL cells may be caused by the inability of B-CLL cells to present tumor-antigens efficiently, we examined the possibility of upregulating critical costimulatory (B7-1 and B7-2) and adhesion molecules (ICAM-1 and LFA-3) on B-CLL cells to improve antigen presentation. The stimulation of B-CLL cells via CD40 by culture on CD40L expressing feeder cells induced a strong upregulation of costimulatory and adhesion molecules and turned the B-CLL cells into efficient antigen-presenting cells (APCs). CD40-activated B-CLL (CD40-CLL) cells stimulated the proliferation of both CD4(+) and CD8(+) T cells. Interestingly, stimulation of allogeneic versus autologous T cells resulted in the expansion of different effector populations. Allogeneic CD40-CLL cells allowed for the expansion of specific CD8(+) cytolytic T cells (CTL). In marked contrast, autologous CD40-CLL cells did not induce a relevant CTL response, but rather stimulated a CD4(+), Th1-like T-cell population that expressed high levels of CD40L and released interferon-gamma in response to stimulation by CD40-CLL cells. Together, these results support the view that CD40 activation of B-CLL cells might reverse T-cell anergy against the neoplastic cell clone, although the character of the immune response depends on the major histocompatibility complex (MHC) background on which the CLL or tumor antigens are presented. These findings may have important implications for the design of cellular immunotherapies for B-CLL.  (+info)

Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. (4/2706)

PURPOSE: Rituximab was recently approved for use in relapsed, low-grade non-Hodgkin's lymphoma; however, few data exist regarding the safety of this agent in patients with a high number of tumor cells in the blood. METHODS AND RESULTS: After the observation at our institution of a rapid reduction of peripheral-blood tumor cells with associated severe pulmonary infusion-related toxicity in two patients with refractory hematologic malignancies, data on three additional cases were collected from physician-submitted reports of adverse events related to rituximab treatment. Five patients with hematologic malignancies possessing a high number of blood tumor cells were treated with rituximab and developed rapid tumor clearance. The median age was 68 years (range, 26 to 78 years). Patients were diagnosed with B-cell prolymphocytic leukemia (n = 2), chronic lymphocytic leukemia (n = 2), or transformed non-Hodgkin's lymphoma (n = 1). All of these patients had bulky adenopathy or organomegaly. All five patients developed a unique syndrome of severe infusion-related reactions, thrombocytopenia, rapid decrement in circulating tumor cell load, and mild electrolyte evidence of tumor lysis, and all required hospitalization. In addition, one patient developed ascites. These events resolved, and four patients were subsequently treated with rituximab without significant complications. CONCLUSION: Rituximab administration in patients who have a high number of tumor cells in the blood may have an increased likelihood of severe initial infusion-related reactions. These data also suggest that rituximab may have activity in a variety of other lymphoid neoplasms, such as chronic lymphocytic leukemia and B-cell prolymphocytic leukemia.  (+info)

Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinemia, and mantle-cell lymphoma. (5/2706)

PURPOSE: Fludarabine phosphate (F-AMP) has significant activity in follicular lymphoma and in B-cell chronic lymphatic leukemia, where it has demonstrated high complete response (CR) rates. Lymphoplasmacytoid (LPC) lymphoma, Waldenstrom's macroglobulinemia (WM), and mantle-cell lymphoma (MCL) also present with advanced-stage disease and are incurable with standard alkylator-based chemotherapy. A phase II trial was undertaken to determine the activity of F-AMP in patients newly diagnosed with these diseases. PATIENTS AND METHODS: Between 1992 and 1996, 78 patients (aged 18 to 75 years) received intravenous F-AMP (25 mg/m2/d for 5 days, every 4 weeks) until maximum response, plus two further cycles as consolidation. The primary end point was response rate; secondary end points included time to progression (TTP), duration of response, and overall survival (OS). RESULTS: Forty-four (62%) of 71 assessable patients had a response to F-AMP (LPC lymphoma, 63%; WM, 79%; MCL, 41%); the CR rate was 15%. At a median follow-up of 1.5 years, 19 of 44 responding patients have had progression of lymphoma; the median duration of response was 2.5 years. The median survival has not yet been reached. There was no significant difference in the duration of response or OS between patients with different histologies; TTP was shorter in patients with MCL (P = .015). Myelosuppression was relatively common, and the treatment-related mortality (TRM) was 5%, mostly associated with pancytopenia and infection. CONCLUSION: Single-agent fludarabine phosphate is active in previously untreated LPC lymphoma and WM, with only moderate activity in MCL. However, the CR rate is low, and the TRM is relatively high. Its role in combination chemotherapy remains to be demonstrated.  (+info)

An alternatively spliced form of CD79b gene may account for altered B-cell receptor expression in B-chronic lymphocytic leukemia. (6/2706)

Several functional anomalies of B-chronic lymphocytic leukemia (B-CLL) cells may be explained by abnormalities of the B-cell receptor (BCR), a multimeric complex formed by the sIg homodimer and the noncovalently bound heterodimer Igalpha/Igbeta (CD79a/CD79b). Because the expression of the extracellular Ig-like domain of CD79b has been reported to be absent in the cells of most CLL cases, we have investigated the molecular mechanisms that may account for this defect. Peripheral blood lymphocytes (PBL) from 50 patients and two cell lines (MEC1, MEC2) obtained from the PBL of one of them were studied. MEC1, MEC2, and 75% of CLL cases did not express detectable levels of the extracellular Ig-like domain of CD79b, which was nevertheless present in greater than 80% CD19(+) cells from normal donors. In healthy subjects the expression of CD79b was equally distributed in CD5(+) and CD5(-) B-cell subsets. Reverse transcription-polymerase chain reaction (RT-PCR) analysis of CD79b RNA from all patients and from MEC1 and MEC2 cell lines consistently yielded two fragments of different size (709 bp and 397 bp). The 709-bp band corresponds to CD79b entire transcript; the 397-bp band corresponds to an alternatively spliced form lacking exon 3 that encodes the extracellular Ig-like domain. Both fragments were also visible in normal PBL. The expression of the 397-bp fragment was increased in normal activated B cells, while no difference was seen between CD5(+) and CD5(-) B cells. To obtain a more accurate estimate of the relative proportions of the two spliced forms, a radioactive PCR was performed in 13 normal and 22 B-CLL samples and the results analyzed using a digital imager. The mean value of the CD79b to the CD79b internally deleted ratio was 0.64 +/- 0.20 SD in normal donors and 0.44 +/- 0.27 SD in B-CLL (P =.01). Direct sequencing of 397-bp RT-PCR products and of genomic DNA corresponding to exon 3 from MEC1, MEC2, their parental cells, and five fresh B-CLL samples did not show any causal mutation. Single-strand conformation polymorphism analysis of exon 3 performed in 18 additional B-CLL cases showed a single abnormal shift corresponding to a TGT --> TGC polymorphic change at amino acid 122. We propose a role for the alternative splicing of CD79b gene in causing the reduced expression of BCR on the surface of B-CLL cells. As normal B cells also present this variant, the mechanism of CD79b posttranscriptional regulation might reflect the activation stage of the normal B cell from which B-CLL derives.  (+info)

Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: a German multicenter phase II study. (7/2706)

PURPOSE: Fludarabine has been reported to be the most effective single-agent in previously treated chronic lymphocytic leukaemia (CLL). Based on the in vitro synergism of fludarabine with anthracyclines and on results showing a higher efficacy of CHOP against COP we attempted to improve treatment results with a combination of fludarabine and an anthracycline. PATIENTS AND METHODS: The aim of the multicenter study was to evaluate the rate and duration of remissions and investigate the toxic and immunosuppressive effects of fludarabine and epirubicin in the treatment of CLL in Binet stages B and C as first-line therapy or in first relapse. Thirty-eight patients were treated with fludarabine 25 mg/m2 on days 1-5 and epirubicin 25 mg/m2 on days 4 and 5. RESULTS: The overall response rate (OR) was 82% (95% confidence interval (95% CI): 66%-92%) with a CR rate of 32% (95% CI: 18%-49%). For the 25 previously untreated patients the OR was 92% (95% CI: 74%-99%) including 40% CRs (95% CI: 21%-61%). Granulocytopenia grade 3 occurred in 23% of all evaluable cycles, and grade 4 in 17%. The median remission duration was 19 months (range 6-37 months). CONCLUSION: The results show that the combination of fludarabine and epirubicin is tolerable and highly effective in the treatment of CLL. With the addition of epirubicin to fludarabine, it appears possible to achieve a higher response rate and a more rapid response, especially of nodal manifestations. This regimen can be administered in an outpatient facility except for the first cycle because of the risk of a tumour lysis. The possible benefit of the combination presented here in the treatment of CLL in comparison to single-agent fludarabine treatment is presently under study in a prospective randomized multicenter study.  (+info)

Constitutive expression of CD26/dipeptidylpeptidase IV on peripheral blood B lymphocytes of patients with B chronic lymphocytic leukaemia. (8/2706)

We have investigated the expression of the ectoenzyme dipeptidylpeptidase IV (DPP IV)/CD26 on lymphocytes obtained from patients with B chronic lymphocytic leukaemia (B-CLL) and compared it with healthy subjects. Using two-colour immunofluorescence analysis with CD26 and CD20 or CD23 monoclonal antibodies, CD26 was found undetectable on peripheral resting B-cells (CD20+ CD23-) from normal donors whereas it was expressed on B-cells activated in vitro with interleukin (IL)-4 and Staphylococcus aureus strain cowan I (CD20+ CD23+). The expression of CD26 on leukaemic B-cells (CD20+ CD23+) was clearly induced in 22 out of 25 patients examined. Consequently, induced levels of CD26 cell surface expression on either normal activated and malignant B-cells coincided with the enhancement of DPP IV activity detected on the surface of these cells. Reverse transcription polymerase chain reaction analyses showed that the transcript levels of the CD26 gene was higher in normal activated B-cells and B-CLL cells than in resting B-cells, suggesting that CD26 was expressed at the level of transcriptional activation. These observations provide evidence of the abnormal expression of DPPIV/CD26 in B-CLL which, therefore, may be considered as a novel marker for B-CLL. Further investigation in relation to CD26 expression and other B malignancies needs to be defined.  (+info)

B-lymphocytes, also known as B-cells, are a type of white blood cell that plays a key role in the immune system's response to infection. They are responsible for producing antibodies, which are proteins that help to neutralize or destroy pathogens such as bacteria and viruses.

When a B-lymphocyte encounters a pathogen, it becomes activated and begins to divide and differentiate into plasma cells, which produce and secrete large amounts of antibodies specific to the antigens on the surface of the pathogen. These antibodies bind to the pathogen, marking it for destruction by other immune cells such as neutrophils and macrophages.

B-lymphocytes also have a role in presenting antigens to T-lymphocytes, another type of white blood cell involved in the immune response. This helps to stimulate the activation and proliferation of T-lymphocytes, which can then go on to destroy infected cells or help to coordinate the overall immune response.

Overall, B-lymphocytes are an essential part of the adaptive immune system, providing long-lasting immunity to previously encountered pathogens and helping to protect against future infections.

Leukemia is a type of cancer that originates from the bone marrow - the soft, inner part of certain bones where new blood cells are made. It is characterized by an abnormal production of white blood cells, known as leukocytes or blasts. These abnormal cells accumulate in the bone marrow and interfere with the production of normal blood cells, leading to a decrease in red blood cells (anemia), platelets (thrombocytopenia), and healthy white blood cells (leukopenia).

There are several types of leukemia, classified based on the specific type of white blood cell affected and the speed at which the disease progresses:

1. Acute Leukemias - These types of leukemia progress rapidly, with symptoms developing over a few weeks or months. They involve the rapid growth and accumulation of immature, nonfunctional white blood cells (blasts) in the bone marrow and peripheral blood. The two main categories are:
- Acute Lymphoblastic Leukemia (ALL) - Originates from lymphoid progenitor cells, primarily affecting children but can also occur in adults.
- Acute Myeloid Leukemia (AML) - Develops from myeloid progenitor cells and is more common in older adults.

2. Chronic Leukemias - These types of leukemia progress slowly, with symptoms developing over a period of months to years. They involve the production of relatively mature, but still abnormal, white blood cells that can accumulate in large numbers in the bone marrow and peripheral blood. The two main categories are:
- Chronic Lymphocytic Leukemia (CLL) - Affects B-lymphocytes and is more common in older adults.
- Chronic Myeloid Leukemia (CML) - Originates from myeloid progenitor cells, characterized by the presence of a specific genetic abnormality called the Philadelphia chromosome. It can occur at any age but is more common in middle-aged and older adults.

Treatment options for leukemia depend on the type, stage, and individual patient factors. Treatments may include chemotherapy, targeted therapy, immunotherapy, stem cell transplantation, or a combination of these approaches.

Acute myeloid leukemia (AML) is a type of cancer that originates in the bone marrow, the soft inner part of certain bones where new blood cells are made. In AML, the immature cells, called blasts, in the bone marrow fail to mature into normal blood cells. Instead, these blasts accumulate and interfere with the production of normal blood cells, leading to a shortage of red blood cells (anemia), platelets (thrombocytopenia), and normal white blood cells (leukopenia).

AML is called "acute" because it can progress quickly and become severe within days or weeks without treatment. It is a type of myeloid leukemia, which means that it affects the myeloid cells in the bone marrow. Myeloid cells are a type of white blood cell that includes monocytes and granulocytes, which help fight infection and defend the body against foreign invaders.

In AML, the blasts can build up in the bone marrow and spread to other parts of the body, including the blood, lymph nodes, liver, spleen, and brain. This can cause a variety of symptoms, such as fatigue, fever, frequent infections, easy bruising or bleeding, and weight loss.

AML is typically treated with a combination of chemotherapy, radiation therapy, and/or stem cell transplantation. The specific treatment plan will depend on several factors, including the patient's age, overall health, and the type and stage of the leukemia.

Chronic lymphocytic leukemia (CLL) is a type of cancer that starts from cells that become certain white blood cells (called lymphocytes) in the bone marrow. The cancer (leukemia) cells start in the bone marrow but then go into the blood.

In CLL, the leukemia cells often build up slowly. Many people don't have any symptoms for at least a few years. But over time, the cells can spread to other parts of the body, including the lymph nodes, liver, and spleen.

The "B-cell" part of the name refers to the fact that the cancer starts in a type of white blood cell called a B lymphocyte or B cell. The "chronic" part means that this leukemia usually progresses more slowly than other types of leukemia.

It's important to note that chronic lymphocytic leukemia is different from chronic myelogenous leukemia (CML). Although both are cancers of the white blood cells, they start in different types of white blood cells and progress differently.

Leukemia, lymphoid is a type of cancer that affects the lymphoid cells, which are a vital part of the body's immune system. It is characterized by the uncontrolled production of abnormal white blood cells (leukocytes or WBCs) in the bone marrow, specifically the lymphocytes. These abnormal lymphocytes accumulate and interfere with the production of normal blood cells, leading to a decrease in red blood cells (anemia), platelets (thrombocytopenia), and healthy white blood cells (leukopenia).

There are two main types of lymphoid leukemia: acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL). Acute lymphoblastic leukemia progresses rapidly, while chronic lymphocytic leukemia has a slower onset and progression.

Symptoms of lymphoid leukemia may include fatigue, frequent infections, easy bruising or bleeding, weight loss, swollen lymph nodes, and bone pain. Treatment options depend on the type, stage, and individual patient factors but often involve chemotherapy, radiation therapy, targeted therapy, immunotherapy, or stem cell transplantation.

Experimental leukemia refers to the stage of research or clinical trials where new therapies, treatments, or diagnostic methods are being studied for leukemia. Leukemia is a type of cancer that affects the blood and bone marrow, leading to an overproduction of abnormal white blood cells.

In the experimental stage, researchers investigate various aspects of leukemia, such as its causes, progression, and potential treatments. They may conduct laboratory studies using cell cultures or animal models to understand the disease better and test new therapeutic approaches. Additionally, clinical trials may be conducted to evaluate the safety and efficacy of novel treatments in human patients with leukemia.

Experimental research in leukemia is crucial for advancing our understanding of the disease and developing more effective treatment strategies. It involves a rigorous and systematic process that adheres to ethical guidelines and scientific standards to ensure the validity and reliability of the findings.

Chronic myelogenous leukemia (CML), BCR-ABL positive is a specific subtype of leukemia that originates in the bone marrow and involves the excessive production of mature granulocytes, a type of white blood cell. It is characterized by the presence of the Philadelphia chromosome, which is formed by a genetic translocation between chromosomes 9 and 22, resulting in the formation of the BCR-ABL fusion gene. This gene encodes for an abnormal protein with increased tyrosine kinase activity, leading to uncontrolled cell growth and division. The presence of this genetic abnormality is used to confirm the diagnosis and guide treatment decisions.

Medical Definition:

Murine leukemia virus (MLV) is a type of retrovirus that primarily infects and causes various types of malignancies such as leukemias and lymphomas in mice. It is a complex genus of viruses, with many strains showing different pathogenic properties.

MLV contains two identical single-stranded RNA genomes and has the ability to reverse transcribe its RNA into DNA upon infection, integrating this proviral DNA into the host cell's genome. This is facilitated by an enzyme called reverse transcriptase, which MLV carries within its viral particle.

The virus can be horizontally transmitted between mice through close contact with infected saliva, urine, or milk. Vertical transmission from mother to offspring can also occur either in-utero or through the ingestion of infected breast milk.

MLV has been extensively studied as a model system for retroviral pathogenesis and tumorigenesis, contributing significantly to our understanding of oncogenes and their role in cancer development. It's important to note that Murine Leukemia Virus does not infect humans.

B-lymphocytes, also known as B-cells, are a type of white blood cell that plays a central role in the humoral immune response. They are responsible for producing antibodies, which are proteins that help to neutralize or destroy pathogens such as viruses and bacteria.

B-lymphocyte subsets refer to distinct populations of B-cells that can be identified based on their surface receptors and functional characteristics. Some common B-lymphocyte subsets include:

1. Naive B-cells: These are mature B-cells that have not yet been exposed to an antigen. They express surface receptors called immunoglobulin M (IgM) and immunoglobulin D (IgD).
2. Memory B-cells: These are B-cells that have previously encountered an antigen and mounted an immune response. They express high levels of surface immunoglobulins and can quickly differentiate into antibody-secreting plasma cells upon re-exposure to the same antigen.
3. Plasma cells: These are fully differentiated B-cells that secrete large amounts of antibodies in response to an antigen. They lack surface immunoglobulins and do not undergo further division.
4. Regulatory B-cells: These are a subset of B-cells that modulate the immune response by producing anti-inflammatory cytokines and suppressing the activation of other immune cells.
5. B-1 cells: These are a population of B-cells that are primarily found in the peripheral blood and mucosal tissues. They produce natural antibodies that provide early protection against pathogens and help to maintain tissue homeostasis.

Understanding the different B-lymphocyte subsets and their functions is important for diagnosing and treating immune-related disorders, including autoimmune diseases, infections, and cancer.

Precursor Cell Lymphoblastic Leukemia-Lymphoma (previously known as Precursor T-lymphoblastic Leukemia/Lymphoma) is a type of cancer that affects the early stages of T-cell development. It is a subtype of acute lymphoblastic leukemia (ALL), which is characterized by the overproduction of immature white blood cells called lymphoblasts in the bone marrow, blood, and other organs.

In Precursor Cell Lymphoblastic Leukemia-Lymphoma, these abnormal lymphoblasts accumulate primarily in the lymphoid tissues such as the thymus and lymph nodes, leading to the enlargement of these organs. This subtype is more aggressive than other forms of ALL and has a higher risk of spreading to the central nervous system (CNS).

The medical definition of Precursor Cell Lymphoblastic Leukemia-Lymphoma includes:

1. A malignant neoplasm of immature T-cell precursors, also known as lymphoblasts.
2. Characterized by the proliferation and accumulation of these abnormal cells in the bone marrow, blood, and lymphoid tissues such as the thymus and lymph nodes.
3. Often associated with chromosomal abnormalities, genetic mutations, or aberrant gene expression that contribute to its aggressive behavior and poor prognosis.
4. Typically presents with symptoms related to bone marrow failure (anemia, neutropenia, thrombocytopenia), lymphadenopathy (swollen lymph nodes), hepatosplenomegaly (enlarged liver and spleen), and potential CNS involvement.
5. Diagnosed through a combination of clinical evaluation, imaging studies, and laboratory tests, including bone marrow aspiration and biopsy, immunophenotyping, cytogenetic analysis, and molecular genetic testing.
6. Treated with intensive multi-agent chemotherapy regimens, often combined with radiation therapy and/or stem cell transplantation to achieve remission and improve survival outcomes.

Leukemia, T-cell is a type of cancer that affects the T-cells or T-lymphocytes, which are a type of white blood cells responsible for cell-mediated immunity. It is characterized by an excessive and uncontrolled production of abnormal T-cells in the bone marrow, leading to the displacement of healthy cells and impairing the body's ability to fight infections and regulate immune responses.

T-cell leukemia can be acute or chronic, depending on the rate at which the disease progresses. Acute T-cell leukemia progresses rapidly, while chronic T-cell leukemia has a slower course of progression. Symptoms may include fatigue, fever, frequent infections, weight loss, easy bruising or bleeding, and swollen lymph nodes. Treatment typically involves chemotherapy, radiation therapy, stem cell transplantation, or targeted therapy, depending on the type and stage of the disease.

Leukemia, B-cell is a type of cancer that affects the blood and bone marrow, characterized by an overproduction of abnormal B-lymphocytes, a type of white blood cell. These abnormal cells accumulate in the bone marrow and interfere with the production of normal blood cells, leading to anemia, infection, and bleeding.

B-cells are a type of lymphocyte that plays a crucial role in the immune system by producing antibodies to help fight off infections. In B-cell leukemia, the cancerous B-cells do not mature properly and accumulate in the bone marrow, leading to a decrease in the number of healthy white blood cells, red blood cells, and platelets.

There are several types of B-cell leukemia, including acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL). ALL is more common in children and young adults, while CLL is more common in older adults. Treatment options for B-cell leukemia depend on the type and stage of the disease and may include chemotherapy, radiation therapy, stem cell transplantation, or targeted therapies.

Acute Monocytic Leukemia (AML-M5) is a subtype of acute myeloid leukemia (AML), which is a type of cancer affecting the blood and bone marrow. In AML-M5, there is an overproduction of abnormal monocytes, a type of white blood cell that normally helps fight infection and is involved in the body's immune response. These abnormal monocytes accumulate in the bone marrow and interfere with the production of normal blood cells, leading to symptoms such as fatigue, frequent infections, and easy bruising or bleeding. The disease progresses rapidly without treatment, making it crucial to begin therapy as soon as possible after diagnosis.

Hairy cell leukemia (HCL) is a rare, slow-growing type of cancer in which the bone marrow makes too many B cells (a type of white blood cell). These excess B cells are often referred to as "hairy cells" because they look abnormal under the microscope, with fine projections or "hair-like" cytoplasmic protrusions.

In HCL, these abnormal B cells can build up in the bone marrow and spleen, causing both of them to enlarge. The accumulation of hairy cells in the bone marrow can crowd out healthy blood cells, leading to a shortage of red blood cells (anemia), platelets (thrombocytopenia), and normal white blood cells (leukopenia). This can result in fatigue, increased risk of infection, and easy bruising or bleeding.

HCL is typically an indolent disease, meaning that it progresses slowly over time. However, some cases may require treatment to manage symptoms and prevent complications. Treatment options for HCL include chemotherapy, immunotherapy, targeted therapy, and stem cell transplantation. Regular follow-up with a healthcare provider is essential to monitor the disease's progression and adjust treatment plans as needed.

The Moloney murine leukemia virus (Mo-MLV) is a type of retrovirus, specifically a gammaretrovirus, that is commonly found in mice. It was first discovered and isolated by John Moloney in 1960. Mo-MLV is known to cause various types of cancerous conditions, particularly leukemia, in susceptible mouse strains.

Mo-MLV has a single-stranded RNA genome that is reverse transcribed into double-stranded DNA upon infection of the host cell. This viral DNA then integrates into the host's genome and utilizes the host's cellular machinery to produce new virus particles. The Mo-MLV genome encodes for several viral proteins, including gag (group-specific antigen), pol (polymerase), and env (envelope) proteins, which are essential for the replication cycle of the virus.

Mo-MLV is widely used in laboratory research as a model retrovirus to study various aspects of viral replication, gene therapy, and oncogenesis. It has also been engineered as a vector for gene delivery applications due to its ability to efficiently integrate into the host genome and deliver large DNA sequences. However, it is important to note that Mo-MLV and other retroviruses have the potential to cause insertional mutagenesis, which can lead to unintended genetic alterations and adverse effects in some cases.

Leukemia L1210 is not a medical definition itself, but it refers to a specific mouse leukemia cell line that was established in 1948. These cells are a type of acute myeloid leukemia (AML) and have been widely used in cancer research as a model for studying the disease, testing new therapies, and understanding the biology of leukemia. The L1210 cell line has contributed significantly to the development of various chemotherapeutic agents and treatment strategies for leukemia and other cancers.

Bovine Leukemia Virus (BLV) is a retrovirus that infects cattle and causes enzootic bovine leukosis, a neoplastic disease characterized by the proliferation of malignant B-lymphocytes. The virus primarily targets the animal's immune system, leading to a decrease in the number of white blood cells (leukopenia) and an increased susceptibility to other infections.

The virus is transmitted horizontally through close contact with infected animals or vertically from mother to offspring via infected milk or colostrum. The majority of BLV-infected cattle remain asymptomatic carriers, but a small percentage develop clinical signs such as lymphoma, weight loss, and decreased milk production.

BLV is closely related to human T-cell leukemia virus (HTLV), and both viruses belong to the Retroviridae family, genus Deltaretrovirus. However, it's important to note that BLV does not cause leukemia or any other neoplastic diseases in humans.

Feline Leukemia Virus (FeLV) is a retrovirus that primarily infects cats, causing a variety of diseases and disorders. It is the causative agent of feline leukemia, a name given to a syndrome characterized by a variety of symptoms such as lymphoma (cancer of the lymphatic system), anemia, immunosuppression, and reproductive disorders. FeLV is typically transmitted through close contact with infected cats, such as through saliva, nasal secretions, urine, and milk. It can also be spread through shared litter boxes and feeding dishes.

FeLV infects cells of the immune system, leading to a weakened immune response and making the cat more susceptible to other infections. The virus can also integrate its genetic material into the host's DNA, potentially causing cancerous changes in infected cells. FeLV is a significant health concern for cats, particularly those that are exposed to outdoor environments or come into contact with other cats. Vaccination and regular veterinary care can help protect cats from this virus.

Lymphocyte activation is the process by which B-cells and T-cells (types of lymphocytes) become activated to perform effector functions in an immune response. This process involves the recognition of specific antigens presented on the surface of antigen-presenting cells, such as dendritic cells or macrophages.

The activation of B-cells leads to their differentiation into plasma cells that produce antibodies, while the activation of T-cells results in the production of cytotoxic T-cells (CD8+ T-cells) that can directly kill infected cells or helper T-cells (CD4+ T-cells) that assist other immune cells.

Lymphocyte activation involves a series of intracellular signaling events, including the binding of co-stimulatory molecules and the release of cytokines, which ultimately result in the expression of genes involved in cell proliferation, differentiation, and effector functions. The activation process is tightly regulated to prevent excessive or inappropriate immune responses that can lead to autoimmunity or chronic inflammation.

Gene expression regulation in leukemia refers to the processes that control the production or activation of specific proteins encoded by genes in leukemic cells. These regulatory mechanisms include various molecular interactions that can either promote or inhibit gene transcription and translation. In leukemia, abnormal gene expression regulation can lead to uncontrolled proliferation, differentiation arrest, and accumulation of malignant white blood cells (leukemia cells) in the bone marrow and peripheral blood.

Dysregulated gene expression in leukemia may involve genetic alterations such as mutations, chromosomal translocations, or epigenetic changes that affect DNA methylation patterns and histone modifications. These changes can result in the overexpression of oncogenes (genes with cancer-promoting functions) or underexpression of tumor suppressor genes (genes that prevent uncontrolled cell growth).

Understanding gene expression regulation in leukemia is crucial for developing targeted therapies and improving diagnostic, prognostic, and treatment strategies.

The spleen is an organ in the upper left side of the abdomen, next to the stomach and behind the ribs. It plays multiple supporting roles in the body:

1. It fights infection by acting as a filter for the blood. Old red blood cells are recycled in the spleen, and platelets and white blood cells are stored there.
2. The spleen also helps to control the amount of blood in the body by removing excess red blood cells and storing platelets.
3. It has an important role in immune function, producing antibodies and removing microorganisms and damaged red blood cells from the bloodstream.

The spleen can be removed without causing any significant problems, as other organs take over its functions. This is known as a splenectomy and may be necessary if the spleen is damaged or diseased.

Immunoglobulin M (IgM) is a type of antibody that is primarily found in the blood and lymph fluid. It is the first antibody to be produced in response to an initial exposure to an antigen, making it an important part of the body's primary immune response. IgM antibodies are large molecules that are composed of five basic units, giving them a pentameric structure. They are primarily found on the surface of B cells as membrane-bound immunoglobulins (mlgM), where they function as receptors for antigens. Once an mlgM receptor binds to an antigen, it triggers the activation and differentiation of the B cell into a plasma cell that produces and secretes large amounts of soluble IgM antibodies.

IgM antibodies are particularly effective at agglutination (clumping) and complement activation, which makes them important in the early stages of an immune response to help clear pathogens from the bloodstream. However, they are not as stable or long-lived as other types of antibodies, such as IgG, and their levels tend to decline after the initial immune response has occurred.

In summary, Immunoglobulin M (IgM) is a type of antibody that plays a crucial role in the primary immune response to antigens by agglutination and complement activation. It is primarily found in the blood and lymph fluid, and it is produced by B cells after they are activated by an antigen.

Cell differentiation is the process by which a less specialized cell, or stem cell, becomes a more specialized cell type with specific functions and structures. This process involves changes in gene expression, which are regulated by various intracellular signaling pathways and transcription factors. Differentiation results in the development of distinct cell types that make up tissues and organs in multicellular organisms. It is a crucial aspect of embryonic development, tissue repair, and maintenance of homeostasis in the body.

A germinal center is a microanatomical structure found within the secondary lymphoid organs, such as the spleen, lymph nodes, and Peyer's patches. It is a transient structure that forms during the humoral immune response, specifically during the activation of B cells by antigens.

Germinal centers are the sites where activated B cells undergo rapid proliferation, somatic hypermutation, and class switch recombination to generate high-affinity antibody-secreting plasma cells and memory B cells. These processes help to refine the immune response and provide long-lasting immunity against pathogens.

The germinal center is composed of two main regions: the dark zone (or proliferation center) and the light zone (or selection area). The dark zone contains rapidly dividing B cells, while the light zone contains follicular dendritic cells that present antigens to the B cells. Through a process called affinity maturation, B cells with higher-affinity antibodies are selected for survival and further differentiation into plasma cells or memory B cells.

Overall, germinal centers play a critical role in the adaptive immune response by generating high-affinity antibodies and providing long-term immunity against pathogens.

Radiation-induced leukemia is a type of cancer that affects the blood-forming tissues of the body, such as the bone marrow. It is caused by exposure to high levels of radiation, which can damage the DNA of cells and lead to their uncontrolled growth and division.

There are several types of radiation-induced leukemia, depending on the specific type of blood cell that becomes cancerous. The most common types are acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). These forms of leukemia tend to progress quickly and require prompt treatment.

Radiation-induced leukemia is a rare complication of radiation therapy, which is used to treat many types of cancer. The risk of developing this type of leukemia increases with the dose and duration of radiation exposure. It is important to note that the benefits of radiation therapy in treating cancer generally outweigh the small increased risk of developing radiation-induced leukemia.

Symptoms of radiation-induced leukemia may include fatigue, fever, frequent infections, easy bruising or bleeding, and weight loss. If you have been exposed to high levels of radiation and are experiencing these symptoms, it is important to seek medical attention promptly. A diagnosis of radiation-induced leukemia is typically made through a combination of physical exam, medical history, and laboratory tests, such as blood counts and bone marrow biopsy. Treatment may include chemotherapy, radiation therapy, and/or stem cell transplantation.

CD19 is a type of protein found on the surface of B cells, which are a type of white blood cell that plays a key role in the body's immune response. CD19 is a marker that helps identify and distinguish B cells from other types of cells in the body. It is also a target for immunotherapy in certain diseases, such as B-cell malignancies.

An antigen is any substance that can stimulate an immune response, particularly the production of antibodies. In the context of CD19, antigens refer to substances that can bind to CD19 and trigger a response from the immune system. This can include proteins, carbohydrates, or other molecules found on the surface of bacteria, viruses, or cancer cells.

Therefore, 'antigens, CD19' refers to any substances that can bind to the CD19 protein on B cells and trigger an immune response. These antigens may be used in the development of immunotherapies for the treatment of B-cell malignancies or other diseases.

Flow cytometry is a medical and research technique used to measure physical and chemical characteristics of cells or particles, one cell at a time, as they flow in a fluid stream through a beam of light. The properties measured include:

* Cell size (light scatter)
* Cell internal complexity (granularity, also light scatter)
* Presence or absence of specific proteins or other molecules on the cell surface or inside the cell (using fluorescent antibodies or other fluorescent probes)

The technique is widely used in cell counting, cell sorting, protein engineering, biomarker discovery and monitoring disease progression, particularly in hematology, immunology, and cancer research.

The Myeloid-Lymphoid Leukemia (MLL) protein, also known as MLL1 or HRX, is a histone methyltransferase that plays a crucial role in the regulation of gene expression. It is involved in various cellular processes, including embryonic development and hematopoiesis (the formation of blood cells).

The MLL protein is encoded by the MLL gene, which is located on chromosome 11q23. This gene is frequently rearranged or mutated in certain types of leukemia, leading to the production of abnormal fusion proteins that contribute to tumor development and progression. These MLL-rearranged leukemias are aggressive and have a poor prognosis, making them an important area of research in the field of oncology.

Immunoglobulin D (IgD) is a type of antibody that is present in the blood and other bodily fluids. It is one of the five classes of immunoglobulins (IgA, IgD, IgE, IgG, and IgM) found in humans and plays a role in the immune response.

IgD is produced by B cells, a type of white blood cell that is responsible for producing antibodies. It is primarily found on the surface of mature B cells, where it functions as a receptor for antigens (foreign substances that trigger an immune response). When an antigen binds to IgD on the surface of a B cell, it activates the B cell and stimulates it to produce and secrete antibodies specific to that antigen.

IgD is found in relatively low concentrations in the blood compared to other immunoglobulins, and its precise functions are not fully understood. However, it is thought to play a role in the regulation of B cell activation and the immune response. Additionally, some research suggests that IgD may have a direct role in protecting against certain types of infections.

It's worth noting that genetic deficiencies in IgD are not typically associated with any significant immunological abnormalities or increased susceptibility to infection.

Immunoglobulin heavy chains are proteins that make up the framework of antibodies, which are Y-shaped immune proteins. These heavy chains, along with light chains, form the antigen-binding sites of an antibody, which recognize and bind to specific foreign substances (antigens) in order to neutralize or remove them from the body.

The heavy chain is composed of a variable region, which contains the antigen-binding site, and constant regions that determine the class and function of the antibody. There are five classes of immunoglobulins (IgA, IgD, IgE, IgG, and IgM) that differ in their heavy chain constant regions and therefore have different functions in the immune response.

Immunoglobulin heavy chains are synthesized by B cells, a type of white blood cell involved in the adaptive immune response. The genetic rearrangement of immunoglobulin heavy chain genes during B cell development results in the production of a vast array of different antibodies with unique antigen-binding sites, allowing for the recognition and elimination of a wide variety of pathogens.

I'm sorry for any confusion, but "Leukemia P388" is not a widely recognized medical term or a specific type of leukemia. The term "P388" is often used to refer to a particular type of mouse leukemia that is commonly used in laboratory research for testing potential anti-cancer drugs.

Leukemia, in general, is a type of cancer that originates in the bone marrow and results in an overproduction of abnormal white blood cells (leukocytes). These abnormal cells crowd out the healthy cells in the bone marrow, leading to a weakened immune system and various complications.

There are many different types of leukemia, classified based on the type of white blood cell affected (myeloid or lymphocytic) and the speed of progression (acute or chronic). If you're looking for information about a specific type of leukemia, I would be happy to help if you could provide more details.

Bone marrow is the spongy tissue found inside certain bones in the body, such as the hips, thighs, and vertebrae. It is responsible for producing blood-forming cells, including red blood cells, white blood cells, and platelets. There are two types of bone marrow: red marrow, which is involved in blood cell production, and yellow marrow, which contains fatty tissue.

Red bone marrow contains hematopoietic stem cells, which can differentiate into various types of blood cells. These stem cells continuously divide and mature to produce new blood cells that are released into the circulation. Red blood cells carry oxygen throughout the body, white blood cells help fight infections, and platelets play a crucial role in blood clotting.

Bone marrow also serves as a site for immune cell development and maturation. It contains various types of immune cells, such as lymphocytes, macrophages, and dendritic cells, which help protect the body against infections and diseases.

Abnormalities in bone marrow function can lead to several medical conditions, including anemia, leukopenia, thrombocytopenia, and various types of cancer, such as leukemia and multiple myeloma. Bone marrow aspiration and biopsy are common diagnostic procedures used to evaluate bone marrow health and function.

C57BL/6 (C57 Black 6) is an inbred strain of laboratory mouse that is widely used in biomedical research. The term "inbred" refers to a strain of animals where matings have been carried out between siblings or other closely related individuals for many generations, resulting in a population that is highly homozygous at most genetic loci.

The C57BL/6 strain was established in 1920 by crossing a female mouse from the dilute brown (DBA) strain with a male mouse from the black strain. The resulting offspring were then interbred for many generations to create the inbred C57BL/6 strain.

C57BL/6 mice are known for their robust health, longevity, and ease of handling, making them a popular choice for researchers. They have been used in a wide range of biomedical research areas, including studies of cancer, immunology, neuroscience, cardiovascular disease, and metabolism.

One of the most notable features of the C57BL/6 strain is its sensitivity to certain genetic modifications, such as the introduction of mutations that lead to obesity or impaired glucose tolerance. This has made it a valuable tool for studying the genetic basis of complex diseases and traits.

Overall, the C57BL/6 inbred mouse strain is an important model organism in biomedical research, providing a valuable resource for understanding the genetic and molecular mechanisms underlying human health and disease.

Biphenotypic acute leukemia (BAL) is a rare subtype of acute leukemia that possesses the features of both myeloid and lymphoid lineages. It is characterized by the presence of blasts that express antigens associated with both cell lines, which can make it challenging to diagnose and treat. BAL is considered an aggressive form of leukemia and requires prompt medical attention and treatment. The exact cause of BAL is not well understood, but like other forms of leukemia, it is thought to result from genetic mutations that lead to uncontrolled cell growth and division.

A cell line is a culture of cells that are grown in a laboratory for use in research. These cells are usually taken from a single cell or group of cells, and they are able to divide and grow continuously in the lab. Cell lines can come from many different sources, including animals, plants, and humans. They are often used in scientific research to study cellular processes, disease mechanisms, and to test new drugs or treatments. Some common types of human cell lines include HeLa cells (which come from a cancer patient named Henrietta Lacks), HEK293 cells (which come from embryonic kidney cells), and HUVEC cells (which come from umbilical vein endothelial cells). It is important to note that cell lines are not the same as primary cells, which are cells that are taken directly from a living organism and have not been grown in the lab.

Friend murine leukemia virus (F-MuLV) is a type of retrovirus that specifically infects mice. It was first discovered by Charlotte Friend in the 1950s and has since been widely used as a model system to study retroviral pathogenesis, oncogenesis, and immune responses.

F-MuLV is a complex retrovirus that contains several accessory genes, including gag, pol, env, and others. The virus can cause leukemia and other malignancies in susceptible mice, particularly when it is transmitted from mother to offspring through the milk.

The virus is also known to induce immunosuppression, which makes infected mice more susceptible to other infections and diseases. F-MuLV has been used extensively in laboratory research to investigate various aspects of retroviral biology, including viral entry, replication, gene expression, and host immune responses.

It is important to note that Friend murine leukemia virus only infects mice and is not known to cause any disease in humans or other animals.

Immunophenotyping is a medical laboratory technique used to identify and classify cells, usually in the context of hematologic (blood) disorders and malignancies (cancers), based on their surface or intracellular expression of various proteins and antigens. This technique utilizes specific antibodies tagged with fluorochromes, which bind to the target antigens on the cell surface or within the cells. The labeled cells are then analyzed using flow cytometry, allowing for the detection and quantification of multiple antigenic markers simultaneously.

Immunophenotyping helps in understanding the distribution of different cell types, their subsets, and activation status, which can be crucial in diagnosing various hematological disorders, immunodeficiencies, and distinguishing between different types of leukemias, lymphomas, and other malignancies. Additionally, it can also be used to monitor the progression of diseases, evaluate the effectiveness of treatments, and detect minimal residual disease (MRD) during follow-up care.

Molecular sequence data refers to the specific arrangement of molecules, most commonly nucleotides in DNA or RNA, or amino acids in proteins, that make up a biological macromolecule. This data is generated through laboratory techniques such as sequencing, and provides information about the exact order of the constituent molecules. This data is crucial in various fields of biology, including genetics, evolution, and molecular biology, allowing for comparisons between different organisms, identification of genetic variations, and studies of gene function and regulation.

'Tumor cells, cultured' refers to the process of removing cancerous cells from a tumor and growing them in controlled laboratory conditions. This is typically done by isolating the tumor cells from a patient's tissue sample, then placing them in a nutrient-rich environment that promotes their growth and multiplication.

The resulting cultured tumor cells can be used for various research purposes, including the study of cancer biology, drug development, and toxicity testing. They provide a valuable tool for researchers to better understand the behavior and characteristics of cancer cells outside of the human body, which can lead to the development of more effective cancer treatments.

It is important to note that cultured tumor cells may not always behave exactly the same way as they do in the human body, so findings from cell culture studies must be validated through further research, such as animal models or clinical trials.

HL-60 cells are a type of human promyelocytic leukemia cell line that is commonly used in scientific research. They are named after the hospital where they were first isolated, the Hospital of the University of Pennsylvania (HUP) and the 60th culture attempt to grow these cells.

HL-60 cells have the ability to differentiate into various types of blood cells, such as granulocytes, monocytes, and macrophages, when exposed to certain chemical compounds or under specific culturing conditions. This makes them a valuable tool for studying the mechanisms of cell differentiation, proliferation, and apoptosis (programmed cell death).

HL-60 cells are also often used in toxicity studies, drug discovery and development, and research on cancer, inflammation, and infectious diseases. They can be easily grown in the lab and have a stable genotype, making them ideal for use in standardized experiments and comparisons between different studies.

CD (cluster of differentiation) antigens are cell-surface proteins that are expressed on leukocytes (white blood cells) and can be used to identify and distinguish different subsets of these cells. They are important markers in the field of immunology and hematology, and are commonly used to diagnose and monitor various diseases, including cancer, autoimmune disorders, and infectious diseases.

CD antigens are designated by numbers, such as CD4, CD8, CD19, etc., which refer to specific proteins found on the surface of different types of leukocytes. For example, CD4 is a protein found on the surface of helper T cells, while CD8 is found on cytotoxic T cells.

CD antigens can be used as targets for immunotherapy, such as monoclonal antibody therapy, in which antibodies are designed to bind to specific CD antigens and trigger an immune response against cancer cells or infected cells. They can also be used as markers to monitor the effectiveness of treatments and to detect minimal residual disease (MRD) after treatment.

It's important to note that not all CD antigens are exclusive to leukocytes, some can be found on other cell types as well, and their expression can vary depending on the activation state or differentiation stage of the cells.

B-lymphoid precursor cells, also known as progenitor B cells, are hematopoietic stem cells that have committed to the B-cell lineage and are in the process of differentiating into mature B cells. These cells originate in the bone marrow and undergo a series of developmental stages, including commitment to the B-cell lineage, rearrangement of immunoglobulin genes, expression of surface immunoglobulins, and selection for a functional B cell receptor.

B-lymphoid precursor cells can be further divided into several subsets based on their stage of differentiation and the expression of specific cell surface markers. These subsets include early pro-B cells, late pro-B cells, pre-B cells, and immature B cells. Each subset represents a distinct stage in B-cell development and is characterized by unique genetic and epigenetic features that regulate its differentiation and function.

Abnormalities in the development and differentiation of B-lymphoid precursor cells can lead to various hematological disorders, including leukemias and lymphomas. Therefore, understanding the biology of these cells is crucial for developing new therapeutic strategies for the treatment of these diseases.

Adult T-cell Leukemia/Lymphoma (ATLL) is a rare and aggressive type of cancer that affects the circulating white blood cells called T-lymphocytes or T-cells. It is caused by the human T-cell leukemia virus type 1 (HTLV-1), which infects CD4+ T-cells and leads to their malignant transformation. The disease can present as either acute or chronic leukemia, or as lymphoma, depending on the clinical features and laboratory findings.

The acute form of ATLL is characterized by the rapid proliferation of abnormal T-cells in the blood, bone marrow, and other organs. Patients with acute ATLL typically have a poor prognosis, with a median survival of only a few months. Symptoms may include skin rashes, lymphadenopathy (swollen lymph nodes), hepatosplenomegaly (enlarged liver and spleen), and hypercalcemia (high levels of calcium in the blood).

The chronic form of ATLL is less aggressive than the acute form, but it can still lead to serious complications. Chronic ATLL is characterized by the accumulation of abnormal T-cells in the blood and lymph nodes, as well as skin lesions and hypercalcemia. The median survival for patients with chronic ATLL is around two years.

ATLL can also present as a lymphoma, which is characterized by the proliferation of abnormal T-cells in the lymph nodes, spleen, and other organs. Lymphoma may occur in isolation or in combination with leukemic features.

The diagnosis of ATLL is based on clinical findings, laboratory tests, and the detection of HTLV-1 antibodies or proviral DNA in the blood or tissue samples. Treatment options for ATLL include chemotherapy, antiretroviral therapy, immunotherapy, and stem cell transplantation. The choice of treatment depends on several factors, including the patient's age, overall health, and the stage and type of ATLL.

"Cells, cultured" is a medical term that refers to cells that have been removed from an organism and grown in controlled laboratory conditions outside of the body. This process is called cell culture and it allows scientists to study cells in a more controlled and accessible environment than they would have inside the body. Cultured cells can be derived from a variety of sources, including tissues, organs, or fluids from humans, animals, or cell lines that have been previously established in the laboratory.

Cell culture involves several steps, including isolation of the cells from the tissue, purification and characterization of the cells, and maintenance of the cells in appropriate growth conditions. The cells are typically grown in specialized media that contain nutrients, growth factors, and other components necessary for their survival and proliferation. Cultured cells can be used for a variety of purposes, including basic research, drug development and testing, and production of biological products such as vaccines and gene therapies.

It is important to note that cultured cells may behave differently than they do in the body, and results obtained from cell culture studies may not always translate directly to human physiology or disease. Therefore, it is essential to validate findings from cell culture experiments using additional models and ultimately in clinical trials involving human subjects.

A base sequence in the context of molecular biology refers to the specific order of nucleotides in a DNA or RNA molecule. In DNA, these nucleotides are adenine (A), guanine (G), cytosine (C), and thymine (T). In RNA, uracil (U) takes the place of thymine. The base sequence contains genetic information that is transcribed into RNA and ultimately translated into proteins. It is the exact order of these bases that determines the genetic code and thus the function of the DNA or RNA molecule.

Cytarabine is a chemotherapeutic agent used in the treatment of various types of cancer, including leukemias and lymphomas. Its chemical name is cytosine arabinoside, and it works by interfering with the DNA synthesis of cancer cells, which ultimately leads to their death.

Cytarabine is often used in combination with other chemotherapy drugs and may be administered through various routes, such as intravenous (IV) or subcutaneous injection, or orally. The specific dosage and duration of treatment will depend on the type and stage of cancer being treated, as well as the patient's overall health status.

Like all chemotherapy drugs, cytarabine can cause a range of side effects, including nausea, vomiting, diarrhea, hair loss, and an increased risk of infection. It may also cause more serious side effects, such as damage to the liver, kidneys, or nervous system, and it is important for patients to be closely monitored during treatment to minimize these risks.

It's important to note that medical treatments should only be administered under the supervision of a qualified healthcare professional, and this information should not be used as a substitute for medical advice.

CD5 is a type of protein found on the surface of certain cells in the human body, including some immune cells like T cells and B cells. It is also known as a cell marker or identifier. Antigens are substances (usually proteins) on the surface of cells that can be recognized by the immune system, triggering an immune response.

In the context of CD5, antigens refer to foreign substances that can bind to the CD5 protein and stimulate an immune response. However, it's important to note that CD5 itself is not typically considered an antigen in the medical community. Instead, it is a marker used to identify certain types of cells and monitor their behavior in health and disease states.

In some cases, abnormal expression or regulation of CD5 has been associated with various diseases, including certain types of cancer. For example, some B-cell lymphomas may overexpress CD5, which can help doctors diagnose and monitor the progression of the disease. However, in these contexts, CD5 is not considered an antigen in the traditional sense.

BALB/c is an inbred strain of laboratory mouse that is widely used in biomedical research. The strain was developed at the Institute of Cancer Research in London by Henry Baldwin and his colleagues in the 1920s, and it has since become one of the most commonly used inbred strains in the world.

BALB/c mice are characterized by their black coat color, which is determined by a recessive allele at the tyrosinase locus. They are also known for their docile and friendly temperament, making them easy to handle and work with in the laboratory.

One of the key features of BALB/c mice that makes them useful for research is their susceptibility to certain types of tumors and immune responses. For example, they are highly susceptible to developing mammary tumors, which can be induced by chemical carcinogens or viral infection. They also have a strong Th2-biased immune response, which makes them useful models for studying allergic diseases and asthma.

BALB/c mice are also commonly used in studies of genetics, neuroscience, behavior, and infectious diseases. Because they are an inbred strain, they have a uniform genetic background, which makes it easier to control for genetic factors in experiments. Additionally, because they have been bred in the laboratory for many generations, they are highly standardized and reproducible, making them ideal subjects for scientific research.

The Immunoglobulin (Ig) variable region is the antigen-binding part of an antibody, which is highly variable in its amino acid sequence and therefore specific to a particular epitope (the site on an antigen that is recognized by the antigen-binding site of an antibody). This variability is generated during the process of V(D)J recombination in the maturation of B cells, allowing for a diverse repertoire of antibodies to be produced and recognizing a wide range of potential pathogens.

The variable region is composed of several sub-regions including:

1. The heavy chain variable region (VH)
2. The light chain variable region (VL)
3. The heavy chain joining region (JH)
4. The light chain joining region (JL)

These regions are further divided into framework regions and complementarity-determining regions (CDRs). The CDRs, particularly CDR3, contain the most variability and are primarily responsible for antigen recognition.

Precursor B-cell Acute Lymphoblastic Leukemia/Lymphoma (also known as Precursor B-cell ALL or Precursor B-cell Non-Hodgkin Lymphoma) is a type of cancer that affects the early stages of B-cell development. It is characterized by the uncontrolled proliferation of immature B-cells, also known as lymphoblasts, in the bone marrow, blood, and sometimes in other organs such as the lymph nodes. These malignant cells accumulate and interfere with the normal production of blood cells, leading to symptoms such as anemia, infection, and bleeding.

The distinction between Precursor B-cell ALL and Precursor B-cell Lymphoma is based on the site of involvement. If the majority of the cancerous cells are found in the bone marrow and/or blood, it is classified as a leukemia (ALL). However, if the malignant cells primarily involve the lymph nodes or other extramedullary sites, it is considered a lymphoma. Despite this distinction, both entities share similar biological features, treatment approaches, and prognoses.

It's important to note that medical definitions can vary slightly based on the source and context. For the most accurate information, consult authoritative resources such as medical textbooks or peer-reviewed articles.

B-cell activating factor (BAFF) is a type of protein belonging to the tumor necrosis factor (TNF) family. Its primary function is to stimulate and activate B cells, which are a type of white blood cell that plays a crucial role in the immune system by producing antibodies. BAFF helps to promote the survival, differentiation, and activation of B cells, thereby contributing to the adaptive immune response.

BAFF binds to its receptor, known as BAFF receptor (BAFF-R), which is expressed on the surface of B cells. This interaction leads to the activation of various signaling pathways that promote B cell survival and proliferation. Overexpression or excessive production of BAFF has been implicated in several autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus (SLE), and Sjogren's syndrome, due to the abnormal activation and expansion of B cells.

In summary, B-cell activating factor is a protein that plays an essential role in the activation and survival of B cells, which are crucial for the immune response. However, its overexpression or dysregulation can contribute to the development of autoimmune diseases.

The AKR murine leukemia virus (AKR MLV) is a type of retrovirus that naturally infects mice of the AKR strain. It is a member of the gammaretrovirus genus and is closely related to other murine leukemia viruses (MLVs).

AKR MLV is transmitted horizontally through close contact with infected animals, as well as vertically from mother to offspring. The virus primarily infects hematopoietic cells, including lymphocytes and macrophages, and can cause a variety of diseases, most notably leukemia and lymphoma.

The AKR MLV genome contains three main structural genes: gag, pol, and env, which encode the viral matrix, capsid, nucleocapsid, reverse transcriptase, integrase, and envelope proteins, respectively. Additionally, the virus carries accessory genes, such as rex and sor, that play a role in regulating viral gene expression and replication.

AKR MLV has been extensively studied as a model system for retrovirus biology and pathogenesis, and its study has contributed significantly to our understanding of the mechanisms of retroviral infection, replication, and disease.

Acute Megakaryoblastic Leukemia (AMKL) is a type of cancer that affects the blood and bone marrow. Specifically, it is a subtype of acute myeloid leukemia (AML), which is characterized by the rapid growth of abnormal cells in the bone marrow that interfere with the production of normal blood cells.

In AMKL, the abnormal cells are megakaryoblasts, which are immature cells that should develop into platelet-producing cells called megakaryocytes. However, in AMKL, these cells do not mature properly and instead accumulate in the bone marrow and bloodstream, leading to a shortage of healthy blood cells.

Symptoms of AMKL may include fatigue, weakness, frequent infections, easy bruising or bleeding, and the appearance of small red spots on the skin (petechiae). Diagnosis typically involves a combination of physical exam, medical history, blood tests, bone marrow aspiration and biopsy, and sometimes imaging studies.

Treatment for AMKL usually involves a combination of chemotherapy, radiation therapy, and/or stem cell transplantation. The specific treatment plan will depend on several factors, including the patient's age, overall health, and the extent of the disease.

B-lymphocyte gene rearrangement is a fundamental biological process that occurs during the development of B-lymphocytes (also known as B cells), which are a type of white blood cell responsible for producing antibodies to help fight infections. This process involves the rearrangement of genetic material within the B-lymphocyte's immunoglobulin genes, specifically the heavy chain (IgH) and light chain (IgL) genes, to create a diverse repertoire of antibodies with unique specificities.

During B-lymphocyte gene rearrangement, large segments of DNA are cut, deleted, or inverted, and then rejoined to form a functional IgH or IgL gene that encodes an antigen-binding site on the antibody molecule. The process occurs in two main steps:

1. Variable (V), diversity (D), and joining (J) gene segments are rearranged to form the heavy chain gene, which is located on chromosome 14. This results in a vast array of possible combinations, allowing for the generation of a diverse set of antibody molecules.
2. A separate variable (V) and joining (J) gene segment rearrangement occurs to form the light chain gene, which can be either kappa or lambda type, located on chromosomes 2 and 22, respectively.

Once the heavy and light chain genes are successfully rearranged, they are transcribed into mRNA and translated into immunoglobulin proteins, forming a functional antibody molecule. If the initial gene rearrangement fails to produce a functional antibody, additional attempts at rearrangement can occur, involving different combinations of V, D, and J segments or the use of alternative reading frames.

Errors in B-lymphocyte gene rearrangement can lead to various genetic disorders, such as lymphomas and leukemias, due to the production of aberrant antibodies or uncontrolled cell growth.

Apoptosis is a programmed and controlled cell death process that occurs in multicellular organisms. It is a natural process that helps maintain tissue homeostasis by eliminating damaged, infected, or unwanted cells. During apoptosis, the cell undergoes a series of morphological changes, including cell shrinkage, chromatin condensation, and fragmentation into membrane-bound vesicles called apoptotic bodies. These bodies are then recognized and engulfed by neighboring cells or phagocytic cells, preventing an inflammatory response. Apoptosis is regulated by a complex network of intracellular signaling pathways that involve proteins such as caspases, Bcl-2 family members, and inhibitors of apoptosis (IAPs).

Immunoglobulins (Igs), also known as antibodies, are proteins produced by the immune system to recognize and neutralize foreign substances such as pathogens or toxins. They are composed of four polypeptide chains: two heavy chains and two light chains, which are held together by disulfide bonds. The variable regions of the heavy and light chains contain loops that form the antigen-binding site, allowing each Ig molecule to recognize a specific epitope (antigenic determinant) on an antigen.

Genes encoding immunoglobulins are located on chromosome 14 (light chain genes) and chromosomes 22 and 2 (heavy chain genes). The diversity of the immune system is generated through a process called V(D)J recombination, where variable (V), diversity (D), and joining (J) gene segments are randomly selected and assembled to form the variable regions of the heavy and light chains. This results in an enormous number of possible combinations, allowing the immune system to recognize and respond to a vast array of potential threats.

There are five classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, each with distinct functions and structures. For example, IgG is the most abundant class in serum and provides long-term protection against pathogens, while IgA is found on mucosal surfaces and helps prevent the entry of pathogens into the body.

Lymphocyte cooperation is a term used in immunology to describe the interaction and communication between different types of lymphocytes, specifically T cells and B cells, to mount an effective immune response against pathogens.

T cells, also known as T lymphocytes, are a type of white blood cell that plays a central role in cell-mediated immunity. They can directly kill infected cells or produce cytokines that regulate the immune response. B cells, on the other hand, are responsible for humoral immunity, producing antibodies that neutralize pathogens or mark them for destruction by other immune cells.

Lymphocyte cooperation occurs when a T cell recognizes an antigen presented to it by an antigen-presenting cell (APC) in the context of major histocompatibility complex (MHC) molecules. Once activated, the T cell can then interact with B cells that have also been activated by recognizing the same antigen. The T cell provides help to the B cell by producing cytokines that stimulate its proliferation and differentiation into antibody-secreting plasma cells.

This cooperation between T and B cells is crucial for an effective immune response, as it allows for the generation of a targeted and specific response against pathogens. Defects in lymphocyte cooperation can lead to immunodeficiency or autoimmune disorders.

B-cell lymphoma is a type of cancer that originates from the B-lymphocytes, which are a part of the immune system and play a crucial role in fighting infections. These cells can develop mutations in their DNA, leading to uncontrolled growth and division, resulting in the formation of a tumor.

B-cell lymphomas can be classified into two main categories: Hodgkin's lymphoma and non-Hodgkin's lymphoma. B-cell lymphomas are further divided into subtypes based on their specific characteristics, such as the appearance of the cells under a microscope, the genetic changes present in the cancer cells, and the aggressiveness of the disease.

Some common types of B-cell lymphomas include diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and Burkitt lymphoma. Treatment options for B-cell lymphomas depend on the specific subtype, stage of the disease, and other individual factors. Treatment may include chemotherapy, radiation therapy, immunotherapy, targeted therapy, or stem cell transplantation.

A fusion protein known as "BCR-ABL" is formed due to a genetic abnormality called the Philadelphia chromosome (derived from a reciprocal translocation between chromosomes 9 and 22). This results in the formation of the oncogenic BCR-ABL tyrosine kinase, which contributes to unregulated cell growth and division, leading to chronic myeloid leukemia (CML) and some types of acute lymphoblastic leukemia (ALL). The BCR-ABL fusion protein has constitutively active tyrosine kinase activity, which results in the activation of various signaling pathways promoting cell proliferation, survival, and inhibition of apoptosis. This genetic alteration is crucial in the development and progression of CML and some types of ALL, making BCR-ABL an important therapeutic target for these malignancies.

Monoclonal antibodies are a type of antibody that are identical because they are produced by a single clone of cells. They are laboratory-produced molecules that act like human antibodies in the immune system. They can be designed to attach to specific proteins found on the surface of cancer cells, making them useful for targeting and treating cancer. Monoclonal antibodies can also be used as a therapy for other diseases, such as autoimmune disorders and inflammatory conditions.

Monoclonal antibodies are produced by fusing a single type of immune cell, called a B cell, with a tumor cell to create a hybrid cell, or hybridoma. This hybrid cell is then able to replicate indefinitely, producing a large number of identical copies of the original antibody. These antibodies can be further modified and engineered to enhance their ability to bind to specific targets, increase their stability, and improve their effectiveness as therapeutic agents.

Monoclonal antibodies have several mechanisms of action in cancer therapy. They can directly kill cancer cells by binding to them and triggering an immune response. They can also block the signals that promote cancer growth and survival. Additionally, monoclonal antibodies can be used to deliver drugs or radiation directly to cancer cells, increasing the effectiveness of these treatments while minimizing their side effects on healthy tissues.

Monoclonal antibodies have become an important tool in modern medicine, with several approved for use in cancer therapy and other diseases. They are continuing to be studied and developed as a promising approach to treating a wide range of medical conditions.

An acute disease is a medical condition that has a rapid onset, develops quickly, and tends to be short in duration. Acute diseases can range from minor illnesses such as a common cold or flu, to more severe conditions such as pneumonia, meningitis, or a heart attack. These types of diseases often have clear symptoms that are easy to identify, and they may require immediate medical attention or treatment.

Acute diseases are typically caused by an external agent or factor, such as a bacterial or viral infection, a toxin, or an injury. They can also be the result of a sudden worsening of an existing chronic condition. In general, acute diseases are distinct from chronic diseases, which are long-term medical conditions that develop slowly over time and may require ongoing management and treatment.

Examples of acute diseases include:

* Acute bronchitis: a sudden inflammation of the airways in the lungs, often caused by a viral infection.
* Appendicitis: an inflammation of the appendix that can cause severe pain and requires surgical removal.
* Gastroenteritis: an inflammation of the stomach and intestines, often caused by a viral or bacterial infection.
* Migraine headaches: intense headaches that can last for hours or days, and are often accompanied by nausea, vomiting, and sensitivity to light and sound.
* Myocardial infarction (heart attack): a sudden blockage of blood flow to the heart muscle, often caused by a buildup of plaque in the coronary arteries.
* Pneumonia: an infection of the lungs that can cause coughing, chest pain, and difficulty breathing.
* Sinusitis: an inflammation of the sinuses, often caused by a viral or bacterial infection.

It's important to note that while some acute diseases may resolve on their own with rest and supportive care, others may require medical intervention or treatment to prevent complications and promote recovery. If you are experiencing symptoms of an acute disease, it is always best to seek medical attention to ensure proper diagnosis and treatment.

Antineoplastic agents are a class of drugs used to treat malignant neoplasms or cancer. These agents work by inhibiting the growth and proliferation of cancer cells, either by killing them or preventing their division and replication. Antineoplastic agents can be classified based on their mechanism of action, such as alkylating agents, antimetabolites, topoisomerase inhibitors, mitotic inhibitors, and targeted therapy agents.

Alkylating agents work by adding alkyl groups to DNA, which can cause cross-linking of DNA strands and ultimately lead to cell death. Antimetabolites interfere with the metabolic processes necessary for DNA synthesis and replication, while topoisomerase inhibitors prevent the relaxation of supercoiled DNA during replication. Mitotic inhibitors disrupt the normal functioning of the mitotic spindle, which is essential for cell division. Targeted therapy agents are designed to target specific molecular abnormalities in cancer cells, such as mutated oncogenes or dysregulated signaling pathways.

It's important to note that antineoplastic agents can also affect normal cells and tissues, leading to various side effects such as nausea, vomiting, hair loss, and myelosuppression (suppression of bone marrow function). Therefore, the use of these drugs requires careful monitoring and management of their potential adverse effects.

Transgenic mice are genetically modified rodents that have incorporated foreign DNA (exogenous DNA) into their own genome. This is typically done through the use of recombinant DNA technology, where a specific gene or genetic sequence of interest is isolated and then introduced into the mouse embryo. The resulting transgenic mice can then express the protein encoded by the foreign gene, allowing researchers to study its function in a living organism.

The process of creating transgenic mice usually involves microinjecting the exogenous DNA into the pronucleus of a fertilized egg, which is then implanted into a surrogate mother. The offspring that result from this procedure are screened for the presence of the foreign DNA, and those that carry the desired genetic modification are used to establish a transgenic mouse line.

Transgenic mice have been widely used in biomedical research to model human diseases, study gene function, and test new therapies. They provide a valuable tool for understanding complex biological processes and developing new treatments for a variety of medical conditions.

Remission induction is a treatment approach in medicine, particularly in the field of oncology and hematology. It refers to the initial phase of therapy aimed at reducing or eliminating the signs and symptoms of active disease, such as cancer or autoimmune disorders. The primary goal of remission induction is to achieve a complete response (disappearance of all detectable signs of the disease) or a partial response (a decrease in the measurable extent of the disease). This phase of treatment is often intensive and may involve the use of multiple drugs or therapies, including chemotherapy, immunotherapy, or targeted therapy. After remission induction, patients may receive additional treatments to maintain the remission and prevent relapse, known as consolidation or maintenance therapy.

Chronic myeloid leukemia (CML) is a type of cancer that starts in certain blood-forming cells of the bone marrow. In chronic phase CML, the disease progresses slowly and may not cause any symptoms for a period of time. It is characterized by the overproduction of mature and immature white blood cells, called myeloid cells. These cells accumulate in the bone marrow and interfere with the production of normal blood cells, leading to anemia, fatigue, easy bruising, and increased risk of infection. The distinguishing genetic feature of CML is the presence of the Philadelphia chromosome, which is formed by a genetic translocation between chromosomes 9 and 22, resulting in the formation of the BCR-ABL fusion gene. This gene produces an abnormal protein that contributes to the development of leukemia. The chronic phase of CML can last for several years and is typically treated with targeted therapy such as tyrosine kinase inhibitors (TKIs) which target the BCR-ABL protein.

CD40 is a type of protein known as a tumor necrosis factor receptor that is found on the surface of various cells in the body, including B cells, dendritic cells, and activated T cells. It plays an important role in the immune system by interacting with another protein called CD154 (also known as CD40 ligand) to activate immune responses.

CD40 antigens are molecules that can stimulate an immune response when introduced into the body because they are recognized as foreign substances by the immune system. They may be used in vaccines or other immunotherapies to induce an immune response against specific targets, such as cancer cells or infectious agents.

CD40 antigens can also be found on some types of tumor cells, and activating CD40 with CD154 has been shown to enhance the anti-tumor immune response in preclinical models. Therefore, CD40 agonists are being investigated as potential cancer therapies.

In summary, CD40 antigens are proteins that can stimulate an immune response and are involved in activating immune cells. They have potential applications in vaccines, immunotherapies, and cancer treatments.

Immunoglobulins (Igs), also known as antibodies, are glycoprotein molecules produced by the immune system's B cells in response to the presence of foreign substances, such as bacteria, viruses, and toxins. These Y-shaped proteins play a crucial role in identifying and neutralizing pathogens and other antigens, thereby protecting the body against infection and disease.

Immunoglobulins are composed of four polypeptide chains: two identical heavy chains and two identical light chains, held together by disulfide bonds. The variable regions of these chains form the antigen-binding sites, which recognize and bind to specific epitopes on antigens. Based on their heavy chain type, immunoglobulins are classified into five main isotypes or classes: IgA, IgD, IgE, IgG, and IgM. Each class has distinct functions in the immune response, such as providing protection in different body fluids and tissues, mediating hypersensitivity reactions, and aiding in the development of immunological memory.

In medical settings, immunoglobulins can be administered therapeutically to provide passive immunity against certain diseases or to treat immune deficiencies, autoimmune disorders, and other conditions that may benefit from immunomodulation.

Signal transduction is the process by which a cell converts an extracellular signal, such as a hormone or neurotransmitter, into an intracellular response. This involves a series of molecular events that transmit the signal from the cell surface to the interior of the cell, ultimately resulting in changes in gene expression, protein activity, or metabolism.

The process typically begins with the binding of the extracellular signal to a receptor located on the cell membrane. This binding event activates the receptor, which then triggers a cascade of intracellular signaling molecules, such as second messengers, protein kinases, and ion channels. These molecules amplify and propagate the signal, ultimately leading to the activation or inhibition of specific cellular responses.

Signal transduction pathways are highly regulated and can be modulated by various factors, including other signaling molecules, post-translational modifications, and feedback mechanisms. Dysregulation of these pathways has been implicated in a variety of diseases, including cancer, diabetes, and neurological disorders.

Lymphoma is a type of cancer that originates from the white blood cells called lymphocytes, which are part of the immune system. These cells are found in various parts of the body such as the lymph nodes, spleen, bone marrow, and other organs. Lymphoma can be classified into two main types: Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).

HL is characterized by the presence of a specific type of abnormal lymphocyte called Reed-Sternberg cells, while NHL includes a diverse group of lymphomas that lack these cells. The symptoms of lymphoma may include swollen lymph nodes, fever, night sweats, weight loss, and fatigue.

The exact cause of lymphoma is not known, but it is believed to result from genetic mutations in the lymphocytes that lead to uncontrolled cell growth and division. Exposure to certain viruses, chemicals, and radiation may increase the risk of developing lymphoma. Treatment options for lymphoma depend on various factors such as the type and stage of the disease, age, and overall health of the patient. Common treatments include chemotherapy, radiation therapy, immunotherapy, and stem cell transplantation.

Immunoglobulin G (IgG) is a type of antibody, which is a protective protein produced by the immune system in response to foreign substances like bacteria or viruses. IgG is the most abundant type of antibody in human blood, making up about 75-80% of all antibodies. It is found in all body fluids and plays a crucial role in fighting infections caused by bacteria, viruses, and toxins.

IgG has several important functions:

1. Neutralization: IgG can bind to the surface of bacteria or viruses, preventing them from attaching to and infecting human cells.
2. Opsonization: IgG coats the surface of pathogens, making them more recognizable and easier for immune cells like neutrophils and macrophages to phagocytose (engulf and destroy) them.
3. Complement activation: IgG can activate the complement system, a group of proteins that work together to help eliminate pathogens from the body. Activation of the complement system leads to the formation of the membrane attack complex, which creates holes in the cell membranes of bacteria, leading to their lysis (destruction).
4. Antibody-dependent cellular cytotoxicity (ADCC): IgG can bind to immune cells like natural killer (NK) cells and trigger them to release substances that cause target cells (such as virus-infected or cancerous cells) to undergo apoptosis (programmed cell death).
5. Immune complex formation: IgG can form immune complexes with antigens, which can then be removed from the body through various mechanisms, such as phagocytosis by immune cells or excretion in urine.

IgG is a critical component of adaptive immunity and provides long-lasting protection against reinfection with many pathogens. It has four subclasses (IgG1, IgG2, IgG3, and IgG4) that differ in their structure, function, and distribution in the body.

A clone is a group of cells that are genetically identical to each other because they are derived from a common ancestor cell through processes such as mitosis or asexual reproduction. Therefore, the term "clone cells" refers to a population of cells that are genetic copies of a single parent cell.

In the context of laboratory research, cells can be cloned by isolating a single cell and allowing it to divide in culture, creating a population of genetically identical cells. This is useful for studying the behavior and characteristics of individual cell types, as well as for generating large quantities of cells for use in experiments.

It's important to note that while clone cells are genetically identical, they may still exhibit differences in their phenotype (physical traits) due to epigenetic factors or environmental influences.

Antigens are substances that can stimulate an immune response, particularly the production of antibodies by B-lymphocytes. Differentiation refers to the process by which cells mature and become more specialized in their functions. In the context of B-lymphocytes, differentiation involves the maturation of naive B-cells into plasma cells that are capable of producing large amounts of antibodies in response to an antigenic stimulus.

B-lymphocytes, also known as B-cells, are a type of white blood cell that plays a critical role in the adaptive immune system. They are responsible for producing antibodies, which are proteins that recognize and bind to specific antigens, marking them for destruction by other immune cells.

When a B-lymphocyte encounters an antigen, it becomes activated and begins to differentiate into a plasma cell. During this process, the B-cell undergoes several changes, including an increase in size, the expression of new surface receptors, and the production of large amounts of antibodies specific to the antigen. These antibodies are then released into the bloodstream, where they can bind to the antigen and help to neutralize or eliminate it.

Overall, the differentiation of B-lymphocytes in response to antigens is a critical component of the adaptive immune system, allowing the body to mount targeted responses to specific pathogens and other foreign substances.

'Gene rearrangement in B-lymphocytes, heavy chain' refers to the biological process that occurs during the development of B-lymphocytes (a type of white blood cell) in the bone marrow. This process involves the rearrangement of genetic material on chromosome 14, specifically within the immunoglobulin heavy chain gene locus.

During B-cell maturation, the variable region of the heavy chain gene is assembled from several gene segments, including the variable (V), diversity (D), and joining (J) segments. Through a series of genetic recombination events, these segments are randomly selected and joined together to form a unique V(D)J exon that encodes the variable region of the immunoglobulin heavy chain protein.

This gene rearrangement process allows for the generation of a diverse repertoire of antibodies with different specificities, enabling B-lymphocytes to recognize and respond to a wide range of foreign antigens. However, if errors occur during this process, it can lead to the production of autoantibodies that target the body's own cells and tissues, contributing to the development of certain immune disorders such as autoimmune diseases.

Siglec-2, also known as CD22, is a type of cell surface protein that belongs to the sialic acid-binding immunoglobulin-like lectins (Siglecs) family. It is primarily expressed on mature B cells and plays a crucial role in regulating B cell activation and function. Siglec-2 recognizes and binds to sialic acid residues on glycoproteins and gangliosides, which are sugars that are attached to proteins and lipids on the surface of cells. This binding can lead to inhibitory signals that dampen B cell activation and help prevent autoimmunity. Siglec-2 has also been implicated in the regulation of B cell migration and adhesion.

Immunologic memory, also known as adaptive immunity, refers to the ability of the immune system to recognize and mount a more rapid and effective response upon subsequent exposure to a pathogen or antigen that it has encountered before. This is a key feature of the vertebrate immune system and allows for long-term protection against infectious diseases.

Immunologic memory is mediated by specialized cells called memory T cells and B cells, which are produced during the initial response to an infection or immunization. These cells persist in the body after the pathogen has been cleared and can quickly respond to future encounters with the same or similar antigens. This rapid response leads to a more effective and efficient elimination of the pathogen, resulting in fewer symptoms and reduced severity of disease.

Immunologic memory is the basis for vaccines, which work by exposing the immune system to a harmless form of a pathogen or its components, inducing an initial response and generating memory cells that provide long-term protection against future infections.

Karyotyping is a medical laboratory test used to study the chromosomes in a cell. It involves obtaining a sample of cells from a patient, usually from blood or bone marrow, and then staining the chromosomes so they can be easily seen under a microscope. The chromosomes are then arranged in pairs based on their size, shape, and other features to create a karyotype. This visual representation allows for the identification and analysis of any chromosomal abnormalities, such as extra or missing chromosomes, or structural changes like translocations or inversions. These abnormalities can provide important information about genetic disorders, diseases, and developmental problems.

Antibody formation, also known as humoral immune response, is the process by which the immune system produces proteins called antibodies in response to the presence of a foreign substance (antigen) in the body. This process involves several steps:

1. Recognition: The antigen is recognized and bound by a type of white blood cell called a B lymphocyte or B cell, which then becomes activated.
2. Differentiation: The activated B cell undergoes differentiation to become a plasma cell, which is a type of cell that produces and secretes large amounts of antibodies.
3. Antibody production: The plasma cells produce and release antibodies, which are proteins made up of four polypeptide chains (two heavy chains and two light chains) arranged in a Y-shape. Each antibody has two binding sites that can recognize and bind to specific regions on the antigen called epitopes.
4. Neutralization or elimination: The antibodies bind to the antigens, neutralizing them or marking them for destruction by other immune cells. This helps to prevent the spread of infection and protect the body from harmful substances.

Antibody formation is an important part of the adaptive immune response, which allows the body to specifically recognize and respond to a wide variety of pathogens and foreign substances.

Prolymphocytic leukemia (PLL) is a rare and aggressive type of chronic leukemia, characterized by the abnormal accumulation of prolymphocytes, a specific type of mature but immature lymphocyte, in the blood, bone marrow, and sometimes in other organs. There are two types of PLL: B-cell prolymphocytic leukemia (B-PLL) and T-cell prolymphocytic leukemia (T-PLL).

B-PLL is a very rare subtype of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), accounting for less than 1% of all leukemias. It primarily affects older adults, with a median age at diagnosis of around 60-70 years. The disease is characterized by the proliferation of malignant B-lymphocytes, known as prolymphocytes, which accumulate in the blood, bone marrow, and sometimes in other organs such as the lymph nodes, spleen, and liver.

T-PLL is an even rarer subtype of leukemia, accounting for less than 1% of all leukemias. It primarily affects older adults, with a median age at diagnosis of around 65 years. T-PLL arises from mature T-lymphocytes, which accumulate in the blood, bone marrow, and sometimes in other organs such as the lymph nodes, spleen, and liver.

The symptoms of PLL can vary but often include fatigue, weight loss, frequent infections, swollen lymph nodes, and a high white blood cell count. The diagnosis of PLL typically involves a combination of clinical evaluation, laboratory tests, imaging studies, and bone marrow aspiration and biopsy. Treatment options for PLL may include chemotherapy, targeted therapy, immunotherapy, stem cell transplantation, or a combination of these approaches.

Plasma cell leukemia (PCL) is a rare and aggressive type of cancer that involves the uncontrolled multiplication of malignant plasma cells in the bone marrow, blood, and sometimes in other organs. Plasma cells are a type of white blood cell that produces antibodies to help fight infections. In PCL, the malignant plasma cells produce abnormal antibodies called M-proteins or paraproteins, which can accumulate in various tissues and cause damage.

PCL is typically classified into two types: primary and secondary. Primary PCL is a distinct clinical entity that presents with more than 20% plasma cells in the bone marrow and/or blood. Secondary PCL is a complication of multiple myeloma, a more common type of plasma cell cancer, and occurs when the malignant plasma cells spread from the bone marrow to the blood.

The symptoms of PCL are similar to those of other types of leukemia and may include fatigue, weakness, weight loss, frequent infections, easy bruising or bleeding, and bone pain. Diagnosis of PCL typically involves a combination of clinical evaluation, laboratory tests, imaging studies, and bone marrow aspiration and biopsy. Treatment options for PCL may include chemotherapy, stem cell transplantation, radiation therapy, and targeted therapies. The prognosis for patients with PCL is generally poor, with a median survival time of less than one year.

A "knockout" mouse is a genetically engineered mouse in which one or more genes have been deleted or "knocked out" using molecular biology techniques. This allows researchers to study the function of specific genes and their role in various biological processes, as well as potential associations with human diseases. The mice are generated by introducing targeted DNA modifications into embryonic stem cells, which are then used to create a live animal. Knockout mice have been widely used in biomedical research to investigate gene function, disease mechanisms, and potential therapeutic targets.

K562 cells are a type of human cancer cell that are commonly used in scientific research. They are derived from a patient with chronic myelogenous leukemia (CML), a type of cancer that affects the blood and bone marrow.

K562 cells are often used as a model system to study various biological processes, including cell signaling, gene expression, differentiation, and apoptosis (programmed cell death). They are also commonly used in drug discovery and development, as they can be used to test the effectiveness of potential new therapies against cancer.

K562 cells have several characteristics that make them useful for research purposes. They are easy to grow and maintain in culture, and they can be manipulated genetically to express or knock down specific genes. Additionally, K562 cells are capable of differentiating into various cell types, such as red blood cells and megakaryocytes, which allows researchers to study the mechanisms of cell differentiation.

It's important to note that while K562 cells are a valuable tool for research, they do not fully recapitulate the complexity of human CML or other cancers. Therefore, findings from studies using K562 cells should be validated in more complex model systems or in clinical trials before they can be translated into treatments for patients.

Burkitt lymphoma is a type of aggressive non-Hodgkin lymphoma (NHL), which is a cancer that originates in the lymphatic system. It is named after Denis Parsons Burkitt, an Irish surgeon who first described this form of cancer in African children in the 1950s.

Burkitt lymphoma is characterized by the rapid growth and spread of abnormal B-lymphocytes (a type of white blood cell), which can affect various organs and tissues, including the lymph nodes, spleen, liver, gastrointestinal tract, and central nervous system.

There are three main types of Burkitt lymphoma: endemic, sporadic, and immunodeficiency-associated. The endemic form is most common in equatorial Africa and is strongly associated with Epstein-Barr virus (EBV) infection. The sporadic form occurs worldwide but is rare, accounting for less than 1% of all NHL cases in the United States. Immunodeficiency-associated Burkitt lymphoma is seen in individuals with weakened immune systems due to HIV/AIDS or immunosuppressive therapy after organ transplantation.

Burkitt lymphoma typically presents as a rapidly growing mass, often involving the jaw, facial bones, or abdominal organs. Symptoms may include swollen lymph nodes, fever, night sweats, weight loss, and fatigue. Diagnosis is made through a biopsy of the affected tissue, followed by immunohistochemical staining and genetic analysis to confirm the presence of characteristic chromosomal translocations involving the MYC oncogene.

Treatment for Burkitt lymphoma typically involves intensive chemotherapy regimens, often combined with targeted therapy or immunotherapy. The prognosis is generally good when treated aggressively and promptly, with a high cure rate in children and young adults. However, the prognosis may be poorer in older patients or those with advanced-stage disease at diagnosis.

Daunorubicin is an anthracycline antibiotic used in the treatment of various types of cancer, including leukemia, Hodgkin's lymphoma, and breast cancer. It works by intercalating with DNA and inhibiting topoisomerase II, which results in DNA damage and ultimately cell death.

The drug is administered intravenously and may cause side effects such as nausea, vomiting, hair loss, mouth sores, and damage to the heart muscle (cardiotoxicity) with long-term use. Regular monitoring of cardiac function is recommended during treatment with daunorubicin.

It's important to note that this medication should only be used under the supervision of a qualified healthcare professional, as it can have serious and potentially life-threatening consequences if not used correctly.

The B-cell activation factor receptor, also known as BAFF-R or CD268, is a protein found on the surface of B cells, which are a type of white blood cell that plays a key role in the immune system. The BAFF-R receptor binds to a protein called BAFF (B-cell activating factor), which is a member of the tumor necrosis factor (TNF) family.

When BAFF binds to BAFF-R, it triggers a series of intracellular signaling events that promote the survival, activation, and differentiation of B cells. This interaction is critical for the normal development and function of the immune system, as it helps to maintain the balance between the proliferation and deletion of B cells.

However, abnormal activation of the BAFF-R pathway has been implicated in several autoimmune diseases, including rheumatoid arthritis, lupus, and Sjogren's syndrome. In these conditions, excessive levels of BAFF can lead to the overactivation of B cells, resulting in the production of autoantibodies that attack the body's own tissues.

Therefore, therapies that target the BAFF-R pathway are being investigated as potential treatments for autoimmune diseases. These include monoclonal antibodies that bind to BAFF or BAFF-R and block their interaction, as well as small molecule inhibitors that interfere with downstream signaling events.

Hematopoietic stem cells (HSCs) are immature, self-renewing cells that give rise to all the mature blood and immune cells in the body. They are capable of both producing more hematopoietic stem cells (self-renewal) and differentiating into early progenitor cells that eventually develop into red blood cells, white blood cells, and platelets. HSCs are found in the bone marrow, umbilical cord blood, and peripheral blood. They have the ability to repair damaged tissues and offer significant therapeutic potential for treating various diseases, including hematological disorders, genetic diseases, and cancer.

Accelerated Phase Leukemia, Myeloid is a stage in the progression of certain myeloid malignancies such as Chronic Myelogenous Leukemia (CML) or Myelodysplastic Syndromes (MDS). During this phase, there is an increase in the number of immature blood cells (blasts) in the bone marrow and/or blood compared to the chronic phase. However, it has not yet reached the level of blast proliferation seen in the blast crisis phase.

The accelerated phase is characterized by various laboratory and clinical features, including:
- A significant increase in the percentage of blasts (10-19%) in the peripheral blood or bone marrow
- An increase in the white blood cell count, typically over 50 x 10^9/L
- The presence of new cytogenetic abnormalities or an increasing number of existing chromosomal changes
- A decrease in platelet count and/or hemoglobin levels
- Increasing symptoms related to bone marrow failure, such as fatigue, infection, and bleeding

The accelerated phase often precedes the blast crisis phase, which is associated with a worse prognosis. Early detection and intervention in the accelerated phase may help improve treatment outcomes and delay progression to blast crisis.

A neoplasm is a tumor or growth that is formed by an abnormal and excessive proliferation of cells, which can be benign or malignant. Neoplasm proteins are therefore any proteins that are expressed or produced in these neoplastic cells. These proteins can play various roles in the development, progression, and maintenance of neoplasms.

Some neoplasm proteins may contribute to the uncontrolled cell growth and division seen in cancer, such as oncogenic proteins that promote cell cycle progression or inhibit apoptosis (programmed cell death). Others may help the neoplastic cells evade the immune system, allowing them to proliferate undetected. Still others may be involved in angiogenesis, the formation of new blood vessels that supply the tumor with nutrients and oxygen.

Neoplasm proteins can also serve as biomarkers for cancer diagnosis, prognosis, or treatment response. For example, the presence or level of certain neoplasm proteins in biological samples such as blood or tissue may indicate the presence of a specific type of cancer, help predict the likelihood of cancer recurrence, or suggest whether a particular therapy will be effective.

Overall, understanding the roles and behaviors of neoplasm proteins can provide valuable insights into the biology of cancer and inform the development of new diagnostic and therapeutic strategies.

Cell division is the process by which a single eukaryotic cell (a cell with a true nucleus) divides into two identical daughter cells. This complex process involves several stages, including replication of DNA, separation of chromosomes, and division of the cytoplasm. There are two main types of cell division: mitosis and meiosis.

Mitosis is the type of cell division that results in two genetically identical daughter cells. It is a fundamental process for growth, development, and tissue repair in multicellular organisms. The stages of mitosis include prophase, prometaphase, metaphase, anaphase, and telophase, followed by cytokinesis, which divides the cytoplasm.

Meiosis, on the other hand, is a type of cell division that occurs in the gonads (ovaries and testes) during the production of gametes (sex cells). Meiosis results in four genetically unique daughter cells, each with half the number of chromosomes as the parent cell. This process is essential for sexual reproduction and genetic diversity. The stages of meiosis include meiosis I and meiosis II, which are further divided into prophase, prometaphase, metaphase, anaphase, and telophase.

In summary, cell division is the process by which a single cell divides into two daughter cells, either through mitosis or meiosis. This process is critical for growth, development, tissue repair, and sexual reproduction in multicellular organisms.

A mutation is a permanent change in the DNA sequence of an organism's genome. Mutations can occur spontaneously or be caused by environmental factors such as exposure to radiation, chemicals, or viruses. They may have various effects on the organism, ranging from benign to harmful, depending on where they occur and whether they alter the function of essential proteins. In some cases, mutations can increase an individual's susceptibility to certain diseases or disorders, while in others, they may confer a survival advantage. Mutations are the driving force behind evolution, as they introduce new genetic variability into populations, which can then be acted upon by natural selection.

Immunoglobulin mu-chains (IgM) are a type of heavy chain found in immunoglobulins, also known as antibodies. IgM is the first antibody to be produced in response to an initial exposure to an antigen and plays a crucial role in the early stages of the immune response.

IgM antibodies are composed of four monomeric units, each consisting of two heavy chains and two light chains. The heavy chains in IgM are called mu-chains, which have a molecular weight of approximately 72 kDa. Each mu-chain contains five domains: one variable (V) domain at the N-terminus, four constant (C) domains (Cμ1-4), and a membrane-spanning region followed by a short cytoplasmic tail.

IgM antibodies are primarily found on the surface of B cells as part of the B cell receptor (BCR). When a B cell encounters an antigen, the BCR binds to it, triggering a series of intracellular signaling events that lead to B cell activation and differentiation into plasma cells. In response to activation, the B cell begins to secrete IgM antibodies into the bloodstream.

IgM antibodies have several unique features that make them effective in the early stages of an immune response. They are highly efficient at agglutination, or clumping together, of pathogens and antigens, which helps to neutralize them. IgM antibodies also activate the complement system, a group of proteins that work together to destroy pathogens.

Overall, Immunoglobulin mu-chains are an essential component of the immune system, providing early protection against pathogens and initiating the adaptive immune response.

Messenger RNA (mRNA) is a type of RNA (ribonucleic acid) that carries genetic information copied from DNA in the form of a series of three-base code "words," each of which specifies a particular amino acid. This information is used by the cell's machinery to construct proteins, a process known as translation. After being transcribed from DNA, mRNA travels out of the nucleus to the ribosomes in the cytoplasm where protein synthesis occurs. Once the protein has been synthesized, the mRNA may be degraded and recycled. Post-transcriptional modifications can also occur to mRNA, such as alternative splicing and addition of a 5' cap and a poly(A) tail, which can affect its stability, localization, and translation efficiency.

A cell line that is derived from tumor cells and has been adapted to grow in culture. These cell lines are often used in research to study the characteristics of cancer cells, including their growth patterns, genetic changes, and responses to various treatments. They can be established from many different types of tumors, such as carcinomas, sarcomas, and leukemias. Once established, these cell lines can be grown and maintained indefinitely in the laboratory, allowing researchers to conduct experiments and studies that would not be feasible using primary tumor cells. It is important to note that tumor cell lines may not always accurately represent the behavior of the original tumor, as they can undergo genetic changes during their time in culture.

CD27 is a protein that is found on the surface of certain immune cells, including T cells and B cells. It is a type of molecule known as a cell-surface antigen, which can be recognized by other immune cells and used to target those cells for activation or destruction. CD27 plays a role in the regulation of the immune response, particularly in the activation and differentiation of T cells.

CD27 is also a member of the tumor necrosis factor receptor (TNFR) superfamily, which means that it has a specific structure and function that allows it to interact with other molecules called ligands. The interaction between CD27 and its ligand, CD70, helps to activate T cells and promote their survival and proliferation.

In addition to its role in the immune response, CD27 has also been studied as a potential target for cancer immunotherapy. Because CD27 is expressed on certain types of tumor cells, it may be possible to use therapies that target CD27 to stimulate an immune response against the tumor and help to destroy it. However, more research is needed to determine the safety and effectiveness of these approaches.

T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive type of leukemia, which is a cancer that affects the blood and bone marrow. Specifically, T-PLL arises from mature T-cells, a type of white blood cell that plays a crucial role in the body's immune response.

In T-PLL, there is an accumulation of abnormal prolymphocytes, a particular stage of T-cell development, in the peripheral blood, bone marrow, and sometimes lymph nodes and spleen. These malignant cells can crowd out healthy cells, leading to impaired immune function, anemia, and increased susceptibility to infections.

T-PLL is primarily a disease of older adults, with a median age at diagnosis around 65 years. It has a poor prognosis, with a median survival of less than two years, although treatment advances have improved outcomes for some patients. Treatment typically involves chemotherapy and/or stem cell transplantation.

DNA-binding proteins are a type of protein that have the ability to bind to DNA (deoxyribonucleic acid), the genetic material of organisms. These proteins play crucial roles in various biological processes, such as regulation of gene expression, DNA replication, repair and recombination.

The binding of DNA-binding proteins to specific DNA sequences is mediated by non-covalent interactions, including electrostatic, hydrogen bonding, and van der Waals forces. The specificity of binding is determined by the recognition of particular nucleotide sequences or structural features of the DNA molecule.

DNA-binding proteins can be classified into several categories based on their structure and function, such as transcription factors, histones, and restriction enzymes. Transcription factors are a major class of DNA-binding proteins that regulate gene expression by binding to specific DNA sequences in the promoter region of genes and recruiting other proteins to modulate transcription. Histones are DNA-binding proteins that package DNA into nucleosomes, the basic unit of chromatin structure. Restriction enzymes are DNA-binding proteins that recognize and cleave specific DNA sequences, and are widely used in molecular biology research and biotechnology applications.

"Gene rearrangement" is a process that involves the alteration of the order, orientation, or copy number of genes or gene segments within an organism's genome. This natural mechanism plays a crucial role in generating diversity and specificity in the immune system, particularly in vertebrates.

In the context of the immune system, gene rearrangement occurs during the development of B-cells and T-cells, which are responsible for adaptive immunity. The process involves breaking and rejoining DNA segments that encode antigen recognition sites, resulting in a unique combination of gene segments and creating a vast array of possible antigen receptors.

There are two main types of gene rearrangement:

1. V(D)J recombination: This process occurs in both B-cells and T-cells. It involves the recombination of variable (V), diversity (D), and joining (J) gene segments to form a functional antigen receptor gene. In humans, there are multiple copies of V, D, and J segments for each antigen receptor gene, allowing for a vast number of possible combinations.
2. Class switch recombination: This process occurs only in mature B-cells after antigen exposure. It involves the replacement of the constant (C) region of the immunoglobulin heavy chain gene with another C region, resulting in the production of different isotypes of antibodies (IgG, IgA, or IgE) that have distinct effector functions while maintaining the same antigen specificity.

These processes contribute to the generation of a diverse repertoire of antigen receptors, allowing the immune system to recognize and respond effectively to a wide range of pathogens.

Cell survival refers to the ability of a cell to continue living and functioning normally, despite being exposed to potentially harmful conditions or treatments. This can include exposure to toxins, radiation, chemotherapeutic drugs, or other stressors that can damage cells or interfere with their normal processes.

In scientific research, measures of cell survival are often used to evaluate the effectiveness of various therapies or treatments. For example, researchers may expose cells to a particular drug or treatment and then measure the percentage of cells that survive to assess its potential therapeutic value. Similarly, in toxicology studies, measures of cell survival can help to determine the safety of various chemicals or substances.

It's important to note that cell survival is not the same as cell proliferation, which refers to the ability of cells to divide and multiply. While some treatments may promote cell survival, they may also inhibit cell proliferation, making them useful for treating diseases such as cancer. Conversely, other treatments may be designed to specifically target and kill cancer cells, even if it means sacrificing some healthy cells in the process.

Complement receptor 3d (CR3d or CD11b/CD18) is not a medical definition in itself, but rather a specific type of integrin receptor that plays a crucial role in the immune system. Here's a breakdown of the components:

1. Complement Receptors: These are proteins found on the surface of various cells, including white blood cells (leukocytes), that recognize and bind to complement components, which are proteins involved in the immune response. The binding of complement components to their receptors helps facilitate communication between cells, enhances phagocytosis (the process by which certain cells engulf and destroy foreign particles or microorganisms), and contributes to the inflammatory response.
2. CR3 (Complement Receptor 3): Complement Receptor 3 is a heterodimeric receptor composed of two subunits, CD11b (also known as integrin alpha M) and CD18 (also known as integrin beta 2). Together, they form the integrin Mac-1 or αMβ2.
3. CR3d (CD11b/CD18): CR3d specifically refers to the CD11b subunit of the Complement Receptor 3 heterodimer. The CD11b subunit is responsible for recognizing and binding to complement component C3b, iC3b, and C4b fragments, as well as other ligands such as fibrinogen, ICAM-1 (Intercellular Adhesion Molecule 1), and factor X.

In summary, Complement Receptor 3d (CR3d or CD11b/CD18) is a type of integrin receptor found on the surface of various immune cells that recognizes and binds to complement components C3b, iC3b, and C4b fragments, as well as other ligands. This binding facilitates communication between cells, enhances phagocytosis, and contributes to the inflammatory response.

Transcription factors are proteins that play a crucial role in regulating gene expression by controlling the transcription of DNA to messenger RNA (mRNA). They function by binding to specific DNA sequences, known as response elements, located in the promoter region or enhancer regions of target genes. This binding can either activate or repress the initiation of transcription, depending on the properties and interactions of the particular transcription factor. Transcription factors often act as part of a complex network of regulatory proteins that determine the precise spatiotemporal patterns of gene expression during development, differentiation, and homeostasis in an organism.

Human T-lymphotropic virus 1 (HTLV-1) is a complex retrovirus that infects CD4+ T lymphocytes and can cause adult T-cell leukemia/lymphoma (ATLL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). The virus is primarily transmitted through breastfeeding, sexual contact, or contaminated blood products. After infection, the virus integrates into the host's genome and can remain latent for years or even decades before leading to disease. HTLV-1 is endemic in certain regions of the world, including Japan, the Caribbean, Central and South America, and parts of Africa.

Core Binding Factor Alpha 2 Subunit, also known as CBF-A2 or CEBP-α, is a protein that forms a complex with other proteins to act as a transcription factor. Transcription factors are proteins that help regulate the expression of genes by binding to specific DNA sequences and controlling the rate of transcription of genetic information from DNA to RNA.

CBF-A2 is a member of the CCAAT/enhancer-binding protein (C/EBP) family of transcription factors, which are important in regulating various biological processes such as cell growth, development, and inflammation. CBF-A2 forms a heterodimer with Core Binding Factor Beta (CBF-β) to form the active transcription factor complex known as the core binding factor (CBF).

The CBF complex binds to the CCAAT box, a specific DNA sequence found in the promoter regions of many genes. By binding to this sequence, the CBF complex can either activate or repress the transcription of target genes, depending on the context and the presence of other regulatory factors.

Mutations in the gene encoding CBF-A2 have been associated with several human diseases, including acute myeloid leukemia (AML) and multiple myeloma. In AML, mutations in the CBF-A2 gene can lead to the formation of abnormal CBF complexes that disrupt normal gene expression patterns and contribute to the development of leukemia.

CD79 is a type of protein that is found on the surface of B cells, which are a type of white blood cell that plays a key role in the immune system. CD79 combines with another protein called CD19 to form a complex that helps to activate B cells and initiate an immune response when the body encounters an antigen.

An antigen is any substance that can stimulate an immune response, particularly the production of antibodies. Antigens can be proteins, polysaccharides, or other molecules found on the surface of viruses, bacteria, or other foreign substances. When a B cell encounters an antigen, it engulfs and processes the antigen, then displays a portion of it on its surface along with CD79 and CD19. This helps to activate the B cell and stimulate it to divide and differentiate into plasma cells, which produce and secrete large amounts of antibodies that recognize and bind to the antigen.

CD79 is an important marker for identifying and studying B cells, and it has been implicated in various B-cell malignancies such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).

Cell proliferation is the process by which cells increase in number, typically through the process of cell division. In the context of biology and medicine, it refers to the reproduction of cells that makes up living tissue, allowing growth, maintenance, and repair. It involves several stages including the transition from a phase of quiescence (G0 phase) to an active phase (G1 phase), DNA replication in the S phase, and mitosis or M phase, where the cell divides into two daughter cells.

Abnormal or uncontrolled cell proliferation is a characteristic feature of many diseases, including cancer, where deregulated cell cycle control leads to excessive and unregulated growth of cells, forming tumors that can invade surrounding tissues and metastasize to distant sites in the body.

CD40 ligand (CD40L or CD154) is a type II transmembrane protein and a member of the tumor necrosis factor (TNF) superfamily. It is primarily expressed on activated CD4+ T cells, but can also be found on other immune cells such as activated B cells, macrophages, and dendritic cells.

CD40 ligand binds to its receptor, CD40, which is mainly expressed on the surface of antigen-presenting cells (APCs) such as B cells, dendritic cells, and macrophages. The interaction between CD40L and CD40 plays a crucial role in the activation and regulation of the immune response.

CD40L-CD40 signaling is essential for T cell-dependent B cell activation, antibody production, and class switching. It also contributes to the activation and maturation of dendritic cells, promoting their ability to stimulate T cell responses. Dysregulation of CD40L-CD40 signaling has been implicated in various autoimmune diseases, transplant rejection, and cancer.

Proto-oncogene proteins are normal cellular proteins that play crucial roles in various cellular processes, such as signal transduction, cell cycle regulation, and apoptosis (programmed cell death). They are involved in the regulation of cell growth, differentiation, and survival under physiological conditions.

When proto-oncogene proteins undergo mutations or aberrations in their expression levels, they can transform into oncogenic forms, leading to uncontrolled cell growth and division. These altered proteins are then referred to as oncogene products or oncoproteins. Oncogenic mutations can occur due to various factors, including genetic predisposition, environmental exposures, and aging.

Examples of proto-oncogene proteins include:

1. Ras proteins: Involved in signal transduction pathways that regulate cell growth and differentiation. Activating mutations in Ras genes are found in various human cancers.
2. Myc proteins: Regulate gene expression related to cell cycle progression, apoptosis, and metabolism. Overexpression of Myc proteins is associated with several types of cancer.
3. EGFR (Epidermal Growth Factor Receptor): A transmembrane receptor tyrosine kinase that regulates cell proliferation, survival, and differentiation. Mutations or overexpression of EGFR are linked to various malignancies, such as lung cancer and glioblastoma.
4. Src family kinases: Intracellular tyrosine kinases that regulate signal transduction pathways involved in cell proliferation, survival, and migration. Dysregulation of Src family kinases is implicated in several types of cancer.
5. Abl kinases: Cytoplasmic tyrosine kinases that regulate various cellular processes, including cell growth, differentiation, and stress responses. Aberrant activation of Abl kinases, as seen in chronic myelogenous leukemia (CML), leads to uncontrolled cell proliferation.

Understanding the roles of proto-oncogene proteins and their dysregulation in cancer development is essential for developing targeted cancer therapies that aim to inhibit or modulate these aberrant signaling pathways.

Bone marrow transplantation (BMT) is a medical procedure in which damaged or destroyed bone marrow is replaced with healthy bone marrow from a donor. Bone marrow is the spongy tissue inside bones that produces blood cells. The main types of BMT are autologous, allogeneic, and umbilical cord blood transplantation.

In autologous BMT, the patient's own bone marrow is used for the transplant. This type of BMT is often used in patients with lymphoma or multiple myeloma who have undergone high-dose chemotherapy or radiation therapy to destroy their cancerous bone marrow.

In allogeneic BMT, bone marrow from a genetically matched donor is used for the transplant. This type of BMT is often used in patients with leukemia, lymphoma, or other blood disorders who have failed other treatments.

Umbilical cord blood transplantation involves using stem cells from umbilical cord blood as a source of healthy bone marrow. This type of BMT is often used in children and adults who do not have a matched donor for allogeneic BMT.

The process of BMT typically involves several steps, including harvesting the bone marrow or stem cells from the donor, conditioning the patient's body to receive the new bone marrow or stem cells, transplanting the new bone marrow or stem cells into the patient's body, and monitoring the patient for signs of engraftment and complications.

BMT is a complex and potentially risky procedure that requires careful planning, preparation, and follow-up care. However, it can be a life-saving treatment for many patients with blood disorders or cancer.

Somatic hypermutation is a process that occurs in the immune system, specifically within B cells, which are a type of white blood cell responsible for producing antibodies. This process involves the introduction of point mutations into the immunoglobulin (Ig) genes, which encode for the variable regions of antibodies.

Somatic hypermutation occurs in the germinal centers of lymphoid follicles in response to antigen stimulation. The activation-induced cytidine deaminase (AID) enzyme is responsible for initiating this process by deaminating cytosines to uracils in the Ig genes. This leads to the introduction of point mutations during DNA replication and repair, which can result in changes to the antibody's binding affinity for the antigen.

The somatic hypermutation process allows for the selection of B cells with higher affinity antibodies that can better recognize and neutralize pathogens. This is an important mechanism for the development of humoral immunity and the generation of long-lived memory B cells. However, excessive or aberrant somatic hypermutation can also contribute to the development of certain types of B cell malignancies, such as lymphomas and leukemias.

An epitope is a specific region on an antigen (a substance that triggers an immune response) that is recognized and bound by an antibody or a B-lymphocyte (a type of white blood cell that produces antibodies). Epitopes are also sometimes referred to as antigenic determinants.

B-lymphocytes, or B cells, are a type of immune cell that plays a key role in the humoral immune response. They produce and secrete antibodies, which are proteins that recognize and bind to specific epitopes on antigens. When a B cell encounters an antigen, it binds to the antigen at its surface receptor, which recognizes a specific epitope on the antigen. This binding activates the B cell, causing it to divide and differentiate into plasma cells, which produce and secrete large amounts of antibody that is specific for the epitope on the antigen.

The ability of an antibody or a B cell to recognize and bind to a specific epitope is determined by the structure of the variable region of the antibody or B cell receptor. The variable region is made up of several loops of amino acids, called complementarity-determining regions (CDRs), that form a binding site for the antigen. The CDRs are highly variable in sequence and length, allowing them to recognize and bind to a wide variety of different epitopes.

In summary, an epitope is a specific region on an antigen that is recognized and bound by an antibody or a B-lymphocyte. The ability of an antibody or a B cell to recognize and bind to a specific epitope is determined by the structure of the variable region of the antibody or B cell receptor.

Precursor T-cell lymphoblastic leukemia-lymphoma (previously known as T-cell acute lymphoblastic leukemia/lymphoma or T-ALL) is a type of cancer that affects the early stages of T-cell development. It is characterized by the uncontrolled proliferation and accumulation of malignant precursor T-cell lymphoblasts in the bone marrow, blood, and sometimes in other organs such as the lymph nodes, spleen, and liver. These malignant cells can interfere with the normal functioning of the bone marrow and immune system, leading to symptoms like fatigue, frequent infections, and anemia. The distinction between precursor T-cell lymphoblastic leukemia and lymphoma is based on the extent of involvement of extramedullary sites (like lymph nodes) and the proportion of bone marrow involvement. Treatment typically involves intensive chemotherapy regimens, with possible additional treatments such as stem cell transplantation or targeted therapy depending on the individual case.

Immunoglobulin kappa-chains are one of the two types of light chains (the other being lambda-chains) that make up an immunoglobulin molecule, also known as an antibody. These light chains combine with heavy chains to form the antigen-binding site of an antibody, which is responsible for recognizing and binding to specific antigens or foreign substances in the body.

Kappa-chains contain a variable region that differs between different antibodies and contributes to the diversity of the immune system's response to various antigens. They also have a constant region, which is consistent across all kappa-chains. Approximately 60% of all human antibodies contain kappa-chains, while the remaining 40% contain lambda-chains. The relative proportions of kappa and lambda chains can be used in diagnostic tests to identify clonal expansions of B cells, which may indicate a malignancy such as multiple myeloma or lymphoma.

Surface antigens are molecules found on the surface of cells that can be recognized by the immune system as being foreign or different from the host's own cells. Antigens are typically proteins or polysaccharides that are capable of stimulating an immune response, leading to the production of antibodies and activation of immune cells such as T-cells.

Surface antigens are important in the context of infectious diseases because they allow the immune system to identify and target infected cells for destruction. For example, viruses and bacteria often display surface antigens that are distinct from those found on host cells, allowing the immune system to recognize and attack them. In some cases, these surface antigens can also be used as targets for vaccines or other immunotherapies.

In addition to their role in infectious diseases, surface antigens are also important in the context of cancer. Tumor cells often display abnormal surface antigens that differ from those found on normal cells, allowing the immune system to potentially recognize and attack them. However, tumors can also develop mechanisms to evade the immune system, making it difficult to mount an effective response.

Overall, understanding the properties and behavior of surface antigens is crucial for developing effective immunotherapies and vaccines against infectious diseases and cancer.

An amino acid sequence is the specific order of amino acids in a protein or peptide molecule, formed by the linking of the amino group (-NH2) of one amino acid to the carboxyl group (-COOH) of another amino acid through a peptide bond. The sequence is determined by the genetic code and is unique to each type of protein or peptide. It plays a crucial role in determining the three-dimensional structure and function of proteins.

Leukemic infiltration is the abnormal spread and accumulation of malignant white blood cells (leukemia cells) in various tissues and organs outside the bone marrow. The bone marrow is the spongy tissue inside bones where blood cells are normally produced. In leukemia, the bone marrow produces large numbers of abnormal white blood cells that do not function properly. These abnormal cells can sometimes spill into the bloodstream and infiltrate other organs, such as the lymph nodes, spleen, liver, and central nervous system (brain and spinal cord). Leukemic infiltration can cause damage to these organs and lead to various symptoms. The pattern of organ involvement and the severity of infiltration depend on the type and stage of leukemia.

Juvenile Myelomonocytic Leukemia (JMML) is a rare and aggressive type of childhood leukemia, characterized by the overproduction of myeloid and monocytic white blood cells in the bone marrow. These cells accumulate in the bloodstream, leading to an increased risk of infection, anemia, and bleeding. JMML is different from other types of leukemia because it involves both the myeloid and monocytic cell lines, and it often affects younger children, typically those under 4 years old. The exact cause of JMML is not fully understood, but it has been linked to genetic mutations in certain genes, such as PTPN11, NRAS, KRAS, CBL, and NF1. Treatment for JMML usually involves a combination of chemotherapy, stem cell transplantation, and supportive care.

Membrane glycoproteins are proteins that contain oligosaccharide chains (glycans) covalently attached to their polypeptide backbone. They are integral components of biological membranes, spanning the lipid bilayer and playing crucial roles in various cellular processes.

The glycosylation of these proteins occurs in the endoplasmic reticulum (ER) and Golgi apparatus during protein folding and trafficking. The attached glycans can vary in structure, length, and composition, which contributes to the diversity of membrane glycoproteins.

Membrane glycoproteins can be classified into two main types based on their orientation within the lipid bilayer:

1. Type I (N-linked): These glycoproteins have a single transmembrane domain and an extracellular N-terminus, where the oligosaccharides are predominantly attached via asparagine residues (Asn-X-Ser/Thr sequon).
2. Type II (C-linked): These glycoproteins possess two transmembrane domains and an intracellular C-terminus, with the oligosaccharides linked to tryptophan residues via a mannose moiety.

Membrane glycoproteins are involved in various cellular functions, such as:

* Cell adhesion and recognition
* Receptor-mediated signal transduction
* Enzymatic catalysis
* Transport of molecules across membranes
* Cell-cell communication
* Immunological responses

Some examples of membrane glycoproteins include cell surface receptors (e.g., growth factor receptors, cytokine receptors), adhesion molecules (e.g., integrins, cadherins), and transporters (e.g., ion channels, ABC transporters).

FMS-like tyrosine kinase 3 (FLT3) is a type of receptor tyrosine kinase, which is a type of enzyme that plays a role in signal transduction within cells. FLT3 is found on the surface of certain types of blood cells, including hematopoietic stem cells and some types of leukemia cells.

FLT3 is activated when it binds to its ligand, FLT3L, leading to activation of various signaling pathways that are involved in cell survival, proliferation, and differentiation. Mutations in the FLT3 gene can lead to constitutive activation of the receptor, even in the absence of its ligand, resulting in uncontrolled cell growth and division. Such mutations are commonly found in certain types of leukemia, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), and are associated with a poor prognosis.

FLT3 inhibitors are a class of drugs that are being developed to target FLT3 mutations in leukemia cells, with the goal of blocking the abnormal signaling pathways that contribute to the growth and survival of these cancer cells.

CXCR5 is a type of chemokine receptor that is primarily expressed on the surface of certain immune cells, including B cells and some T cells. It belongs to the family of G protein-coupled receptors (GPCRs) and plays a crucial role in the trafficking and homing of these immune cells to specific tissues in the body.

CXCR5 specifically binds to a chemokine ligand called CXCL13, which is produced by various cell types, including stromal cells in lymphoid organs. The binding of CXCL13 to CXCR5 triggers a signaling cascade that leads to the activation of several downstream signaling pathways, ultimately resulting in the migration and accumulation of immune cells in the vicinity of the CXCL13 source.

In the context of the immune system, CXCR5 is essential for the formation of germinal centers, which are specialized structures within lymphoid organs where B cells undergo activation, proliferation, and differentiation into antibody-secreting plasma cells. The interaction between CXCL13 and CXCR5 helps to recruit B cells and follicular T helper (Tfh) cells to the germinal center, where they can engage in productive interactions that drive humoral immune responses.

Abnormalities in CXCR5 signaling have been implicated in various pathological conditions, including autoimmune diseases, cancer, and infectious diseases. Therefore, understanding the molecular mechanisms underlying CXCR5 function is of great interest for the development of novel therapeutic strategies to target these disorders.

The Abelson murine leukemia virus (Abelson murine leukemia virus, or A-MuLV) is a type of retrovirus that can cause cancer in mice. It was first discovered in 1970 and has since been widely studied as a model system for understanding the mechanisms of retroviral infection and cancer development.

A-MuLV is named after Peter Nowell and David A. Harrison, who first described the virus and its ability to cause leukemia in mice. The virus contains an oncogene called "v-abl," which encodes a tyrosine kinase enzyme that can activate various signaling pathways involved in cell growth and division. When the v-abl oncogene is integrated into the genome of an infected mouse cell, it can cause uncontrolled cell growth and division, leading to the development of leukemia.

A-MuLV has been used extensively in laboratory research to study the molecular mechanisms of cancer development and to develop new therapies for treating cancer. It has also been used as a tool for introducing specific genetic modifications into mouse cells, allowing researchers to study the effects of those modifications on cell behavior and function.

'Gene rearrangement in B-lymphocytes, light chain' refers to the biological process that occurs during the development of B-lymphocytes (a type of white blood cell) in the bone marrow. Specifically, it relates to the rearrangement of genes that code for the light chains of immunoglobulins, which are antibodies that help the immune system recognize and fight off foreign substances.

During gene rearrangement, the variable region genes of the light chain locus (which consist of multiple gene segments, including V, D, and J segments) undergo a series of DNA recombination events to form a functional variable region exon. This process allows for the generation of a vast diversity of antibody molecules with different specificities, enabling the immune system to recognize and respond to a wide range of potential threats.

Abnormalities in this gene rearrangement process can lead to various immunodeficiency disorders or malignancies such as B-cell lymphomas.

Lymphocytes are a type of white blood cell that is an essential part of the immune system. They are responsible for recognizing and responding to potentially harmful substances such as viruses, bacteria, and other foreign invaders. There are two main types of lymphocytes: B-lymphocytes (B-cells) and T-lymphocytes (T-cells).

B-lymphocytes produce antibodies, which are proteins that help to neutralize or destroy foreign substances. When a B-cell encounters a foreign substance, it becomes activated and begins to divide and differentiate into plasma cells, which produce and secrete large amounts of antibodies. These antibodies bind to the foreign substance, marking it for destruction by other immune cells.

T-lymphocytes, on the other hand, are involved in cell-mediated immunity. They directly attack and destroy infected cells or cancerous cells. T-cells can also help to regulate the immune response by producing chemical signals that activate or inhibit other immune cells.

Lymphocytes are produced in the bone marrow and mature in either the bone marrow (B-cells) or the thymus gland (T-cells). They circulate throughout the body in the blood and lymphatic system, where they can be found in high concentrations in lymph nodes, the spleen, and other lymphoid organs.

Abnormalities in the number or function of lymphocytes can lead to a variety of immune-related disorders, including immunodeficiency diseases, autoimmune disorders, and cancer.

Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a laboratory technique used in molecular biology to amplify and detect specific DNA sequences. This technique is particularly useful for the detection and quantification of RNA viruses, as well as for the analysis of gene expression.

The process involves two main steps: reverse transcription and polymerase chain reaction (PCR). In the first step, reverse transcriptase enzyme is used to convert RNA into complementary DNA (cDNA) by reading the template provided by the RNA molecule. This cDNA then serves as a template for the PCR amplification step.

In the second step, the PCR reaction uses two primers that flank the target DNA sequence and a thermostable polymerase enzyme to repeatedly copy the targeted cDNA sequence. The reaction mixture is heated and cooled in cycles, allowing the primers to anneal to the template, and the polymerase to extend the new strand. This results in exponential amplification of the target DNA sequence, making it possible to detect even small amounts of RNA or cDNA.

RT-PCR is a sensitive and specific technique that has many applications in medical research and diagnostics, including the detection of viruses such as HIV, hepatitis C virus, and SARS-CoV-2 (the virus that causes COVID-19). It can also be used to study gene expression, identify genetic mutations, and diagnose genetic disorders.

Acute basophilic leukemia (ABL) is a rare and aggressive subtype of acute myeloid leukemia (AML), a type of cancer that affects the blood and bone marrow. In ABL, the malignancy originates from the transformation of hematopoietic stem cells into abnormal blast cells, specifically basophils, in the bone marrow. These blasts proliferate rapidly and disrupt normal blood cell production, leading to a significant decrease in functional red and white blood cells and platelets.

The medical definition of acute basophilic leukemia is:

A malignant neoplasm of hematopoietic stem cells characterized by the uncontrolled proliferation and accumulation of immature basophils (basophilic blasts) in the bone marrow, blood, and occasionally other tissues. This rapidly progressing disorder is accompanied by a decline in the production of normal blood cells, resulting in symptoms such as anemia, fatigue, infection, easy bruising, and bleeding. The diagnosis of ABL typically involves bone marrow aspiration and biopsy, cytogenetic analysis, immunophenotyping, and molecular genetic testing to confirm the presence of leukemic blasts and identify specific genetic abnormalities that can inform prognosis and treatment decisions.

Anti-idiotypic antibodies are a type of immune protein that recognizes and binds to the unique identifying region (idiotype) of another antibody. These antibodies are produced by the immune system as part of a regulatory feedback mechanism, where they can modulate or inhibit the activity of the original antibody. They have been studied for their potential use in immunotherapy and vaccine development.

Retroviridae is a family of viruses that includes human immunodeficiency virus (HIV) and other viruses that primarily use RNA as their genetic material. The name "retrovirus" comes from the fact that these viruses reverse transcribe their RNA genome into DNA, which then becomes integrated into the host cell's genome. This is a unique characteristic of retroviruses, as most other viruses use DNA as their genetic material.

Retroviruses can cause a variety of diseases in animals and humans, including cancer, neurological disorders, and immunodeficiency syndromes like AIDS. They have a lipid membrane envelope that contains glycoprotein spikes, which allow them to attach to and enter host cells. Once inside the host cell, the viral RNA is reverse transcribed into DNA by the enzyme reverse transcriptase, which is then integrated into the host genome by the enzyme integrase.

Retroviruses can remain dormant in the host genome for extended periods of time, and may be reactivated under certain conditions to produce new viral particles. This ability to integrate into the host genome has also made retroviruses useful tools in molecular biology, where they are used as vectors for gene therapy and other genetic manipulations.

Polymerase Chain Reaction (PCR) is a laboratory technique used to amplify specific regions of DNA. It enables the production of thousands to millions of copies of a particular DNA sequence in a rapid and efficient manner, making it an essential tool in various fields such as molecular biology, medical diagnostics, forensic science, and research.

The PCR process involves repeated cycles of heating and cooling to separate the DNA strands, allow primers (short sequences of single-stranded DNA) to attach to the target regions, and extend these primers using an enzyme called Taq polymerase, resulting in the exponential amplification of the desired DNA segment.

In a medical context, PCR is often used for detecting and quantifying specific pathogens (viruses, bacteria, fungi, or parasites) in clinical samples, identifying genetic mutations or polymorphisms associated with diseases, monitoring disease progression, and evaluating treatment effectiveness.

Cell separation is a process used to separate and isolate specific cell types from a heterogeneous mixture of cells. This can be accomplished through various physical or biological methods, depending on the characteristics of the cells of interest. Some common techniques for cell separation include:

1. Density gradient centrifugation: In this method, a sample containing a mixture of cells is layered onto a density gradient medium and then centrifuged. The cells are separated based on their size, density, and sedimentation rate, with denser cells settling closer to the bottom of the tube and less dense cells remaining near the top.

2. Magnetic-activated cell sorting (MACS): This technique uses magnetic beads coated with antibodies that bind to specific cell surface markers. The labeled cells are then passed through a column placed in a magnetic field, which retains the magnetically labeled cells while allowing unlabeled cells to flow through.

3. Fluorescence-activated cell sorting (FACS): In this method, cells are stained with fluorochrome-conjugated antibodies that recognize specific cell surface or intracellular markers. The stained cells are then passed through a laser beam, which excites the fluorophores and allows for the detection and sorting of individual cells based on their fluorescence profile.

4. Filtration: This simple method relies on the physical size differences between cells to separate them. Cells can be passed through filters with pore sizes that allow smaller cells to pass through while retaining larger cells.

5. Enzymatic digestion: In some cases, cells can be separated by enzymatically dissociating tissues into single-cell suspensions and then using various separation techniques to isolate specific cell types.

These methods are widely used in research and clinical settings for applications such as isolating immune cells, stem cells, or tumor cells from biological samples.

Inbred strains of mice are defined as lines of mice that have been brother-sister mated for at least 20 consecutive generations. This results in a high degree of homozygosity, where the mice of an inbred strain are genetically identical to one another, with the exception of spontaneous mutations.

Inbred strains of mice are widely used in biomedical research due to their genetic uniformity and stability, which makes them useful for studying the genetic basis of various traits, diseases, and biological processes. They also provide a consistent and reproducible experimental system, as compared to outbred or genetically heterogeneous populations.

Some commonly used inbred strains of mice include C57BL/6J, BALB/cByJ, DBA/2J, and 129SvEv. Each strain has its own unique genetic background and phenotypic characteristics, which can influence the results of experiments. Therefore, it is important to choose the appropriate inbred strain for a given research question.

Chromosome aberrations refer to structural and numerical changes in the chromosomes that can occur spontaneously or as a result of exposure to mutagenic agents. These changes can affect the genetic material encoded in the chromosomes, leading to various consequences such as developmental abnormalities, cancer, or infertility.

Structural aberrations include deletions, duplications, inversions, translocations, and rings, which result from breaks and rearrangements of chromosome segments. Numerical aberrations involve changes in the number of chromosomes, such as aneuploidy (extra or missing chromosomes) or polyploidy (multiples of a complete set of chromosomes).

Chromosome aberrations can be detected and analyzed using various cytogenetic techniques, including karyotyping, fluorescence in situ hybridization (FISH), and comparative genomic hybridization (CGH). These methods allow for the identification and characterization of chromosomal changes at the molecular level, providing valuable information for genetic counseling, diagnosis, and research.

Asparaginase is a medication that is used in the treatment of certain types of cancer, such as acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). It is an enzyme that breaks down the amino acid asparagine, which is a building block of proteins. Some cancer cells are unable to produce their own asparagine and rely on obtaining it from the bloodstream. By reducing the amount of asparagine in the blood, asparaginase can help to slow or stop the growth of these cancer cells.

Asparaginase is usually given as an injection into a muscle (intramuscularly) or into a vein (intravenously). It may be given alone or in combination with other chemotherapy drugs. The specific dosage and duration of treatment will depend on the individual's medical history, the type and stage of cancer being treated, and how well the person tolerates the medication.

Like all medications, asparaginase can cause side effects. Common side effects include nausea, vomiting, loss of appetite, and changes in liver function tests. Less common but more serious side effects may include allergic reactions, pancreatitis, and blood clotting problems. It is important for patients to discuss the potential risks and benefits of asparaginase with their healthcare provider before starting treatment.

T-independent antigens are types of antigens that can stimulate an immune response without the help of T cells. They are typically small molecules with repetitive structures, such as polysaccharides found on bacterial cell walls, that can directly activate B cells through their surface receptors. This results in the production of antibodies specific to the antigen, but it does not lead to the development of immunological memory. Therefore, immunity to T-independent antigens is usually short-lived and provides limited protection against future infections.

SCID mice is an acronym for Severe Combined Immunodeficiency mice. These are genetically modified mice that lack a functional immune system due to the mutation or knockout of several key genes required for immunity. This makes them ideal for studying the human immune system, infectious diseases, and cancer, as well as testing new therapies and treatments in a controlled environment without the risk of interference from the mouse's own immune system. SCID mice are often used in xenotransplantation studies, where human cells or tissues are transplanted into the mouse to study their behavior and interactions with the human immune system.

The Philadelphia chromosome is a specific genetic alteration in certain types of leukemia and lymphoma, including chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). It is the result of a translocation between chromosomes 9 and 22, which forms an abnormal fusion gene called BCR-ABL. This gene produces an abnormal protein that leads to unregulated cell growth and division, causing cancer. The Philadelphia chromosome was first discovered in Philadelphia, USA, hence the name.

Prognosis is a medical term that refers to the prediction of the likely outcome or course of a disease, including the chances of recovery or recurrence, based on the patient's symptoms, medical history, physical examination, and diagnostic tests. It is an important aspect of clinical decision-making and patient communication, as it helps doctors and patients make informed decisions about treatment options, set realistic expectations, and plan for future care.

Prognosis can be expressed in various ways, such as percentages, categories (e.g., good, fair, poor), or survival rates, depending on the nature of the disease and the available evidence. However, it is important to note that prognosis is not an exact science and may vary depending on individual factors, such as age, overall health status, and response to treatment. Therefore, it should be used as a guide rather than a definitive forecast.

Antineoplastic combined chemotherapy protocols refer to a treatment plan for cancer that involves the use of more than one antineoplastic (chemotherapy) drug given in a specific sequence and schedule. The combination of drugs is used because they may work better together to destroy cancer cells compared to using a single agent alone. This approach can also help to reduce the likelihood of cancer cells becoming resistant to the treatment.

The choice of drugs, dose, duration, and frequency are determined by various factors such as the type and stage of cancer, patient's overall health, and potential side effects. Combination chemotherapy protocols can be used in various settings, including as a primary treatment, adjuvant therapy (given after surgery or radiation to kill any remaining cancer cells), neoadjuvant therapy (given before surgery or radiation to shrink the tumor), or palliative care (to alleviate symptoms and prolong survival).

It is important to note that while combined chemotherapy protocols can be effective in treating certain types of cancer, they can also cause significant side effects, including nausea, vomiting, hair loss, fatigue, and an increased risk of infection. Therefore, patients undergoing such treatment should be closely monitored and managed by a healthcare team experienced in administering chemotherapy.

Lymphoid tissue is a specialized type of connective tissue that is involved in the immune function of the body. It is composed of lymphocytes (a type of white blood cell), which are responsible for producing antibodies and destroying infected or cancerous cells. Lymphoid tissue can be found throughout the body, but it is particularly concentrated in certain areas such as the lymph nodes, spleen, tonsils, and Peyer's patches in the small intestine.

Lymphoid tissue provides a site for the activation, proliferation, and differentiation of lymphocytes, which are critical components of the adaptive immune response. It also serves as a filter for foreign particles, such as bacteria and viruses, that may enter the body through various routes. The lymphatic system, which includes lymphoid tissue, helps to maintain the health and integrity of the body by protecting it from infection and disease.

A lymphocyte count is a laboratory test that measures the number of white blood cells called lymphocytes in a sample of blood. Lymphocytes are a vital part of the immune system and help fight off infections and diseases. A normal lymphocyte count ranges from 1,000 to 4,800 cells per microliter (µL) of blood for adults.

An abnormal lymphocyte count can indicate an infection, immune disorder, or blood cancer. A low lymphocyte count is called lymphopenia, while a high lymphocyte count is called lymphocytosis. The cause of an abnormal lymphocyte count should be investigated through further testing and clinical evaluation.

Autoantibodies are defined as antibodies that are produced by the immune system and target the body's own cells, tissues, or organs. These antibodies mistakenly identify certain proteins or molecules in the body as foreign invaders and attack them, leading to an autoimmune response. Autoantibodies can be found in various autoimmune diseases such as rheumatoid arthritis, lupus, and thyroiditis. The presence of autoantibodies can also be used as a diagnostic marker for certain conditions.

"Preleukemia" is a term that was used historically to describe conditions characterized by the presence of preleukemic cells or certain genetic changes that could potentially progress into acute leukemia. However, this terminology has largely been replaced in modern medicine.

Currently, the preferred terms are "clonal hematopoiesis" or "clonal cytopenias of undetermined significance (CCUS)" for conditions where there is an expansion of blood cells with certain genetic mutations but without evidence of progression to acute leukemia.

One example of this is a condition called "clonal hematopoiesis of indeterminate potential" (CHIP), which is defined by the presence of certain somatic mutations in hematopoietic stem cells, but without evidence of cytopenias or progression to malignancy.

It's important to note that not all individuals with CHIP will develop leukemia, and many may never experience any symptoms related to this condition. However, the presence of CHIP has been associated with an increased risk of hematologic cancers, as well as cardiovascular disease.

Chronic myeloid leukemia (CML), atypical, BCR-ABL negative is a rare subtype of CML that does not have the typical Philadelphia chromosome abnormality or the resulting BCR-ABL fusion gene. This means that the disease lacks the constitutively active tyrosine kinase that is targeted by imatinib mesylate (Gleevec) and other similar drugs.

The atypical form of CML is often characterized by a more aggressive clinical course, with a higher risk of transformation to acute leukemia compared to the classic form of CML. It can be difficult to diagnose and treat due to its rarity and heterogeneity. Treatment options may include chemotherapy, targeted therapy, stem cell transplantation, or a combination of these approaches. Regular follow-up with blood tests and bone marrow examinations is essential for monitoring the disease course and adjusting treatment as necessary.

The "Graft versus Leukemia (GvL) Effect" is a term used in the field of hematopoietic stem cell transplantation to describe a desirable outcome where the donor's immune cells (graft) recognize and attack the recipient's leukemia cells (host). This effect occurs when the donor's T-lymphocytes, natural killer cells, and other immune cells become activated against the recipient's malignant cells.

The GvL effect is often observed in patients who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT), where the donor and recipient are not genetically identical. The genetic disparity between the donor and recipient creates an environment that allows for the recognition of host leukemia cells as foreign, triggering an immune response against them.

While the GvL effect can be beneficial in eliminating residual leukemia cells, it can also lead to complications such as graft-versus-host disease (GvHD), where the donor's immune cells attack the recipient's healthy tissues. Balancing the GvL effect and minimizing GvHD remains a significant challenge in allo-HSCT.

Medical Definition of "Herpesvirus 4, Human" (Epstein-Barr Virus)

"Herpesvirus 4, Human," also known as Epstein-Barr virus (EBV), is a member of the Herpesviridae family and is one of the most common human viruses. It is primarily transmitted through saliva and is often referred to as the "kissing disease."

EBV is the causative agent of infectious mononucleosis (IM), also known as glandular fever, which is characterized by symptoms such as fatigue, sore throat, fever, and swollen lymph nodes. The virus can also cause other diseases, including certain types of cancer, such as Burkitt's lymphoma, Hodgkin's lymphoma, and nasopharyngeal carcinoma.

Once a person becomes infected with EBV, the virus remains in the body for the rest of their life, residing in certain white blood cells called B lymphocytes. In most people, the virus remains dormant and does not cause any further symptoms. However, in some individuals, the virus may reactivate, leading to recurrent or persistent symptoms.

EBV infection is diagnosed through various tests, including blood tests that detect antibodies against the virus or direct detection of the virus itself through polymerase chain reaction (PCR) assays. There is no cure for EBV infection, and treatment is generally supportive, focusing on relieving symptoms and managing complications. Prevention measures include practicing good hygiene, avoiding close contact with infected individuals, and not sharing personal items such as toothbrushes or drinking glasses.

Interleukin-4 (IL-4) is a type of cytokine, which is a cell signaling molecule that mediates communication between cells in the immune system. Specifically, IL-4 is produced by activated T cells and mast cells, among other cells, and plays an important role in the differentiation and activation of immune cells called Th2 cells.

Th2 cells are involved in the immune response to parasites, as well as in allergic reactions. IL-4 also promotes the growth and survival of B cells, which produce antibodies, and helps to regulate the production of certain types of antibodies. In addition, IL-4 has anti-inflammatory effects and can help to downregulate the immune response in some contexts.

Defects in IL-4 signaling have been implicated in a number of diseases, including asthma, allergies, and certain types of cancer.

Autoimmunity is a medical condition in which the body's immune system mistakenly attacks and destroys healthy tissues within the body. In normal function, the immune system recognizes and fights off foreign substances such as bacteria, viruses, and toxins. However, when autoimmunity occurs, the immune system identifies self-molecules or tissues as foreign and produces an immune response against them.

This misguided response can lead to chronic inflammation, tissue damage, and impaired organ function. Autoimmune diseases can affect various parts of the body, including the joints, skin, glands, muscles, and blood vessels. Some common examples of autoimmune diseases are rheumatoid arthritis, lupus, multiple sclerosis, type 1 diabetes, Hashimoto's thyroiditis, and Graves' disease.

The exact cause of autoimmunity is not fully understood, but it is believed to involve a combination of genetic, environmental, and lifestyle factors that trigger an abnormal immune response in susceptible individuals. Treatment for autoimmune diseases typically involves managing symptoms, reducing inflammation, and suppressing the immune system's overactive response using medications such as corticosteroids, immunosuppressants, and biologics.

A phenotype is the physical or biochemical expression of an organism's genes, or the observable traits and characteristics resulting from the interaction of its genetic constitution (genotype) with environmental factors. These characteristics can include appearance, development, behavior, and resistance to disease, among others. Phenotypes can vary widely, even among individuals with identical genotypes, due to differences in environmental influences, gene expression, and genetic interactions.

Neoplastic stem cells, also known as cancer stem cells (CSCs), are a subpopulation of cells within a tumor that are capable of self-renewal and generating the heterogeneous lineages of cells that comprise the tumor. These cells are believed to be responsible for the initiation, maintenance, and progression of cancer, as well as its recurrence and resistance to therapy.

CSCs share some similarities with normal stem cells, such as their ability to divide asymmetrically and give rise to differentiated progeny. However, they also have distinct characteristics that distinguish them from their normal counterparts, including aberrant gene expression, altered signaling pathways, and increased resistance to apoptosis (programmed cell death).

The existence of CSCs has important implications for cancer diagnosis, treatment, and prevention. Targeting these cells specifically may be necessary to achieve durable remissions and prevent relapse, as they are thought to survive conventional therapies that target the bulk of the tumor. Further research is needed to better understand the biology of CSCs and develop effective strategies for their elimination.

Retroviridae infections refer to diseases caused by retroviruses, which are a type of virus that integrates its genetic material into the DNA of the host cell. This allows the virus to co-opt the cell's own machinery to produce new viral particles and infect other cells.

Some well-known retroviruses include human immunodeficiency virus (HIV), which causes AIDS, and human T-lymphotropic virus (HTLV), which can cause certain types of cancer and neurological disorders.

Retroviral infections can have a range of clinical manifestations depending on the specific virus and the host's immune response. HIV infection, for example, is characterized by progressive immunodeficiency that makes the infected individual susceptible to a wide range of opportunistic infections and cancers. HTLV infection, on the other hand, can cause adult T-cell leukemia/lymphoma or tropical spastic paraparesis, a neurological disorder.

Prevention and treatment strategies for retroviral infections depend on the specific virus but may include antiretroviral therapy (ART), vaccination, and behavioral modifications to reduce transmission risk.

Neoplastic cell transformation is a process in which a normal cell undergoes genetic alterations that cause it to become cancerous or malignant. This process involves changes in the cell's DNA that result in uncontrolled cell growth and division, loss of contact inhibition, and the ability to invade surrounding tissues and metastasize (spread) to other parts of the body.

Neoplastic transformation can occur as a result of various factors, including genetic mutations, exposure to carcinogens, viral infections, chronic inflammation, and aging. These changes can lead to the activation of oncogenes or the inactivation of tumor suppressor genes, which regulate cell growth and division.

The transformation of normal cells into cancerous cells is a complex and multi-step process that involves multiple genetic and epigenetic alterations. It is characterized by several hallmarks, including sustained proliferative signaling, evasion of growth suppressors, resistance to cell death, enabling replicative immortality, induction of angiogenesis, activation of invasion and metastasis, reprogramming of energy metabolism, and evading immune destruction.

Neoplastic cell transformation is a fundamental concept in cancer biology and is critical for understanding the molecular mechanisms underlying cancer development and progression. It also has important implications for cancer diagnosis, prognosis, and treatment, as identifying the specific genetic alterations that underlie neoplastic transformation can help guide targeted therapies and personalized medicine approaches.

Protein-Tyrosine Kinases (PTKs) are a type of enzyme that plays a crucial role in various cellular functions, including signal transduction, cell growth, differentiation, and metabolism. They catalyze the transfer of a phosphate group from ATP to the tyrosine residues of proteins, thereby modifying their activity, localization, or interaction with other molecules.

PTKs can be divided into two main categories: receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (NRTKs). RTKs are transmembrane proteins that become activated upon binding to specific ligands, such as growth factors or hormones. NRTKs, on the other hand, are intracellular enzymes that can be activated by various signals, including receptor-mediated signaling and intracellular messengers.

Dysregulation of PTK activity has been implicated in several diseases, such as cancer, diabetes, and inflammatory disorders. Therefore, PTKs are important targets for drug development and therapy.

A residual neoplasm is a term used in pathology and oncology to describe the remaining abnormal tissue or cancer cells after a surgical procedure or treatment aimed at completely removing a tumor. This means that some cancer cells have been left behind and continue to persist in the body. The presence of residual neoplasm can increase the risk of recurrence or progression of the disease, as these remaining cells may continue to grow and divide.

Residual neoplasm is often assessed during follow-up appointments and monitoring, using imaging techniques like CT scans, MRIs, or PET scans, and sometimes through biopsies. The extent of residual neoplasm can influence the choice of further treatment options, such as additional surgery, radiation therapy, chemotherapy, or targeted therapies, to eliminate the remaining cancer cells and reduce the risk of recurrence.

Leukemia Inhibitory Factor Receptor alpha Subunit (LIFR-α) is a protein that forms part of the Leukemia Inhibitory Factor (LIF) receptor complex. LIF is a cytokine, or signaling molecule, that plays important roles in various biological processes such as cell differentiation, survival, and proliferation.

The LIFR-α subunit combines with the glycoprotein 130 (gp130) subunit to form a functional receptor for LIF. When LIF binds to this receptor complex, it triggers a series of intracellular signaling events that ultimately regulate gene expression and cell behavior.

Mutations in the LIFR-α gene have been associated with certain diseases, including some forms of cancer. For example, reduced expression of LIFR-α has been observed in leukemia cells, suggesting that it may play a role in the development or progression of this disease. However, more research is needed to fully understand the functional significance of LIFR-α and its role in human health and disease.

In the field of medicine, "time factors" refer to the duration of symptoms or time elapsed since the onset of a medical condition, which can have significant implications for diagnosis and treatment. Understanding time factors is crucial in determining the progression of a disease, evaluating the effectiveness of treatments, and making critical decisions regarding patient care.

For example, in stroke management, "time is brain," meaning that rapid intervention within a specific time frame (usually within 4.5 hours) is essential to administering tissue plasminogen activator (tPA), a clot-busting drug that can minimize brain damage and improve patient outcomes. Similarly, in trauma care, the "golden hour" concept emphasizes the importance of providing definitive care within the first 60 minutes after injury to increase survival rates and reduce morbidity.

Time factors also play a role in monitoring the progression of chronic conditions like diabetes or heart disease, where regular follow-ups and assessments help determine appropriate treatment adjustments and prevent complications. In infectious diseases, time factors are crucial for initiating antibiotic therapy and identifying potential outbreaks to control their spread.

Overall, "time factors" encompass the significance of recognizing and acting promptly in various medical scenarios to optimize patient outcomes and provide effective care.

Recurrence, in a medical context, refers to the return of symptoms or signs of a disease after a period of improvement or remission. It indicates that the condition has not been fully eradicated and may require further treatment. Recurrence is often used to describe situations where a disease such as cancer comes back after initial treatment, but it can also apply to other medical conditions. The likelihood of recurrence varies depending on the type of disease and individual patient factors.

Proto-oncogene proteins c-bcl-2 are a group of proteins that play a role in regulating cell death (apoptosis). The c-bcl-2 gene produces one of these proteins, which helps to prevent cells from undergoing apoptosis. This protein is located on the membrane of mitochondria and endoplasmic reticulum and it can inhibit the release of cytochrome c, a key player in the activation of caspases, which are enzymes that trigger apoptosis.

In normal cells, the regulation of c-bcl-2 protein helps to maintain a balance between cell proliferation and cell death, ensuring proper tissue homeostasis. However, when the c-bcl-2 gene is mutated or its expression is dysregulated, it can contribute to cancer development by allowing cancer cells to survive and proliferate. High levels of c-bcl-2 protein have been found in many types of cancer, including leukemia, lymphoma, and carcinomas, and are often associated with a poor prognosis.

Antibody-producing cells, also known as plasma cells, are a type of white blood cell that is responsible for producing and secreting antibodies in response to a foreign substance or antigen. These cells are derived from B lymphocytes, which become activated upon encountering an antigen and differentiate into plasma cells.

Once activated, plasma cells can produce large amounts of specific antibodies that bind to the antigen, marking it for destruction by other immune cells. Antibody-producing cells play a crucial role in the body's humoral immune response, which helps protect against infection and disease.

The term "DNA, neoplasm" is not a standard medical term or concept. DNA refers to deoxyribonucleic acid, which is the genetic material present in the cells of living organisms. A neoplasm, on the other hand, is a tumor or growth of abnormal tissue that can be benign (non-cancerous) or malignant (cancerous).

In some contexts, "DNA, neoplasm" may refer to genetic alterations found in cancer cells. These genetic changes can include mutations, amplifications, deletions, or rearrangements of DNA sequences that contribute to the development and progression of cancer. Identifying these genetic abnormalities can help doctors diagnose and treat certain types of cancer more effectively.

However, it's important to note that "DNA, neoplasm" is not a term that would typically be used in medical reports or research papers without further clarification. If you have any specific questions about DNA changes in cancer cells or neoplasms, I would recommend consulting with a healthcare professional or conducting further research on the topic.

Growth inhibitors, in a medical context, refer to substances or agents that reduce or prevent the growth and proliferation of cells. They play an essential role in regulating normal cellular growth and can be used in medical treatments to control the excessive growth of unwanted cells, such as cancer cells.

There are two main types of growth inhibitors:

1. Endogenous growth inhibitors: These are naturally occurring molecules within the body that help regulate cell growth and division. Examples include retinoids, which are vitamin A derivatives, and interferons, which are signaling proteins released by host cells in response to viruses.

2. Exogenous growth inhibitors: These are synthetic or natural substances from outside the body that can be used to inhibit cell growth. Many chemotherapeutic agents and targeted therapies for cancer treatment fall into this category. They work by interfering with specific pathways involved in cell division, such as DNA replication or mitosis, or by inducing apoptosis (programmed cell death) in cancer cells.

It is important to note that growth inhibitors may also affect normal cells, which can lead to side effects during treatment. The challenge for medical researchers is to develop targeted therapies that specifically inhibit the growth of abnormal cells while minimizing harm to healthy cells.

Drug resistance in neoplasms (also known as cancer drug resistance) refers to the ability of cancer cells to withstand the effects of chemotherapeutic agents or medications designed to kill or inhibit the growth of cancer cells. This can occur due to various mechanisms, including changes in the cancer cell's genetic makeup, alterations in drug targets, increased activity of drug efflux pumps, and activation of survival pathways.

Drug resistance can be intrinsic (present at the beginning of treatment) or acquired (developed during the course of treatment). It is a significant challenge in cancer therapy as it often leads to reduced treatment effectiveness, disease progression, and poor patient outcomes. Strategies to overcome drug resistance include the use of combination therapies, development of new drugs that target different mechanisms, and personalized medicine approaches that consider individual patient and tumor characteristics.

Immunoglobulin light chains are the smaller protein subunits of an immunoglobulin, also known as an antibody. They are composed of two polypeptide chains, called kappa (κ) and lambda (λ), which are produced by B cells during the immune response. Each immunoglobulin molecule contains either two kappa or two lambda light chains, in association with two heavy chains.

Light chains play a crucial role in the antigen-binding site of an antibody, where they contribute to the specificity and affinity of the interaction between the antibody and its target antigen. In addition to their role in immune function, abnormal production or accumulation of light chains can lead to various diseases, such as multiple myeloma and amyloidosis.

Cytogenetic analysis is a laboratory technique used to identify and study the structure and function of chromosomes, which are the structures in the cell that contain genetic material. This type of analysis involves examining the number, size, shape, and banding pattern of chromosomes in cells, typically during metaphase when they are at their most condensed state.

There are several methods used for cytogenetic analysis, including karyotyping, fluorescence in situ hybridization (FISH), and comparative genomic hybridization (CGH). Karyotyping involves staining the chromosomes with a dye to visualize their banding patterns and then arranging them in pairs based on their size and shape. FISH uses fluorescent probes to label specific DNA sequences, allowing for the detection of genetic abnormalities such as deletions, duplications, or translocations. CGH compares the DNA content of two samples to identify differences in copy number, which can be used to detect chromosomal imbalances.

Cytogenetic analysis is an important tool in medical genetics and is used for a variety of purposes, including prenatal diagnosis, cancer diagnosis and monitoring, and the identification of genetic disorders.

'Gene expression regulation' refers to the processes that control whether, when, and where a particular gene is expressed, meaning the production of a specific protein or functional RNA encoded by that gene. This complex mechanism can be influenced by various factors such as transcription factors, chromatin remodeling, DNA methylation, non-coding RNAs, and post-transcriptional modifications, among others. Proper regulation of gene expression is crucial for normal cellular function, development, and maintaining homeostasis in living organisms. Dysregulation of gene expression can lead to various diseases, including cancer and genetic disorders.

Treatment outcome is a term used to describe the result or effect of medical treatment on a patient's health status. It can be measured in various ways, such as through symptoms improvement, disease remission, reduced disability, improved quality of life, or survival rates. The treatment outcome helps healthcare providers evaluate the effectiveness of a particular treatment plan and make informed decisions about future care. It is also used in clinical research to compare the efficacy of different treatments and improve patient care.

B-cell-specific activator protein, also known as BASP1, is a protein that belongs to the family of intracellular signaling molecules called "activator proteins." It is specifically expressed in B cells, which are a type of white blood cell that plays a central role in the immune system.

BASP1 has been shown to interact with several other proteins involved in signal transduction pathways and regulation of gene expression. It has been implicated in various cellular processes, including cell proliferation, differentiation, and survival. Dysregulation of BASP1 has been associated with certain diseases, such as cancer and autoimmune disorders.

In B cells, BASP1 is involved in regulating the activation and differentiation of these cells in response to antigen stimulation. It has been shown to interact with the B-cell receptor (BCR) complex and modulate its signaling pathways. Additionally, BASP1 may play a role in the development and progression of certain B-cell malignancies, such as lymphomas and leukemias.

Overall, while further research is needed to fully understand the functions and mechanisms of BASP1 in B cells, it is clear that this protein plays an important role in regulating immune responses and maintaining homeostasis in the body.

Immunoglobulin lambda-chains (Igλ) are one type of light chain found in the immunoglobulins, also known as antibodies. Antibodies are proteins that play a crucial role in the immune system's response to foreign substances, such as bacteria and viruses.

Immunoglobulins are composed of two heavy chains and two light chains, which are interconnected by disulfide bonds. There are two types of light chains: kappa (κ) and lambda (λ). Igλ chains are one type of light chain that can be found in association with heavy chains to form functional antibodies.

Igλ chains contain a variable region, which is responsible for recognizing and binding to specific antigens, and a constant region, which determines the class of the immunoglobulin (e.g., IgA, IgD, IgE, IgG, or IgM).

In humans, approximately 60% of all antibodies contain Igλ chains, while the remaining 40% contain Igκ chains. The ratio of Igλ to Igκ chains can vary depending on the type of immunoglobulin and its function in the immune response.

Large granular lymphocytic (LGL) leukemia is a rare type of blood cancer that affects a specific group of white blood cells called large granular lymphocytes (LGLs), which include both T-cell and natural killer (NK) cell populations. This disorder is characterized by an abnormal increase in the number of these LGL cells in the peripheral blood, bone marrow, and spleen.

In LGL leukemia, the overproduction of these abnormal lymphocytes can lead to cytopenias (low counts) of one or more types of blood cells, such as anemia, neutropenia, or thrombocytopenia. These cytopenias are caused by the abnormal LGL cells infiltrating and disrupting the normal function of the bone marrow, where blood cells are produced.

There are two main types of large granular lymphocytic leukemia: T-cell LGL leukemia and natural killer (NK)-cell LGL leukemia. The T-cell type is more common and tends to have a better prognosis compared to the NK-cell type.

Symptoms of LGL leukemia can vary but may include fatigue, recurrent infections, easy bruising or bleeding, and enlarged lymph nodes. The diagnosis typically involves a combination of blood tests, bone marrow aspiration and biopsy, and sometimes immunophenotyping to identify the specific type of LGL cells involved. Treatment options may include chemotherapy, immunosuppressive therapy, or targeted therapies, depending on the individual case and the patient's overall health.

Lymphopoiesis is the process of formation and development of lymphocytes, which are a type of white blood cell that plays a crucial role in the immune system. Lymphocytes include B cells, T cells, and natural killer (NK) cells, which are responsible for defending the body against infectious diseases and cancer.

Lymphopoiesis occurs in the bone marrow and lymphoid organs such as the spleen, lymph nodes, and tonsils. In the bone marrow, hematopoietic stem cells differentiate into common lymphoid progenitors (CLPs), which then give rise to B cells, T cells, and NK cells through a series of intermediate stages.

B cells mature in the bone marrow, while T cells mature in the thymus gland. Once matured, these lymphocytes migrate to the peripheral lymphoid organs where they can encounter foreign antigens and mount an immune response. The process of lymphopoiesis is tightly regulated by various growth factors, cytokines, and transcription factors that control the differentiation, proliferation, and survival of lymphocytes.

Immunoglobulins, also known as antibodies, are proteins produced by the immune system to recognize and neutralize foreign substances like pathogens or antigens. The term "immunoglobulin isotypes" refers to the different classes of immunoglobulins that share a similar structure but have distinct functions and properties.

There are five main isotypes of immunoglobulins in humans, namely IgA, IgD, IgE, IgG, and IgM. Each isotype has a unique heavy chain constant region (CH) that determines its effector functions, such as binding to Fc receptors, complement activation, or protection against pathogens.

IgA is primarily found in external secretions like tears, saliva, and breast milk, providing localized immunity at mucosal surfaces. IgD is expressed on the surface of B cells and plays a role in their activation and differentiation. IgE is associated with allergic responses and binds to mast cells and basophils, triggering the release of histamine and other mediators of inflammation.

IgG is the most abundant isotype in serum and has several subclasses (IgG1, IgG2, IgG3, and IgG4) that differ in their effector functions. IgG can cross the placenta, providing passive immunity to the fetus. IgM is the first antibody produced during an immune response and is primarily found in the bloodstream, where it forms large pentameric complexes that are effective at agglutination and complement activation.

Overall, immunoglobulin isotypes play a crucial role in the adaptive immune response, providing specific and diverse mechanisms for recognizing and neutralizing foreign substances.

CD38 is a type of antigen that is found on the surface of many different types of cells in the human body, including immune cells such as T-cells and B-cells. Antigens are substances (usually proteins) on the surface of cells that can be recognized by the immune system, triggering an immune response.

CD38 plays a role in several different cellular processes, including the regulation of calcium levels within cells, the production of energy in the form of ATP, and the modulation of immune responses. It is also involved in the activation and proliferation of T-cells and B-cells, which are critical components of the adaptive immune system.

CD38 can be targeted by certain types of immunotherapy, such as monoclonal antibodies, to help stimulate an immune response against cancer cells that express this antigen on their surface.

Genetic transcription is the process by which the information in a strand of DNA is used to create a complementary RNA molecule. This process is the first step in gene expression, where the genetic code in DNA is converted into a form that can be used to produce proteins or functional RNAs.

During transcription, an enzyme called RNA polymerase binds to the DNA template strand and reads the sequence of nucleotide bases. As it moves along the template, it adds complementary RNA nucleotides to the growing RNA chain, creating a single-stranded RNA molecule that is complementary to the DNA template strand. Once transcription is complete, the RNA molecule may undergo further processing before it can be translated into protein or perform its functional role in the cell.

Transcription can be either "constitutive" or "regulated." Constitutive transcription occurs at a relatively constant rate and produces essential proteins that are required for basic cellular functions. Regulated transcription, on the other hand, is subject to control by various intracellular and extracellular signals, allowing cells to respond to changing environmental conditions or developmental cues.

Medical Definition:
Myeloid Cell Leukemia Sequence 1 Protein (MCSFR1) is a transmembrane receptor protein that belongs to the class III receptor tyrosine kinase family. It is also known as CD115 or CSF1R. This protein plays a crucial role in the survival, differentiation, and proliferation of mononuclear phagocytes, including macrophages and osteoclasts. The MCSFR1 protein binds to its ligands, colony-stimulating factor 1 (CSF1) and interleukin-34 (IL-34), leading to the activation of various intracellular signaling pathways that regulate cellular functions.

In the context of cancer, particularly in myeloid leukemias, chromosomal rearrangements can lead to the formation of the MCSFR1 fusion proteins, which have been implicated in the pathogenesis of certain types of leukemia, such as acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML). These fusion proteins can lead to constitutive activation of signaling pathways, promoting cell growth and survival, ultimately contributing to leukemic transformation.

'Inbred AKR mice' is a strain of laboratory mice used in biomedical research. The 'AKR' designation stands for "Akita Radioactive," referring to the location where this strain was first developed in Akita, Japan. These mice are inbred, meaning that they have been produced by many generations of brother-sister matings, resulting in a genetically homogeneous population with minimal genetic variation.

Inbred AKR mice are known for their susceptibility to certain types of leukemia and lymphoma, making them valuable models for studying these diseases and testing potential therapies. They also develop age-related cataracts and have a higher incidence of diabetes than some other strains.

It is important to note that while inbred AKR mice are widely used in research, their genetic uniformity may limit the applicability of findings to more genetically diverse human populations.

Vidarabine is an antiviral medication used to treat herpes simplex infections, particularly severe cases such as herpes encephalitis (inflammation of the brain caused by the herpes simplex virus). It works by interfering with the DNA replication of the virus.

In medical terms, vidarabine is a nucleoside analogue that is phosphorylated intracellularly to the active form, vidarabine triphosphate. This compound inhibits viral DNA polymerase and incorporates into viral DNA, causing termination of viral DNA synthesis.

Vidarabine was previously used as an injectable medication but has largely been replaced by more modern antiviral drugs such as acyclovir due to its greater efficacy and lower toxicity.

Neoplasm antigens, also known as tumor antigens, are substances that are produced by cancer cells (neoplasms) and can stimulate an immune response. These antigens can be proteins, carbohydrates, or other molecules that are either unique to the cancer cells or are overexpressed or mutated versions of normal cellular proteins.

Neoplasm antigens can be classified into two main categories: tumor-specific antigens (TSAs) and tumor-associated antigens (TAAs). TSAs are unique to cancer cells and are not expressed by normal cells, while TAAs are present at low levels in normal cells but are overexpressed or altered in cancer cells.

TSAs can be further divided into viral antigens and mutated antigens. Viral antigens are produced when cancer is caused by a virus, such as human papillomavirus (HPV) in cervical cancer. Mutated antigens are the result of genetic mutations that occur during cancer development and are unique to each patient's tumor.

Neoplasm antigens play an important role in the immune response against cancer. They can be recognized by the immune system, leading to the activation of immune cells such as T cells and natural killer (NK) cells, which can then attack and destroy cancer cells. However, cancer cells often develop mechanisms to evade the immune response, allowing them to continue growing and spreading.

Understanding neoplasm antigens is important for the development of cancer immunotherapies, which aim to enhance the body's natural immune response against cancer. These therapies include checkpoint inhibitors, which block proteins that inhibit T cell activation, and therapeutic vaccines, which stimulate an immune response against specific tumor antigens.

Homologous transplantation is a type of transplant surgery where organs or tissues are transferred between two genetically non-identical individuals of the same species. The term "homologous" refers to the similarity in structure and function of the donated organ or tissue to the recipient's own organ or tissue.

For example, a heart transplant from one human to another is an example of homologous transplantation because both organs are hearts and perform the same function. Similarly, a liver transplant, kidney transplant, lung transplant, and other types of organ transplants between individuals of the same species are also considered homologous transplantations.

Homologous transplantation is in contrast to heterologous or xenogeneic transplantation, where organs or tissues are transferred from one species to another, such as a pig heart transplanted into a human. Homologous transplantation is more commonly performed than heterologous transplantation due to the increased risk of rejection and other complications associated with xenogeneic transplants.

Nuclear proteins are a category of proteins that are primarily found in the nucleus of a eukaryotic cell. They play crucial roles in various nuclear functions, such as DNA replication, transcription, repair, and RNA processing. This group includes structural proteins like lamins, which form the nuclear lamina, and regulatory proteins, such as histones and transcription factors, that are involved in gene expression. Nuclear localization signals (NLS) often help target these proteins to the nucleus by interacting with importin proteins during active transport across the nuclear membrane.

An antigen is a substance (usually a protein) that is recognized as foreign by the immune system and stimulates an immune response, leading to the production of antibodies or activation of T-cells. Antigens can be derived from various sources, including bacteria, viruses, fungi, parasites, and tumor cells. They can also come from non-living substances such as pollen, dust mites, or chemicals.

Antigens contain epitopes, which are specific regions on the antigen molecule that are recognized by the immune system. The immune system's response to an antigen depends on several factors, including the type of antigen, its size, and its location in the body.

In general, antigens can be classified into two main categories:

1. T-dependent antigens: These require the help of T-cells to stimulate an immune response. They are typically larger, more complex molecules that contain multiple epitopes capable of binding to both MHC class II molecules on antigen-presenting cells and T-cell receptors on CD4+ T-cells.
2. T-independent antigens: These do not require the help of T-cells to stimulate an immune response. They are usually smaller, simpler molecules that contain repetitive epitopes capable of cross-linking B-cell receptors and activating them directly.

Understanding antigens and their properties is crucial for developing vaccines, diagnostic tests, and immunotherapies.

Chemokine (C-X-C motif) ligand 13 (CXCL13), also known as B cell-attracting chemokine 1 (BCA-1) or B lymphocyte chemoattractant (BLC), is a small signaling protein belonging to the CXC chemokine family. Chemokines are a group of chemotactic cytokines that play crucial roles in immunological and inflammatory processes, mainly by recruiting and activating various leukocytes.

CXCL13 is primarily produced by stromal cells, including follicular dendritic cells (FDCs) within secondary lymphoid organs such as lymph nodes, spleen, and Peyer's patches. This chemokine specifically binds to the C-X-C chemokine receptor type 5 (CXCR5), which is expressed on various immune cells, most notably B cells, follicular helper T cells (Tfh), and some dendritic cell subsets.

The primary function of CXCL13 is to orchestrate the migration and positioning of immune cells, particularly B cells, within secondary lymphoid organs during an immune response. By attracting CXCR5-expressing B cells and Tfh cells, CXCL13 plays a critical role in the formation and maintenance of germinal centers (GCs), which are specialized microanatomical structures where affinity maturation and class switch recombination of B cells occur.

Abnormal levels or functions of CXCL13 have been implicated in several pathological conditions, including autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus (SLE), certain types of cancer, and neurological disorders like multiple sclerosis (MS) and Alzheimer's disease.

Lymph nodes are small, bean-shaped organs that are part of the immune system. They are found throughout the body, especially in the neck, armpits, groin, and abdomen. Lymph nodes filter lymph fluid, which carries waste and unwanted substances such as bacteria, viruses, and cancer cells. They contain white blood cells called lymphocytes that help fight infections and diseases by attacking and destroying the harmful substances found in the lymph fluid. When an infection or disease is present, lymph nodes may swell due to the increased number of immune cells and fluid accumulation as they work to fight off the invaders.

Follicular dendritic cells (FDCs) are a specialized type of dendritic cell that reside in the germinal centers of secondary lymphoid organs, such as the spleen, lymph nodes, and Peyer's patches. They play a critical role in the adaptive immune response by presenting antigens to B cells and helping to regulate their activation, differentiation, and survival.

FDCs are characterized by their extensive network of dendrites, which can trap and retain antigens on their surface for extended periods. They also express a variety of surface receptors that allow them to interact with other immune cells, including complement receptors, Fc receptors, and cytokine receptors.

FDCs are derived from mesenchymal stem cells and are distinct from classical dendritic cells, which are derived from hematopoietic stem cells. They are long-lived cells that can survive for months or even years in the body, making them important players in the maintenance of immune memory.

Overall, follicular dendritic cells play a critical role in the adaptive immune response by helping to regulate B cell activation and differentiation, and by contributing to the development of immune memory.

Monoclonal murine-derived antibodies are a type of laboratory-produced antibody that is identical in structure, having been derived from a single clone of cells. These antibodies are created using mouse cells and are therefore composed entirely of mouse immune proteins. They are designed to bind specifically to a particular target protein or antigen, making them useful tools for research, diagnostic testing, and therapeutic applications.

Monoclonal antibodies offer several advantages over polyclonal antibodies (which are derived from multiple clones of cells and can recognize multiple epitopes on an antigen). Monoclonal antibodies have a consistent and uniform structure, making them more reliable for research and diagnostic purposes. They also have higher specificity and affinity for their target antigens, allowing for more sensitive detection and measurement.

However, there are some limitations to using monoclonal murine-derived antibodies in therapeutic applications. Because they are composed entirely of mouse proteins, they can elicit an immune response in humans, leading to the production of human anti-mouse antibodies (HAMA) that can neutralize their effectiveness. To overcome this limitation, researchers have developed chimeric and humanized monoclonal antibodies that incorporate human protein sequences, reducing the risk of an immune response.

I'm sorry for any confusion, but "oxides" is not a term that has a specific medical definition. Oxides are a class of chemical compounds that contain at least one oxygen atom and one other element. They can be formed through the process of oxidation, which involves the combination of oxygen with another substance.

In a broader sense, you might encounter the term "oxide" in a medical context when discussing various materials or substances used in medical devices, treatments, or research. For instance, titanium dioxide is a common ingredient in medical-grade sunscreens due to its ability to block and scatter UV light. However, it's important to note that the term "oxides" itself doesn't have a direct connection to medicine or human health.

Arsenicals are a group of chemicals that contain arsenic, a naturally occurring element that is toxic to humans and animals. Arsenic can combine with other elements such as chlorine, sulfur, or carbon to form various inorganic and organic compounds known as arsenicals. These compounds have been used in a variety of industrial and agricultural applications, including wood preservatives, pesticides, and herbicides.

Exposure to high levels of arsenic can cause serious health effects, including skin damage, circulatory problems, and increased risk of cancer. Long-term exposure to lower levels of arsenic can also lead to chronic health issues, such as neurological damage and diabetes. Therefore, the use of arsenicals is regulated in many countries to minimize human and environmental exposure.

A gene product is the biochemical material, such as a protein or RNA, that is produced by the expression of a gene. Gene products are the result of the translation and transcription of genetic information encoded in DNA or RNA.

In the context of "tax," this term is not typically used in a medical definition of gene products. However, it may refer to the concept of taxing or regulating gene products in the context of genetic engineering or synthetic biology. This could involve imposing fees or restrictions on the production, use, or sale of certain gene products, particularly those that are genetically modified or engineered. The regulation of gene products is an important aspect of ensuring their safe and effective use in various applications, including medical treatments, agricultural production, and industrial processes.

Gibbon Ape Leukemia Virus (GaLV) is not exactly a "leukemia virus" in the sense that it directly causes leukemia in humans. Instead, GaLV is a type of retrovirus that primarily infects gibbons and some other non-human primates. It's important to note that GaLV is not known to infect or cause disease in healthy human beings.

GaLV has four subtypes (A, B, C, and D), with A and B being the most well-studied. These viruses have a close genetic relationship with certain human retroviruses, such as Human T-cell Leukemia Virus types I and II (HTLV-I/II). Although GaLV is not known to cause leukemia or any other diseases in humans directly, it has served as an important model for understanding the biology and pathogenesis of retroviruses, including those that can cause leukemia and other malignancies in humans.

The term "leukemia virus" is often used to describe retroviruses that can cause leukemia or lymphoma, such as HTLV-I/II and Human Immunodeficiency Virus (HIV). GaLV does not fit into this category for humans, but it's essential to understand its role in the context of retroviral research and comparative primatology.

Gene expression is the process by which the information encoded in a gene is used to synthesize a functional gene product, such as a protein or RNA molecule. This process involves several steps: transcription, RNA processing, and translation. During transcription, the genetic information in DNA is copied into a complementary RNA molecule, known as messenger RNA (mRNA). The mRNA then undergoes RNA processing, which includes adding a cap and tail to the mRNA and splicing out non-coding regions called introns. The resulting mature mRNA is then translated into a protein on ribosomes in the cytoplasm through the process of translation.

The regulation of gene expression is a complex and highly controlled process that allows cells to respond to changes in their environment, such as growth factors, hormones, and stress signals. This regulation can occur at various stages of gene expression, including transcriptional activation or repression, RNA processing, mRNA stability, and translation. Dysregulation of gene expression has been implicated in many diseases, including cancer, genetic disorders, and neurological conditions.

Tretinoin is a form of vitamin A that is used in the treatment of acne vulgaris, fine wrinkles, and dark spots caused by aging or sun damage. It works by increasing the turnover of skin cells, helping to unclog pores and promote the growth of new skin cells. Tretinoin is available as a cream, gel, or liquid, and is usually applied to the affected area once a day in the evening. Common side effects include redness, dryness, and peeling of the skin. It is important to avoid sunlight and use sunscreen while using tretinoin, as it can make the skin more sensitive to the sun.

Transfection is a term used in molecular biology that refers to the process of deliberately introducing foreign genetic material (DNA, RNA or artificial gene constructs) into cells. This is typically done using chemical or physical methods, such as lipofection or electroporation. Transfection is widely used in research and medical settings for various purposes, including studying gene function, producing proteins, developing gene therapies, and creating genetically modified organisms. It's important to note that transfection is different from transduction, which is the process of introducing genetic material into cells using viruses as vectors.

A "cell line, transformed" is a type of cell culture that has undergone a stable genetic alteration, which confers the ability to grow indefinitely in vitro, outside of the organism from which it was derived. These cells have typically been immortalized through exposure to chemical or viral carcinogens, or by introducing specific oncogenes that disrupt normal cell growth regulation pathways.

Transformed cell lines are widely used in scientific research because they offer a consistent and renewable source of biological material for experimentation. They can be used to study various aspects of cell biology, including signal transduction, gene expression, drug discovery, and toxicity testing. However, it is important to note that transformed cells may not always behave identically to their normal counterparts, and results obtained using these cells should be validated in more physiologically relevant systems when possible.

Immune tolerance, also known as immunological tolerance or specific immune tolerance, is a state of unresponsiveness or non-reactivity of the immune system towards a particular substance (antigen) that has the potential to elicit an immune response. This occurs when the immune system learns to distinguish "self" from "non-self" and does not attack the body's own cells, tissues, and organs.

In the context of transplantation, immune tolerance refers to the absence of a destructive immune response towards the transplanted organ or tissue, allowing for long-term graft survival without the need for immunosuppressive therapy. Immune tolerance can be achieved through various strategies, including hematopoietic stem cell transplantation, costimulation blockade, and regulatory T cell induction.

In summary, immune tolerance is a critical mechanism that prevents the immune system from attacking the body's own structures while maintaining the ability to respond appropriately to foreign pathogens and antigens.

Idarubicin is an anthracycline antibiotic used in the treatment of various types of cancer, including leukemia and lymphoma. It works by interfering with the DNA of cancer cells, which prevents them from dividing and growing. Idarubicin is often administered intravenously in a hospital or clinic setting. Common side effects include nausea, vomiting, hair loss, and an increased risk of infection due to lowered white blood cell counts. It can also cause damage to the heart muscle, so regular monitoring of cardiac function is necessary during treatment.

Cell transformation, viral refers to the process by which a virus causes normal cells to become cancerous or tumorigenic. This occurs when the genetic material of the virus integrates into the DNA of the host cell and alters its regulation, leading to uncontrolled cell growth and division. Some viruses known to cause cell transformation include human papillomavirus (HPV), hepatitis B virus (HBV), and certain types of herpesviruses.

CD4-positive T-lymphocytes, also known as CD4+ T cells or helper T cells, are a type of white blood cell that plays a crucial role in the immune response. They express the CD4 receptor on their surface and help coordinate the immune system's response to infectious agents such as viruses and bacteria.

CD4+ T cells recognize and bind to specific antigens presented by antigen-presenting cells, such as dendritic cells or macrophages. Once activated, they can differentiate into various subsets of effector cells, including Th1, Th2, Th17, and Treg cells, each with distinct functions in the immune response.

CD4+ T cells are particularly important in the immune response to HIV (human immunodeficiency virus), which targets and destroys these cells, leading to a weakened immune system and increased susceptibility to opportunistic infections. The number of CD4+ T cells is often used as a marker of disease progression in HIV infection, with lower counts indicating more advanced disease.

IgE receptors, also known as Fc epsilon RI receptors, are membrane-bound proteins found on the surface of mast cells and basophils. They play a crucial role in the immune response to parasitic infections and allergies. IgE receptors bind to the Fc region of immunoglobulin E (IgE) antibodies, which are produced by B cells in response to certain antigens. When an allergen cross-links two adjacent IgE molecules bound to the same IgE receptor, it triggers a signaling cascade that leads to the release of mediators such as histamine, leukotrienes, and prostaglandins. These mediators cause the symptoms associated with allergic reactions, including inflammation, itching, and vasodilation. IgE receptors are also involved in the activation of the adaptive immune response by promoting the presentation of antigens to T cells.

Lymphopenia is a term used in medicine to describe an abnormally low count of lymphocytes, which are a type of white blood cell that plays a crucial role in the body's immune system. Lymphocytes help fight off infections and diseases by producing antibodies and attacking infected cells.

A normal lymphocyte count ranges from 1,000 to 4,800 cells per microliter (cells/μL) of blood in adults. A lymphocyte count lower than 1,000 cells/μL is generally considered lymphopenia.

Several factors can cause lymphopenia, including viral infections, certain medications, autoimmune disorders, and cancer. It's important to note that a low lymphocyte count alone may not indicate a specific medical condition, and further testing may be necessary to determine the underlying cause. If left untreated, lymphopenia can increase the risk of infections and other complications.

I'm happy to help! However, I believe there might be a slight mistake in your question. The correct term is "ABL" (Abelson murine leukemia viral oncogene homolog 1), which refers to a specific gene that encodes a tyrosine kinase protein. ABL genes can play a role in the development of certain types of cancer when they become mutated or dysregulated. Here's a brief medical definition:

ABL (Abelson murine leukemia viral oncogene homolog 1) gene:
A gene located on chromosome 9q34.1 that encodes a tyrosine kinase protein involved in various cellular processes, such as regulation of the cell cycle, differentiation, and apoptosis (programmed cell death). The ABL gene can become dysregulated or mutated, leading to the production of an abnormal tyrosine kinase protein that contributes to the development of certain types of cancer, most notably chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). The Philadelphia chromosome, a result of a reciprocal translocation between chromosomes 9 and 22, creates the abnormal fusion gene BCR-ABL, which encodes a constitutively active tyrosine kinase that drives the development of CML. Targeted therapy using tyrosine kinase inhibitors, such as imatinib (Gleevec), has been successful in treating CML and some forms of ALL with ABL mutations.

Enzootic bovine leukosis (EBL) is a slow-developing, persistent virus infection that primarily affects cattle. It is caused by the bovine leukemia virus (BLV), which is part of the retrovirus family. The term "enzootic" refers to an animal disease that is constantly present in a particular geographic area or population.

EBL is typically characterized by the development of malignant lymphosarcoma, a type of cancer affecting the lymphoid system, in mature animals. Infected animals may not show any clinical signs for several years, and some never develop the disease. However, when clinical symptoms do appear, they can include weight loss, decreased milk production, enlarged lymph nodes, difficulty swallowing, and paralysis.

The virus is primarily spread through contact with infected blood or other bodily fluids, such as during castration, dehorning, or veterinary procedures. It can also be transmitted from an infected mother to her calf through colostrum and milk. EBL has been reported in many countries worldwide, but control and eradication programs have significantly reduced its prevalence in some regions, including the United States and Western Europe.

It is important to note that enzootic bovine leukosis should not be confused with bovine spongiform encephalopathy (BSE), also known as "mad cow disease," which is a completely different and unrelated condition affecting cattle.

A leukocyte count, also known as a white blood cell (WBC) count, is a laboratory test that measures the number of leukocytes in a sample of blood. Leukocytes are a vital part of the body's immune system and help fight infection and inflammation. A high or low leukocyte count may indicate an underlying medical condition, such as an infection, inflammation, or a bone marrow disorder. The normal range for a leukocyte count in adults is typically between 4,500 and 11,000 cells per microliter (mcL) of blood. However, the normal range can vary slightly depending on the laboratory and the individual's age and sex.

Human chromosome pair 21 consists of two rod-shaped structures present in the nucleus of each cell in the human body. Each member of the pair is a single chromosome, and they are identical to each other. Chromosomes are made up of DNA, which contains genetic information that determines many of an individual's traits and characteristics.

Chromosome pair 21 is one of the 23 pairs of human autosomal chromosomes, meaning they are not sex chromosomes (X or Y). Chromosome pair 21 is the smallest of the human chromosomes, and it contains approximately 48 million base pairs of DNA. It contains around 200-300 genes that provide instructions for making proteins and regulating various cellular processes.

Down syndrome, a genetic disorder characterized by intellectual disability, developmental delays, distinct facial features, and sometimes heart defects, is caused by an extra copy of chromosome pair 21 or a part of it. This additional genetic material can lead to abnormalities in brain development and function, resulting in the characteristic symptoms of Down syndrome.

Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease that can affect almost any organ or system in the body. In SLE, the immune system produces an exaggerated response, leading to the production of autoantibodies that attack the body's own cells and tissues, causing inflammation and damage. The symptoms and severity of SLE can vary widely from person to person, but common features include fatigue, joint pain, skin rashes (particularly a "butterfly" rash across the nose and cheeks), fever, hair loss, and sensitivity to sunlight.

Systemic lupus erythematosus can also affect the kidneys, heart, lungs, brain, blood vessels, and other organs, leading to a wide range of symptoms such as kidney dysfunction, chest pain, shortness of breath, seizures, and anemia. The exact cause of SLE is not fully understood, but it is believed to involve a combination of genetic, environmental, and hormonal factors. Treatment typically involves medications to suppress the immune system and manage symptoms, and may require long-term management by a team of healthcare professionals.

Cytidine deaminase is an enzyme that catalyzes the removal of an amino group from cytidine, converting it to uridine. This reaction is part of the process of RNA degradation and also plays a role in the immune response to viral infections.

Cytidine deaminase can be found in various organisms, including bacteria, humans, and other mammals. In humans, cytidine deaminase is encoded by the APOBEC3 gene family, which consists of several different enzymes that have distinct functions and expression patterns. Some members of this gene family are involved in the restriction of retroviruses, such as HIV-1, while others play a role in the regulation of endogenous retroelements and the modification of cellular RNA.

Mutations in cytidine deaminase genes have been associated with various diseases, including cancer and autoimmune disorders. For example, mutations in the APOBEC3B gene have been linked to an increased risk of breast cancer, while mutations in other members of the APOBEC3 family have been implicated in the development of lymphoma and other malignancies. Additionally, aberrant expression of cytidine deaminase enzymes has been observed in some autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus, suggesting a potential role for these enzymes in the pathogenesis of these conditions.

Proto-oncogenes are normal genes that are present in all cells and play crucial roles in regulating cell growth, division, and death. They code for proteins that are involved in signal transduction pathways that control various cellular processes such as proliferation, differentiation, and survival. When these genes undergo mutations or are activated abnormally, they can become oncogenes, which have the potential to cause uncontrolled cell growth and lead to cancer. Oncogenes can contribute to tumor formation through various mechanisms, including promoting cell division, inhibiting programmed cell death (apoptosis), and stimulating blood vessel growth (angiogenesis).

Down-regulation is a process that occurs in response to various stimuli, where the number or sensitivity of cell surface receptors or the expression of specific genes is decreased. This process helps maintain homeostasis within cells and tissues by reducing the ability of cells to respond to certain signals or molecules.

In the context of cell surface receptors, down-regulation can occur through several mechanisms:

1. Receptor internalization: After binding to their ligands, receptors can be internalized into the cell through endocytosis. Once inside the cell, these receptors may be degraded or recycled back to the cell surface in smaller numbers.
2. Reduced receptor synthesis: Down-regulation can also occur at the transcriptional level, where the expression of genes encoding for specific receptors is decreased, leading to fewer receptors being produced.
3. Receptor desensitization: Prolonged exposure to a ligand can lead to a decrease in receptor sensitivity or affinity, making it more difficult for the cell to respond to the signal.

In the context of gene expression, down-regulation refers to the decreased transcription and/or stability of specific mRNAs, leading to reduced protein levels. This process can be induced by various factors, including microRNA (miRNA)-mediated regulation, histone modification, or DNA methylation.

Down-regulation is an essential mechanism in many physiological processes and can also contribute to the development of several diseases, such as cancer and neurodegenerative disorders.

'Cell lineage' is a term used in biology and medicine to describe the developmental history or relationship of a cell or group of cells to other cells, tracing back to the original progenitor or stem cell. It refers to the series of cell divisions and differentiation events that give rise to specific types of cells in an organism over time.

In simpler terms, cell lineage is like a family tree for cells, showing how they are related to each other through a chain of cell division and specialization events. This concept is important in understanding the development, growth, and maintenance of tissues and organs in living beings.

Autoantigens are substances that are typically found in an individual's own body, but can stimulate an immune response because they are recognized as foreign by the body's own immune system. In autoimmune diseases, the immune system mistakenly attacks and damages healthy tissues and organs because it recognizes some of their components as autoantigens. These autoantigens can be proteins, DNA, or other molecules that are normally present in the body but have become altered or exposed due to various factors such as infection, genetics, or environmental triggers. The immune system then produces antibodies and activates immune cells to attack these autoantigens, leading to tissue damage and inflammation.

Cytogenetics is a branch of genetics that deals with the study of chromosomes and their structure, function, and abnormalities. It involves the examination of chromosome number and structure in the cells of an organism, usually through microscopic analysis of chromosomes prepared from cell cultures or tissue samples. Cytogenetic techniques can be used to identify chromosomal abnormalities associated with genetic disorders, cancer, and other diseases.

The process of cytogenetics typically involves staining the chromosomes to make them visible under a microscope, and then analyzing their number, size, shape, and banding pattern. Chromosomal abnormalities such as deletions, duplications, inversions, translocations, and aneuploidy (abnormal number of chromosomes) can be detected through cytogenetic analysis.

Cytogenetics is an important tool in medical genetics and has many clinical applications, including prenatal diagnosis, cancer diagnosis and monitoring, and identification of genetic disorders. Advances in molecular cytogenetic techniques, such as fluorescence in situ hybridization (FISH) and comparative genomic hybridization (CGH), have improved the resolution and accuracy of chromosome analysis and expanded its clinical applications.

Regulatory B-lymphocytes (Bregs) are a subset of B cells that play a role in modulating the immune response and maintaining immune tolerance. They function to suppress the activation and proliferation of other immune cells, such as T cells, and help to prevent autoimmune diseases and chronic inflammation.

Bregs produce regulatory cytokines, such as IL-10 and TGF-β, which can inhibit the activation and effector functions of immune cells. They also express surface molecules, such as PD-L1 and FasL, that can induce apoptosis or inhibit the function of other immune cells.

Regulatory B cells are an important component of the immune system and have been shown to play a role in the regulation of various physiological and pathological processes, including allergy, infection, and cancer. Dysregulation of Bregs has been implicated in the development of various autoimmune diseases and chronic inflammatory conditions.

Human chromosome pair 11 consists of two rod-shaped structures present in the nucleus of each cell in the human body. Each member of the pair is a single chromosome, and together they contain the genetic material that is inherited from both parents. They are located on the eleventh position in the standard karyotype, which is a visual representation of the 23 pairs of human chromosomes.

Chromosome 11 is one of the largest human chromosomes and contains an estimated 135 million base pairs. It contains approximately 1,400 genes that provide instructions for making proteins, as well as many non-coding RNA molecules that play a role in regulating gene expression.

Chromosome 11 is known to contain several important genes and genetic regions associated with various human diseases and conditions. For example, it contains the Wilms' tumor 1 (WT1) gene, which is associated with kidney cancer in children, and the neurofibromatosis type 1 (NF1) gene, which is associated with a genetic disorder that causes benign tumors to grow on nerves throughout the body. Additionally, chromosome 11 contains the region where the ABO blood group genes are located, which determine a person's blood type.

It's worth noting that human chromosomes come in pairs because they contain two copies of each gene, one inherited from the mother and one from the father. This redundancy allows for genetic diversity and provides a backup copy of essential genes, ensuring their proper function and maintaining the stability of the genome.

Immunologic deficiency syndromes refer to a group of disorders characterized by defective functioning of the immune system, leading to increased susceptibility to infections and malignancies. These deficiencies can be primary (genetic or congenital) or secondary (acquired due to environmental factors, medications, or diseases).

Primary immunodeficiency syndromes (PIDS) are caused by inherited genetic mutations that affect the development and function of immune cells, such as T cells, B cells, and phagocytes. Examples include severe combined immunodeficiency (SCID), common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, and X-linked agammaglobulinemia.

Secondary immunodeficiency syndromes can result from various factors, including:

1. HIV/AIDS: Human Immunodeficiency Virus infection leads to the depletion of CD4+ T cells, causing profound immune dysfunction and increased vulnerability to opportunistic infections and malignancies.
2. Medications: Certain medications, such as chemotherapy, immunosuppressive drugs, and long-term corticosteroid use, can impair immune function and increase infection risk.
3. Malnutrition: Deficiencies in essential nutrients like protein, vitamins, and minerals can weaken the immune system and make individuals more susceptible to infections.
4. Aging: The immune system naturally declines with age, leading to an increased incidence of infections and poorer vaccine responses in older adults.
5. Other medical conditions: Chronic diseases such as diabetes, cancer, and chronic kidney or liver disease can also compromise the immune system and contribute to immunodeficiency syndromes.

Immunologic deficiency syndromes require appropriate diagnosis and management strategies, which may include antimicrobial therapy, immunoglobulin replacement, hematopoietic stem cell transplantation, or targeted treatments for the underlying cause.

T-lymphocytes, also known as T-cells, are a type of white blood cell that plays a key role in the adaptive immune system's response to infection. They are produced in the bone marrow and mature in the thymus gland. There are several different types of T-cells, including CD4+ helper T-cells, CD8+ cytotoxic T-cells, and regulatory T-cells (Tregs).

CD4+ helper T-cells assist in activating other immune cells, such as B-lymphocytes and macrophages. They also produce cytokines, which are signaling molecules that help coordinate the immune response. CD8+ cytotoxic T-cells directly kill infected cells by releasing toxic substances. Regulatory T-cells help maintain immune tolerance and prevent autoimmune diseases by suppressing the activity of other immune cells.

T-lymphocytes are important in the immune response to viral infections, cancer, and other diseases. Dysfunction or depletion of T-cells can lead to immunodeficiency and increased susceptibility to infections. On the other hand, an overactive T-cell response can contribute to autoimmune diseases and chronic inflammation.

Up-regulation is a term used in molecular biology and medicine to describe an increase in the expression or activity of a gene, protein, or receptor in response to a stimulus. This can occur through various mechanisms such as increased transcription, translation, or reduced degradation of the molecule. Up-regulation can have important functional consequences, for example, enhancing the sensitivity or response of a cell to a hormone, neurotransmitter, or drug. It is a normal physiological process that can also be induced by disease or pharmacological interventions.

Deoxyribonucleic acid (DNA) is the genetic material present in the cells of organisms where it is responsible for the storage and transmission of hereditary information. DNA is a long molecule that consists of two strands coiled together to form a double helix. Each strand is made up of a series of four nucleotide bases - adenine (A), guanine (G), cytosine (C), and thymine (T) - that are linked together by phosphate and sugar groups. The sequence of these bases along the length of the molecule encodes genetic information, with A always pairing with T and C always pairing with G. This base-pairing allows for the replication and transcription of DNA, which are essential processes in the functioning and reproduction of all living organisms.

Cladribine is a medication used in the treatment of certain types of cancer and multiple sclerosis. It is a type of drug called a purine nucleoside analog, which means it interferes with the production of DNA and RNA, the genetic material of cells. This can help to stop the growth and multiplication of abnormal cells in the body.

In cancer treatment, cladribine is used to treat hairy cell leukemia and certain types of lymphoma. In multiple sclerosis, it is used to reduce the frequency of relapses and slow down the progression of disability. Cladribine works by selectively targeting and depleting certain white blood cells called lymphocytes, which are thought to play a role in the immune response that damages the nervous system in multiple sclerosis.

Cladribine is usually given as an injection into a vein or under the skin, and it may be given on its own or in combination with other medications. Common side effects of cladribine include nausea, vomiting, diarrhea, and weakness. It can also lower the body's ability to fight infections, so patients may need to take precautions to avoid infection while receiving treatment. Cladribine should be used with caution in people with a history of certain medical conditions, such as liver or kidney disease, and it should not be used during pregnancy or breastfeeding.

Feline Leukemia (FeLV) is a retroviral infection that affects cats, causing a variety of potential symptoms and health problems. It is the most common cause of cancer in cats and can also lead to immune suppression, making the cat more susceptible to other infections. The virus is transmitted through close contact with infected cats, especially through saliva and nasal secretions. There is no known cure for FeLV, but supportive care and medications can help manage the symptoms and secondary infections. Regular testing and vaccination of at-risk cats is recommended to control the spread of this disease.

RNA (Ribonucleic acid) is a single-stranded molecule similar in structure to DNA, involved in the process of protein synthesis in the cell. It acts as a messenger carrying genetic information from DNA to the ribosomes, where proteins are produced.

A neoplasm, on the other hand, is an abnormal growth of cells, which can be benign or malignant. Benign neoplasms are not cancerous and do not invade nearby tissues or spread to other parts of the body. Malignant neoplasms, however, are cancerous and have the potential to invade surrounding tissues and spread to distant sites in the body through a process called metastasis.

Therefore, an 'RNA neoplasm' is not a recognized medical term as RNA is not a type of growth or tumor. However, there are certain types of cancer-causing viruses known as oncoviruses that contain RNA as their genetic material and can cause neoplasms. For example, human T-cell leukemia virus (HTLV-1) and hepatitis C virus (HCV) are RNA viruses that can cause certain types of cancer in humans.

"CBA" is an abbreviation for a specific strain of inbred mice that were developed at the Cancer Research Institute in London. The "Inbred CBA" mice are genetically identical individuals within the same strain, due to many generations of brother-sister matings. This results in a homozygous population, making them valuable tools for research because they reduce variability and increase reproducibility in experimental outcomes.

The CBA strain is known for its susceptibility to certain diseases, such as autoimmune disorders and cancer, which makes it a popular choice for researchers studying those conditions. Additionally, the CBA strain has been widely used in studies related to transplantation immunology, infectious diseases, and genetic research.

It's important to note that while "Inbred CBA" mice are a well-established and useful tool in biomedical research, they represent only one of many inbred strains available for scientific investigation. Each strain has its own unique characteristics and advantages, depending on the specific research question being asked.

Tumor Necrosis Factor Ligand Superfamily Member 13 (TNFSF13), also known as APRIL (A Proliferation-Inducing Ligand), is a type II transmembrane protein and a member of the tumor necrosis factor (TNF) ligand superfamily. It plays a crucial role in the immune system, particularly in the activation, proliferation, and differentiation of B cells, which are key players in the humoral immune response.

TNFSF13 is expressed by various cell types, including macrophages, dendritic cells, and neutrophils. It binds to two receptors: TACI (Transmembrane Activator and Calcium Modulator and Cyclophilin Ligand Interactor) and BCMA (B-cell Maturation Antigen), which are primarily found on the surface of B cells. The interaction between TNFSF13 and its receptors promotes the survival, proliferation, and differentiation of B cells into plasma cells, ultimately leading to increased antibody production.

Dysregulation of TNFSF13 has been implicated in several autoimmune and inflammatory diseases, such as rheumatoid arthritis, systemic lupus erythematosus (SLE), and multiple sclerosis (MS). Therefore, targeting this molecule or its signaling pathways has been a focus of research for the development of novel therapeutic strategies in these conditions.

Gene expression profiling is a laboratory technique used to measure the activity (expression) of thousands of genes at once. This technique allows researchers and clinicians to identify which genes are turned on or off in a particular cell, tissue, or organism under specific conditions, such as during health, disease, development, or in response to various treatments.

The process typically involves isolating RNA from the cells or tissues of interest, converting it into complementary DNA (cDNA), and then using microarray or high-throughput sequencing technologies to determine which genes are expressed and at what levels. The resulting data can be used to identify patterns of gene expression that are associated with specific biological states or processes, providing valuable insights into the underlying molecular mechanisms of diseases and potential targets for therapeutic intervention.

In recent years, gene expression profiling has become an essential tool in various fields, including cancer research, drug discovery, and personalized medicine, where it is used to identify biomarkers of disease, predict patient outcomes, and guide treatment decisions.

Western blotting is a laboratory technique used in molecular biology to detect and quantify specific proteins in a mixture of many different proteins. This technique is commonly used to confirm the expression of a protein of interest, determine its size, and investigate its post-translational modifications. The name "Western" blotting distinguishes this technique from Southern blotting (for DNA) and Northern blotting (for RNA).

The Western blotting procedure involves several steps:

1. Protein extraction: The sample containing the proteins of interest is first extracted, often by breaking open cells or tissues and using a buffer to extract the proteins.
2. Separation of proteins by electrophoresis: The extracted proteins are then separated based on their size by loading them onto a polyacrylamide gel and running an electric current through the gel (a process called sodium dodecyl sulfate-polyacrylamide gel electrophoresis or SDS-PAGE). This separates the proteins according to their molecular weight, with smaller proteins migrating faster than larger ones.
3. Transfer of proteins to a membrane: After separation, the proteins are transferred from the gel onto a nitrocellulose or polyvinylidene fluoride (PVDF) membrane using an electric current in a process called blotting. This creates a replica of the protein pattern on the gel but now immobilized on the membrane for further analysis.
4. Blocking: The membrane is then blocked with a blocking agent, such as non-fat dry milk or bovine serum albumin (BSA), to prevent non-specific binding of antibodies in subsequent steps.
5. Primary antibody incubation: A primary antibody that specifically recognizes the protein of interest is added and allowed to bind to its target protein on the membrane. This step may be performed at room temperature or 4°C overnight, depending on the antibody's properties.
6. Washing: The membrane is washed with a buffer to remove unbound primary antibodies.
7. Secondary antibody incubation: A secondary antibody that recognizes the primary antibody (often coupled to an enzyme or fluorophore) is added and allowed to bind to the primary antibody. This step may involve using a horseradish peroxidase (HRP)-conjugated or alkaline phosphatase (AP)-conjugated secondary antibody, depending on the detection method used later.
8. Washing: The membrane is washed again to remove unbound secondary antibodies.
9. Detection: A detection reagent is added to visualize the protein of interest by detecting the signal generated from the enzyme-conjugated or fluorophore-conjugated secondary antibody. This can be done using chemiluminescent, colorimetric, or fluorescent methods.
10. Analysis: The resulting image is analyzed to determine the presence and quantity of the protein of interest in the sample.

Western blotting is a powerful technique for identifying and quantifying specific proteins within complex mixtures. It can be used to study protein expression, post-translational modifications, protein-protein interactions, and more. However, it requires careful optimization and validation to ensure accurate and reproducible results.

The cell cycle is a series of events that take place in a cell leading to its division and duplication. It consists of four main phases: G1 phase, S phase, G2 phase, and M phase.

During the G1 phase, the cell grows in size and synthesizes mRNA and proteins in preparation for DNA replication. In the S phase, the cell's DNA is copied, resulting in two complete sets of chromosomes. During the G2 phase, the cell continues to grow and produces more proteins and organelles necessary for cell division.

The M phase is the final stage of the cell cycle and consists of mitosis (nuclear division) and cytokinesis (cytoplasmic division). Mitosis results in two genetically identical daughter nuclei, while cytokinesis divides the cytoplasm and creates two separate daughter cells.

The cell cycle is regulated by various checkpoints that ensure the proper completion of each phase before progressing to the next. These checkpoints help prevent errors in DNA replication and division, which can lead to mutations and cancer.

Jurkat cells are a type of human immortalized T lymphocyte (a type of white blood cell) cell line that is commonly used in scientific research. They were originally isolated from the peripheral blood of a patient with acute T-cell leukemia. Jurkat cells are widely used as a model system to study T-cell activation, signal transduction, and apoptosis (programmed cell death). They are also used in the study of HIV infection and replication, as they can be infected with the virus and used to investigate viral replication and host cell responses.

Proto-oncogene proteins c-bcr are a group of intracellular signaling proteins that play a role in regulating cell growth, differentiation, and apoptosis (programmed cell death). They are encoded by the c-bcr gene located on chromosome 22. The c-bcr gene can fuse with the c-abl gene (located on chromosome 9) as a result of a chromosomal translocation, leading to the formation of the BCR-ABL fusion protein. This fusion protein has constitutively active tyrosine kinase activity and is associated with the development of certain types of leukemia, such as chronic myelogenous leukemia (CML).

The c-bcr gene can also fuse with other genes, leading to the formation of different fusion proteins that have been implicated in the development of other types of cancer. The normal function of c-bcr proteins is not fully understood, but they are thought to play a role in regulating the actin cytoskeleton and intracellular signaling pathways.

Recombinant proteins are artificially created proteins produced through the use of recombinant DNA technology. This process involves combining DNA molecules from different sources to create a new set of genes that encode for a specific protein. The resulting recombinant protein can then be expressed, purified, and used for various applications in research, medicine, and industry.

Recombinant proteins are widely used in biomedical research to study protein function, structure, and interactions. They are also used in the development of diagnostic tests, vaccines, and therapeutic drugs. For example, recombinant insulin is a common treatment for diabetes, while recombinant human growth hormone is used to treat growth disorders.

The production of recombinant proteins typically involves the use of host cells, such as bacteria, yeast, or mammalian cells, which are engineered to express the desired protein. The host cells are transformed with a plasmid vector containing the gene of interest, along with regulatory elements that control its expression. Once the host cells are cultured and the protein is expressed, it can be purified using various chromatography techniques.

Overall, recombinant proteins have revolutionized many areas of biology and medicine, enabling researchers to study and manipulate proteins in ways that were previously impossible.

DNA primers are short single-stranded DNA molecules that serve as a starting point for DNA synthesis. They are typically used in laboratory techniques such as the polymerase chain reaction (PCR) and DNA sequencing. The primer binds to a complementary sequence on the DNA template through base pairing, providing a free 3'-hydroxyl group for the DNA polymerase enzyme to add nucleotides and synthesize a new strand of DNA. This allows for specific and targeted amplification or analysis of a particular region of interest within a larger DNA molecule.

Interleukin-2 (IL-2) is a type of cytokine, which are signaling molecules that mediate and regulate immunity, inflammation, and hematopoiesis. Specifically, IL-2 is a growth factor for T cells, a type of white blood cell that plays a central role in the immune response. It is primarily produced by CD4+ T cells (also known as T helper cells) and stimulates the proliferation and differentiation of activated T cells, including effector T cells and regulatory T cells. IL-2 also has roles in the activation and function of other immune cells, such as B cells, natural killer cells, and dendritic cells. Dysregulation of IL-2 production or signaling can contribute to various pathological conditions, including autoimmune diseases, chronic infections, and cancer.

Disease-free survival (DFS) is a term used in medical research and clinical practice, particularly in the field of oncology. It refers to the length of time after primary treatment for a cancer during which no evidence of the disease can be found. This means that the patient shows no signs or symptoms of the cancer, and any imaging studies or other tests do not reveal any tumors or other indications of the disease.

DFS is often used as an important endpoint in clinical trials to evaluate the effectiveness of different treatments for cancer. By measuring the length of time until the cancer recurs or a new cancer develops, researchers can get a better sense of how well a particular treatment is working and whether it is improving patient outcomes.

It's important to note that DFS is not the same as overall survival (OS), which refers to the length of time from primary treatment until death from any cause. While DFS can provide valuable information about the effectiveness of cancer treatments, it does not necessarily reflect the impact of those treatments on patients' overall survival.

Phosphorylation is the process of adding a phosphate group (a molecule consisting of one phosphorus atom and four oxygen atoms) to a protein or other organic molecule, which is usually done by enzymes called kinases. This post-translational modification can change the function, localization, or activity of the target molecule, playing a crucial role in various cellular processes such as signal transduction, metabolism, and regulation of gene expression. Phosphorylation is reversible, and the removal of the phosphate group is facilitated by enzymes called phosphatases.

Methotrexate is a medication used in the treatment of certain types of cancer and autoimmune diseases. It is an antimetabolite that inhibits the enzyme dihydrofolate reductase, which is necessary for the synthesis of purines and pyrimidines, essential components of DNA and RNA. By blocking this enzyme, methotrexate interferes with cell division and growth, making it effective in treating rapidly dividing cells such as cancer cells.

In addition to its use in cancer treatment, methotrexate is also used to manage autoimmune diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. In these conditions, methotrexate modulates the immune system and reduces inflammation.

It's important to note that methotrexate can have significant side effects and should be used under the close supervision of a healthcare provider. Regular monitoring of blood counts, liver function, and kidney function is necessary during treatment with methotrexate.

Southern blotting is a type of membrane-based blotting technique that is used in molecular biology to detect and locate specific DNA sequences within a DNA sample. This technique is named after its inventor, Edward M. Southern.

In Southern blotting, the DNA sample is first digested with one or more restriction enzymes, which cut the DNA at specific recognition sites. The resulting DNA fragments are then separated based on their size by gel electrophoresis. After separation, the DNA fragments are denatured to convert them into single-stranded DNA and transferred onto a nitrocellulose or nylon membrane.

Once the DNA has been transferred to the membrane, it is hybridized with a labeled probe that is complementary to the sequence of interest. The probe can be labeled with radioactive isotopes, fluorescent dyes, or chemiluminescent compounds. After hybridization, the membrane is washed to remove any unbound probe and then exposed to X-ray film (in the case of radioactive probes) or scanned (in the case of non-radioactive probes) to detect the location of the labeled probe on the membrane.

The position of the labeled probe on the membrane corresponds to the location of the specific DNA sequence within the original DNA sample. Southern blotting is a powerful tool for identifying and characterizing specific DNA sequences, such as those associated with genetic diseases or gene regulation.

Lymphokines are a type of cytokines that are produced and released by activated lymphocytes, a type of white blood cell, in response to an antigenic stimulation. They play a crucial role in the regulation of immune responses and inflammation. Lymphokines can mediate various biological activities such as chemotaxis, activation, proliferation, and differentiation of different immune cells including lymphocytes, monocytes, macrophages, and eosinophils. Examples of lymphokines include interleukins (ILs), interferons (IFNs), tumor necrosis factor (TNF), and colony-stimulating factors (CSFs).

Hematopoiesis is the process of forming and developing blood cells. It occurs in the bone marrow and includes the production of red blood cells (erythropoiesis), white blood cells (leukopoiesis), and platelets (thrombopoiesis). This process is regulated by various growth factors, hormones, and cytokines. Hematopoiesis begins early in fetal development and continues throughout a person's life. Disorders of hematopoiesis can result in conditions such as anemia, leukopenia, leukocytosis, thrombocytopenia, or thrombocytosis.

Antinuclear antibodies (ANA) are a type of autoantibody that target structures found in the nucleus of a cell. These antibodies are produced by the immune system and attack the body's own cells and tissues, leading to inflammation and damage. The presence of ANA is often used as a marker for certain autoimmune diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome, rheumatoid arthritis, scleroderma, and polymyositis.

ANA can be detected through a blood test called the antinuclear antibody test. A positive result indicates the presence of ANA in the blood, but it does not necessarily mean that a person has an autoimmune disease. Further testing is usually needed to confirm a diagnosis and determine the specific type of autoantibodies present.

It's important to note that ANA can also be found in healthy individuals, particularly as they age. Therefore, the test results should be interpreted in conjunction with other clinical findings and symptoms.

Recombinant fusion proteins are artificially created biomolecules that combine the functional domains or properties of two or more different proteins into a single protein entity. They are generated through recombinant DNA technology, where the genes encoding the desired protein domains are linked together and expressed as a single, chimeric gene in a host organism, such as bacteria, yeast, or mammalian cells.

The resulting fusion protein retains the functional properties of its individual constituent proteins, allowing for novel applications in research, diagnostics, and therapeutics. For instance, recombinant fusion proteins can be designed to enhance protein stability, solubility, or immunogenicity, making them valuable tools for studying protein-protein interactions, developing targeted therapies, or generating vaccines against infectious diseases or cancer.

Examples of recombinant fusion proteins include:

1. Etaglunatide (ABT-523): A soluble Fc fusion protein that combines the heavy chain fragment crystallizable region (Fc) of an immunoglobulin with the extracellular domain of the human interleukin-6 receptor (IL-6R). This fusion protein functions as a decoy receptor, neutralizing IL-6 and its downstream signaling pathways in rheumatoid arthritis.
2. Etanercept (Enbrel): A soluble TNF receptor p75 Fc fusion protein that binds to tumor necrosis factor-alpha (TNF-α) and inhibits its proinflammatory activity, making it a valuable therapeutic option for treating autoimmune diseases like rheumatoid arthritis, ankylosing spondylitis, and psoriasis.
3. Abatacept (Orencia): A fusion protein consisting of the extracellular domain of cytotoxic T-lymphocyte antigen 4 (CTLA-4) linked to the Fc region of an immunoglobulin, which downregulates T-cell activation and proliferation in autoimmune diseases like rheumatoid arthritis.
4. Belimumab (Benlysta): A monoclonal antibody that targets B-lymphocyte stimulator (BLyS) protein, preventing its interaction with the B-cell surface receptor and inhibiting B-cell activation in systemic lupus erythematosus (SLE).
5. Romiplostim (Nplate): A fusion protein consisting of a thrombopoietin receptor agonist peptide linked to an immunoglobulin Fc region, which stimulates platelet production in patients with chronic immune thrombocytopenia (ITP).
6. Darbepoetin alfa (Aranesp): A hyperglycosylated erythropoiesis-stimulating protein that functions as a longer-acting form of recombinant human erythropoietin, used to treat anemia in patients with chronic kidney disease or cancer.
7. Palivizumab (Synagis): A monoclonal antibody directed against the F protein of respiratory syncytial virus (RSV), which prevents RSV infection and is administered prophylactically to high-risk infants during the RSV season.
8. Ranibizumab (Lucentis): A recombinant humanized monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A (VEGF-A), used in the treatment of age-related macular degeneration, diabetic retinopathy, and other ocular disorders.
9. Cetuximab (Erbitux): A chimeric monoclonal antibody that binds to epidermal growth factor receptor (EGFR), used in the treatment of colorectal cancer and head and neck squamous cell carcinoma.
10. Adalimumab (Humira): A fully humanized monoclonal antibody that targets tumor necrosis factor-alpha (TNF-α), used in the treatment of various inflammatory diseases, including rheumatoid arthritis, psoriasis, and Crohn's disease.
11. Bevacizumab (Avastin): A recombinant humanized monoclonal antibody that binds to VEGF-A, used in the treatment of various cancers, including colorectal, lung, breast, and kidney cancer.
12. Trastuzumab (Herceptin): A humanized monoclonal antibody that targets HER2/neu receptor, used in the treatment of breast cancer.
13. Rituximab (Rituxan): A chimeric monoclonal antibody that binds to CD20 antigen on B cells, used in the treatment of non-Hodgkin's lymphoma and rheumatoid arthritis.
14. Palivizumab (Synagis): A humanized monoclonal antibody that binds to the F protein of respiratory syncytial virus, used in the prevention of respiratory syncytial virus infection in high-risk infants.
15. Infliximab (Remicade): A chimeric monoclonal antibody that targets TNF-α, used in the treatment of various inflammatory diseases, including Crohn's disease, ulcerative colitis, rheumatoid arthritis, and ankylosing spondylitis.
16. Natalizumab (Tysabri): A humanized monoclonal antibody that binds to α4β1 integrin, used in the treatment of multiple sclerosis and Crohn's disease.
17. Adalimumab (Humira): A fully human monoclonal antibody that targets TNF-α, used in the treatment of various inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis.
18. Golimumab (Simponi): A fully human monoclonal antibody that targets TNF-α, used in the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.
19. Certolizumab pegol (Cimzia): A PEGylated Fab' fragment of a humanized monoclonal antibody that targets TNF-α, used in the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease.
20. Ustekinumab (Stelara): A fully human monoclonal antibody that targets IL-12 and IL-23, used in the treatment of psoriasis, psoriatic arthritis, and Crohn's disease.
21. Secukinumab (Cosentyx): A fully human monoclonal antibody that targets IL-17A, used in the treatment of psoriasis, psoriatic arthritis, and ankylosing spondylitis.
22. Ixekizumab (Taltz): A fully human monoclonal antibody that targets IL-17A, used in the treatment of psoriasis and psoriatic arthritis.
23. Brodalumab (Siliq): A fully human monoclonal antibody that targets IL-17 receptor A, used in the treatment of psoriasis.
24. Sarilumab (Kevzara): A fully human monoclonal antibody that targets the IL-6 receptor, used in the treatment of rheumatoid arthritis.
25. Tocilizumab (Actemra): A humanized monoclonal antibody that targets the IL-6 receptor, used in the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, and chimeric antigen receptor T-cell-induced cytokine release syndrome.
26. Siltuximab (Sylvant): A chimeric monoclonal antibody that targets IL-6, used in the treatment of multicentric Castleman disease.
27. Satralizumab (Enspryng): A humanized monoclonal antibody that targets IL-6 receptor alpha, used in the treatment of neuromyelitis optica spectrum disorder.
28. Sirukumab (Plivensia): A human monoclonal antibody that targets IL-6, used in the treatment

A "mutant strain of mice" in a medical context refers to genetically engineered mice that have specific genetic mutations introduced into their DNA. These mutations can be designed to mimic certain human diseases or conditions, allowing researchers to study the underlying biological mechanisms and test potential therapies in a controlled laboratory setting.

Mutant strains of mice are created through various techniques, including embryonic stem cell manipulation, gene editing technologies such as CRISPR-Cas9, and radiation-induced mutagenesis. These methods allow scientists to introduce specific genetic changes into the mouse genome, resulting in mice that exhibit altered physiological or behavioral traits.

These strains of mice are widely used in biomedical research because their short lifespan, small size, and high reproductive rate make them an ideal model organism for studying human diseases. Additionally, the mouse genome has been well-characterized, and many genetic tools and resources are available to researchers working with these animals.

Examples of mutant strains of mice include those that carry mutations in genes associated with cancer, neurodegenerative disorders, metabolic diseases, and immunological conditions. These mice provide valuable insights into the pathophysiology of human diseases and help advance our understanding of potential therapeutic interventions.

Antibody specificity refers to the ability of an antibody to bind to a specific epitope or antigenic determinant on an antigen. Each antibody has a unique structure that allows it to recognize and bind to a specific region of an antigen, typically a small portion of the antigen's surface made up of amino acids or sugar residues. This highly specific binding is mediated by the variable regions of the antibody's heavy and light chains, which form a pocket that recognizes and binds to the epitope.

The specificity of an antibody is determined by its unique complementarity-determining regions (CDRs), which are loops of amino acids located in the variable domains of both the heavy and light chains. The CDRs form a binding site that recognizes and interacts with the epitope on the antigen. The precise fit between the antibody's binding site and the epitope is critical for specificity, as even small changes in the structure of either can prevent binding.

Antibody specificity is important in immune responses because it allows the immune system to distinguish between self and non-self antigens. This helps to prevent autoimmune reactions where the immune system attacks the body's own cells and tissues. Antibody specificity also plays a crucial role in diagnostic tests, such as ELISA assays, where antibodies are used to detect the presence of specific antigens in biological samples.

Antigen presentation is the process by which certain cells in the immune system, known as antigen presenting cells (APCs), display foreign or abnormal proteins (antigens) on their surface to other immune cells, such as T-cells. This process allows the immune system to recognize and mount a response against harmful pathogens, infected or damaged cells.

There are two main types of antigen presentation: major histocompatibility complex (MHC) class I and MHC class II presentation.

1. MHC class I presentation: APCs, such as dendritic cells, macrophages, and B-cells, process and load antigens onto MHC class I molecules, which are expressed on the surface of almost all nucleated cells in the body. The MHC class I-antigen complex is then recognized by CD8+ T-cells (cytotoxic T-cells), leading to the destruction of infected or damaged cells.
2. MHC class II presentation: APCs, particularly dendritic cells and B-cells, process and load antigens onto MHC class II molecules, which are mainly expressed on the surface of professional APCs. The MHC class II-antigen complex is then recognized by CD4+ T-cells (helper T-cells), leading to the activation of other immune cells, such as B-cells and macrophages, to eliminate the pathogen or damaged cells.

In summary, antigen presentation is a crucial step in the adaptive immune response, allowing for the recognition and elimination of foreign or abnormal substances that could potentially harm the body.

The thymus gland is an essential organ of the immune system, located in the upper chest, behind the sternum and surrounding the heart. It's primarily active until puberty and begins to shrink in size and activity thereafter. The main function of the thymus gland is the production and maturation of T-lymphocytes (T-cells), which are crucial for cell-mediated immunity, helping to protect the body from infection and cancer.

The thymus gland provides a protected environment where immune cells called pre-T cells develop into mature T cells. During this process, they learn to recognize and respond appropriately to foreign substances while remaining tolerant to self-tissues, which is crucial for preventing autoimmune diseases.

Additionally, the thymus gland produces hormones like thymosin that regulate immune cell activities and contribute to the overall immune response.

Non-Hodgkin lymphoma (NHL) is a type of cancer that originates in the lymphatic system, which is part of the immune system. It involves the abnormal growth and proliferation of malignant lymphocytes (a type of white blood cell), leading to the formation of tumors in lymph nodes, spleen, bone marrow, or other organs. NHL can be further classified into various subtypes based on the specific type of lymphocyte involved and its characteristics.

The symptoms of Non-Hodgkin lymphoma may include:

* Painless swelling of lymph nodes in the neck, armpits, or groin
* Persistent fatigue
* Unexplained weight loss
* Fever
* Night sweats
* Itchy skin

The exact cause of Non-Hodgkin lymphoma is not well understood, but it has been associated with certain risk factors such as age (most common in people over 60), exposure to certain chemicals, immune system deficiencies, and infection with viruses like Epstein-Barr virus or HIV.

Treatment for Non-Hodgkin lymphoma depends on the stage and subtype of the disease, as well as the patient's overall health. Treatment options may include chemotherapy, radiation therapy, immunotherapy, targeted therapy, stem cell transplantation, or a combination of these approaches. Regular follow-up care is essential to monitor the progression of the disease and manage any potential long-term side effects of treatment.

Bone marrow cells are the types of cells found within the bone marrow, which is the spongy tissue inside certain bones in the body. The main function of bone marrow is to produce blood cells. There are two types of bone marrow: red and yellow. Red bone marrow is where most blood cell production takes place, while yellow bone marrow serves as a fat storage site.

The three main types of bone marrow cells are:

1. Hematopoietic stem cells (HSCs): These are immature cells that can differentiate into any type of blood cell, including red blood cells, white blood cells, and platelets. They have the ability to self-renew, meaning they can divide and create more hematopoietic stem cells.
2. Red blood cell progenitors: These are immature cells that will develop into mature red blood cells, also known as erythrocytes. Red blood cells carry oxygen from the lungs to the body's tissues and carbon dioxide back to the lungs.
3. Myeloid and lymphoid white blood cell progenitors: These are immature cells that will develop into various types of white blood cells, which play a crucial role in the body's immune system by fighting infections and diseases. Myeloid progenitors give rise to granulocytes (neutrophils, eosinophils, and basophils), monocytes, and megakaryocytes (which eventually become platelets). Lymphoid progenitors differentiate into B cells, T cells, and natural killer (NK) cells.

Bone marrow cells are essential for maintaining a healthy blood cell count and immune system function. Abnormalities in bone marrow cells can lead to various medical conditions, such as anemia, leukopenia, leukocytosis, thrombocytopenia, or thrombocytosis, depending on the specific type of blood cell affected. Additionally, bone marrow cells are often used in transplantation procedures to treat patients with certain types of cancer, such as leukemia and lymphoma, or other hematologic disorders.

Vincristine is an antineoplastic agent, specifically a vinca alkaloid. It is derived from the Madagascar periwinkle plant (Catharanthus roseus). Vincristine binds to tubulin, a protein found in microtubules, and inhibits their polymerization, which results in disruption of mitotic spindles leading to cell cycle arrest and apoptosis (programmed cell death). It is used in the treatment of various types of cancer including leukemias, lymphomas, and solid tumors. Common side effects include peripheral neuropathy, constipation, and alopecia.

A hybridoma is a type of hybrid cell that is created in a laboratory by fusing a cancer cell (usually a B cell) with a normal immune cell. The resulting hybrid cell combines the ability of the cancer cell to grow and divide indefinitely with the ability of the immune cell to produce antibodies, which are proteins that help the body fight infection.

Hybridomas are commonly used to produce monoclonal antibodies, which are identical copies of a single antibody produced by a single clone of cells. These antibodies can be used for a variety of purposes, including diagnostic tests and treatments for diseases such as cancer and autoimmune disorders.

To create hybridomas, B cells are first isolated from the spleen or blood of an animal that has been immunized with a specific antigen (a substance that triggers an immune response). The B cells are then fused with cancer cells using a chemical agent such as polyethylene glycol. The resulting hybrid cells are called hybridomas and are grown in culture medium, where they can be selected for their ability to produce antibodies specific to the antigen of interest. These antibody-producing hybridomas can then be cloned to produce large quantities of monoclonal antibodies.

Medical survival rate is a statistical measure used to determine the percentage of patients who are still alive for a specific period of time after their diagnosis or treatment for a certain condition or disease. It is often expressed as a five-year survival rate, which refers to the proportion of people who are alive five years after their diagnosis. Survival rates can be affected by many factors, including the stage of the disease at diagnosis, the patient's age and overall health, the effectiveness of treatment, and other health conditions that the patient may have. It is important to note that survival rates are statistical estimates and do not necessarily predict an individual patient's prognosis.

Immunoglobulin A (IgA) is a type of antibody that plays a crucial role in the immune function of the human body. It is primarily found in external secretions, such as saliva, tears, breast milk, and sweat, as well as in mucous membranes lining the respiratory and gastrointestinal tracts. IgA exists in two forms: a monomeric form found in serum and a polymeric form found in secretions.

The primary function of IgA is to provide immune protection at mucosal surfaces, which are exposed to various environmental antigens, such as bacteria, viruses, parasites, and allergens. By doing so, it helps prevent the entry and colonization of pathogens into the body, reducing the risk of infections and inflammation.

IgA functions by binding to antigens present on the surface of pathogens or allergens, forming immune complexes that can neutralize their activity. These complexes are then transported across the epithelial cells lining mucosal surfaces and released into the lumen, where they prevent the adherence and invasion of pathogens.

In summary, Immunoglobulin A (IgA) is a vital antibody that provides immune defense at mucosal surfaces by neutralizing and preventing the entry of harmful antigens into the body.

DNA nucleotidylexotransferase is not a widely recognized or established medical term. It appears to be a combination of the terms "DNA," "nucleotide," and "lexotransferase," but the specific meaning or function of this enzyme is unclear.

"DNA" refers to deoxyribonucleic acid, which is the genetic material found in the cells of most living organisms.

"Nucleotide" refers to a molecule that consists of a nitrogenous base, a sugar, and one or more phosphate groups. Nucleotides are the building blocks of DNA and RNA.

"Lexotransferase" is not a recognized enzyme class or function. It may be a typographical error or a term that has been misused or misunderstood.

Therefore, it is not possible to provide a medical definition for 'DNA nucleotidylexotransferase'. If you have more information about the context in which this term was used, I may be able to provide further clarification.

CD45 is a protein that is found on the surface of many types of white blood cells, including T-cells, B-cells, and natural killer (NK) cells. It is also known as leukocyte common antigen because it is present on almost all leukocytes. CD45 is a tyrosine phosphatase that plays a role in regulating the activity of various proteins involved in cell signaling pathways.

As an antigen, CD45 is used as a marker to identify and distinguish different types of white blood cells. It has several isoforms that are generated by alternative splicing of its mRNA, resulting in different molecular weights. The size of the CD45 isoform can be used to distinguish between different subsets of T-cells and B-cells.

CD45 is an important molecule in the immune system, and abnormalities in its expression or function have been implicated in various diseases, including autoimmune disorders and cancer.

Trinitrobenzenes are not typically referred to in the context of medical definitions, as they are chemical compounds that do not have direct relevance to medical fields. However, I can provide you with some general information about trinitrobenzenes.

Trinitrobenzenes are a group of chemical compounds consisting of a benzene ring (a cyclic aromatic hydrocarbon) with three nitro groups (-NO2) attached to it. The most common and well-known compound in this group is 1,3,5-trinitrobenzene (TNB). These compounds are highly explosive and have been used in military and industrial applications for their energetic properties.

In a medical or clinical context, trinitrobenzenes may be encountered only if someone is exposed to these chemicals in an occupational or accidental setting. Exposure can lead to local skin irritation, eye damage, or respiratory issues. Chronic exposure or high-dose acute exposure might cause more severe health problems, including damage to the liver and kidneys. However, trinitrobenzenes are not used as therapeutic agents or diagnostic tools in medicine.

Hematopoietic Stem Cell Transplantation (HSCT) is a medical procedure where hematopoietic stem cells (immature cells that give rise to all blood cell types) are transplanted into a patient. This procedure is often used to treat various malignant and non-malignant disorders affecting the hematopoietic system, such as leukemias, lymphomas, multiple myeloma, aplastic anemia, inherited immune deficiency diseases, and certain genetic metabolic disorders.

The transplantation can be autologous (using the patient's own stem cells), allogeneic (using stem cells from a genetically matched donor, usually a sibling or unrelated volunteer), or syngeneic (using stem cells from an identical twin).

The process involves collecting hematopoietic stem cells, most commonly from the peripheral blood or bone marrow. The collected cells are then infused into the patient after the recipient's own hematopoietic system has been ablated (or destroyed) using high-dose chemotherapy and/or radiation therapy. This allows the donor's stem cells to engraft, reconstitute, and restore the patient's hematopoietic system.

HSCT is a complex and potentially risky procedure with various complications, including graft-versus-host disease, infections, and organ damage. However, it offers the potential for cure or long-term remission in many patients with otherwise fatal diseases.

Interleukin-6 (IL-6) is a cytokine, a type of protein that plays a crucial role in communication between cells, especially in the immune system. It is produced by various cells including T-cells, B-cells, fibroblasts, and endothelial cells in response to infection, injury, or inflammation.

IL-6 has diverse effects on different cell types. In the immune system, it stimulates the growth and differentiation of B-cells into plasma cells that produce antibodies. It also promotes the activation and survival of T-cells. Moreover, IL-6 plays a role in fever induction by acting on the hypothalamus to raise body temperature during an immune response.

In addition to its functions in the immune system, IL-6 has been implicated in various physiological processes such as hematopoiesis (the formation of blood cells), bone metabolism, and neural development. However, abnormal levels of IL-6 have also been associated with several diseases, including autoimmune disorders, chronic inflammation, and cancer.

Survival analysis is a branch of statistics that deals with the analysis of time to event data. It is used to estimate the time it takes for a certain event of interest to occur, such as death, disease recurrence, or treatment failure. The event of interest is called the "failure" event, and survival analysis estimates the probability of not experiencing the failure event until a certain point in time, also known as the "survival" probability.

Survival analysis can provide important information about the effectiveness of treatments, the prognosis of patients, and the identification of risk factors associated with the event of interest. It can handle censored data, which is common in medical research where some participants may drop out or be lost to follow-up before the event of interest occurs.

Survival analysis typically involves estimating the survival function, which describes the probability of surviving beyond a certain time point, as well as hazard functions, which describe the instantaneous rate of failure at a given time point. Other important concepts in survival analysis include median survival times, restricted mean survival times, and various statistical tests to compare survival curves between groups.

Histocompatibility antigens Class II are a group of cell surface proteins that play a crucial role in the immune system's response to foreign substances. They are expressed on the surface of various cells, including immune cells such as B lymphocytes, macrophages, dendritic cells, and activated T lymphocytes.

Class II histocompatibility antigens are encoded by the major histocompatibility complex (MHC) class II genes, which are located on chromosome 6 in humans. These antigens are composed of two non-covalently associated polypeptide chains, an alpha (α) and a beta (β) chain, which form a heterodimer. There are three main types of Class II histocompatibility antigens, known as HLA-DP, HLA-DQ, and HLA-DR.

Class II histocompatibility antigens present peptide antigens to CD4+ T helper cells, which then activate other immune cells, such as B cells and macrophages, to mount an immune response against the presented antigen. Because of their role in initiating an immune response, Class II histocompatibility antigens are important in transplantation medicine, where mismatches between donor and recipient can lead to rejection of the transplanted organ or tissue.

An epitope is a specific region on the surface of an antigen (a molecule that can trigger an immune response) that is recognized by an antibody, B-cell receptor, or T-cell receptor. It is also commonly referred to as an antigenic determinant. Epitopes are typically composed of linear amino acid sequences or conformational structures made up of discontinuous amino acids in the antigen. They play a crucial role in the immune system's ability to differentiate between self and non-self molecules, leading to the targeted destruction of foreign substances like viruses and bacteria. Understanding epitopes is essential for developing vaccines, diagnostic tests, and immunotherapies.

6-Mercaptopurine (6-MP) is a medication used primarily in the treatment of cancer, specifically acute lymphoblastic leukemia (ALL), and to prevent rejection in organ transplantation. It is an antimetabolite that works by interfering with the synthesis of DNA and RNA, thereby inhibiting cell division and growth.

6-MP is a prodrug, meaning it requires metabolic activation in the body to exert its therapeutic effects. Once absorbed, 6-MP is converted into several active metabolites, including thioguanine nucleotides (TGN), which are incorporated into DNA and RNA, leading to cytotoxicity and cell death.

Common side effects of 6-MP include nausea, vomiting, diarrhea, mouth sores, and increased susceptibility to infections. Long-term use of the medication can also lead to liver toxicity, pancreatitis, and anemia. Regular monitoring of blood counts, liver function tests, and TGN levels is necessary during treatment with 6-MP to minimize potential side effects and ensure safe and effective dosing.

'DBA' is an abbreviation for 'Database of Genotypes and Phenotypes,' but in the context of "Inbred DBA mice," it refers to a specific strain of laboratory mice that have been inbred for many generations. The DBA strain is one of the oldest inbred strains, and it was established in 1909 by C.C. Little at the Bussey Institute of Harvard University.

The "Inbred DBA" mice are genetically identical mice that have been produced by brother-sister matings for more than 20 generations. This extensive inbreeding results in a homozygous population, where all members of the strain have the same genetic makeup. The DBA strain is further divided into several sub-strains, including DBA/1, DBA/2, and DBA/J, among others.

DBA mice are known for their black coat color, which can fade to gray with age, and they exhibit a range of phenotypic traits that make them useful for research purposes. For example, DBA mice have a high incidence of retinal degeneration, making them a valuable model for studying eye diseases. They also show differences in behavior, immune response, and susceptibility to various diseases compared to other inbred strains.

In summary, "Inbred DBA" mice are a specific strain of laboratory mice that have been inbred for many generations, resulting in a genetically identical population with distinct phenotypic traits. They are widely used in biomedical research to study various diseases and biological processes.

A dose-response relationship in the context of drugs refers to the changes in the effects or symptoms that occur as the dose of a drug is increased or decreased. Generally, as the dose of a drug is increased, the severity or intensity of its effects also increases. Conversely, as the dose is decreased, the effects of the drug become less severe or may disappear altogether.

The dose-response relationship is an important concept in pharmacology and toxicology because it helps to establish the safe and effective dosage range for a drug. By understanding how changes in the dose of a drug affect its therapeutic and adverse effects, healthcare providers can optimize treatment plans for their patients while minimizing the risk of harm.

The dose-response relationship is typically depicted as a curve that shows the relationship between the dose of a drug and its effect. The shape of the curve may vary depending on the drug and the specific effect being measured. Some drugs may have a steep dose-response curve, meaning that small changes in the dose can result in large differences in the effect. Other drugs may have a more gradual dose-response curve, where larger changes in the dose are needed to produce significant effects.

In addition to helping establish safe and effective dosages, the dose-response relationship is also used to evaluate the potential therapeutic benefits and risks of new drugs during clinical trials. By systematically testing different doses of a drug in controlled studies, researchers can identify the optimal dosage range for the drug and assess its safety and efficacy.

Promoter regions in genetics refer to specific DNA sequences located near the transcription start site of a gene. They serve as binding sites for RNA polymerase and various transcription factors that regulate the initiation of gene transcription. These regulatory elements help control the rate of transcription and, therefore, the level of gene expression. Promoter regions can be composed of different types of sequences, such as the TATA box and CAAT box, and their organization and composition can vary between different genes and species.

Inbred NOD (Nonobese Diabetic) mice are a strain of laboratory mice that are genetically predisposed to develop autoimmune diabetes. This strain was originally developed in Japan and has been widely used as an animal model for studying type 1 diabetes and its complications.

NOD mice typically develop diabetes spontaneously at around 12-14 weeks of age, although the onset and severity of the disease can vary between individual mice. The disease is caused by a breakdown in immune tolerance, leading to an autoimmune attack on the insulin-producing beta cells of the pancreas.

Inbred NOD mice are highly valuable for research purposes because they exhibit many of the same genetic and immunological features as human patients with type 1 diabetes. By studying these mice, researchers can gain insights into the underlying mechanisms of the disease and develop new treatments and therapies.

Cytokines are a broad and diverse category of small signaling proteins that are secreted by various cells, including immune cells, in response to different stimuli. They play crucial roles in regulating the immune response, inflammation, hematopoiesis, and cellular communication.

Cytokines mediate their effects by binding to specific receptors on the surface of target cells, which triggers intracellular signaling pathways that ultimately result in changes in gene expression, cell behavior, and function. Some key functions of cytokines include:

1. Regulating the activation, differentiation, and proliferation of immune cells such as T cells, B cells, natural killer (NK) cells, and macrophages.
2. Coordinating the inflammatory response by recruiting immune cells to sites of infection or tissue damage and modulating their effector functions.
3. Regulating hematopoiesis, the process of blood cell formation in the bone marrow, by controlling the proliferation, differentiation, and survival of hematopoietic stem and progenitor cells.
4. Modulating the development and function of the nervous system, including neuroinflammation, neuroprotection, and neuroregeneration.

Cytokines can be classified into several categories based on their structure, function, or cellular origin. Some common types of cytokines include interleukins (ILs), interferons (IFNs), tumor necrosis factors (TNFs), chemokines, colony-stimulating factors (CSFs), and transforming growth factors (TGFs). Dysregulation of cytokine production and signaling has been implicated in various pathological conditions, such as autoimmune diseases, chronic inflammation, cancer, and neurodegenerative disorders.

Granulocytes are a type of white blood cell that plays a crucial role in the body's immune system. They are called granulocytes because they contain small granules in their cytoplasm, which are filled with various enzymes and proteins that help them fight off infections and destroy foreign substances.

There are three types of granulocytes: neutrophils, eosinophils, and basophils. Neutrophils are the most abundant type and are primarily responsible for fighting bacterial infections. Eosinophils play a role in defending against parasitic infections and regulating immune responses. Basophils are involved in inflammatory reactions and allergic responses.

Granulocytes are produced in the bone marrow and released into the bloodstream, where they circulate and patrol for any signs of infection or foreign substances. When they encounter a threat, they quickly move to the site of infection or injury and release their granules to destroy the invading organisms or substances.

Abnormal levels of granulocytes in the blood can indicate an underlying medical condition, such as an infection, inflammation, or a bone marrow disorder.

Neoplastic gene expression regulation refers to the processes that control the production of proteins and other molecules from genes in neoplastic cells, or cells that are part of a tumor or cancer. In a normal cell, gene expression is tightly regulated to ensure that the right genes are turned on or off at the right time. However, in cancer cells, this regulation can be disrupted, leading to the overexpression or underexpression of certain genes.

Neoplastic gene expression regulation can be affected by a variety of factors, including genetic mutations, epigenetic changes, and signals from the tumor microenvironment. These changes can lead to the activation of oncogenes (genes that promote cancer growth and development) or the inactivation of tumor suppressor genes (genes that prevent cancer).

Understanding neoplastic gene expression regulation is important for developing new therapies for cancer, as targeting specific genes or pathways involved in this process can help to inhibit cancer growth and progression.

Antibodies are proteins produced by the immune system in response to the presence of a foreign substance, such as a bacterium or virus. They are capable of identifying and binding to specific antigens (foreign substances) on the surface of these invaders, marking them for destruction by other immune cells. Antibodies are also known as immunoglobulins and come in several different types, including IgA, IgD, IgE, IgG, and IgM, each with a unique function in the immune response. They are composed of four polypeptide chains, two heavy chains and two light chains, that are held together by disulfide bonds. The variable regions of the heavy and light chains form the antigen-binding site, which is specific to a particular antigen.

In situ hybridization, fluorescence (FISH) is a type of molecular cytogenetic technique used to detect and localize the presence or absence of specific DNA sequences on chromosomes through the use of fluorescent probes. This technique allows for the direct visualization of genetic material at a cellular level, making it possible to identify chromosomal abnormalities such as deletions, duplications, translocations, and other rearrangements.

The process involves denaturing the DNA in the sample to separate the double-stranded molecules into single strands, then adding fluorescently labeled probes that are complementary to the target DNA sequence. The probe hybridizes to the complementary sequence in the sample, and the location of the probe is detected by fluorescence microscopy.

FISH has a wide range of applications in both clinical and research settings, including prenatal diagnosis, cancer diagnosis and monitoring, and the study of gene expression and regulation. It is a powerful tool for identifying genetic abnormalities and understanding their role in human disease.

Protein kinase inhibitors (PKIs) are a class of drugs that work by interfering with the function of protein kinases. Protein kinases are enzymes that play a crucial role in many cellular processes by adding a phosphate group to specific proteins, thereby modifying their activity, localization, or interaction with other molecules. This process of adding a phosphate group is known as phosphorylation and is a key mechanism for regulating various cellular functions, including signal transduction, metabolism, and cell division.

In some diseases, such as cancer, protein kinases can become overactive or mutated, leading to uncontrolled cell growth and division. Protein kinase inhibitors are designed to block the activity of these dysregulated kinases, thereby preventing or slowing down the progression of the disease. These drugs can be highly specific, targeting individual protein kinases or families of kinases, making them valuable tools for targeted therapy in cancer and other diseases.

Protein kinase inhibitors can work in various ways to block the activity of protein kinases. Some bind directly to the active site of the enzyme, preventing it from interacting with its substrates. Others bind to allosteric sites, changing the conformation of the enzyme and making it inactive. Still, others target upstream regulators of protein kinases or interfere with their ability to form functional complexes.

Examples of protein kinase inhibitors include imatinib (Gleevec), which targets the BCR-ABL kinase in chronic myeloid leukemia, and gefitinib (Iressa), which inhibits the EGFR kinase in non-small cell lung cancer. These drugs have shown significant clinical benefits in treating these diseases and have become important components of modern cancer therapy.

An Enzyme-Linked Immunosorbent Assay (ELISA) is a type of analytical biochemistry assay used to detect and quantify the presence of a substance, typically a protein or peptide, in a liquid sample. It takes its name from the enzyme-linked antibodies used in the assay.

In an ELISA, the sample is added to a well containing a surface that has been treated to capture the target substance. If the target substance is present in the sample, it will bind to the surface. Next, an enzyme-linked antibody specific to the target substance is added. This antibody will bind to the captured target substance if it is present. After washing away any unbound material, a substrate for the enzyme is added. If the enzyme is present due to its linkage to the antibody, it will catalyze a reaction that produces a detectable signal, such as a color change or fluorescence. The intensity of this signal is proportional to the amount of target substance present in the sample, allowing for quantification.

ELISAs are widely used in research and clinical settings to detect and measure various substances, including hormones, viruses, and bacteria. They offer high sensitivity, specificity, and reproducibility, making them a reliable choice for many applications.

A provirus is a form of the genetic material of a retrovirus that is integrated into the DNA of the host cell it has infected. Once integrated, the provirus is replicated along with the host's own DNA every time the cell divides, and it becomes a permanent part of the host's genome.

The process of integration involves the reverse transcription of the retroviral RNA genome into DNA by the enzyme reverse transcriptase, followed by the integration of the resulting double-stranded proviral DNA into the host chromosome by the enzyme integrase.

Proviruses can remain dormant and inactive for long periods of time, or they can become active and produce new viral particles that can infect other cells. In some cases, proviruses can also disrupt the normal functioning of host genes, leading to various diseases such as cancer.

Interleukins (ILs) are a group of naturally occurring proteins that are important in the immune system. They are produced by various cells, including immune cells like lymphocytes and macrophages, and they help regulate the immune response by facilitating communication between different types of cells. Interleukins can have both pro-inflammatory and anti-inflammatory effects, depending on the specific interleukin and the context in which it is produced. They play a role in various biological processes, including the development of immune responses, inflammation, and hematopoiesis (the formation of blood cells).

There are many different interleukins that have been identified, and they are numbered according to the order in which they were discovered. For example, IL-1, IL-2, IL-3, etc. Each interleukin has a specific set of functions and targets certain types of cells. Dysregulation of interleukins has been implicated in various diseases, including autoimmune disorders, infections, and cancer.

The Fluorescent Antibody Technique (FAT) is a type of immunofluorescence assay used in laboratory medicine and pathology for the detection and localization of specific antigens or antibodies in tissues, cells, or microorganisms. In this technique, a fluorescein-labeled antibody is used to selectively bind to the target antigen or antibody, forming an immune complex. When excited by light of a specific wavelength, the fluorescein label emits light at a longer wavelength, typically visualized as green fluorescence under a fluorescence microscope.

The FAT is widely used in diagnostic microbiology for the identification and characterization of various bacteria, viruses, fungi, and parasites. It has also been applied in the diagnosis of autoimmune diseases and certain cancers by detecting specific antibodies or antigens in patient samples. The main advantage of FAT is its high sensitivity and specificity, allowing for accurate detection and differentiation of various pathogens and disease markers. However, it requires specialized equipment and trained personnel to perform and interpret the results.

Immunoglobulin E (IgE) is a type of antibody that plays a key role in the immune response to parasitic infections and allergies. It is produced by B cells in response to stimulation by antigens, such as pollen, pet dander, or certain foods. Once produced, IgE binds to receptors on the surface of mast cells and basophils, which are immune cells found in tissues and blood respectively. When an individual with IgE antibodies encounters the allergen again, the cross-linking of IgE molecules bound to the FcεRI receptor triggers the release of mediators such as histamine, leukotrienes, prostaglandins, and various cytokines from these cells. These mediators cause the symptoms of an allergic reaction, such as itching, swelling, and redness. IgE also plays a role in protecting against certain parasitic infections by activating eosinophils, which can kill the parasites.

In summary, Immunoglobulin E (IgE) is a type of antibody that plays a crucial role in the immune response to allergens and parasitic infections, it binds to receptors on the surface of mast cells and basophils, when an individual with IgE antibodies encounters the allergen again, it triggers the release of mediators from these cells causing the symptoms of an allergic reaction.

Human chromosomes are thread-like structures that contain genetic material, composed of DNA and proteins, present in the nucleus of human cells. Each chromosome is a single, long DNA molecule that carries hundreds to thousands of genes.

Chromosomes 21, 22, and Y are three of the 23 pairs of human chromosomes. Here's what you need to know about each:

* Chromosome 21 is the smallest human autosomal chromosome, with a total length of about 47 million base pairs. It contains an estimated 200-300 genes and is associated with several genetic disorders, most notably Down syndrome, which occurs when there is an extra copy of this chromosome (trisomy 21).
* Chromosome 22 is the second smallest human autosomal chromosome, with a total length of about 50 million base pairs. It contains an estimated 500-600 genes and is associated with several genetic disorders, including DiGeorge syndrome and cat-eye syndrome.
* The Y chromosome is one of the two sex chromosomes (the other being the X chromosome) and is found only in males. It is much smaller than the X chromosome, with a total length of about 59 million base pairs and an estimated 70-200 genes. The Y chromosome determines maleness by carrying the gene for the testis-determining factor (TDF), which triggers male development in the embryo.

It's worth noting that while we have a standard set of 23 pairs of chromosomes, there can be variations and abnormalities in the number or structure of these chromosomes that can lead to genetic disorders.

Antigens are substances (usually proteins) on the surface of cells, viruses, fungi, or bacteria that can be recognized by the immune system and provoke an immune response. In the context of differentiation, antigens refer to specific markers that identify the developmental stage or lineage of a cell.

Differentiation antigens are proteins or carbohydrates expressed on the surface of cells during various stages of differentiation, which can be used to distinguish between cells at different maturation stages or of different cell types. These antigens play an essential role in the immune system's ability to recognize and respond to abnormal or infected cells while sparing healthy cells.

Examples of differentiation antigens include:

1. CD (cluster of differentiation) molecules: A group of membrane proteins used to identify and define various cell types, such as T cells, B cells, natural killer cells, monocytes, and granulocytes.
2. Lineage-specific antigens: Antigens that are specific to certain cell lineages, such as CD3 for T cells or CD19 for B cells.
3. Maturation markers: Antigens that indicate the maturation stage of a cell, like CD34 and CD38 on hematopoietic stem cells.

Understanding differentiation antigens is crucial in immunology, cancer research, transplantation medicine, and vaccine development.

Viral DNA refers to the genetic material present in viruses that consist of DNA as their core component. Deoxyribonucleic acid (DNA) is one of the two types of nucleic acids that are responsible for storing and transmitting genetic information in living organisms. Viruses are infectious agents much smaller than bacteria that can only replicate inside the cells of other organisms, called hosts.

Viral DNA can be double-stranded (dsDNA) or single-stranded (ssDNA), depending on the type of virus. Double-stranded DNA viruses have a genome made up of two complementary strands of DNA, while single-stranded DNA viruses contain only one strand of DNA.

Examples of dsDNA viruses include Adenoviruses, Herpesviruses, and Poxviruses, while ssDNA viruses include Parvoviruses and Circoviruses. Viral DNA plays a crucial role in the replication cycle of the virus, encoding for various proteins necessary for its multiplication and survival within the host cell.

A hapten is a small molecule that can elicit an immune response only when it is attached to a larger carrier protein. On its own, a hapten is too small to be recognized by the immune system as a foreign substance. However, when it binds to a carrier protein, it creates a new antigenic site that can be detected by the immune system. This process is known as haptenization.

Haptens are important in the study of immunology and allergies because they can cause an allergic response when they bind to proteins in the body. For example, certain chemicals found in cosmetics, drugs, or industrial products can act as haptens and trigger an allergic reaction when they come into contact with the skin or mucous membranes. The resulting immune response can cause symptoms such as rash, itching, or inflammation.

Haptens can also be used in the development of vaccines and diagnostic tests, where they are attached to carrier proteins to stimulate an immune response and produce specific antibodies that can be measured or used for therapy.

Trans-activators are proteins that increase the transcriptional activity of a gene or a set of genes. They do this by binding to specific DNA sequences and interacting with the transcription machinery, thereby enhancing the recruitment and assembly of the complexes needed for transcription. In some cases, trans-activators can also modulate the chromatin structure to make the template more accessible to the transcription machinery.

In the context of HIV (Human Immunodeficiency Virus) infection, the term "trans-activator" is often used specifically to refer to the Tat protein. The Tat protein is a viral regulatory protein that plays a critical role in the replication of HIV by activating the transcription of the viral genome. It does this by binding to a specific RNA structure called the Trans-Activation Response Element (TAR) located at the 5' end of all nascent HIV transcripts, and recruiting cellular cofactors that enhance the processivity and efficiency of RNA polymerase II, leading to increased viral gene expression.

Mast cell leukemia is a rare and aggressive type of leukemia, which is a cancer of the white blood cells. Specifically, mast cell leukemia affects a particular type of white blood cell called a mast cell. Mast cells are part of the immune system and play a role in allergic reactions and inflammation.

In mast cell leukemia, the bone marrow produces too many immature mast cells, which then enter the bloodstream. These abnormal mast cells can accumulate in various organs, such as the spleen, liver, and lymph nodes, causing damage and enlargement of these organs.

Symptoms of mast cell leukemia may include fatigue, weight loss, frequent infections, easy bruising or bleeding, bone pain, and enlarged lymph nodes. Diagnosis typically involves blood tests, bone marrow aspiration and biopsy, and imaging studies to assess the extent of organ involvement.

Mast cell leukemia is a very aggressive cancer with a poor prognosis, and treatment options are limited. Current treatments may include chemotherapy, stem cell transplantation, and targeted therapy with drugs that target specific molecular abnormalities in mast cells. However, the response to treatment is often not durable, and the disease can progress rapidly.

Adoptive transfer is a medical procedure in which immune cells are transferred from a donor to a recipient with the aim of providing immunity or treating a disease, such as cancer. This technique is often used in the field of immunotherapy and involves isolating specific immune cells (like T-cells) from the donor, expanding their numbers in the laboratory, and then infusing them into the patient. The transferred cells are expected to recognize and attack the target cells, such as malignant or infected cells, leading to a therapeutic effect. This process requires careful matching of donor and recipient to minimize the risk of rejection and graft-versus-host disease.

Pre-B cell receptors (pre-BCRs) are multi-protein complexes found on the surface of developing B cells, or lymphocytes, in the bone marrow. They play a critical role in the early stages of B cell development and maturation.

Pre-BCRs consist of a membrane-bound immunoglobulin M (IgM) molecule, called the surrogate light chain, which is non-covalently associated with a heterodimer of two signaling chains, λ5 and Igα/Igβ. The pre-BCR is assembled after the successful rearrangement of the heavy chain gene segments during B cell development.

The primary function of pre-BCRs is to initiate a signaling cascade that triggers further genetic rearrangements, known as light chain gene rearrangements, and ensures the proper assembly of complete IgM molecules on the surface of mature B cells. Pre-BCR signaling also contributes to the selection and survival of developing B cells, helping to maintain a diverse and functional repertoire of B cell receptors (BCRs) in the immune system.

Dysregulation or abnormalities in pre-BCR function can lead to various B cell developmental disorders and malignancies, such as leukemias and lymphomas.

Autoimmune diseases are a group of disorders in which the immune system, which normally protects the body from foreign invaders like bacteria and viruses, mistakenly attacks the body's own cells and tissues. This results in inflammation and damage to various organs and tissues in the body.

In autoimmune diseases, the body produces autoantibodies that target its own proteins or cell receptors, leading to their destruction or malfunction. The exact cause of autoimmune diseases is not fully understood, but it is believed that a combination of genetic and environmental factors contribute to their development.

There are over 80 different types of autoimmune diseases, including rheumatoid arthritis, lupus, multiple sclerosis, type 1 diabetes, Hashimoto's thyroiditis, Graves' disease, psoriasis, and inflammatory bowel disease. Symptoms can vary widely depending on the specific autoimmune disease and the organs or tissues affected. Treatment typically involves managing symptoms and suppressing the immune system to prevent further damage.

Lymphoproliferative disorders (LPDs) are a group of diseases characterized by the excessive proliferation of lymphoid cells, which are crucial components of the immune system. These disorders can arise from both B-cells and T-cells, leading to various clinical manifestations ranging from benign to malignant conditions.

LPDs can be broadly classified into reactive and neoplastic categories:

1. Reactive Lymphoproliferative Disorders: These are typically triggered by infections, autoimmune diseases, or immunodeficiency states. They involve an exaggerated response of the immune system leading to the excessive proliferation of lymphoid cells. Examples include:
* Infectious mononucleosis (IM) caused by Epstein-Barr virus (EBV)
* Lymph node enlargement due to various infections or autoimmune disorders
* Post-transplant lymphoproliferative disorder (PTLD), which occurs in the context of immunosuppression following organ transplantation
2. Neoplastic Lymphoproliferative Disorders: These are malignant conditions characterized by uncontrolled growth and accumulation of abnormal lymphoid cells, leading to the formation of tumors. They can be further classified into Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Examples include:
* Hodgkin lymphoma (HL): Classical HL and nodular lymphocyte-predominant HL
* Non-Hodgkin lymphoma (NHL): Various subtypes, such as diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and Burkitt lymphoma

It is important to note that the distinction between reactive and neoplastic LPDs can sometimes be challenging, requiring careful clinical, histopathological, immunophenotypic, and molecular evaluations. Proper diagnosis and classification of LPDs are crucial for determining appropriate treatment strategies and predicting patient outcomes.

Antibody diversity refers to the variety of different antibodies that an organism can produce in response to exposure to various antigens. This diversity is generated through a process called V(D)J recombination, which occurs during the development of B cells in the bone marrow.

The variable regions of heavy and light chains of antibody molecules are generated by the random selection and rearrangement of gene segments (V, D, and J) from different combinations. This results in a unique antigen-binding site for each antibody molecule, allowing the immune system to recognize and respond to a vast array of potential pathogens.

Further diversity is generated through the processes of somatic hypermutation and class switch recombination, which introduce additional changes in the variable regions of antibodies during an immune response. These processes allow for the affinity maturation of antibodies, where the binding strength between the antibody and antigen is increased over time, leading to a more effective immune response.

Overall, antibody diversity is critical for the adaptive immune system's ability to recognize and respond to a wide range of pathogens and protect against infection and disease.

Membrane proteins are a type of protein that are embedded in the lipid bilayer of biological membranes, such as the plasma membrane of cells or the inner membrane of mitochondria. These proteins play crucial roles in various cellular processes, including:

1. Cell-cell recognition and signaling
2. Transport of molecules across the membrane (selective permeability)
3. Enzymatic reactions at the membrane surface
4. Energy transduction and conversion
5. Mechanosensation and signal transduction

Membrane proteins can be classified into two main categories: integral membrane proteins, which are permanently associated with the lipid bilayer, and peripheral membrane proteins, which are temporarily or loosely attached to the membrane surface. Integral membrane proteins can further be divided into three subcategories based on their topology:

1. Transmembrane proteins, which span the entire width of the lipid bilayer with one or more alpha-helices or beta-barrels.
2. Lipid-anchored proteins, which are covalently attached to lipids in the membrane via a glycosylphosphatidylinositol (GPI) anchor or other lipid modifications.
3. Monotopic proteins, which are partially embedded in the membrane and have one or more domains exposed to either side of the bilayer.

Membrane proteins are essential for maintaining cellular homeostasis and are targets for various therapeutic interventions, including drug development and gene therapy. However, their structural complexity and hydrophobicity make them challenging to study using traditional biochemical methods, requiring specialized techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and single-particle cryo-electron microscopy (cryo-EM).

Immunological models are simplified representations or simulations of the immune system's structure, function, and interactions with pathogens or other entities. These models can be theoretical (conceptual), mathematical, or computational and are used to understand, explain, and predict immunological phenomena. They help researchers study complex immune processes and responses that cannot be easily observed or manipulated in vivo.

Theoretical immunological models provide conceptual frameworks for understanding immune system behavior, often using diagrams or flowcharts to illustrate interactions between immune components. Mathematical models use mathematical equations to describe immune system dynamics, allowing researchers to simulate and analyze the outcomes of various scenarios. Computational models, also known as in silico models, are created using computer software and can incorporate both theoretical and mathematical concepts to create detailed simulations of immunological processes.

Immunological models are essential tools for advancing our understanding of the immune system and developing new therapies and vaccines. They enable researchers to test hypotheses, explore the implications of different assumptions, and identify areas requiring further investigation.

I'm sorry for any confusion, but "Hemolytic Plaque Technique" is not a widely recognized or established medical term. It seems like it might be a combination of two different concepts in medical and scientific research: the Hemolytic Assay and the Plaque Assay technique.

A Hemolytic Assay is a method used to measure the amount of hemolysis, or the rupturing of red blood cells, caused by a substance such as a toxin or an antibody. This assay can help determine the concentration of the hemolysin in a sample.

On the other hand, the Plaque Assay Technique is a method used to measure the number of infectious virus particles in a sample. It involves adding a layer of cells (like bacteria) that the virus can infect and then covering it with a nutrient agar overlay. After a period of incubation, clear areas or "plaques" appear in the agar where the viruses have infected and lysed the cells. By counting these plaques, researchers can estimate the number of infectious virus particles present in the original sample.

Therefore, if you're looking for a definition of a Hemolytic Plaque Technique, it might refer to a research method that combines both concepts, possibly measuring the amount of a substance (like an antibody) that causes hemolysis in red blood cells and correlating it with the number of infectious virus particles present. However, I would recommend consulting the original source or author for clarification on their intended meaning.

I'm sorry for any confusion, but "Immunoglobulin Light Chains, Surrogate" is not a recognized medical term or concept in the immunology field. Immunoglobulins, also known as antibodies, are proteins produced by the immune system to identify and neutralize foreign substances like bacteria and viruses. They consist of two heavy chains and two light chains, which can be either kappa or lambda. However, there is no such thing as "surrogate" light chains in this context.

If you have any other questions about medical terminology or concepts, I'd be happy to help!

A "second primary neoplasm" is a distinct, new cancer or malignancy that develops in a person who has already had a previous cancer. It is not a recurrence or metastasis of the original tumor, but rather an independent cancer that arises in a different location or organ system. The development of second primary neoplasms can be influenced by various factors such as genetic predisposition, environmental exposures, and previous treatments like chemotherapy or radiation therapy.

It is important to note that the definition of "second primary neoplasm" may vary slightly depending on the specific source or context. In general medical usage, it refers to a new, separate cancer; however, in some research or clinical settings, there might be more precise criteria for defining and diagnosing second primary neoplasms.

Lymphocytosis is a medical term that refers to an abnormal increase in the number of lymphocytes (a type of white blood cell) in the peripheral blood. A normal lymphocyte count ranges from 1,000 to 4,800 cells per microliter (μL) of blood in adults. Lymphocytosis is typically defined as a lymphocyte count greater than 4,800 cells/μL in adults or higher than age-specific normal values in children.

There are various causes of lymphocytosis, including viral infections (such as mononucleosis), bacterial infections, tuberculosis, fungal infections, parasitic infections, autoimmune disorders, allergies, and certain cancers like chronic lymphocytic leukemia or lymphoma. It is essential to investigate the underlying cause of lymphocytosis through a thorough clinical evaluation, medical history, physical examination, and appropriate diagnostic tests, such as blood tests, imaging studies, or biopsies.

It's important to note that an isolated episode of mild lymphocytosis is often not clinically significant and may resolve on its own without any specific treatment. However, persistent or severe lymphocytosis requires further evaluation and management based on the underlying cause.

Siglec-3, also known as CD33, is a type of Siglec (Sialic acid-binding immunoglobulin-like lectin) that is primarily expressed on the surface of myeloid cells, including monocytes, macrophages, and some dendritic cell subsets. It is a transmembrane protein with an extracellular domain containing an N-terminal V-set immunoglobulin-like domain, followed by one to three C2-set immunoglobulin-like domains, a transmembrane region, and a cytoplasmic tail. Siglec-3 selectively binds to sialic acid residues on glycoproteins and gangliosides, and its function is thought to regulate immune cell activation and inflammation. It has been implicated in the pathogenesis of several diseases, including cancer, Alzheimer's disease, and HIV infection.

Protein binding, in the context of medical and biological sciences, refers to the interaction between a protein and another molecule (known as the ligand) that results in a stable complex. This process is often reversible and can be influenced by various factors such as pH, temperature, and concentration of the involved molecules.

In clinical chemistry, protein binding is particularly important when it comes to drugs, as many of them bind to proteins (especially albumin) in the bloodstream. The degree of protein binding can affect a drug's distribution, metabolism, and excretion, which in turn influence its therapeutic effectiveness and potential side effects.

Protein-bound drugs may be less available for interaction with their target tissues, as only the unbound or "free" fraction of the drug is active. Therefore, understanding protein binding can help optimize dosing regimens and minimize adverse reactions.

OSM-LIF receptors are a type of cell surface receptor that bind to the cytokines Oncostatin M (OSM) and Leukemia Inhibitory Factor (LIF). These receptors are part of the class I cytokine receptor family, which share a common structure and signaling mechanism.

The OSM-LIF receptor is composed of two subunits: gp130 and LIFR (LIF receptor beta). The binding of OSM or LIF to the extracellular domain of the LIFR subunit results in the recruitment of gp130, which then activates a series of intracellular signaling pathways, including the JAK-STAT and MAPK pathways.

OSM-LIF receptors play important roles in various biological processes, such as cell proliferation, differentiation, survival, and inflammation. Dysregulation of OSM-LIF signaling has been implicated in several diseases, including cancer, autoimmune disorders, and neurological disorders. Therefore, targeting OSM-LIF receptors has emerged as a potential therapeutic strategy for these conditions.

Cyclophosphamide is an alkylating agent, which is a type of chemotherapy medication. It works by interfering with the DNA of cancer cells, preventing them from dividing and growing. This helps to stop the spread of cancer in the body. Cyclophosphamide is used to treat various types of cancer, including lymphoma, leukemia, multiple myeloma, and breast cancer. It can be given orally as a tablet or intravenously as an injection.

Cyclophosphamide can also have immunosuppressive effects, which means it can suppress the activity of the immune system. This makes it useful in treating certain autoimmune diseases, such as rheumatoid arthritis and lupus. However, this immunosuppression can also increase the risk of infections and other side effects.

Like all chemotherapy medications, cyclophosphamide can cause a range of side effects, including nausea, vomiting, hair loss, fatigue, and increased susceptibility to infections. It is important for patients receiving cyclophosphamide to be closely monitored by their healthcare team to manage these side effects and ensure the medication is working effectively.

Nitrophenols are organic compounds that contain a hydroxyl group (-OH) attached to a phenyl ring (aromatic hydrocarbon) and one or more nitro groups (-NO2). They have the general structure R-C6H4-NO2, where R represents the hydroxyl group.

Nitrophenols are known for their distinctive yellow to brown color and can be found in various natural sources such as plants and microorganisms. Some common nitrophenols include:

* p-Nitrophenol (4-nitrophenol)
* o-Nitrophenol (2-nitrophenol)
* m-Nitrophenol (3-nitrophenol)

These compounds are used in various industrial applications, including dyes, pharmaceuticals, and agrochemicals. However, they can also be harmful to human health and the environment, as some nitrophenols have been identified as potential environmental pollutants and may pose risks to human health upon exposure.

Pentostatin is a medication used in the treatment of certain types of cancer, including hairy cell leukemia and certain T-cell lymphomas. It is a type of drug called a purine nucleoside analog, which works by interfering with the production of DNA and RNA, the genetic material found in cells. This can help to stop the growth and multiplication of cancer cells.

Pentostatin is given intravenously (through an IV) in a healthcare setting, such as a hospital or clinic. It is usually administered on a schedule of every other week. Common side effects of pentostatin include nausea, vomiting, diarrhea, and loss of appetite. It can also cause more serious side effects, such as low blood cell counts, infections, and liver problems.

It's important to note that this is a medical definition of the drug and its use, and it should not be used as a substitute for professional medical advice. If you have any questions about pentostatin or your treatment, it is best to speak with your healthcare provider.

Immunoglobulin J-chains are small protein structures that play a role in the assembly and structure of certain types of antibodies, specifically IgM and IgA. The J-chain is a polypeptide chain that contains multiple cysteine residues, which allow it to form disulfide bonds with the heavy chains of IgM and IgA molecules.

In IgM antibodies, the J-chain helps to link the five identical heavy chain units together to form a pentameric structure. In IgA antibodies, the J-chain links two dimeric structures together to form a tetrameric structure. This polymerization of IgM and IgA molecules is important for their function in the immune system, as it allows them to form large complexes that can effectively agglutinate and neutralize pathogens.

The J-chain is synthesized by a specialized group of B cells called plasma cells, which are responsible for producing and secreting antibodies. Once synthesized, the J-chain is covalently linked to the heavy chains of IgM or IgA molecules during their assembly in the endoplasmic reticulum of the plasma cell.

Overall, the Immunoglobulin J-chain plays a crucial role in the structure and function of certain classes of antibodies, contributing to their ability to effectively combat pathogens and protect the body from infection.

Deltaretroviruses are a genus of retroviruses that include human T-lymphotropic virus (HTLV) types 1 and 2, bovine leukemia virus (BLV), and simian T-lymphotropic viruses. These viruses are characterized by their ability to cause persistent infections and can lead to the development of various diseases such as adult T-cell leukemia/lymphoma (ATLL) and tropical spastic paraparesis/HTLV-associated myelopathy (TSP/HAM).

The genome of deltaretroviruses contains two copies of single-stranded RNA, which are reverse transcribed into double-stranded DNA during the replication process. The viral DNA is then integrated into the host cell's genome, leading to a lifelong infection.

Deltaretroviruses primarily infect CD4+ T cells and other immune cells, and transmission typically occurs through bodily fluids such as breast milk, blood, and sexual contact. Prevention measures include avoiding high-risk behaviors, screening blood products, and implementing strict infection control practices in healthcare settings.

Oncogenes are genes that have the potential to cause cancer. They can do this by promoting cell growth and division (cellular proliferation), preventing cell death (apoptosis), or enabling cells to invade surrounding tissue and spread to other parts of the body (metastasis). Oncogenes can be formed when normal genes, called proto-oncogenes, are mutated or altered in some way. This can happen as a result of exposure to certain chemicals or radiation, or through inherited genetic mutations. When activated, oncogenes can contribute to the development of cancer by causing cells to divide and grow in an uncontrolled manner.

The Transmembrane Activator and CAML Interactor protein (also known as TACI or TNFRSF13B) is a type I transmembrane protein that belongs to the tumor necrosis factor receptor superfamily. It is involved in the regulation of immune responses, specifically in the activation and differentiation of B cells, which are a type of white blood cell that plays a central role in the humoral immune response.

TACI has two main ligands, or binding partners: A Proliferation-Inducing Ligand (APRIL) and B cell Activating Factor (BAFF). These ligands bind to TACI and activate downstream signaling pathways that lead to the activation and differentiation of B cells.

Mutations in the TACI gene have been associated with various immune disorders, including common variable immunodeficiency (CVID), a primary immunodeficiency disorder characterized by low levels of antibodies and recurrent infections. Additionally, variations in the TACI gene have been linked to an increased risk of developing autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

Lymphocyte subsets refer to distinct populations of white blood cells called lymphocytes, which are crucial components of the adaptive immune system. There are two main types of lymphocytes: T cells and B cells, and each type has several subsets based on their surface receptors, functions, and activation status.

1. T cell subsets: These include CD4+ T helper cells (Th cells), CD8+ cytotoxic T cells (Tc cells), regulatory T cells (Tregs), and memory T cells. Th cells are further divided into Th1, Th2, Th17, and Tfh cells based on their cytokine production profiles and functions.
* CD4+ T helper cells (Th cells) play a central role in orchestrating the immune response by producing various cytokines that activate other immune cells.
* CD8+ cytotoxic T cells (Tc cells) directly kill virus-infected or malignant cells upon recognition of specific antigens presented on their surface.
* Regulatory T cells (Tregs) suppress the activation and proliferation of other immune cells to maintain self-tolerance and prevent autoimmunity.
* Memory T cells are long-lived cells that remain in the body after an initial infection or immunization, providing rapid protection upon subsequent encounters with the same pathogen.
2. B cell subsets: These include naïve B cells, memory B cells, and plasma cells. Upon activation by antigens, B cells differentiate into antibody-secreting plasma cells that produce specific antibodies to neutralize or eliminate pathogens.
* Naïve B cells are resting cells that have not yet encountered their specific antigen.
* Memory B cells are long-lived cells generated after initial antigen exposure, which can quickly differentiate into antibody-secreting plasma cells upon re-exposure to the same antigen.
* Plasma cells are terminally differentiated B cells that secrete large amounts of specific antibodies.

Analyzing lymphocyte subsets is essential for understanding immune system function and dysfunction, as well as monitoring the effectiveness of immunotherapies and vaccinations.

A tumor virus infection is a condition in which a person's cells become cancerous or transformed due to the integration and disruption of normal cellular functions by a viral pathogen. These viruses are also known as oncoviruses, and they can cause tumors or cancer by altering the host cell's genetic material, promoting uncontrolled cell growth and division, evading immune surveillance, and inhibiting apoptosis (programmed cell death).

Examples of tumor viruses include:

1. DNA tumor viruses: These are double-stranded DNA viruses that can cause cancer in humans. Examples include human papillomavirus (HPV), hepatitis B virus (HBV), and Merkel cell polyomavirus (MCV).
2. RNA tumor viruses: Also known as retroviruses, these single-stranded RNA viruses can cause cancer in humans. Examples include human T-cell leukemia virus type 1 (HTLV-1) and human immunodeficiency virus (HIV).

Tumor virus infections are responsible for approximately 15-20% of all cancer cases worldwide, making them a significant public health concern. Prevention strategies, such as vaccination against HPV and HBV, have been shown to reduce the incidence of associated cancers.

Drug synergism is a pharmacological concept that refers to the interaction between two or more drugs, where the combined effect of the drugs is greater than the sum of their individual effects. This means that when these drugs are administered together, they produce an enhanced therapeutic response compared to when they are given separately.

Drug synergism can occur through various mechanisms, such as:

1. Pharmacodynamic synergism - When two or more drugs interact with the same target site in the body and enhance each other's effects.
2. Pharmacokinetic synergism - When one drug affects the metabolism, absorption, distribution, or excretion of another drug, leading to an increased concentration of the second drug in the body and enhanced therapeutic effect.
3. Physiochemical synergism - When two drugs interact physically, such as when one drug enhances the solubility or permeability of another drug, leading to improved absorption and bioavailability.

It is important to note that while drug synergism can result in enhanced therapeutic effects, it can also increase the risk of adverse reactions and toxicity. Therefore, healthcare providers must carefully consider the potential benefits and risks when prescribing combinations of drugs with known or potential synergistic effects.

The Radiation Leukemia Virus (RLV) is not a recognized medical term or a virus with clinical significance in human medicine. However, it appears to be a term used in some scientific research, particularly in the field of molecular biology and genetics, where it refers to a retrovirus that was first isolated from mice exposed to high levels of radiation.

Radiation Leukemia Virus (RLV) is a murine leukemia virus that was originally discovered in 1976 in mice that had been exposed to high doses of radiation. RLV is a retrovirus, which means it contains RNA as its genetic material and uses an enzyme called reverse transcriptase to create DNA copies of its genome that can integrate into the host cell's chromosomes.

RLV has been used in laboratory studies to investigate the mechanisms of retroviral infection, gene regulation, and tumorigenesis. However, it is not a human virus and does not cause leukemia or any other diseases in humans.

CD34 is a type of antigen that is found on the surface of certain cells in the human body. Specifically, CD34 antigens are present on hematopoietic stem cells, which are immature cells that can develop into different types of blood cells. These stem cells are found in the bone marrow and are responsible for producing red blood cells, white blood cells, and platelets.

CD34 antigens are a type of cell surface marker that is used in medical research and clinical settings to identify and isolate hematopoietic stem cells. They are also used in the development of stem cell therapies and transplantation procedures. CD34 antigens can be detected using various laboratory techniques, such as flow cytometry or immunohistochemistry.

It's important to note that while CD34 is a useful marker for identifying hematopoietic stem cells, it is not exclusive to these cells and can also be found on other cell types, such as endothelial cells that line blood vessels. Therefore, additional markers are often used in combination with CD34 to more specifically identify and isolate hematopoietic stem cells.

Chronic neutrophilic leukemia (CNL) is a rare type of chronic leukemia, which is a cancer of the white blood cells. Specifically, CNL is characterized by an overproduction of mature neutrophils, a type of white blood cell that helps fight infection.

The medical definition of CNL, as per the World Health Organization (WHO) classification, is as follows:

Chronic Neutrophilic Leukemia (CNL): A clonal hematopoietic stem cell disorder characterized by sustained peripheral blood neutrophilia >25 × 109/L, with a left shift and often toxic granulations, without evidence of another myeloid neoplasm. The bone marrow shows hypercellularity with an increase in mature neutrophils, including bands, segmented forms, and occasionally toxic granulations or Döhle bodies. There is no significant increase in blasts, promyelocytes, or other immature granulocytic precursors (

Fc receptors (FcRs) are specialized proteins found on the surface of various immune cells, including neutrophils, monocytes, macrophages, eosinophils, basophils, mast cells, and B lymphocytes. They play a crucial role in the immune response by recognizing and binding to the Fc region of antibodies (IgG, IgA, and IgE) after they have interacted with their specific antigens.

FcRs can be classified into several types based on the class of antibody they bind:

1. FcγRs - bind to the Fc region of IgG antibodies
2. FcαRs - bind to the Fc region of IgA antibodies
3. FcεRs - bind to the Fc region of IgE antibodies

The binding of antibodies to Fc receptors triggers various cellular responses, such as phagocytosis, degranulation, and antibody-dependent cellular cytotoxicity (ADCC), which contribute to the elimination of pathogens, immune complexes, and other foreign substances. Dysregulation of Fc receptor function has been implicated in several diseases, including autoimmune disorders and allergies.

Immunoglobulin delta-chains (IgD) are a type of heavy chain found in immunoglobulins, which are also known as antibodies. Antibodies are proteins that play a crucial role in the immune system's response to foreign substances, such as bacteria and viruses.

The heavy chains of an antibody consist of four polypeptide regions: the variable region, which varies between different antibodies and is responsible for recognizing and binding to specific antigens; and three constant regions, known as Cμ, Cγ, Cα, or Cδ, which determine the class of the antibody and its effector functions.

IgD heavy chains contain a single Cδ region and are found only in a small subset of antibodies, primarily located on the surface of mature B cells. IgD is co-expressed with IgM on the surface of naive B cells and plays a role in activating the immune response by binding to antigens and initiating signal transduction pathways that lead to B cell activation and differentiation into antibody-secreting plasma cells.

While the function of IgD is not fully understood, it is thought to play a role in regulating the immune response, including modulating allergic reactions and protecting against autoimmunity. Additionally, IgD has been found to have a role in the development and survival of B cells, as well as in the regulation of calcium signaling in B cells.

NF-κB (Nuclear Factor kappa-light-chain-enhancer of activated B cells) is a protein complex that plays a crucial role in regulating the immune response to infection and inflammation, as well as in cell survival, differentiation, and proliferation. It is composed of several subunits, including p50, p52, p65 (RelA), c-Rel, and RelB, which can form homodimers or heterodimers that bind to specific DNA sequences called κB sites in the promoter regions of target genes.

Under normal conditions, NF-κB is sequestered in the cytoplasm by inhibitory proteins known as IκBs (inhibitors of κB). However, upon stimulation by various signals such as cytokines, bacterial or viral products, and stress, IκBs are phosphorylated, ubiquitinated, and degraded, leading to the release and activation of NF-κB. Activated NF-κB then translocates to the nucleus, where it binds to κB sites and regulates the expression of target genes involved in inflammation, immunity, cell survival, and proliferation.

Dysregulation of NF-κB signaling has been implicated in various pathological conditions such as cancer, chronic inflammation, autoimmune diseases, and neurodegenerative disorders. Therefore, targeting NF-κB signaling has emerged as a potential therapeutic strategy for the treatment of these diseases.

Molecular cloning is a laboratory technique used to create multiple copies of a specific DNA sequence. This process involves several steps:

1. Isolation: The first step in molecular cloning is to isolate the DNA sequence of interest from the rest of the genomic DNA. This can be done using various methods such as PCR (polymerase chain reaction), restriction enzymes, or hybridization.
2. Vector construction: Once the DNA sequence of interest has been isolated, it must be inserted into a vector, which is a small circular DNA molecule that can replicate independently in a host cell. Common vectors used in molecular cloning include plasmids and phages.
3. Transformation: The constructed vector is then introduced into a host cell, usually a bacterial or yeast cell, through a process called transformation. This can be done using various methods such as electroporation or chemical transformation.
4. Selection: After transformation, the host cells are grown in selective media that allow only those cells containing the vector to grow. This ensures that the DNA sequence of interest has been successfully cloned into the vector.
5. Amplification: Once the host cells have been selected, they can be grown in large quantities to amplify the number of copies of the cloned DNA sequence.

Molecular cloning is a powerful tool in molecular biology and has numerous applications, including the production of recombinant proteins, gene therapy, functional analysis of genes, and genetic engineering.

Neoplasm transplantation is not a recognized or established medical procedure in the field of oncology. The term "neoplasm" refers to an abnormal growth of cells, which can be benign or malignant (cancerous). "Transplantation" typically refers to the surgical transfer of living cells, tissues, or organs from one part of the body to another or between individuals.

The concept of neoplasm transplantation may imply the transfer of cancerous cells or tissues from a donor to a recipient, which is not a standard practice due to ethical considerations and the potential harm it could cause to the recipient. In some rare instances, researchers might use laboratory animals to study the transmission and growth of human cancer cells, but this is done for scientific research purposes only and under strict regulatory guidelines.

In summary, there is no medical definition for 'Neoplasm Transplantation' as it does not represent a standard or ethical medical practice.

'Antibodies, Neoplasm' is a medical term that refers to abnormal antibodies produced by neoplastic cells, which are cells that have undergone uncontrolled division and form a tumor or malignancy. These antibodies can be produced in large quantities and may have altered structures or functions compared to normal antibodies.

Neoplastic antibodies can arise from various types of malignancies, including leukemias, lymphomas, and multiple myeloma. In some cases, these abnormal antibodies can interfere with the normal functioning of the immune system and contribute to the progression of the disease.

In addition, neoplastic antibodies can also be used as tumor markers for diagnostic purposes. For example, certain types of monoclonal gammopathy, such as multiple myeloma, are characterized by the overproduction of a single type of immunoglobulin, which can be detected in the blood or urine and used to monitor the disease.

Overall, 'Antibodies, Neoplasm' is a term that encompasses a wide range of abnormal antibodies produced by neoplastic cells, which can have significant implications for both the diagnosis and treatment of malignancies.

Coculture techniques refer to a type of experimental setup in which two or more different types of cells or organisms are grown and studied together in a shared culture medium. This method allows researchers to examine the interactions between different cell types or species under controlled conditions, and to study how these interactions may influence various biological processes such as growth, gene expression, metabolism, and signal transduction.

Coculture techniques can be used to investigate a wide range of biological phenomena, including the effects of host-microbe interactions on human health and disease, the impact of different cell types on tissue development and homeostasis, and the role of microbial communities in shaping ecosystems. These techniques can also be used to test the efficacy and safety of new drugs or therapies by examining their effects on cells grown in coculture with other relevant cell types.

There are several different ways to establish cocultures, depending on the specific research question and experimental goals. Some common methods include:

1. Mixed cultures: In this approach, two or more cell types are simply mixed together in a culture dish or flask and allowed to grow and interact freely.
2. Cell-layer cultures: Here, one cell type is grown on a porous membrane or other support structure, while the second cell type is grown on top of it, forming a layered coculture.
3. Conditioned media cultures: In this case, one cell type is grown to confluence and its culture medium is collected and then used to grow a second cell type. This allows the second cell type to be exposed to any factors secreted by the first cell type into the medium.
4. Microfluidic cocultures: These involve growing cells in microfabricated channels or chambers, which allow for precise control over the spatial arrangement and flow of nutrients, waste products, and signaling molecules between different cell types.

Overall, coculture techniques provide a powerful tool for studying complex biological systems and gaining insights into the mechanisms that underlie various physiological and pathological processes.

Thioguanine is a medication that belongs to a class of drugs called antimetabolites. It is primarily used in the treatment of acute myeloid leukemia (AML) and other various types of cancer.

In medical terms, thioguanine is a purine analogue that gets metabolically converted into active thiopurine nucleotides, which then get incorporated into DNA and RNA, thereby interfering with the synthesis of genetic material in cancer cells. This interference leads to inhibition of cell division and growth, ultimately resulting in cell death (apoptosis) of the cancer cells.

It is important to note that thioguanine can also affect normal cells in the body, leading to various side effects. Therefore, it should be administered under the close supervision of a healthcare professional who can monitor its effectiveness and potential side effects.

Intracellular signaling peptides and proteins are molecules that play a crucial role in transmitting signals within cells, which ultimately lead to changes in cell behavior or function. These signals can originate from outside the cell (extracellular) or within the cell itself. Intracellular signaling molecules include various types of peptides and proteins, such as:

1. G-protein coupled receptors (GPCRs): These are seven-transmembrane domain receptors that bind to extracellular signaling molecules like hormones, neurotransmitters, or chemokines. Upon activation, they initiate a cascade of intracellular signals through G proteins and secondary messengers.
2. Receptor tyrosine kinases (RTKs): These are transmembrane receptors that bind to growth factors, cytokines, or hormones. Activation of RTKs leads to autophosphorylation of specific tyrosine residues, creating binding sites for intracellular signaling proteins such as adapter proteins, phosphatases, and enzymes like Ras, PI3K, and Src family kinases.
3. Second messenger systems: Intracellular second messengers are small molecules that amplify and propagate signals within the cell. Examples include cyclic adenosine monophosphate (cAMP), cyclic guanosine monophosphate (cGMP), diacylglycerol (DAG), inositol triphosphate (IP3), calcium ions (Ca2+), and nitric oxide (NO). These second messengers activate or inhibit various downstream effectors, leading to changes in cellular responses.
4. Signal transduction cascades: Intracellular signaling proteins often form complex networks of interacting molecules that relay signals from the plasma membrane to the nucleus. These cascades involve kinases (protein kinases A, B, C, etc.), phosphatases, and adapter proteins, which ultimately regulate gene expression, cell cycle progression, metabolism, and other cellular processes.
5. Ubiquitination and proteasome degradation: Intracellular signaling pathways can also control protein stability by modulating ubiquitin-proteasome degradation. E3 ubiquitin ligases recognize specific substrates and conjugate them with ubiquitin molecules, targeting them for proteasomal degradation. This process regulates the abundance of key signaling proteins and contributes to signal termination or amplification.

In summary, intracellular signaling pathways involve a complex network of interacting proteins that relay signals from the plasma membrane to various cellular compartments, ultimately regulating gene expression, metabolism, and other cellular processes. Dysregulation of these pathways can contribute to disease development and progression, making them attractive targets for therapeutic intervention.

Dendritic cells (DCs) are a type of immune cell that play a critical role in the body's defense against infection and cancer. They are named for their dendrite-like projections, which they use to interact with and sample their environment. DCs are responsible for processing antigens (foreign substances that trigger an immune response) and presenting them to T cells, a type of white blood cell that plays a central role in the immune system's response to infection and cancer.

DCs can be found throughout the body, including in the skin, mucous membranes, and lymphoid organs. They are able to recognize and respond to a wide variety of antigens, including those from bacteria, viruses, fungi, and parasites. Once they have processed an antigen, DCs migrate to the lymph nodes, where they present the antigen to T cells. This interaction activates the T cells, which then go on to mount a targeted immune response against the invading pathogen or cancerous cells.

DCs are a diverse group of cells that can be divided into several subsets based on their surface markers and function. Some DCs, such as Langerhans cells and dermal DCs, are found in the skin and mucous membranes, where they serve as sentinels for invading pathogens. Other DCs, such as plasmacytoid DCs and conventional DCs, are found in the lymphoid organs, where they play a role in activating T cells and initiating an immune response.

Overall, dendritic cells are essential for the proper functioning of the immune system, and dysregulation of these cells has been implicated in a variety of diseases, including autoimmune disorders and cancer.

T-cell lymphoma is a type of cancer that affects the T-cells, which are a specific type of white blood cell responsible for immune function. These lymphomas develop from mature T-cells and can be classified into various subtypes based on their clinical and pathological features.

T-cell lymphomas can arise in many different organs, including the lymph nodes, skin, and other soft tissues. They often present with symptoms such as enlarged lymph nodes, fever, night sweats, and weight loss. The diagnosis of T-cell lymphoma typically involves a biopsy of the affected tissue, followed by immunophenotyping and genetic analysis to determine the specific subtype.

Treatment for T-cell lymphomas may include chemotherapy, radiation therapy, immunotherapy, or stem cell transplantation, depending on the stage and aggressiveness of the disease. The prognosis for T-cell lymphoma varies widely depending on the subtype and individual patient factors.

Neprilysin (NEP), also known as membrane metallo-endopeptidase or CD10, is a type II transmembrane glycoprotein that functions as a zinc-dependent metalloprotease. It is widely expressed in various tissues, including the kidney, brain, heart, and vasculature. Neprilysin plays a crucial role in the breakdown and regulation of several endogenous bioactive peptides, such as natriuretic peptides, bradykinin, substance P, and angiotensin II. By degrading these peptides, neprilysin helps maintain cardiovascular homeostasis, modulate inflammation, and regulate neurotransmission. In the context of heart failure, neprilysin inhibitors have been developed to increase natriuretic peptide levels, promoting diuresis and vasodilation, ultimately improving cardiac function.

In the context of medicine and pharmacology, "kinetics" refers to the study of how a drug moves throughout the body, including its absorption, distribution, metabolism, and excretion (often abbreviated as ADME). This field is called "pharmacokinetics."

1. Absorption: This is the process of a drug moving from its site of administration into the bloodstream. Factors such as the route of administration (e.g., oral, intravenous, etc.), formulation, and individual physiological differences can affect absorption.

2. Distribution: Once a drug is in the bloodstream, it gets distributed throughout the body to various tissues and organs. This process is influenced by factors like blood flow, protein binding, and lipid solubility of the drug.

3. Metabolism: Drugs are often chemically modified in the body, typically in the liver, through processes known as metabolism. These changes can lead to the formation of active or inactive metabolites, which may then be further distributed, excreted, or undergo additional metabolic transformations.

4. Excretion: This is the process by which drugs and their metabolites are eliminated from the body, primarily through the kidneys (urine) and the liver (bile).

Understanding the kinetics of a drug is crucial for determining its optimal dosing regimen, potential interactions with other medications or foods, and any necessary adjustments for special populations like pediatric or geriatric patients, or those with impaired renal or hepatic function.

Human chromosome pair 8 consists of two rod-shaped structures present in the nucleus of each cell of the human body. Each chromosome is made up of DNA tightly coiled around histone proteins, forming a complex structure known as a chromatin.

Human cells have 23 pairs of chromosomes, for a total of 46 chromosomes. Pair 8 is one of the autosomal pairs, meaning that it is not a sex chromosome (X or Y). Each member of chromosome pair 8 has a similar size, shape, and banding pattern, and they are identical in males and females.

Chromosome pair 8 contains several genes that are essential for various cellular functions and human development. Some of the genes located on chromosome pair 8 include those involved in the regulation of metabolism, nerve function, immune response, and cell growth and division.

Abnormalities in chromosome pair 8 can lead to genetic disorders such as Wolf-Hirschhorn syndrome, which is caused by a partial deletion of the short arm of chromosome 4, or partial trisomy 8, which results from an extra copy of all or part of chromosome 8. Both of these conditions are associated with developmental delays, intellectual disability, and various physical abnormalities.

Phenylacetates are a group of organic compounds that contain a phenyl group (a benzene ring with a hydroxyl group) and an acetic acid group. In the context of medicine, sodium phenylacetate is used in the treatment of certain metabolic disorders, such as urea cycle disorders, to help remove excess ammonia from the body. It does this by conjugating with glycine to form phenylacetylglutamine, which can then be excreted in the urine.

It is important to note that the use of phenylacetates should be under the supervision of a medical professional, as improper use or dosage can lead to serious side effects.

Immunoglobulin G (IgG) gamma chains are the heavy, constant region proteins found in IgG immunoglobulins, which are a type of antibody. These gamma chains are composed of four subunits - two heavy chains and two light chains - and play a crucial role in the immune response by recognizing and binding to specific antigens, such as pathogens or foreign substances.

IgG is the most abundant type of antibody in human serum and provides long-term immunity against bacterial and viral infections. The gamma chains contain a region that binds to Fc receptors found on various immune cells, which facilitates the destruction of pathogens or foreign substances. Additionally, IgG can cross the placenta, providing passive immunity to the fetus.

Abnormalities in the production or function of IgG gamma chains can lead to various immunodeficiency disorders, such as X-linked agammaglobulinemia, which is characterized by a lack of functional B cells and low levels of IgG antibodies.

Antimetabolites are a class of antineoplastic (chemotherapy) drugs that interfere with the metabolism of cancer cells and inhibit their growth and proliferation. These agents are structurally similar to naturally occurring metabolites, such as amino acids, nucleotides, and folic acid, which are essential for cellular replication and growth. Antimetabolites act as false analogs and get incorporated into the growing cells' DNA or RNA, causing disruption of the normal synthesis process, leading to cell cycle arrest and apoptosis (programmed cell death).

Examples of antimetabolite drugs include:

1. Folate antagonists: Methotrexate, Pemetrexed
2. Purine analogs: Mercaptopurine, Thioguanine, Fludarabine, Cladribine
3. Pyrimidine analogs: 5-Fluorouracil (5-FU), Capecitabine, Cytarabine, Gemcitabine

These drugs are used to treat various types of cancers, such as leukemias, lymphomas, breast, ovarian, and gastrointestinal cancers. Due to their mechanism of action, antimetabolites can also affect normal, rapidly dividing cells in the body, leading to side effects like myelosuppression (decreased production of blood cells), mucositis (inflammation and ulceration of the gastrointestinal tract), and alopecia (hair loss).

Pokeweed mitogens are substances derived from the pokeweed plant (Phytolacca americana) that have the ability to stimulate the production and proliferation of various types of cells, particularly white blood cells (lymphocytes). They are often used in laboratory settings as tools for studying the immune system and cell biology.

Pokeweed mitogens are typically extracted from the roots or leaves of the pokeweed plant and purified for use in research and diagnostic applications. When introduced to cells, they bind to specific receptors on the surface of lymphocytes and trigger a series of intracellular signaling events that lead to cell division and growth.

These mitogens are commonly used in immunological assays to measure immune function, such as assessing the proliferative response of lymphocytes to mitogenic stimulation. They can also be used to study the mechanisms of signal transduction and gene regulation in lymphocytes and other cell types.

It is important to note that pokeweed mitogens should only be handled by trained professionals in a controlled laboratory setting, as they can cause adverse reactions if improperly administered or ingested.

Mononuclear leukocytes are a type of white blood cells (leukocytes) that have a single, large nucleus. They include lymphocytes (B-cells, T-cells, and natural killer cells), monocytes, and dendritic cells. These cells play important roles in the body's immune system, including defending against infection and disease, and participating in immune responses and surveillance. Mononuclear leukocytes can be found in the bloodstream as well as in tissues throughout the body. They are involved in both innate and adaptive immunity, providing specific and nonspecific defense mechanisms to protect the body from harmful pathogens and other threats.

'Mice, Inbred MRL-lpr' refers to a specific strain of laboratory mice that are used in biomedical research. The 'MRL' part of the name stands for the breeding colony where they were originally developed, which is the Mouse Repository at the Jackson Laboratory in Bar Harbor, Maine. The 'lpr' designation indicates that these mice carry a mutation in the Fas gene, also known as lpr (lymphoproliferation) gene, which leads to an autoimmune disorder characterized by lymphadenopathy (enlarged lymph nodes), splenomegaly (enlarged spleen), and production of autoantibodies.

The MRL-lpr mice are known for their accelerated aging phenotype, which includes the development of a variety of age-related diseases such as atherosclerosis, osteoporosis, and cancer. They also develop a severe form of systemic lupus erythematosus (SLE), an autoimmune disease that affects many organs in the body. The MRL-lpr mice are widely used as a model to study the pathogenesis of SLE and other autoimmune diseases, as well as to test potential therapies for these conditions.

It is important to note that while inbred mouse strains like MRL-lpr provide valuable insights into human disease mechanisms, they do not perfectly replicate all aspects of human disease, and results obtained in mice may not always translate directly to humans. Therefore, findings from mouse studies should be interpreted with caution and validated in human studies before being applied in clinical practice.

Toll-like receptor 9 (TLR9) is a type of protein belonging to the family of Toll-like receptors, which play a crucial role in the innate immune system. TLR9 is primarily expressed on the endosomal membranes of various immune cells, including dendritic cells, B cells, and macrophages. It recognizes specific molecular patterns, particularly unmethylated CpG DNA motifs, which are commonly found in bacterial and viral genomes but are underrepresented in vertebrate DNA.

Upon recognition and binding to its ligands, TLR9 initiates a signaling cascade that activates various transcription factors, such as NF-κB and IRF7, leading to the production of proinflammatory cytokines, type I interferons, and the activation of adaptive immune responses. This process is essential for the clearance of pathogens and the development of immunity against them. Dysregulation of TLR9 signaling has been implicated in several autoimmune diseases and chronic inflammatory conditions.

Prolymphocytic Leukemia, B-Cell is a rare and aggressive type of leukemia, which is a cancer of the white blood cells. Specifically, it affects B-cell lymphocytes, a type of white blood cell that helps fight infections. In this condition, the bone marrow produces excessive numbers of prolymphocytes, which are immature and abnormal B-cells. These abnormal cells accumulate in the blood, bone marrow, and sometimes lymph nodes, interfering with the normal functioning of the body's immune system.

The symptoms of Prolymphocytic Leukemia, B-Cell may include fatigue, frequent infections, weight loss, swollen lymph nodes, and a feeling of fullness in the abdomen due to an enlarged spleen. The diagnosis is usually made through blood tests, bone marrow aspiration and biopsy, and imaging studies. Treatment options may include chemotherapy, targeted therapy, immunotherapy, stem cell transplantation, or a combination of these approaches.

It's important to note that Prolymphocytic Leukemia, B-Cell is a rare type of cancer, and the prognosis and treatment options can vary depending on several factors, including the patient's age, overall health, and the extent of the disease at the time of diagnosis.

The Immunoglobulin Joining Region (IgJ or J chain) is a polypeptide chain that is a component of certain immunoglobulins, specifically IgM and IgA. The J chain plays a crucial role in the polymerization of these immunoglobulins, allowing them to form higher-order structures such as pentamers (in the case of IgM) or dimers (in the case of IgA). This polymerization is important for the functioning of these immunoglobulins in the immune response. The J chain contains multiple cysteine residues that form disulfide bonds with each other and with the heavy chains of the immunoglobulin molecules, helping to stabilize the polymeric structure.

Drug screening assays for antitumor agents are laboratory tests used to identify and evaluate the effectiveness of potential drugs or compounds that can inhibit the growth of tumor cells or induce their death. These assays are typically performed in vitro (in a test tube or petri dish) using cell cultures of various types of cancer cells.

The assays measure different parameters such as cell viability, proliferation, apoptosis (programmed cell death), and cytotoxicity to determine the ability of the drug to kill or inhibit the growth of tumor cells. The results of these assays can help researchers identify promising antitumor agents that can be further developed for clinical use in cancer treatment.

There are different types of drug screening assays for antitumor agents, including high-throughput screening (HTS) assays, which allow for the rapid and automated testing of a large number of compounds against various cancer cell lines. Other types of assays include phenotypic screening assays, target-based screening assays, and functional screening assays, each with its own advantages and limitations.

Overall, drug screening assays for antitumor agents play a critical role in the development of new cancer therapies by providing valuable information on the activity and safety of potential drugs, helping to identify effective treatments and reduce the time and cost associated with bringing new drugs to market.

ZAP-70 (zeta-associated protein-70) is a protein tyrosine kinase that plays a critical role in T-cell antigen receptor (TCR) signal transduction. It is primarily expressed in T-cells and natural killer cells. Upon TCR engagement, ZAP-70 becomes activated and phosphorylates downstream signaling molecules, leading to the activation of various cellular responses such as cytokine production, proliferation, differentiation, and survival.

Defects in ZAP-70 function have been implicated in various immune disorders, including severe combined immunodeficiency (SCID) and autoimmune diseases. Mutations in the ZAP-70 gene can lead to impaired T-cell activation and differentiation, resulting in immunodeficiency. On the other hand, overactivation of ZAP-70 has been associated with the development of autoimmunity. Therefore, maintaining appropriate regulation of ZAP-70 activity is essential for normal immune function.

ADP-ribosyl cyclase is an enzyme that catalyzes the conversion of nicotinamide adenine dinucleotide (NAD+) to cyclic ADP-ribose (cADPR). This enzyme plays a role in intracellular signaling, particularly in calcium mobilization in various cell types including immune cells and neurons. The regulation of this enzyme has been implicated in several physiological processes as well as in the pathophysiology of some diseases such as cancer and neurodegenerative disorders.

Hemocyanin is a copper-containing protein found in the blood of some mollusks and arthropods, responsible for oxygen transport. Unlike hemoglobin in vertebrates, which uses iron to bind oxygen, hemocyanins have copper ions that reversibly bind to oxygen, turning the blood blue when oxygenated. When deoxygenated, the color of the blood is pale blue-gray. Hemocyanins are typically found in a multi-subunit form and are released into the hemolymph (the equivalent of blood in vertebrates) upon exposure to air or oxygen. They play a crucial role in supplying oxygen to various tissues and organs within these invertebrate organisms.

CD95 (also known as Fas or APO-1) is a type of cell surface receptor that can bind to specific proteins and trigger programmed cell death, also known as apoptosis. It is an important regulator of the immune system and helps to control the activation and deletion of immune cells. CD95 ligand (CD95L), the protein that binds to CD95, is expressed on activated T-cells and can induce apoptosis in other cells that express CD95, including other T-cells and tumor cells.

An antigen is any substance that can stimulate an immune response, leading to the production of antibodies or activation of immune cells. In the context of CD95, antigens may refer to substances that can induce the expression of CD95 on the surface of cells, making them susceptible to CD95L-mediated apoptosis. These antigens could include viral proteins, tumor antigens, or other substances that trigger an immune response.

Therefore, the medical definition of 'antigens, CD95' may refer to substances that can induce the expression of CD95 on the surface of cells and make them targets for CD95L-mediated apoptosis.

Antibiotics are a type of medication used to treat infections caused by bacteria. They work by either killing the bacteria or inhibiting their growth.

Antineoplastics, also known as chemotherapeutic agents, are a class of drugs used to treat cancer. These medications target and destroy rapidly dividing cells, such as cancer cells, although they can also affect other quickly dividing cells in the body, such as those in the hair follicles or digestive tract, which can lead to side effects.

Antibiotics and antineoplastics are two different classes of drugs with distinct mechanisms of action and uses. It is important to use them appropriately and under the guidance of a healthcare professional.

Rosette formation is a term used in pathology and histology, which refers to the circular arrangement of cells or structures around a central point, creating a pattern that resembles a rose flower. This phenomenon can be observed in various tissues and diseases. For example, in the context of cancer, rosette formation may be seen in certain types of tumors, such as medulloblastomas or retinoblastomas, where cancer cells cluster around blood vessels or form distinctive arrangements that are characteristic of these malignancies. In some cases, rosette formation can provide valuable clues for the diagnosis and classification of neoplasms. However, it is essential to consider other histological features and clinical context when interpreting rosette formation in diagnostic pathology.

Cytokine receptors are specialized protein molecules found on the surface of cells that selectively bind to specific cytokines. Cytokines are signaling molecules used for communication between cells, and they play crucial roles in regulating immune responses, inflammation, hematopoiesis, and cell survival.

Cytokine receptors have specific binding sites that recognize and interact with the corresponding cytokines. This interaction triggers a series of intracellular signaling events that ultimately lead to changes in gene expression and various cellular responses. Cytokine receptors can be found on many different types of cells, including immune cells, endothelial cells, and structural cells like fibroblasts.

Cytokine receptors are typically composed of multiple subunits, which may include both extracellular and intracellular domains. The extracellular domain is responsible for cytokine binding, while the intracellular domain is involved in signal transduction. Cytokine receptors can be classified into several families based on their structural features and signaling mechanisms, such as the hematopoietic cytokine receptor family, the interferon receptor family, the tumor necrosis factor receptor family, and the interleukin-1 receptor family.

Dysregulation of cytokine receptors and their signaling pathways has been implicated in various diseases, including autoimmune disorders, chronic inflammation, and cancer. Therefore, understanding the biology of cytokine receptors is essential for developing targeted therapies to treat these conditions.

'C3H' is the name of an inbred strain of laboratory mice that was developed at the Jackson Laboratory in Bar Harbor, Maine. The mice are characterized by their uniform genetic background and have been widely used in biomedical research for many decades.

The C3H strain is particularly notable for its susceptibility to certain types of cancer, including mammary tumors and lymphomas. It also has a high incidence of age-related macular degeneration and other eye diseases. The strain is often used in studies of immunology, genetics, and carcinogenesis.

Like all inbred strains, the C3H mice are the result of many generations of brother-sister matings, which leads to a high degree of genetic uniformity within the strain. This makes them useful for studying the effects of specific genes or environmental factors on disease susceptibility and other traits. However, it also means that they may not always be representative of the genetic diversity found in outbred populations, including humans.

Immunoglobulin heavy chains (IgH) are proteins that make up the framework of antibodies, which are crucial components of the adaptive immune system. These heavy chains are produced by B cells and plasma cells, and they contain variable regions that can bind to specific antigens, as well as constant regions that determine the effector functions of the antibody.

The genes that encode for immunoglobulin heavy chains are located on chromosome 14 in humans, within a region known as the IgH locus. These genes undergo a complex process of rearrangement during B cell development, whereby different gene segments (V, D, and J) are joined together to create a unique variable region that can recognize a specific antigen. This process of gene rearrangement is critical for the diversity and specificity of the antibody response.

Therefore, the medical definition of 'Genes, Immunoglobulin Heavy Chain' refers to the set of genetic elements that encode for the immunoglobulin heavy chain proteins, and their complex process of rearrangement during B cell development.

Enzyme activation refers to the process by which an enzyme becomes biologically active and capable of carrying out its specific chemical or biological reaction. This is often achieved through various post-translational modifications, such as proteolytic cleavage, phosphorylation, or addition of cofactors or prosthetic groups to the enzyme molecule. These modifications can change the conformation or structure of the enzyme, exposing or creating a binding site for the substrate and allowing the enzymatic reaction to occur.

For example, in the case of proteolytic cleavage, an inactive precursor enzyme, known as a zymogen, is cleaved into its active form by a specific protease. This is seen in enzymes such as trypsin and chymotrypsin, which are initially produced in the pancreas as inactive precursors called trypsinogen and chymotrypsinogen, respectively. Once they reach the small intestine, they are activated by enteropeptidase, a protease that cleaves a specific peptide bond, releasing the active enzyme.

Phosphorylation is another common mechanism of enzyme activation, where a phosphate group is added to a specific serine, threonine, or tyrosine residue on the enzyme by a protein kinase. This modification can alter the conformation of the enzyme and create a binding site for the substrate, allowing the enzymatic reaction to occur.

Enzyme activation is a crucial process in many biological pathways, as it allows for precise control over when and where specific reactions take place. It also provides a mechanism for regulating enzyme activity in response to various signals and stimuli, such as hormones, neurotransmitters, or changes in the intracellular environment.

Carrier proteins, also known as transport proteins, are a type of protein that facilitates the movement of molecules across cell membranes. They are responsible for the selective and active transport of ions, sugars, amino acids, and other molecules from one side of the membrane to the other, against their concentration gradient. This process requires energy, usually in the form of ATP (adenosine triphosphate).

Carrier proteins have a specific binding site for the molecule they transport, and undergo conformational changes upon binding, which allows them to move the molecule across the membrane. Once the molecule has been transported, the carrier protein returns to its original conformation, ready to bind and transport another molecule.

Carrier proteins play a crucial role in maintaining the balance of ions and other molecules inside and outside of cells, and are essential for many physiological processes, including nerve impulse transmission, muscle contraction, and nutrient uptake.

T-lymphocyte subsets refer to distinct populations of T-cells, which are a type of white blood cell that plays a central role in cell-mediated immunity. The two main types of T-lymphocytes are CD4+ and CD8+ cells, which are defined by the presence or absence of specific proteins called cluster differentiation (CD) molecules on their surface.

CD4+ T-cells, also known as helper T-cells, play a crucial role in activating other immune cells, such as B-lymphocytes and macrophages, to mount an immune response against pathogens. They also produce cytokines that help regulate the immune response.

CD8+ T-cells, also known as cytotoxic T-cells, directly kill infected cells or tumor cells by releasing toxic substances such as perforins and granzymes.

The balance between these two subsets of T-cells is critical for maintaining immune homeostasis and mounting effective immune responses against pathogens while avoiding excessive inflammation and autoimmunity. Therefore, the measurement of T-lymphocyte subsets is essential in diagnosing and monitoring various immunological disorders, including HIV infection, cancer, and autoimmune diseases.

Immunization is defined medically as the process where an individual is made immune or resistant to an infectious disease, typically through the administration of a vaccine. The vaccine stimulates the body's own immune system to recognize and fight off the specific disease-causing organism, thereby preventing or reducing the severity of future infections with that organism.

Immunization can be achieved actively, where the person is given a vaccine to trigger an immune response, or passively, where antibodies are transferred to the person through immunoglobulin therapy. Immunizations are an important part of preventive healthcare and have been successful in controlling and eliminating many infectious diseases worldwide.

Complementarity Determining Regions (CDRs) are the portions of an antibody that recognize and bind to a specific antigen. These regions are located in the variable domains of both the heavy and light chains of the antibody molecule. The CDRs are formed by the hypervariable loops within these domains, which have unique sequences that allow them to bind specifically to a particular epitope on an antigen. There are three CDRs in each variable domain, for a total of six CDRs per antibody. The CDRs are primarily responsible for the antigen-binding specificity and affinity of an antibody.

Viral genes refer to the genetic material present in viruses that contains the information necessary for their replication and the production of viral proteins. In DNA viruses, the genetic material is composed of double-stranded or single-stranded DNA, while in RNA viruses, it is composed of single-stranded or double-stranded RNA.

Viral genes can be classified into three categories: early, late, and structural. Early genes encode proteins involved in the replication of the viral genome, modulation of host cell processes, and regulation of viral gene expression. Late genes encode structural proteins that make up the viral capsid or envelope. Some viruses also have structural genes that are expressed throughout their replication cycle.

Understanding the genetic makeup of viruses is crucial for developing antiviral therapies and vaccines. By targeting specific viral genes, researchers can develop drugs that inhibit viral replication and reduce the severity of viral infections. Additionally, knowledge of viral gene sequences can inform the development of vaccines that stimulate an immune response to specific viral proteins.

Monocytes are a type of white blood cell that are part of the immune system. They are large cells with a round or oval shape and a nucleus that is typically indented or horseshoe-shaped. Monocytes are produced in the bone marrow and then circulate in the bloodstream, where they can differentiate into other types of immune cells such as macrophages and dendritic cells.

Monocytes play an important role in the body's defense against infection and tissue damage. They are able to engulf and digest foreign particles, microorganisms, and dead or damaged cells, which helps to clear them from the body. Monocytes also produce cytokines, which are signaling molecules that help to coordinate the immune response.

Elevated levels of monocytes in the bloodstream can be a sign of an ongoing infection, inflammation, or other medical conditions such as cancer or autoimmune disorders.

Etoposide is a chemotherapy medication used to treat various types of cancer, including lung cancer, testicular cancer, and certain types of leukemia. It works by inhibiting the activity of an enzyme called topoisomerase II, which is involved in DNA replication and transcription. By doing so, etoposide can interfere with the growth and multiplication of cancer cells.

Etoposide is often administered intravenously in a hospital or clinic setting, although it may also be given orally in some cases. The medication can cause a range of side effects, including nausea, vomiting, hair loss, and an increased risk of infection. It can also have more serious side effects, such as bone marrow suppression, which can lead to anemia, bleeding, and a weakened immune system.

Like all chemotherapy drugs, etoposide is not without risks and should only be used under the close supervision of a qualified healthcare provider. It is important for patients to discuss the potential benefits and risks of this medication with their doctor before starting treatment.

Cell communication, also known as cell signaling, is the process by which cells exchange and transmit signals between each other and their environment. This complex system allows cells to coordinate their functions and maintain tissue homeostasis. Cell communication can occur through various mechanisms including:

1. Autocrine signaling: When a cell releases a signal that binds to receptors on the same cell, leading to changes in its behavior or function.
2. Paracrine signaling: When a cell releases a signal that binds to receptors on nearby cells, influencing their behavior or function.
3. Endocrine signaling: When a cell releases a hormone into the bloodstream, which then travels to distant target cells and binds to specific receptors, triggering a response.
4. Synaptic signaling: In neurons, communication occurs through the release of neurotransmitters that cross the synapse and bind to receptors on the postsynaptic cell, transmitting electrical or chemical signals.
5. Contact-dependent signaling: When cells physically interact with each other, allowing for the direct exchange of signals and information.

Cell communication is essential for various physiological processes such as growth, development, differentiation, metabolism, immune response, and tissue repair. Dysregulation in cell communication can contribute to diseases, including cancer, diabetes, and neurological disorders.

A chimera, in the context of medicine and biology, is a single organism that is composed of cells with different genetics. This can occur naturally in some situations, such as when fraternal twins do not fully separate in utero and end up sharing some organs or tissues. The term "chimera" can also refer to an organism that contains cells from two different species, which can happen in certain types of genetic research or medical treatments. For example, a patient's cells might be genetically modified in a lab and then introduced into their body to treat a disease; if some of these modified cells mix with the patient's original cells, the result could be a chimera.

It's worth noting that the term "chimera" comes from Greek mythology, where it referred to a fire-breathing monster that was part lion, part goat, and part snake. In modern scientific usage, the term has a specific technical meaning related to genetics and organisms, but it may still evoke images of fantastical creatures for some people.

DNA Mutational Analysis is a laboratory test used to identify genetic variations or changes (mutations) in the DNA sequence of a gene. This type of analysis can be used to diagnose genetic disorders, predict the risk of developing certain diseases, determine the most effective treatment for cancer, or assess the likelihood of passing on an inherited condition to offspring.

The test involves extracting DNA from a patient's sample (such as blood, saliva, or tissue), amplifying specific regions of interest using polymerase chain reaction (PCR), and then sequencing those regions to determine the precise order of nucleotide bases in the DNA molecule. The resulting sequence is then compared to reference sequences to identify any variations or mutations that may be present.

DNA Mutational Analysis can detect a wide range of genetic changes, including single-nucleotide polymorphisms (SNPs), insertions, deletions, duplications, and rearrangements. The test is often used in conjunction with other diagnostic tests and clinical evaluations to provide a comprehensive assessment of a patient's genetic profile.

It is important to note that not all mutations are pathogenic or associated with disease, and the interpretation of DNA Mutational Analysis results requires careful consideration of the patient's medical history, family history, and other relevant factors.

Lipopolysaccharides (LPS) are large molecules found in the outer membrane of Gram-negative bacteria. They consist of a hydrophilic polysaccharide called the O-antigen, a core oligosaccharide, and a lipid portion known as Lipid A. The Lipid A component is responsible for the endotoxic activity of LPS, which can trigger a powerful immune response in animals, including humans. This response can lead to symptoms such as fever, inflammation, and septic shock, especially when large amounts of LPS are introduced into the bloodstream.

Proto-oncogene proteins c-BCL-6, also known as B-cell lymphoma 6 protein, are normal cellular proteins that play a role in regulating gene expression and controlling cell growth and differentiation. They function as transcriptional repressors, which means they bind to DNA and inhibit the transcription of specific genes.

The c-BCL-6 proto-oncogene is located on chromosome 3 (3q27) and encodes a nuclear phosphoprotein that contains several functional domains, including a zinc finger domain, a BTB/POZ domain, and a C-terminal activation domain. These domains allow c-BCL-6 to interact with other proteins and regulate gene expression.

In normal cells, c-BCL-6 is involved in the development and differentiation of B cells, a type of white blood cell that produces antibodies. However, when the c-BCL-6 gene is mutated or its expression is deregulated, it can contribute to the development of cancer. In particular, c-BCL-6 has been implicated in the pathogenesis of several types of B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and Burkitt lymphoma (BL).

In these cancers, c-BCL-6 can act as an oncogene by inhibiting the transcription of tumor suppressor genes and promoting cell survival and proliferation. Overexpression of c-BCL-6 has been associated with poor clinical outcomes in patients with DLBCL and FL, making it a potential target for cancer therapy.

Animal disease models are specialized animals, typically rodents such as mice or rats, that have been genetically engineered or exposed to certain conditions to develop symptoms and physiological changes similar to those seen in human diseases. These models are used in medical research to study the pathophysiology of diseases, identify potential therapeutic targets, test drug efficacy and safety, and understand disease mechanisms.

The genetic modifications can include knockout or knock-in mutations, transgenic expression of specific genes, or RNA interference techniques. The animals may also be exposed to environmental factors such as chemicals, radiation, or infectious agents to induce the disease state.

Examples of animal disease models include:

1. Mouse models of cancer: Genetically engineered mice that develop various types of tumors, allowing researchers to study cancer initiation, progression, and metastasis.
2. Alzheimer's disease models: Transgenic mice expressing mutant human genes associated with Alzheimer's disease, which exhibit amyloid plaque formation and cognitive decline.
3. Diabetes models: Obese and diabetic mouse strains like the NOD (non-obese diabetic) or db/db mice, used to study the development of type 1 and type 2 diabetes, respectively.
4. Cardiovascular disease models: Atherosclerosis-prone mice, such as ApoE-deficient or LDLR-deficient mice, that develop plaque buildup in their arteries when fed a high-fat diet.
5. Inflammatory bowel disease models: Mice with genetic mutations affecting intestinal barrier function and immune response, such as IL-10 knockout or SAMP1/YitFc mice, which develop colitis.

Animal disease models are essential tools in preclinical research, but it is important to recognize their limitations. Differences between species can affect the translatability of results from animal studies to human patients. Therefore, researchers must carefully consider the choice of model and interpret findings cautiously when applying them to human diseases.

Antigen-presenting cells (APCs) are a group of specialized cells in the immune system that play a critical role in initiating and regulating immune responses. They have the ability to engulf, process, and present antigens (molecules derived from pathogens or other foreign substances) on their surface in conjunction with major histocompatibility complex (MHC) molecules. This presentation of antigens allows APCs to activate T cells, which are crucial for adaptive immunity.

There are several types of APCs, including:

1. Dendritic cells (DCs): These are the most potent and professional APCs, found in various tissues throughout the body. DCs can capture antigens from their environment, process them, and migrate to lymphoid organs where they present antigens to T cells.
2. Macrophages: These large phagocytic cells are found in many tissues and play a role in both innate and adaptive immunity. They can engulf and digest pathogens, then present processed antigens on their MHC class II molecules to activate CD4+ T helper cells.
3. B cells: These are primarily responsible for humoral immune responses by producing antibodies against antigens. When activated, B cells can also function as APCs and present antigens on their MHC class II molecules to CD4+ T cells.

The interaction between APCs and T cells is critical for the development of an effective immune response against pathogens or other foreign substances. This process helps ensure that the immune system can recognize and eliminate threats while minimizing damage to healthy tissues.

Genetic recombination is the process by which genetic material is exchanged between two similar or identical molecules of DNA during meiosis, resulting in new combinations of genes on each chromosome. This exchange occurs during crossover, where segments of DNA are swapped between non-sister homologous chromatids, creating genetic diversity among the offspring. It is a crucial mechanism for generating genetic variability and facilitating evolutionary change within populations. Additionally, recombination also plays an essential role in DNA repair processes through mechanisms such as homologous recombinational repair (HRR) and non-homologous end joining (NHEJ).

Interleukin-7 (IL-7) is a small signaling protein that is involved in the development and function of immune cells, particularly T cells and B cells. It is produced by stromal cells found in the bone marrow, thymus, and lymphoid organs. IL-7 binds to its receptor, IL-7R, which is expressed on the surface of immature T cells and B cells, as well as some mature immune cells.

IL-7 plays a critical role in the survival, proliferation, and differentiation of T cells and B cells during their development in the thymus and bone marrow, respectively. It also helps to maintain the homeostasis of these cell populations in peripheral tissues by promoting their survival and preventing apoptosis.

In addition to its role in immune cell development and homeostasis, IL-7 has been shown to have potential therapeutic applications in the treatment of various diseases, including cancer, infectious diseases, and autoimmune disorders. However, further research is needed to fully understand its mechanisms of action and potential side effects before it can be widely used in clinical settings.

A genetic vector is a vehicle, often a plasmid or a virus, that is used to introduce foreign DNA into a host cell as part of genetic engineering or gene therapy techniques. The vector contains the desired gene or genes, along with regulatory elements such as promoters and enhancers, which are needed for the expression of the gene in the target cells.

The choice of vector depends on several factors, including the size of the DNA to be inserted, the type of cell to be targeted, and the efficiency of uptake and expression required. Commonly used vectors include plasmids, adenoviruses, retroviruses, and lentiviruses.

Plasmids are small circular DNA molecules that can replicate independently in bacteria. They are often used as cloning vectors to amplify and manipulate DNA fragments. Adenoviruses are double-stranded DNA viruses that infect a wide range of host cells, including human cells. They are commonly used as gene therapy vectors because they can efficiently transfer genes into both dividing and non-dividing cells.

Retroviruses and lentiviruses are RNA viruses that integrate their genetic material into the host cell's genome. This allows for stable expression of the transgene over time. Lentiviruses, a subclass of retroviruses, have the advantage of being able to infect non-dividing cells, making them useful for gene therapy applications in post-mitotic tissues such as neurons and muscle cells.

Overall, genetic vectors play a crucial role in modern molecular biology and medicine, enabling researchers to study gene function, develop new therapies, and modify organisms for various purposes.

Immunoglobulin idiotypes refer to the unique antigenic determinants found on the variable regions of an immunoglobulin (antibody) molecule. These determinants are specific to each individual antibody and can be used to distinguish between different antibodies produced by a single individual or between antibodies produced by different individuals.

The variable region of an antibody is responsible for recognizing and binding to a specific antigen. The amino acid sequence in this region varies between different antibodies, and it is these variations that give rise to the unique idiotypes. Idiotypes can be used as markers to study the immune response, including the clonal selection and affinity maturation of B cells during an immune response.

Immunoglobulin idiotypes are also important in the development of monoclonal antibodies for therapeutic use. By identifying and isolating a specific antibody with the desired idiotype, it is possible to produce large quantities of identical antibodies that can be used to treat various diseases, including cancer and autoimmune disorders.

Chlorambucil is a medication that belongs to a class of drugs called alkylating agents. It is an antineoplastic drug, which means it is used to treat cancer. Chlorambucil works by interfering with the DNA in cells, which prevents them from dividing and growing. This makes it useful for treating certain types of cancer, such as chronic lymphocytic leukemia (CLL) and Hodgkin's lymphoma.

Chlorambucil is available in tablet form and is typically taken once a day. It is important to take chlorambucil exactly as directed by your healthcare provider, as the dosage and schedule will depend on your individual medical condition and response to treatment.

Like all medications, chlorambucil can cause side effects. Common side effects of chlorambucil include nausea, vomiting, diarrhea, and loss of appetite. It can also cause more serious side effects, such as a decrease in the number of white blood cells (which can increase the risk of infection), anemia (low red blood cell count), and thrombocytopenia (low platelet count). Chlorambucil may also increase the risk of certain types of cancer, such as acute myeloid leukemia (AML) and solid tumors.

It is important to discuss the potential risks and benefits of chlorambucil with your healthcare provider before starting treatment. They can help you understand the potential side effects and how to manage them, as well as any other precautions you should take while taking this medication.

Null lymphocytes are a type of immune cells that do not express typical surface markers found on mature T lymphocytes or B lymphocytes. They lack both CD4 and CD8 proteins, which are commonly used to identify T cells, as well as CD19 and CD20 proteins, which are used to identify B cells.

Null lymphocytes can be further divided into two subsets: double negative (DN) and double positive (DP) null cells. DN null cells lack both CD4 and CD8 proteins, while DP null cells express both of these proteins simultaneously. The function of null lymphocytes is not well understood, but they are thought to play a role in the immune response, particularly in the early stages of an infection or inflammation.

It's worth noting that null lymphocytes can also be found in some pathological conditions, such as certain types of leukemia and lymphoma, where they can accumulate in large numbers and contribute to the disease process.

Tumor markers are substances that can be found in the body and their presence can indicate the presence of certain types of cancer or other conditions. Biological tumor markers refer to those substances that are produced by cancer cells or by other cells in response to cancer or certain benign (non-cancerous) conditions. These markers can be found in various bodily fluids such as blood, urine, or tissue samples.

Examples of biological tumor markers include:

1. Proteins: Some tumor markers are proteins that are produced by cancer cells or by other cells in response to the presence of cancer. For example, prostate-specific antigen (PSA) is a protein produced by normal prostate cells and in higher amounts by prostate cancer cells.
2. Genetic material: Tumor markers can also include genetic material such as DNA, RNA, or microRNA that are shed by cancer cells into bodily fluids. For example, circulating tumor DNA (ctDNA) is genetic material from cancer cells that can be found in the bloodstream.
3. Metabolites: Tumor markers can also include metabolic products produced by cancer cells or by other cells in response to cancer. For example, lactate dehydrogenase (LDH) is an enzyme that is released into the bloodstream when cancer cells break down glucose for energy.

It's important to note that tumor markers are not specific to cancer and can be elevated in non-cancerous conditions as well. Therefore, they should not be used alone to diagnose cancer but rather as a tool in conjunction with other diagnostic tests and clinical evaluations.

Tumor suppressor proteins are a type of regulatory protein that helps control the cell cycle and prevent cells from dividing and growing in an uncontrolled manner. They work to inhibit tumor growth by preventing the formation of tumors or slowing down their progression. These proteins can repair damaged DNA, regulate gene expression, and initiate programmed cell death (apoptosis) if the damage is too severe for repair.

Mutations in tumor suppressor genes, which provide the code for these proteins, can lead to a decrease or loss of function in the resulting protein. This can result in uncontrolled cell growth and division, leading to the formation of tumors and cancer. Examples of tumor suppressor proteins include p53, Rb (retinoblastoma), and BRCA1/2.

Self tolerance, also known as immunological tolerance or biological tolerance, is a critical concept in the field of immunology. It refers to the ability of the immune system to distinguish between "self" and "non-self" antigens and to refrain from mounting an immune response against its own cells, tissues, and organs.

In other words, self tolerance is the state of immune non-responsiveness to self antigens, which are molecules or structures that are normally present in an individual's own body. This ensures that the immune system does not attack the body's own cells and cause autoimmune diseases.

Self tolerance is established during the development and maturation of the immune system, particularly in the thymus gland for T cells and the bone marrow for B cells. During this process, immature immune cells that recognize self antigens are either eliminated or rendered tolerant to them, so that they do not mount an immune response against the body's own tissues.

Maintaining self tolerance is essential for the proper functioning of the immune system and for preventing the development of autoimmune diseases, in which the immune system mistakenly attacks the body's own cells and tissues.

Adaptor proteins are a type of protein that play a crucial role in intracellular signaling pathways by serving as a link between different components of the signaling complex. Specifically, "signal transducing adaptor proteins" refer to those adaptor proteins that are involved in signal transduction processes, where they help to transmit signals from the cell surface receptors to various intracellular effectors. These proteins typically contain modular domains that allow them to interact with multiple partners, thereby facilitating the formation of large signaling complexes and enabling the integration of signals from different pathways.

Signal transducing adaptor proteins can be classified into several families based on their structural features, including the Src homology 2 (SH2) domain, the Src homology 3 (SH3) domain, and the phosphotyrosine-binding (PTB) domain. These domains enable the adaptor proteins to recognize and bind to specific motifs on other signaling molecules, such as receptor tyrosine kinases, G protein-coupled receptors, and cytokine receptors.

One well-known example of a signal transducing adaptor protein is the growth factor receptor-bound protein 2 (Grb2), which contains an SH2 domain that binds to phosphotyrosine residues on activated receptor tyrosine kinases. Grb2 also contains an SH3 domain that interacts with proline-rich motifs on other signaling proteins, such as the guanine nucleotide exchange factor SOS. This interaction facilitates the activation of the Ras small GTPase and downstream signaling pathways involved in cell growth, differentiation, and survival.

Overall, signal transducing adaptor proteins play a critical role in regulating various cellular processes by modulating intracellular signaling pathways in response to extracellular stimuli. Dysregulation of these proteins has been implicated in various diseases, including cancer and inflammatory disorders.

A Colony-Forming Units (CFU) assay is a type of laboratory test used to measure the number of viable, or living, cells in a sample. It is commonly used to enumerate bacteria, yeast, and other microorganisms. The test involves placing a known volume of the sample onto a nutrient-agar plate, which provides a solid growth surface for the cells. The plate is then incubated under conditions that allow the cells to grow and form colonies. Each colony that forms on the plate represents a single viable cell from the original sample. By counting the number of colonies and multiplying by the known volume of the sample, the total number of viable cells in the sample can be calculated. This information is useful in a variety of applications, including monitoring microbial populations, assessing the effectiveness of disinfection procedures, and studying microbial growth and survival.

Antigens are substances (usually proteins) on the surface of cells, viruses, fungi, or bacteria that the immune system recognizes as foreign and mounts a response against.

Differentiation in the context of T-lymphocytes refers to the process by which immature T-cells mature and develop into different types of T-cells with specific functions, such as CD4+ helper T-cells or CD8+ cytotoxic T-cells.

T-lymphocytes, also known as T-cells, are a type of white blood cell that plays a central role in cell-mediated immunity. They are produced in the bone marrow and mature in the thymus gland. Once mature, they circulate throughout the body in search of foreign antigens to attack and destroy.

Therefore, 'Antigens, Differentiation, T-Lymphocyte' refers to the process by which T-lymphocytes mature and develop the ability to recognize and respond to specific foreign antigens.

Chromosome disorders are a group of genetic conditions caused by abnormalities in the number or structure of chromosomes. Chromosomes are thread-like structures located in the nucleus of cells that contain most of the body's genetic material, which is composed of DNA and proteins. Normally, humans have 23 pairs of chromosomes, for a total of 46 chromosomes.

Chromosome disorders can result from changes in the number of chromosomes (aneuploidy) or structural abnormalities in one or more chromosomes. Some common examples of chromosome disorders include:

1. Down syndrome: a condition caused by an extra copy of chromosome 21, resulting in intellectual disability, developmental delays, and distinctive physical features.
2. Turner syndrome: a condition that affects only females and is caused by the absence of all or part of one X chromosome, resulting in short stature, lack of sexual development, and other symptoms.
3. Klinefelter syndrome: a condition that affects only males and is caused by an extra copy of the X chromosome, resulting in tall stature, infertility, and other symptoms.
4. Cri-du-chat syndrome: a condition caused by a deletion of part of the short arm of chromosome 5, resulting in intellectual disability, developmental delays, and a distinctive cat-like cry.
5. Fragile X syndrome: a condition caused by a mutation in the FMR1 gene on the X chromosome, resulting in intellectual disability, behavioral problems, and physical symptoms.

Chromosome disorders can be diagnosed through various genetic tests, such as karyotyping, chromosomal microarray analysis (CMA), or fluorescence in situ hybridization (FISH). Treatment for these conditions depends on the specific disorder and its associated symptoms and may include medical interventions, therapies, and educational support.

Graft-versus-host disease (GVHD) is a condition that can occur after an allogeneic hematopoietic stem cell transplantation (HSCT), where the donated immune cells (graft) recognize the recipient's tissues (host) as foreign and attack them. This results in inflammation and damage to various organs, particularly the skin, gastrointestinal tract, and liver.

Acute GVHD typically occurs within 100 days of transplantation and is characterized by symptoms such as rash, diarrhea, and liver dysfunction. Chronic GVHD, on the other hand, can occur after 100 days or even years post-transplant and may present with a wider range of symptoms, including dry eyes and mouth, skin changes, lung involvement, and issues with mobility and flexibility in joints.

GVHD is a significant complication following allogeneic HSCT and can have a substantial impact on the patient's quality of life and overall prognosis. Preventative measures, such as immunosuppressive therapy, are often taken to reduce the risk of GVHD, but its management remains a challenge in transplant medicine.

Large B-cell lymphoma, diffuse is a type of cancer that starts in cells called B-lymphocytes, which are part of the body's immune system. "Large B-cell" refers to the size and appearance of the abnormal cells when viewed under a microscope. "Diffuse" means that the abnormal cells are spread throughout the lymph node or tissue where the cancer has started, rather than being clustered in one area.

This type of lymphoma is typically aggressive, which means it grows and spreads quickly. It can occur almost anywhere in the body, but most commonly affects the lymph nodes, spleen, and bone marrow. Symptoms may include swollen lymph nodes, fever, night sweats, weight loss, and fatigue.

Treatment for large B-cell lymphoma, diffuse typically involves chemotherapy, radiation therapy, or a combination of both. In some cases, stem cell transplantation or targeted therapy may also be recommended. The prognosis varies depending on several factors, including the stage and location of the cancer, as well as the patient's age and overall health.

Interferon-gamma (IFN-γ) is a soluble cytokine that is primarily produced by the activation of natural killer (NK) cells and T lymphocytes, especially CD4+ Th1 cells and CD8+ cytotoxic T cells. It plays a crucial role in the regulation of the immune response against viral and intracellular bacterial infections, as well as tumor cells. IFN-γ has several functions, including activating macrophages to enhance their microbicidal activity, increasing the presentation of major histocompatibility complex (MHC) class I and II molecules on antigen-presenting cells, stimulating the proliferation and differentiation of T cells and NK cells, and inducing the production of other cytokines and chemokines. Additionally, IFN-γ has direct antiproliferative effects on certain types of tumor cells and can enhance the cytotoxic activity of immune cells against infected or malignant cells.

Clonal deletion is a process in the immune system where T cells or B cells that have receptors which are highly reactive to self-antigens are eliminated during development in the thymus or bone marrow, respectively. This helps prevent the development of autoimmune diseases, where the immune system attacks the body's own tissues and organs.

During the development of T cells in the thymus, immature T cells undergo a selection process to ensure that they do not react strongly to self-antigens. Those that do are eliminated through a process called negative selection or clonal deletion. Similarly, developing B cells in the bone marrow that produce antibodies with high affinity for self-antigens are also deleted.

Clonal deletion is an essential mechanism for maintaining self-tolerance and preventing the development of autoimmune diseases. However, if this process fails or is impaired, it can lead to the development of autoimmunity.

Myeloproliferative disorders (MPDs) are a group of rare, chronic blood cancers that originate from the abnormal proliferation or growth of one or more types of blood-forming cells in the bone marrow. These disorders result in an overproduction of mature but dysfunctional blood cells, which can lead to serious complications such as blood clots, bleeding, and organ damage.

There are several subtypes of MPDs, including:

1. Chronic Myeloid Leukemia (CML): A disorder characterized by the overproduction of mature granulocytes (a type of white blood cell) in the bone marrow, leading to an increased number of these cells in the blood. CML is caused by a genetic mutation that results in the formation of the BCR-ABL fusion protein, which drives uncontrolled cell growth and division.
2. Polycythemia Vera (PV): A disorder characterized by the overproduction of all three types of blood cells - red blood cells, white blood cells, and platelets - in the bone marrow. This can lead to an increased risk of blood clots, bleeding, and enlargement of the spleen.
3. Essential Thrombocythemia (ET): A disorder characterized by the overproduction of platelets in the bone marrow, leading to an increased risk of blood clots and bleeding.
4. Primary Myelofibrosis (PMF): A disorder characterized by the replacement of normal bone marrow tissue with scar tissue, leading to impaired blood cell production and anemia, enlargement of the spleen, and increased risk of infections and bleeding.
5. Chronic Neutrophilic Leukemia (CNL): A rare disorder characterized by the overproduction of neutrophils (a type of white blood cell) in the bone marrow, leading to an increased number of these cells in the blood. CNL can lead to an increased risk of infections and organ damage.

MPDs are typically treated with a combination of therapies, including chemotherapy, targeted therapy, immunotherapy, and stem cell transplantation. The choice of treatment depends on several factors, including the subtype of MPD, the patient's age and overall health, and the presence of any comorbidities.

Viral proteins are the proteins that are encoded by the viral genome and are essential for the viral life cycle. These proteins can be structural or non-structural and play various roles in the virus's replication, infection, and assembly process. Structural proteins make up the physical structure of the virus, including the capsid (the protein shell that surrounds the viral genome) and any envelope proteins (that may be present on enveloped viruses). Non-structural proteins are involved in the replication of the viral genome and modulation of the host cell environment to favor viral replication. Overall, a thorough understanding of viral proteins is crucial for developing antiviral therapies and vaccines.

A binding site on an antibody refers to the specific region on the surface of the antibody molecule that can recognize and bind to a specific antigen. Antibodies are proteins produced by the immune system in response to the presence of foreign substances called antigens. They have two main functions: to neutralize the harmful effects of antigens and to help eliminate them from the body.

The binding site of an antibody is located at the tips of its Y-shaped structure, formed by the variable regions of the heavy and light chains of the antibody molecule. These regions contain unique amino acid sequences that determine the specificity of the antibody for a particular antigen. The binding site can recognize and bind to a specific epitope or region on the antigen, forming an antigen-antibody complex.

The binding between the antibody and antigen is highly specific and depends on non-covalent interactions such as hydrogen bonds, van der Waals forces, and electrostatic attractions. This interaction plays a crucial role in the immune response, as it allows the immune system to recognize and eliminate pathogens and other foreign substances from the body.

Immunologic cytotoxicity refers to the damage or destruction of cells that occurs as a result of an immune response. This process involves the activation of immune cells, such as cytotoxic T cells and natural killer (NK) cells, which release toxic substances, such as perforins and granzymes, that can kill target cells.

In addition, antibodies produced by B cells can also contribute to immunologic cytotoxicity by binding to antigens on the surface of target cells and triggering complement-mediated lysis or antibody-dependent cellular cytotoxicity (ADCC) by activating immune effector cells.

Immunologic cytotoxicity plays an important role in the body's defense against viral infections, cancer cells, and other foreign substances. However, it can also contribute to tissue damage and autoimmune diseases if the immune system mistakenly targets healthy cells or tissues.

A radiation chimera is not a widely used or recognized medical term. However, in the field of genetics and radiation biology, a "chimera" refers to an individual that contains cells with different genetic backgrounds. A radiation chimera, therefore, could refer to an organism that has become a chimera as a result of exposure to radiation, which can cause mutations and changes in the genetic makeup of cells.

Ionizing radiation, such as that used in cancer treatments or nuclear accidents, can cause DNA damage and mutations in cells. If an organism is exposed to radiation and some of its cells undergo mutations while others do not, this could result in a chimera with genetically distinct populations of cells.

However, it's important to note that the term "radiation chimera" is not commonly used in medical literature or clinical settings. If you encounter this term in a different context, I would recommend seeking clarification from the source to ensure a proper understanding.

An antigen is any substance that can stimulate an immune response, particularly the production of antibodies. Viral antigens are antigens that are found on or produced by viruses. They can be proteins, glycoproteins, or carbohydrates present on the surface or inside the viral particle.

Viral antigens play a crucial role in the immune system's recognition and response to viral infections. When a virus infects a host cell, it may display its antigens on the surface of the infected cell. This allows the immune system to recognize and target the infected cells for destruction, thereby limiting the spread of the virus.

Viral antigens are also important targets for vaccines. Vaccines typically work by introducing a harmless form of a viral antigen to the body, which then stimulates the production of antibodies and memory T-cells that can recognize and respond quickly and effectively to future infections with the actual virus.

It's worth noting that different types of viruses have different antigens, and these antigens can vary between strains of the same virus. This is why there are often different vaccines available for different viral diseases, and why flu vaccines need to be updated every year to account for changes in the circulating influenza virus strains.

A gammaretrovirus is a type of retrovirus, which is a virus that contains RNA as its genetic material and uses the reverse transcriptase enzyme to produce DNA from its RNA genome. Gammaretroviruses are enveloped viruses, meaning they have a lipid membrane derived from the host cell. They are also classified as simple retroviruses because their genome only contains the genes gag, pol, and env.

Gammaretroviruses are known to cause diseases in animals, including leukemias and immunodeficiencies. One example of a gammaretrovirus is the feline leukemia virus (FeLV), which can cause a variety of symptoms in cats, including anemia, lymphoma, and immune suppression.

Gammaretroviruses have also been implicated in some human diseases, although they are not thought to be major causes of human disease. For example, the human T-cell leukemia virus type 1 (HTLV-1) is a retrovirus that is closely related to gammaretroviruses and can cause adult T-cell leukemia/lymphoma and tropical spastic paraparesis/ HTLV-associated myelopathy (TSP/HAM).

It's important to note that the classification of retroviruses has evolved over time, and some viruses that were once classified as gammaretroviruses are now considered to be part of other retrovirus genera.

1. Receptors: In the context of physiology and medicine, receptors are specialized proteins found on the surface of cells or inside cells that detect and respond to specific molecules, known as ligands. These interactions can trigger a range of responses within the cell, such as starting a signaling pathway or changing the cell's behavior. There are various types of receptors, including ion channels, G protein-coupled receptors, and enzyme-linked receptors.

2. Antigen: An antigen is any substance (usually a protein) that can be recognized by the immune system, specifically by antibodies or T-cells, as foreign and potentially harmful. Antigens can be derived from various sources, such as bacteria, viruses, fungi, parasites, or even non-living substances like pollen, chemicals, or toxins. An antigen typically contains epitopes, which are the specific regions that antibodies or T-cell receptors recognize and bind to.

3. T-Cell: Also known as T lymphocytes, T-cells are a type of white blood cell that plays a crucial role in cell-mediated immunity, a part of the adaptive immune system. They are produced in the bone marrow and mature in the thymus gland. There are several types of T-cells, including CD4+ helper T-cells, CD8+ cytotoxic T-cells, and regulatory T-cells (Tregs). T-cells recognize antigens presented to them by antigen-presenting cells (APCs) via their surface receptors called the T-cell receptor (TCR). Once activated, T-cells can proliferate and differentiate into various effector cells that help eliminate infected or damaged cells.

Human chromosome pair 12 consists of two rod-shaped structures present in the nucleus of each cell in the human body. Each chromosome is made up of DNA tightly coiled around histone proteins, forming a complex structure called a chromatin.

Chromosomes come in pairs, with one chromosome inherited from each parent. In humans, there are 23 pairs of chromosomes, for a total of 46 chromosomes in each cell. Chromosome pair 12 is the 12th pair of autosomal chromosomes, meaning they are not sex chromosomes (X or Y).

Chromosome 12 is a medium-sized chromosome and contains an estimated 130 million base pairs of DNA. It contains around 1,200 genes that provide instructions for making proteins and regulating various cellular processes. Some of the genes located on chromosome 12 include those involved in metabolism, development, and response to environmental stimuli.

Abnormalities in chromosome 12 can lead to genetic disorders, such as partial trisomy 12q, which is characterized by an extra copy of the long arm of chromosome 12, and Jacobsen syndrome, which is caused by a deletion of the distal end of the long arm of chromosome 12.

Mitoxantrone is a synthetic antineoplastic anthracenedione drug, which means it is used to treat cancer. Its medical definition can be found in various authoritative sources such as the Merck Manual or Stedman's Medical Dictionary. Here's a brief version of the definition from MedlinePlus, a service of the US National Library of Medicine:

"Mitoxantrone is used to treat certain types of cancer (e.g., breast cancer, leukemia, non-Hodgkin's lymphoma). It works by slowing or stopping the growth of cancer cells. Mitoxantrone belongs to a class of drugs known as antitumor antibiotics."

Please note that this is a simplified definition meant for general information purposes and does not include all the details that might be present in a comprehensive medical definition. Always consult a healthcare professional or refer to authoritative resources for accurate, detailed, and up-to-date information.

IgG receptors, also known as Fcγ receptors (Fc gamma receptors), are specialized protein molecules found on the surface of various immune cells, such as neutrophils, monocytes, macrophages, and some lymphocytes. These receptors recognize and bind to the Fc region of IgG antibodies, one of the five classes of immunoglobulins in the human body.

IgG receptors play a crucial role in immune responses by mediating different effector functions, including:

1. Antibody-dependent cellular cytotoxicity (ADCC): IgG receptors on natural killer (NK) cells and other immune cells bind to IgG antibodies coated on the surface of virus-infected or cancer cells, leading to their destruction.
2. Phagocytosis: When IgG antibodies tag pathogens or foreign particles, phagocytes like neutrophils and macrophages recognize and bind to these immune complexes via IgG receptors, facilitating the engulfment and removal of the targeted particles.
3. Antigen presentation: IgG receptors on antigen-presenting cells (APCs) can internalize immune complexes, process the antigens, and present them to T cells, thereby initiating adaptive immune responses.
4. Inflammatory response regulation: IgG receptors can modulate inflammation by activating or inhibiting downstream signaling pathways in immune cells, depending on the specific type of Fcγ receptor and its activation state.

There are several types of IgG receptors (FcγRI, FcγRII, FcγRIII, and FcγRIV) with varying affinities for different subclasses of IgG antibodies (IgG1, IgG2, IgG3, and IgG4). The distinct functions and expression patterns of these receptors contribute to the complexity and fine-tuning of immune responses in the human body.

Virus replication is the process by which a virus produces copies or reproduces itself inside a host cell. This involves several steps:

1. Attachment: The virus attaches to a specific receptor on the surface of the host cell.
2. Penetration: The viral genetic material enters the host cell, either by invagination of the cell membrane or endocytosis.
3. Uncoating: The viral genetic material is released from its protective coat (capsid) inside the host cell.
4. Replication: The viral genetic material uses the host cell's machinery to produce new viral components, such as proteins and nucleic acids.
5. Assembly: The newly synthesized viral components are assembled into new virus particles.
6. Release: The newly formed viruses are released from the host cell, often through lysis (breaking) of the cell membrane or by budding off the cell membrane.

The specific mechanisms and details of virus replication can vary depending on the type of virus. Some viruses, such as DNA viruses, use the host cell's DNA polymerase to replicate their genetic material, while others, such as RNA viruses, use their own RNA-dependent RNA polymerase or reverse transcriptase enzymes. Understanding the process of virus replication is important for developing antiviral therapies and vaccines.

Human chromosome pair 17 consists of two rod-shaped structures present in the nucleus of each human cell. Each chromosome is made up of DNA tightly coiled around histone proteins, forming a complex called chromatin. Chromosomes carry genetic information in the form of genes, which are segments of DNA that contain instructions for the development and function of an organism.

Human cells typically have 23 pairs of chromosomes, for a total of 46 chromosomes. Pair 17 is one of the autosomal pairs, meaning it is not a sex chromosome (X or Y). Chromosome 17 is a medium-sized chromosome and contains an estimated 800 million base pairs of DNA. It contains approximately 1,500 genes that provide instructions for making proteins and regulating various cellular processes.

Chromosome 17 is associated with several genetic disorders, including inherited cancer syndromes such as Li-Fraumeni syndrome and hereditary nonpolyposis colorectal cancer (HNPCC). Mutations in genes located on chromosome 17 can increase the risk of developing various types of cancer, including breast, ovarian, colon, and pancreatic cancer.

Combined modality therapy (CMT) is a medical treatment approach that utilizes more than one method or type of therapy simultaneously or in close succession, with the goal of enhancing the overall effectiveness of the treatment. In the context of cancer care, CMT often refers to the combination of two or more primary treatment modalities, such as surgery, radiation therapy, and systemic therapies (chemotherapy, immunotherapy, targeted therapy, etc.).

The rationale behind using combined modality therapy is that each treatment method can target cancer cells in different ways, potentially increasing the likelihood of eliminating all cancer cells and reducing the risk of recurrence. The specific combination and sequence of treatments will depend on various factors, including the type and stage of cancer, patient's overall health, and individual preferences.

For example, a common CMT approach for locally advanced rectal cancer may involve preoperative (neoadjuvant) chemoradiation therapy, followed by surgery to remove the tumor, and then postoperative (adjuvant) chemotherapy. This combined approach allows for the reduction of the tumor size before surgery, increases the likelihood of complete tumor removal, and targets any remaining microscopic cancer cells with systemic chemotherapy.

It is essential to consult with a multidisciplinary team of healthcare professionals to determine the most appropriate CMT plan for each individual patient, considering both the potential benefits and risks associated with each treatment method.

A ligand, in the context of biochemistry and medicine, is a molecule that binds to a specific site on a protein or a larger biomolecule, such as an enzyme or a receptor. This binding interaction can modify the function or activity of the target protein, either activating it or inhibiting it. Ligands can be small molecules, like hormones or neurotransmitters, or larger structures, like antibodies. The study of ligand-protein interactions is crucial for understanding cellular processes and developing drugs, as many therapeutic compounds function by binding to specific targets within the body.

Deltaretroviruses are a genus of retroviruses that can cause chronic infections in humans and animals. The two main deltaretroviruses that infect humans are the Human T-cell Leukemia Virus type 1 (HTLV-1) and Human T-cell Leukemia Virus type 2 (HTLV-2).

HTLV-1 is primarily transmitted through breastfeeding, sexual contact, and contaminated blood products. It can cause several diseases, including Adult T-cell Leukemia/Lymphoma (ATLL) and a neurological disorder called HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP).

HTLV-2 is primarily transmitted through intravenous drug use and sexual contact. While it has been associated with some diseases, such as neurological disorders and rare cases of leukemia, the link between HTLV-2 and disease is not as clear as it is for HTLV-1.

Deltaretrovirus infections can be diagnosed through blood tests that detect antibodies to the viruses or through genetic testing to detect the virus itself. There is currently no cure for deltaretrovirus infections, but antiretroviral therapy (ART) may help manage the infection and reduce the risk of transmission.

It's important to note that deltaretrovirus infections are relatively rare, and most people who are infected do not develop symptoms or disease. However, if you believe you may have been exposed to these viruses, it is important to speak with a healthcare provider for further evaluation and testing.

Immunologic receptors are specialized proteins found on the surface of immune cells that recognize and bind to specific molecules, known as antigens, on the surface of pathogens or infected cells. This binding triggers a series of intracellular signaling events that activate the immune cell and initiate an immune response.

There are several types of immunologic receptors, including:

1. T-cell receptors (TCRs): These receptors are found on the surface of T cells and recognize antigens presented in the context of major histocompatibility complex (MHC) molecules.
2. B-cell receptors (BCRs): These receptors are found on the surface of B cells and recognize free antigens in solution.
3. Pattern recognition receptors (PRRs): These receptors are found inside immune cells and recognize conserved molecular patterns associated with pathogens, such as lipopolysaccharides and flagellin.
4. Fc receptors: These receptors are found on the surface of various immune cells and bind to the constant region of antibodies, mediating effector functions such as phagocytosis and antibody-dependent cellular cytotoxicity (ADCC).

Immunologic receptors play a critical role in the recognition and elimination of pathogens and infected cells, and dysregulation of these receptors can lead to immune disorders and diseases.

Immunohistochemistry (IHC) is a technique used in pathology and laboratory medicine to identify specific proteins or antigens in tissue sections. It combines the principles of immunology and histology to detect the presence and location of these target molecules within cells and tissues. This technique utilizes antibodies that are specific to the protein or antigen of interest, which are then tagged with a detection system such as a chromogen or fluorophore. The stained tissue sections can be examined under a microscope, allowing for the visualization and analysis of the distribution and expression patterns of the target molecule in the context of the tissue architecture. Immunohistochemistry is widely used in diagnostic pathology to help identify various diseases, including cancer, infectious diseases, and immune-mediated disorders.

Hypergammaglobulinemia is a medical condition characterized by an elevated level of gamma globulins (a type of immunoglobulins or antibodies) in the blood. These proteins are part of the body's immune system and help to fight off infections. However, when their levels become too high, it can indicate an underlying medical disorder.

There are several types of hypergammaglobulinemia, including:

1. Primary hypergammaglobulinemia: This is a rare condition that is present at birth or develops during early childhood. It is caused by genetic mutations that lead to overproduction of immunoglobulins.
2. Secondary hypergammaglobulinemia: This type is more common and is caused by an underlying medical condition, such as chronic infections, autoimmune disorders, or certain types of cancer.

Symptoms of hypergammaglobulinemia can vary depending on the cause and severity of the condition. They may include recurrent infections, fatigue, swelling of the lymph nodes, and joint pain. Treatment typically involves addressing the underlying cause of the condition, if possible, as well as managing symptoms and preventing complications.

Mitogens are substances that stimulate mitosis, or cell division, in particular, the proliferation of cells derived from the immune system. They are often proteins or glycoproteins found on the surface of certain bacteria, viruses, and other cells, which can bind to receptors on the surface of immune cells and trigger a signal transduction pathway that leads to cell division.

Mitogens are commonly used in laboratory research to study the growth and behavior of immune cells, as well as to assess the function of the immune system. For example, mitogens can be added to cultures of lymphocytes (a type of white blood cell) to stimulate their proliferation and measure their response to various stimuli.

Examples of mitogens include phytohemagglutinin (PHA), concanavalin A (ConA), and pokeweed mitogen (PWM). It's important to note that while mitogens can be useful tools in research, they can also have harmful effects if they are introduced into the body in large quantities or inappropriately, as they can stimulate an overactive immune response.

Antibodies, viral are proteins produced by the immune system in response to an infection with a virus. These antibodies are capable of recognizing and binding to specific antigens on the surface of the virus, which helps to neutralize or destroy the virus and prevent its replication. Once produced, these antibodies can provide immunity against future infections with the same virus.

Viral antibodies are typically composed of four polypeptide chains - two heavy chains and two light chains - that are held together by disulfide bonds. The binding site for the antigen is located at the tip of the Y-shaped structure, formed by the variable regions of the heavy and light chains.

There are five classes of antibodies in humans: IgA, IgD, IgE, IgG, and IgM. Each class has a different function and is distributed differently throughout the body. For example, IgG is the most common type of antibody found in the bloodstream and provides long-term immunity against viruses, while IgA is found primarily in mucous membranes and helps to protect against respiratory and gastrointestinal infections.

In addition to their role in the immune response, viral antibodies can also be used as diagnostic tools to detect the presence of a specific virus in a patient's blood or other bodily fluids.

A cell membrane, also known as the plasma membrane, is a thin semi-permeable phospholipid bilayer that surrounds all cells in animals, plants, and microorganisms. It functions as a barrier to control the movement of substances in and out of the cell, allowing necessary molecules such as nutrients, oxygen, and signaling molecules to enter while keeping out harmful substances and waste products. The cell membrane is composed mainly of phospholipids, which have hydrophilic (water-loving) heads and hydrophobic (water-fearing) tails. This unique structure allows the membrane to be flexible and fluid, yet selectively permeable. Additionally, various proteins are embedded in the membrane that serve as channels, pumps, receptors, and enzymes, contributing to the cell's overall functionality and communication with its environment.

Immunologic capping is a biological process that occurs in immune cells, particularly B lymphocytes and neutrophils. It refers to the redistribution and clustering of immunoglobulin receptors or antibodies on the cell surface upon engagement with their specific antigens. This phenomenon leads to the formation of a cap-like structure at one pole of the cell, which is then internalized by endocytosis, followed by the degradation of the antigen-antibody complex in lysosomes. Immunologic capping helps regulate immune responses and contributes to the elimination of antigens from the cell surface.

Peyer's patches are specialized lymphoid nodules found in the mucosa of the ileum, a part of the small intestine. They are a component of the immune system and play a crucial role in monitoring and defending against harmful pathogens that are ingested with food and drink. Peyer's patches contain large numbers of B-lymphocytes, T-lymphocytes, and macrophages, which work together to identify and eliminate potential threats. They also have a unique structure that allows them to sample and analyze the contents of the intestinal lumen, providing an early warning system for the immune system.

Muramidase, also known as lysozyme, is an enzyme that hydrolyzes the glycosidic bond between N-acetylmuramic acid and N-acetylglucosamine in peptidoglycan, a polymer found in bacterial cell walls. This enzymatic activity plays a crucial role in the innate immune system by contributing to the destruction of invading bacteria. Muramidase is widely distributed in various tissues and bodily fluids, such as tears, saliva, and milk, and is also found in several types of white blood cells, including neutrophils and monocytes.

Oligonucleotide Array Sequence Analysis is a type of microarray analysis that allows for the simultaneous measurement of the expression levels of thousands of genes in a single sample. In this technique, oligonucleotides (short DNA sequences) are attached to a solid support, such as a glass slide, in a specific pattern. These oligonucleotides are designed to be complementary to specific target mRNA sequences from the sample being analyzed.

During the analysis, labeled RNA or cDNA from the sample is hybridized to the oligonucleotide array. The level of hybridization is then measured and used to determine the relative abundance of each target sequence in the sample. This information can be used to identify differences in gene expression between samples, which can help researchers understand the underlying biological processes involved in various diseases or developmental stages.

It's important to note that this technique requires specialized equipment and bioinformatics tools for data analysis, as well as careful experimental design and validation to ensure accurate and reproducible results.

Inbred A mice are a strain of laboratory mice that have been produced by many generations of brother-sister matings. This results in a high degree of genetic similarity among individuals within the strain, making them useful for research purposes where a consistent genetic background is desired. The Inbred A strain is maintained through continued brother-sister mating. It's important to note that while these mice are called "Inbred A," the designation does not refer to any specific medical condition or characteristic. Instead, it refers to the breeding practices used to create and maintain this particular strain of laboratory mice.

Retrospective studies, also known as retrospective research or looking back studies, are a type of observational study that examines data from the past to draw conclusions about possible causal relationships between risk factors and outcomes. In these studies, researchers analyze existing records, medical charts, or previously collected data to test a hypothesis or answer a specific research question.

Retrospective studies can be useful for generating hypotheses and identifying trends, but they have limitations compared to prospective studies, which follow participants forward in time from exposure to outcome. Retrospective studies are subject to biases such as recall bias, selection bias, and information bias, which can affect the validity of the results. Therefore, retrospective studies should be interpreted with caution and used primarily to generate hypotheses for further testing in prospective studies.

Retroviridae proteins, oncogenic, refer to the proteins expressed by retroviruses that have the ability to transform normal cells into cancerous ones. These oncogenic proteins are typically encoded by viral genes known as "oncogenes," which are acquired through the process of transduction from the host cell's DNA during retroviral replication.

The most well-known example of an oncogenic retrovirus is the Human T-cell Leukemia Virus Type 1 (HTLV-1), which encodes the Tax and HBZ oncoproteins. These proteins manipulate various cellular signaling pathways, leading to uncontrolled cell growth and malignant transformation.

It is important to note that not all retroviruses are oncogenic, and only a small subset of them have been associated with cancer development in humans or animals.

Arabinonucleosides are glycosylamines derived from arabinose, a monosaccharide (simple sugar) that is a component of certain complex carbohydrates. In an arabinonucleoside, the arabinose molecule is linked to a nitrogenous base, such as adenine, guanine, cytosine, uracil, or thymine, through a glycosidic bond. These types of compounds are not typically found in nature but can be synthesized in the laboratory for research purposes. They may have potential applications in the development of new drugs, particularly in the area of antiviral and anticancer therapy.

Notch 1 is a type of receptor that belongs to the family of single-transmembrane receptors known as Notch receptors. It is a heterodimeric transmembrane protein composed of an extracellular domain and an intracellular domain, which play crucial roles in cell fate determination, proliferation, differentiation, and apoptosis during embryonic development and adult tissue homeostasis.

The Notch 1 receptor is activated through a conserved mechanism of ligand-receptor interaction, where the extracellular domain of the receptor interacts with the membrane-bound ligands Jagged 1 or 2 and Delta-like 1, 3, or 4 expressed on adjacent cells. This interaction triggers a series of proteolytic cleavages that release the intracellular domain of Notch 1 (NICD) from the membrane. NICD then translocates to the nucleus and interacts with the DNA-binding protein CSL (CBF1/RBPJκ in mammals) and coactivators Mastermind-like proteins to regulate the expression of target genes, including members of the HES and HEY families.

Mutations in NOTCH1 have been associated with various human diseases, such as T-cell acute lymphoblastic leukemia (T-ALL), a type of cancer that affects the immune system's T cells, and vascular diseases, including arterial calcification, atherosclerosis, and aneurysms.

A bone marrow examination is a medical procedure in which a sample of bone marrow, the spongy tissue inside bones where blood cells are produced, is removed and examined. This test is used to diagnose or monitor various conditions affecting blood cell production, such as infections, leukemia, anemia, and other disorders of the bone marrow.

The sample is typically taken from the hipbone (iliac crest) or breastbone (sternum) using a special needle. The procedure may be done under local anesthesia or with sedation to minimize discomfort. Once the sample is obtained, it is examined under a microscope for the presence of abnormal cells, changes in cell size and shape, and other characteristics that can help diagnose specific conditions. Various stains, cultures, and other tests may also be performed on the sample to provide additional information.

Bone marrow examination is an important diagnostic tool in hematology and oncology, as it allows for a detailed assessment of blood cell production and can help guide treatment decisions for patients with various blood disorders.

Immunotherapy is a type of medical treatment that uses the body's own immune system to fight against diseases, such as cancer. It involves the use of substances (like vaccines, medications, or immune cells) that stimulate or suppress the immune system to help it recognize and destroy harmful disease-causing cells or agents, like tumor cells.

Immunotherapy can work in several ways:

1. Activating the immune system: Certain immunotherapies boost the body's natural immune responses, helping them recognize and attack cancer cells more effectively.
2. Suppressing immune system inhibitors: Some immunotherapies target and block proteins or molecules that can suppress the immune response, allowing the immune system to work more efficiently against diseases.
3. Replacing or enhancing specific immune cells: Immunotherapy can also involve administering immune cells (like T-cells) that have been genetically engineered or modified to recognize and destroy cancer cells.

Immunotherapies have shown promising results in treating various types of cancer, autoimmune diseases, and allergies. However, they can also cause side effects, as an overactive immune system may attack healthy tissues and organs. Therefore, careful monitoring is necessary during immunotherapy treatment.

A Tumor Stem Cell Assay is not a widely accepted or standardized medical definition. However, in the context of cancer research, a tumor stem cell assay generally refers to an experimental procedure used to identify and isolate cancer stem cells (also known as tumor-initiating cells) from a tumor sample.

Cancer stem cells are a subpopulation of cells within a tumor that are believed to be responsible for driving tumor growth, metastasis, and resistance to therapy. They have the ability to self-renew and differentiate into various cell types within the tumor, making them a promising target for cancer therapies.

A tumor stem cell assay typically involves isolating cells from a tumor sample and subjecting them to various tests to identify those with stem cell-like properties. These tests may include assessing their ability to form tumors in animal models or their expression of specific surface markers associated with cancer stem cells. The goal of the assay is to provide researchers with a better understanding of the biology of cancer stem cells and to develop new therapies that target them specifically.

Interleukin-10 (IL-10) is an anti-inflammatory cytokine that plays a crucial role in the modulation of immune responses. It is produced by various cell types, including T cells, macrophages, and dendritic cells. IL-10 inhibits the production of pro-inflammatory cytokines, such as TNF-α, IL-1, IL-6, IL-8, and IL-12, and downregulates the expression of costimulatory molecules on antigen-presenting cells. This results in the suppression of T cell activation and effector functions, which ultimately helps to limit tissue damage during inflammation and promote tissue repair. Dysregulation of IL-10 has been implicated in various pathological conditions, including chronic infections, autoimmune diseases, and cancer.

A fatal outcome is a term used in medical context to describe a situation where a disease, injury, or illness results in the death of an individual. It is the most severe and unfortunate possible outcome of any medical condition, and is often used as a measure of the severity and prognosis of various diseases and injuries. In clinical trials and research, fatal outcome may be used as an endpoint to evaluate the effectiveness and safety of different treatments or interventions.

Homeodomain proteins are a group of transcription factors that play crucial roles in the development and differentiation of cells in animals and plants. They are characterized by the presence of a highly conserved DNA-binding domain called the homeodomain, which is typically about 60 amino acids long. The homeodomain consists of three helices, with the third helix responsible for recognizing and binding to specific DNA sequences.

Homeodomain proteins are involved in regulating gene expression during embryonic development, tissue maintenance, and organismal growth. They can act as activators or repressors of transcription, depending on the context and the presence of cofactors. Mutations in homeodomain proteins have been associated with various human diseases, including cancer, congenital abnormalities, and neurological disorders.

Some examples of homeodomain proteins include PAX6, which is essential for eye development, HOX genes, which are involved in body patterning, and NANOG, which plays a role in maintaining pluripotency in stem cells.

Multiple myeloma is a type of cancer that forms in a type of white blood cell called a plasma cell. Plasma cells help your body fight infection by producing antibodies. In multiple myeloma, cancerous plasma cells accumulate in the bone marrow and crowd out healthy blood cells. Rather than producing useful antibodies, the cancer cells produce abnormal proteins that can cause complications such as kidney damage, bone pain and fractures.

Multiple myeloma is a type of cancer called a plasma cell neoplasm. Plasma cell neoplasms are diseases in which there is an overproduction of a single clone of plasma cells. In multiple myeloma, this results in the crowding out of normal plasma cells, red and white blood cells and platelets, leading to many of the complications associated with the disease.

The abnormal proteins produced by the cancer cells can also cause damage to organs and tissues in the body. These abnormal proteins can be detected in the blood or urine and are often used to monitor the progression of multiple myeloma.

Multiple myeloma is a relatively uncommon cancer, but it is the second most common blood cancer after non-Hodgkin lymphoma. It typically occurs in people over the age of 65, and men are more likely to develop multiple myeloma than women. While there is no cure for multiple myeloma, treatments such as chemotherapy, radiation therapy, and stem cell transplantation can help manage the disease and its symptoms, and improve quality of life.

HTLV-I (Human T-lymphotropic virus type 1) infection is a viral infection that attacks the CD4+ T-cells (a type of white blood cell) and can lead to the development of various diseases, including Adult T-cell Leukemia/Lymphoma (ATLL) and HTLV-I Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP). The virus is primarily transmitted through breastfeeding, sexual contact, or contaminated blood products. After infection, the virus becomes integrated into the host's DNA and can remain dormant for years, even decades, before leading to the development of disease. Most people infected with HTLV-I do not develop any symptoms, but a small percentage will go on to develop serious complications.

In the context of medical and biological sciences, a "binding site" refers to a specific location on a protein, molecule, or cell where another molecule can attach or bind. This binding interaction can lead to various functional changes in the original protein or molecule. The other molecule that binds to the binding site is often referred to as a ligand, which can be a small molecule, ion, or even another protein.

The binding between a ligand and its target binding site can be specific and selective, meaning that only certain ligands can bind to particular binding sites with high affinity. This specificity plays a crucial role in various biological processes, such as signal transduction, enzyme catalysis, or drug action.

In the case of drug development, understanding the location and properties of binding sites on target proteins is essential for designing drugs that can selectively bind to these sites and modulate protein function. This knowledge can help create more effective and safer therapeutic options for various diseases.

Follow-up studies are a type of longitudinal research that involve repeated observations or measurements of the same variables over a period of time, in order to understand their long-term effects or outcomes. In medical context, follow-up studies are often used to evaluate the safety and efficacy of medical treatments, interventions, or procedures.

In a typical follow-up study, a group of individuals (called a cohort) who have received a particular treatment or intervention are identified and then followed over time through periodic assessments or data collection. The data collected may include information on clinical outcomes, adverse events, changes in symptoms or functional status, and other relevant measures.

The results of follow-up studies can provide important insights into the long-term benefits and risks of medical interventions, as well as help to identify factors that may influence treatment effectiveness or patient outcomes. However, it is important to note that follow-up studies can be subject to various biases and limitations, such as loss to follow-up, recall bias, and changes in clinical practice over time, which must be carefully considered when interpreting the results.

Nucleic acid hybridization is a process in molecular biology where two single-stranded nucleic acids (DNA, RNA) with complementary sequences pair together to form a double-stranded molecule through hydrogen bonding. The strands can be from the same type of nucleic acid or different types (i.e., DNA-RNA or DNA-cDNA). This process is commonly used in various laboratory techniques, such as Southern blotting, Northern blotting, polymerase chain reaction (PCR), and microarray analysis, to detect, isolate, and analyze specific nucleic acid sequences. The hybridization temperature and conditions are critical to ensure the specificity of the interaction between the two strands.

A dose-response relationship in immunology refers to the quantitative relationship between the dose or amount of an antigen (a substance that triggers an immune response) and the magnitude or strength of the resulting immune response. Generally, as the dose of an antigen increases, the intensity and/or duration of the immune response also increase, up to a certain point. This relationship helps in determining the optimal dosage for vaccines and immunotherapies, ensuring sufficient immune activation while minimizing potential adverse effects.

Antibody affinity refers to the strength and specificity of the interaction between an antibody and its corresponding antigen at a molecular level. It is a measure of how strongly and selectively an antibody binds to its target antigen. A higher affinity indicates a more stable and specific binding, while a lower affinity suggests weaker and less specific interactions. Affinity is typically measured in terms of the dissociation constant (Kd), which describes the concentration of antigen needed to achieve half-maximal binding to an antibody. Generally, a smaller Kd value corresponds to a higher affinity, indicating a tighter and more selective bond. This parameter is crucial in the development of diagnostic and therapeutic applications, such as immunoassays and targeted therapies, where high-affinity antibodies are preferred for improved sensitivity and specificity.

Thymus neoplasms are abnormal growths in the thymus gland that result from uncontrolled cell division. The term "neoplasm" refers to any new and abnormal growth of tissue, also known as a tumor. Thymus neoplasms can be benign or malignant (cancerous).

Malignant thymus neoplasms are called thymomas or thymic carcinomas. Thymomas are the most common type and tend to grow slowly, invading nearby tissues and organs. They can also spread (metastasize) to other parts of the body. Thymic carcinomas are rarer and more aggressive, growing and spreading more quickly than thymomas.

Symptoms of thymus neoplasms may include coughing, chest pain, difficulty breathing, or swelling in the neck or upper chest. Treatment options for thymus neoplasms depend on the type, size, location, and stage of the tumor, as well as the patient's overall health. Treatment may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

Tetradecanoylphorbol acetate (TPA) is defined as a pharmacological agent that is a derivative of the phorbol ester family. It is a potent tumor promoter and activator of protein kinase C (PKC), a group of enzymes that play a role in various cellular processes such as signal transduction, proliferation, and differentiation. TPA has been widely used in research to study PKC-mediated signaling pathways and its role in cancer development and progression. It is also used in topical treatments for skin conditions such as psoriasis.

Ikaros is a family of transcription factors that are primarily expressed in hematopoietic cells, which are the cells that give rise to all blood cells. Transcription factors are proteins that regulate gene expression by binding to specific DNA sequences and controlling the flow of genetic information from DNA to messenger RNA.

The Ikaros family includes several different proteins, including IKAROS, AIOLOS, and HELIOS, which share a similar structure and function. These proteins contain multiple C2H2-type zinc finger domains, which are regions of the protein that bind to DNA, as well as a helix-loop-helix domain, which is involved in protein-protein interactions.

Ikaros transcription factors play important roles in the development and function of the immune system. They are involved in the differentiation and activation of various types of immune cells, including T cells, B cells, and natural killer (NK) cells. Ikaros proteins can also act as transcriptional repressors, inhibiting the expression of certain genes that are not needed at a given time or in a particular cell type.

Mutations in the genes encoding Ikaros transcription factors have been associated with various immune disorders, including immunodeficiency and autoimmunity. Further research is needed to fully understand the functions of these proteins and their role in human health and disease.

Disease progression is the worsening or advancement of a medical condition over time. It refers to the natural course of a disease, including its development, the severity of symptoms and complications, and the impact on the patient's overall health and quality of life. Understanding disease progression is important for developing appropriate treatment plans, monitoring response to therapy, and predicting outcomes.

The rate of disease progression can vary widely depending on the type of medical condition, individual patient factors, and the effectiveness of treatment. Some diseases may progress rapidly over a short period of time, while others may progress more slowly over many years. In some cases, disease progression may be slowed or even halted with appropriate medical interventions, while in other cases, the progression may be inevitable and irreversible.

In clinical practice, healthcare providers closely monitor disease progression through regular assessments, imaging studies, and laboratory tests. This information is used to guide treatment decisions and adjust care plans as needed to optimize patient outcomes and improve quality of life.

Caspases are a family of protease enzymes that play essential roles in programmed cell death, also known as apoptosis. These enzymes are produced as inactive precursors and are activated when cells receive signals to undergo apoptosis. Once activated, caspases cleave specific protein substrates, leading to the characteristic morphological changes and DNA fragmentation associated with apoptotic cell death. Caspases also play roles in other cellular processes, including inflammation and differentiation. There are two types of caspases: initiator caspases (caspase-2, -8, -9, and -10) and effector caspases (caspase-3, -6, and -7). Initiator caspases are activated in response to various apoptotic signals and then activate the effector caspases, which carry out the proteolytic cleavage of cellular proteins. Dysregulation of caspase activity has been implicated in a variety of diseases, including neurodegenerative disorders, ischemic injury, and cancer.

Doxorubicin is a type of chemotherapy medication known as an anthracycline. It works by interfering with the DNA in cancer cells, which prevents them from growing and multiplying. Doxorubicin is used to treat a wide variety of cancers, including leukemia, lymphoma, breast cancer, lung cancer, ovarian cancer, and many others. It may be given alone or in combination with other chemotherapy drugs.

Doxorubicin is usually administered through a vein (intravenously) and can cause side effects such as nausea, vomiting, hair loss, mouth sores, and increased risk of infection. It can also cause damage to the heart muscle, which can lead to heart failure in some cases. For this reason, doctors may monitor patients' heart function closely while they are receiving doxorubicin treatment.

It is important for patients to discuss the potential risks and benefits of doxorubicin therapy with their healthcare provider before starting treatment.

CD7 is a type of protein found on the surface of certain cells in the human body, including some immune cells like T-cells and natural killer cells. It is a type of antigen that can be recognized by other immune cells and their receptors, and it plays a role in the regulation of the immune response.

CD7 antigens are often used as targets for immunotherapy in certain types of cancer, as they are overexpressed on the surface of some cancer cells. For example, anti-CD7 monoclonal antibodies have been developed to target and kill CD7-positive cancer cells, or to deliver drugs or radiation directly to those cells.

It's important to note that while CD7 is a well-established target for immunotherapy in certain types of cancer, it is not a specific disease or condition itself. Rather, it is a molecular marker that can be used to identify and target certain types of cells in the body.

Blood cells are the formed elements in the blood, including red blood cells (erythrocytes), white blood cells (leukocytes), and platelets (thrombocytes). These cells are produced in the bone marrow and play crucial roles in the body's functions. Red blood cells are responsible for carrying oxygen to tissues and carbon dioxide away from them, while white blood cells are part of the immune system and help defend against infection and disease. Platelets are cell fragments that are essential for normal blood clotting.

Gene deletion is a type of mutation where a segment of DNA, containing one or more genes, is permanently lost or removed from a chromosome. This can occur due to various genetic mechanisms such as homologous recombination, non-homologous end joining, or other types of genomic rearrangements.

The deletion of a gene can have varying effects on the organism, depending on the function of the deleted gene and its importance for normal physiological processes. If the deleted gene is essential for survival, the deletion may result in embryonic lethality or developmental abnormalities. However, if the gene is non-essential or has redundant functions, the deletion may not have any noticeable effects on the organism's phenotype.

Gene deletions can also be used as a tool in genetic research to study the function of specific genes and their role in various biological processes. For example, researchers may use gene deletion techniques to create genetically modified animal models to investigate the impact of gene deletion on disease progression or development.

SRC-family kinases (SFKs) are a group of non-receptor tyrosine kinases that play important roles in various cellular processes, including cell proliferation, differentiation, survival, and migration. They are named after the founding member, SRC, which was first identified as an oncogene in Rous sarcoma virus.

SFKs share a common structure, consisting of an N-terminal unique domain, a SH3 domain, a SH2 domain, a catalytic kinase domain, and a C-terminal regulatory tail with a negative regulatory tyrosine residue (Y527 in human SRC). In their inactive state, SFKs are maintained in a closed conformation through intramolecular interactions between the SH3 domain, SH2 domain, and the phosphorylated C-terminal tyrosine.

Upon activation by various signals, such as growth factors, cytokines, or integrin engagement, SFKs are activated through a series of events that involve dephosphorylation of the regulatory tyrosine residue, recruitment to membrane receptors via their SH2 and SH3 domains, and trans-autophosphorylation of the activation loop in the kinase domain.

Once activated, SFKs can phosphorylate a wide range of downstream substrates, including other protein kinases, adaptor proteins, and cytoskeletal components, thereby regulating various signaling pathways that control cell behavior. Dysregulation of SFK activity has been implicated in various diseases, including cancer, inflammation, and neurological disorders.

A case-control study is an observational research design used to identify risk factors or causes of a disease or health outcome. In this type of study, individuals with the disease or condition (cases) are compared with similar individuals who do not have the disease or condition (controls). The exposure history or other characteristics of interest are then compared between the two groups to determine if there is an association between the exposure and the disease.

Case-control studies are often used when it is not feasible or ethical to conduct a randomized controlled trial, as they can provide valuable insights into potential causes of diseases or health outcomes in a relatively short period of time and at a lower cost than other study designs. However, because case-control studies rely on retrospective data collection, they are subject to biases such as recall bias and selection bias, which can affect the validity of the results. Therefore, it is important to carefully design and conduct case-control studies to minimize these potential sources of bias.

Oligodeoxyribonucleotides (ODNs) are relatively short, synthetic single-stranded DNA molecules. They typically contain 15 to 30 nucleotides, but can range from 2 to several hundred nucleotides in length. ODNs are often used as tools in molecular biology research for various applications such as:

1. Nucleic acid detection and quantification (e.g., real-time PCR)
2. Gene regulation (antisense, RNA interference)
3. Gene editing (CRISPR-Cas systems)
4. Vaccine development
5. Diagnostic purposes

Due to their specificity and affinity towards complementary DNA or RNA sequences, ODNs can be designed to target a particular gene or sequence of interest. This makes them valuable tools in understanding gene function, regulation, and interaction with other molecules within the cell.

Thiazoles are organic compounds that contain a heterocyclic ring consisting of a nitrogen atom and a sulfur atom, along with two carbon atoms and two hydrogen atoms. They have the chemical formula C3H4NS. Thiazoles are present in various natural and synthetic substances, including some vitamins, drugs, and dyes. In the context of medicine, thiazole derivatives have been developed as pharmaceuticals for their diverse biological activities, such as anti-inflammatory, antifungal, antibacterial, and antihypertensive properties. Some well-known examples include thiazide diuretics (e.g., hydrochlorothiazide) used to treat high blood pressure and edema, and the antidiabetic drug pioglitazone.

Repressor proteins are a type of regulatory protein in molecular biology that suppress the transcription of specific genes into messenger RNA (mRNA) by binding to DNA. They function as part of gene regulation processes, often working in conjunction with an operator region and a promoter region within the DNA molecule. Repressor proteins can be activated or deactivated by various signals, allowing for precise control over gene expression in response to changing cellular conditions.

There are two main types of repressor proteins:

1. DNA-binding repressors: These directly bind to specific DNA sequences (operator regions) near the target gene and prevent RNA polymerase from transcribing the gene into mRNA.
2. Allosteric repressors: These bind to effector molecules, which then cause a conformational change in the repressor protein, enabling it to bind to DNA and inhibit transcription.

Repressor proteins play crucial roles in various biological processes, such as development, metabolism, and stress response, by controlling gene expression patterns in cells.

Whole-Body Irradiation (WBI) is a medical procedure that involves the exposure of the entire body to a controlled dose of ionizing radiation, typically used in the context of radiation therapy for cancer treatment. The purpose of WBI is to destroy cancer cells or suppress the immune system prior to a bone marrow transplant. It can be delivered using various sources of radiation, such as X-rays, gamma rays, or electrons, and is carefully planned and monitored to minimize harm to healthy tissues while maximizing the therapeutic effect on cancer cells. Potential side effects include nausea, vomiting, fatigue, and an increased risk of infection due to decreased white blood cell counts.

RAG-1 (Recombination Activating Gene 1) is a protein involved in the process of V(D)J recombination, which is a crucial step in the development of the immune system. Specifically, RAG-1 plays a role in generating diversity in the antigen receptors of T and B cells by rearranging gene segments that encode for the variable regions of these receptors.

RAG-1 forms a complex with another protein called RAG-2, and together they initiate the V(D)J recombination process by introducing DNA double-strand breaks at specific sites within the antigen receptor genes. This allows for the precise joining of different gene segments to create a functional antigen receptor that can recognize a wide variety of foreign molecules (antigens).

Mutations in the RAG-1 gene can lead to severe combined immunodeficiency (SCID), a condition characterized by an impaired immune system and increased susceptibility to infections.

CD8-positive T-lymphocytes, also known as CD8+ T cells or cytotoxic T cells, are a type of white blood cell that plays a crucial role in the adaptive immune system. They are named after the CD8 molecule found on their surface, which is a protein involved in cell signaling and recognition.

CD8+ T cells are primarily responsible for identifying and destroying virus-infected cells or cancerous cells. When activated, they release cytotoxic granules that contain enzymes capable of inducing apoptosis (programmed cell death) in the target cells. They also produce cytokines such as interferon-gamma, which can help coordinate the immune response and activate other immune cells.

CD8+ T cells are generated in the thymus gland and are a type of T cell, which is a lymphocyte that matures in the thymus and plays a central role in cell-mediated immunity. They recognize and respond to specific antigens presented on the surface of infected or cancerous cells in conjunction with major histocompatibility complex (MHC) class I molecules.

Overall, CD8+ T cells are an essential component of the immune system's defense against viral infections and cancer.

Proto-oncogene proteins, such as c-Myc, are crucial regulators of normal cell growth, differentiation, and apoptosis (programmed cell death). When proto-oncogenes undergo mutations or alterations in their regulation, they can become overactive or overexpressed, leading to the formation of oncogenes. Oncogenic forms of c-Myc contribute to uncontrolled cell growth and division, which can ultimately result in cancer development.

The c-Myc protein is a transcription factor that binds to specific DNA sequences, influencing the expression of target genes involved in various cellular processes, such as:

1. Cell cycle progression: c-Myc promotes the expression of genes required for the G1 to S phase transition, driving cells into the DNA synthesis and division phase.
2. Metabolism: c-Myc regulates genes associated with glucose metabolism, glycolysis, and mitochondrial function, enhancing energy production in rapidly dividing cells.
3. Apoptosis: c-Myc can either promote or inhibit apoptosis, depending on the cellular context and the presence of other regulatory factors.
4. Differentiation: c-Myc generally inhibits differentiation by repressing genes that are necessary for specialized cell functions.
5. Angiogenesis: c-Myc can induce the expression of pro-angiogenic factors, promoting the formation of new blood vessels to support tumor growth.

Dysregulation of c-Myc is frequently observed in various types of cancer, making it an important therapeutic target for cancer treatment.

Prednisone is a synthetic glucocorticoid, which is a type of corticosteroid hormone. It is primarily used to reduce inflammation in various conditions such as asthma, allergies, arthritis, and autoimmune disorders. Prednisone works by mimicking the effects of natural hormones produced by the adrenal glands, suppressing the immune system's response and reducing the release of substances that cause inflammation.

It is available in oral tablet form and is typically prescribed to be taken at specific times during the day, depending on the condition being treated. Common side effects of prednisone include increased appetite, weight gain, mood changes, insomnia, and easy bruising. Long-term use or high doses can lead to more serious side effects such as osteoporosis, diabetes, cataracts, and increased susceptibility to infections.

Healthcare providers closely monitor patients taking prednisone for extended periods to minimize the risk of adverse effects. It is essential to follow the prescribed dosage regimen and not discontinue the medication abruptly without medical supervision, as this can lead to withdrawal symptoms or a rebound of the underlying condition.

Bcl-x is a protein that belongs to the Bcl-2 family, which regulates programmed cell death (apoptosis). Specifically, Bcl-x has both pro-survival and pro-apoptotic functions, depending on its splice variants. The long form of Bcl-x (Bcl-xL) is a potent inhibitor of apoptosis, while the short form (Bcl-xS) promotes cell death. Bcl-x plays critical roles in various cellular processes, including development, homeostasis, and stress responses, by controlling the mitochondrial outer membrane permeabilization and the release of cytochrome c, which eventually leads to caspase activation and apoptosis. Dysregulation of Bcl-x has been implicated in several diseases, such as cancer and neurodegenerative disorders.

A lymphocyte transfusion is not a standard medical practice. However, the term "lymphocyte transfusion" generally refers to the infusion of lymphocytes, a type of white blood cell, from a donor to a recipient. This procedure is rarely performed and primarily used in research or experimental settings, such as in the context of adoptive immunotherapy for cancer treatment.

In adoptive immunotherapy, T lymphocytes (a subtype of lymphocytes) are collected from the patient or a donor, activated, expanded in the laboratory, and then reinfused into the patient to enhance their immune response against cancer cells. This is not a common procedure and should only be performed under the guidance of experienced medical professionals in specialized centers.

It's important to note that lymphocyte transfusions are different from stem cell or bone marrow transplants, which involve the infusion of hematopoietic stem cells to reconstitute the recipient's entire blood and immune system.

Enzyme inhibitors are substances that bind to an enzyme and decrease its activity, preventing it from catalyzing a chemical reaction in the body. They can work by several mechanisms, including blocking the active site where the substrate binds, or binding to another site on the enzyme to change its shape and prevent substrate binding. Enzyme inhibitors are often used as drugs to treat various medical conditions, such as high blood pressure, abnormal heart rhythms, and bacterial infections. They can also be found naturally in some foods and plants, and can be used in research to understand enzyme function and regulation.

CD3 antigens are a group of proteins found on the surface of T-cells, which are a type of white blood cell that plays a central role in the immune response. The CD3 antigens are composed of several different subunits (ε, δ, γ, and α) that associate to form the CD3 complex, which is involved in T-cell activation and signal transduction.

The CD3 complex is associated with the T-cell receptor (TCR), which recognizes and binds to specific antigens presented by antigen-presenting cells. When the TCR binds to an antigen, it triggers a series of intracellular signaling events that lead to T-cell activation and the initiation of an immune response.

CD3 antigens are important targets for immunotherapy in some diseases, such as certain types of cancer. For example, monoclonal antibodies that target CD3 have been developed to activate T-cells and enhance their ability to recognize and destroy tumor cells. However, CD3-targeted therapies can also cause side effects, such as cytokine release syndrome, which can be serious or life-threatening in some cases.

Immunoglobulin alpha-chains (IgA) are a type of immunoglobulin or antibody that plays a crucial role in the immune system. They are composed of two heavy chains, known as alpha-chains, and two light chains. IgA is primarily found in secretions such as tears, saliva, breast milk, and respiratory and intestinal mucus, where they provide protection against pathogens that enter the body through these surfaces.

IgA can exist in two forms: a monomeric form, which consists of a single IgA molecule, and a polymeric form, which consists of several IgA molecules joined together by a J chain. The polymeric form is more common in secretions, where it provides an effective barrier against pathogens.

IgA functions by binding to antigens on the surface of pathogens, preventing them from attaching to and infecting host cells. It can also neutralize toxins produced by some bacteria and viruses. Additionally, IgA can activate the complement system, a group of proteins that work together to destroy pathogens, and initiate an immune response by recruiting other immune cells to the site of infection.

Deficiencies in IgA are relatively common and usually do not cause any significant health problems. However, in some cases, people with IgA deficiency may develop recurrent infections or allergies.

Humoral immunity is a type of immune response in which the body produces proteins called antibodies that circulate in bodily fluids such as blood and help to protect against infection. This form of immunity involves the interaction between antigens (foreign substances that trigger an immune response) and soluble factors, including antibodies, complement proteins, and cytokines.

When a pathogen enters the body, it is recognized as foreign by the immune system, which triggers the production of specific antibodies to bind to and neutralize or destroy the pathogen. These antibodies are produced by B cells, a type of white blood cell that is part of the adaptive immune system.

Humoral immunity provides protection against extracellular pathogens, such as bacteria and viruses, that exist outside of host cells. It is an important component of the body's defense mechanisms and plays a critical role in preventing and fighting off infections.

The Immunoglobulin (Ig) switch region, also known as the switch (S) region or switch area, is a segment of DNA located within the heavy chain constant region (Cμ, Cδ, Cγ, Cε, and Cα) genes of the immunoglobulin locus. These regions are found in chromosome 14 in humans.

The Ig switch regions are crucial for antibody class switching, a process that allows B cells to change the type of heavy chain constant region (Cμ, Cδ, Cγ, Cε, or Cα) expressed in their immunoglobulin, thus modifying the effector functions of the antibodies they produce without altering their antigen specificity. This mechanism enables the immune system to generate a more diverse response against various pathogens and adapt to new challenges.

The switch regions are composed of repetitive DNA sequences that vary in length and sequence between different immunoglobulin isotypes (IgM, IgD, IgG, IgA, and IgE). During class switching, an activated B cell utilizes the enzyme activation-induced cytidine deaminase (AID) to introduce DNA double-strand breaks within a specific switch region. The broken ends of the DNA are then joined together through a process called class switch recombination (CSR), resulting in the deletion of the intervening DNA and the fusion of the upstream V(D)J region with a new downstream constant region gene, thereby altering the isotype of the expressed antibody.

"Angioimmunoblastic T-Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Novel Form of Composite ... Chronic Lymphocytic Leukemia. CRC Press. p. 19. ISBN 9781420068962. "Chronic Lymphocytic Leukemia Treatment". National Cancer ... untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)". Blood ... "CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia". ...
cite book}}: ,journal= ignored (help) "B-cell Prolymphocytic Leukemia (B-PLL) , Chronic Lymphocytic Leukemia". www.knowcancer. ... Ravandi, Farhad; O'Brien, Susan (December 2005). "Chronic Lymphoid Leukemias Other Than Chronic Lymphocytic Leukemia: Diagnosis ... "Leukemia - B-cell Prolymphocytic Leukemia and Hairy Cell Leukemia: Treatment Options , Cancer.Net". Cancer.Net. 2012-06-25. ... This type of leukemia is characterized by: More than 55% of circulating cells in peripheral blood (red blood cells, white blood ...
Chronic lymphocytic leukemia (CLL); including hairy cell leukemia and other chronic B-cell leukemias. Limited or suggested ... This list now includes B cell leukemias, such as hairy cell leukemia, Parkinson's disease and ischemic heart disease, these ... chronic lymphocytic leukemia, and spina bifida in children of veterans exposed to Agent Orange as conditions associated with ... including chronic B-cell leukemia, Hodgkin's lymphoma, multiple myeloma, non-Hodgkin's lymphoma, prostate cancer, respiratory ...
The first human disease discovered to be associated with deregulation of miRNAs was chronic lymphocytic leukemia. Other B cell ... "MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias". Proc Natl Acad Sci U S A. 101 (32): ... The first human disease known to be associated with miRNA deregulation was chronic lymphocytic leukemia. Many other miRNAs also ... The first human disease associated with deregulation of miRNAs was chronic lymphocytic leukemia. In this disorder, the miRNAs ...
Chronic lymphocytic leukemia presents with an elevated lymphocyte count and abnormal lymphocyte morphology, in which the ... Blast cell Blast cells are very immature cells that are normally found in the bone marrow, where they develop into mature cells ... For example, lymphoma cells may be found on the manual differential in some cases of lymphoma, and in mast cell leukemia, mast ... Basophilia and eosinophilia can occur along with other white blood cell abnormalities in chronic myeloid leukemia and other ...
"Leukemia - Chronic T-Cell Lymphocytic - Stages". Cancer.Net. 2012-06-25. Retrieved 2020-04-07. Khalade, Abdul; Jaakkola, ... Distinct from adult T-cell leukemia where T-cell lymphotropic virus Type I causes malignant maturation of T-cells, T-ALL is a ... T-cell acute lymphoblastic leukemia (T-ALL) is a type of acute lymphoblastic leukemia with aggressive malignant neoplasm of the ... "Pediatric T-Cell Acute Lymphoblastic Leukemia". atlasgeneticsoncology.org. Retrieved 2020-04-07. "Acute lymphoblastic leukemia ...
Hairy cell leukemia (HCL) is sometimes considered a subset of chronic lymphocytic leukemia, but does not fit neatly into this ... Large granular lymphocytic leukemia may involve either T-cells or NK cells; like hairy cell leukemia, which involves solely B ... chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML)-as well as a number of less common types. Leukemias and ... Gribben JG (January 2009). "Stem cell transplantation in chronic lymphocytic leukemia". Biology of Blood and Marrow ...
Rosi F, Carlucci F, Marinello E, Tabucchi A (March 2002). "Ecto-5'-nucleotidase in B-cell chronic lymphocytic leukemia". ... Specialized immune cells such as myeloid-derived suppressor cells and regulatory T cells also mediate their effects via ... Tumor infiltration by cells which express NT5E such as myeloid derived suppressor cells (MDSC), Treg's, dendritic cells (DC) ... They affect proliferation and function of T cell. CD73 also occurs on anergic CD4 + T cells, thereby maintaining self tolerance ...
... including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic Lymphoma (CLL/SLL). It may be used both ... and for the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The most common ... had received orphan drug designation in the United States for mantle cell lymphoma and chronic lymphocytic leukemia (CLL), and ... January 2016). "Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia". The New England Journal of Medicine. 374 (4 ...
2003). "Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia". Blood. 101 (6): 2328-34. doi:10.1182/blood-2002- ... 2003). "Coupling of CFTR-mediated anion secretion to nucleoside transporters and adenosine homeostasis in Calu-3 cells". J. ... in renal epithelial cells". Am. J. Physiol. Renal Physiol. 284 (5): F902-10. doi:10.1152/ajprenal.00215.2002. PMID 12527552. ... insensitive nucleoside transporter ei by functional expression in a transport-deficient cell line". J Biol Chem. 273 (9): 5288- ...
2003). "Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia". Blood. 101 (6): 2328-34. doi:10.1182/blood-2002- ... J. Physiol., Cell Physiol. 288 (1): C39-45. doi:10.1152/ajpcell.00192.2004. PMID 15456697. S2CID 27633580. Fernández-Veledo S, ... Lai Y, Bakken AH, Unadkat JD (2002). "Simultaneous expression of hCNT1-CFP and hENT1-YFP in Madin-Darby canine kidney cells. ... 2007). "Transcription factors involved in the expression of SLC28 genes in human liver parenchymal cells". Biochem. Biophys. ...
November 2019). "Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia ... for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) which utilized umbralisib in ... It has undergone clinical studies for chronic lymphocytic leukemia (CLL). Three year data (including follicular lymphoma and ... It is in combination trials for various leukemias and lymphomas, such as mantle cell lymphoma (MCL) and other lymphomas. ...
2003). "Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia". Blood. 101 (6): 2328-34. doi:10.1182/blood-2002- ... 2007). "Transcription factors involved in the expression of SLC28 genes in human liver parenchymal cells". Biochem. Biophys. ... and nicotine with human concentrative nucleoside transporters 1 and 2 stably produced in a transport-defective human cell line ...
Rassenti LZ, Kipps TJ (Apr 1997). "Lack of allelic exclusion in B cell chronic lymphocytic leukemia". The Journal of ... Isoforms of the p41 subunit may adapt the functions of the complex to different cell types or developmental stages. Indeed, it ... The Journal of Cell Biology. 138 (2): 375-84. doi:10.1083/jcb.138.2.375. PMC 2138188. PMID 9230079. Machesky LM, Reeves E, ... Nature Cell Biology. 18 (1): 76-86. doi:10.1038/ncb3286. PMID 26655834. S2CID 2916212. Kahr, Walter H. A.; Pluthero, Fred G.; ...
"Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX". Blood. 100 (6): 2123-31. doi:10.1182/ ... "X-linked and cellular IAPs modulate the stability of C-RAF kinase and cell motility". Nature Cell Biology. 10 (12): 1447-55. ... Shimura H, Schwartz D, Gygi SP, Kosik KS (Feb 2004). "CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell ... Molecular Cell. 10 (1): 55-67. doi:10.1016/s1097-2765(02)00583-x. PMID 12150907. Li X, Huang M, Zheng H, Wang Y, Ren F, Shang Y ...
B-cell prolymphocytic leukemia and T-cell prolymphocytic leukemia. It is usually classified as a kind of chronic lymphocytic ... Prolymphocytic leukemia is divided into two types according to the kind of cell involved: ... Hsi, Eric D. (1 January 2012). "12 - B-Cell Leukemias of Mature Lymphocytes". Hematopathology (Second ed.). W.B. Saunders. pp. ... v t e (Articles with short description, Short description is different from Wikidata, Lymphocytic leukemia, All stub articles, ...
Strati P, Shanafelt TD (July 2015). "Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, ... Hairy cell leukemia: The monoclonal B-cells in this usually indolent CLL/SLL-like leukemia have a distinctive morphology and ... These cells, similar to the monoclonal cells in Hairy cell leukemia, may have the V600E mutation in the BRAF gene. Patients ... "Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic ...
Caligaris-Cappio F, Hamblin TJ (1999). "B-cell chronic lymphocytic leukemia: a bird of a different feather". J Clin Oncol. 17 ( ... and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia". Blood. 97 (7): 2098-2104 ... a region commonly deleted in B-cell chronic lymphocytic leukemia". Cancer Res. 61 (7): 2870-2877. PMID 11306461. Rondeau G, ... of chromosome 13q14.3 and characterisation of an alternative splice form of LEU1 in B cell chronic lymphocytic leukemia". ...
T-cell LGL leukemia (T-LGLL) and natural-killer (NK)-cell LGL leukemia (NK-LGLL). As the name suggests, T-cell large granular ... Large granular lymphocytic (LGL) leukemia is a chronic lymphoproliferative disorder that exhibits an unexplained, chronic (> 6 ... The postulated cells of origin of T-LGLL leukemia are transformed CD8+ T-cell with clonal rearrangements of β chain T-cell ... Alemtuzumab has been investigated for use in treatment of refractory T-cell large granular lymphocytic leukemia. Experimental ...
"Regulation of CD23 expression by Notch2 in B-cell chronic lymphocytic leukemia". Leuk. Lymphoma. 46 (2): 157-65. doi:10.1080/ ... "Notch signaling induces cell cycle arrest in small cell lung cancer cells". Cancer Res. 61 (7): 3200-5. PMID 11306509. Shimizu ... Cell. Biol. 20 (18): 6913-22. doi:10.1128/MCB.20.18.6913-6922.2000. PMC 88767. PMID 10958687. Wu L, Aster JC, Blacklow SC, Lake ... Cell. Biol. 18 (4): 2324-33. doi:10.1128/mcb.18.4.2324. PMC 121486. PMID 9528802. Berezovska O, Xia MQ, Hyman BT (1998). "Notch ...
As with B-cell chronic lymphocytic leukemia, mutations in the IGHV on hairy cells are associated with better responses to ... In 2013 the Hairy Cell Leukemia Foundation was created when the Hairy Cell Leukemia Consortium and the Hairy Cell Leukemia ... Similar to B-cell prolymphocytic leukemia (B-PLL) in chronic lymphocytic leukemia, HCL-V is a more aggressive disease. ... It is usually classified as a subtype of chronic lymphocytic leukemia (CLL). Hairy cell leukemia makes up about 2% of all ...
October 2005). "A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia". N. Engl. J. ... Cell. Proteomics. 3 (4): 355-66. doi:10.1074/mcp.R400006-MCP200. PMID 14764655. Gilad S, Meiri E, Yogev Y, et al. (2008). " ... March 2006). "Unique microRNA molecular profiles in lung cancer diagnosis and prognosis". Cancer Cell. 9 (3): 189-98. doi: ... free floating microRNAs are found to be protected from endogenous RNAase activity as compared to microRNAs within the cells of ...
Sana I, Mantione ME, Angelillo P, Muzio M (2021). "Role of NFAT in Chronic Lymphocytic Leukemia and Other B-Cell Malignancies ... Although discovered in T cells it is becoming more obvious that NFAT is also expressed in different cell types. In B cells ... There are two main populations of Treg cells: natural Treg (nTreg) cells which develop in Thymus and induced Treg (iTreg) cells ... Hogan PG (May 2017). "Calcium-NFAT transcriptional signalling in T cell activation and T cell exhaustion". Cell Calcium. 63: 66 ...
"Regulation of CD23 expression by Notch2 in B-cell chronic lymphocytic leukemia". Leukemia & Lymphoma. 46 (2): 157-65. doi: ... CD23 is helpful in the differentiation of chronic lymphocytic leukemia (CD23-positive) from mantle cell lymphoma (CD23-negative ... "HIV-gp 160-induced T cell-dependent B cell differentiation. Role of T cell-B cell activation molecule and IL-6". Journal of ... The antigen is then transferred from CD23+ B cells to CD11c+ antigen presenting cells. The CD11c+ cells in turn present the ...
Yodoi, J; Takatsuki, K; Masuda, T (1974). "Letter: Two cases of T-cell chronic lymphocytic leukemia in Japan". New England ... Types of T-cell acute lymphoblastic leukemia include adult T-cell leukemia/lymphoma and (precursor) T-lymphoblastic leukemia/ ... myeloid leukemia Acute myeloid leukemia Chronic myelogenous leukemia Peripheral blood stain of chronic myelogenous leukemia in ... Blast crisis of chronic myelogenous leukemia. T-lymphoblastic cells of acute leukemia in the bone marrow Acute erythroid ...
... mainly in early B cells, CD4+ T cells. Its dysfunction has been linked to the development of chronic lymphocytic leukemia. In ... IKZF1 is upregulated in granulocytes, B cells, CD4 and CD8 T cells, and NK cells, and downregulated in erythroblasts, ... New insights in the malignant transformation to chronic lymphocytic leukemia". Journal of Leukocyte Biology. 106 (3): 581-594. ... New insights in the malignant transformation to chronic lymphocytic leukemia". Journal of Leukocyte Biology. 106 (3): 581-594. ...
... may refer to: Chronic myelogenous leukemia Chronic lymphocytic leukemia, including Hairy cell leukemia ... Chronic leukemia is an increase of abnormal white blood cells. It differs from acute leukemia, and is categorized as ... chronic neutrophilic leukemia , and chronic eosinophilic leukemia. This article includes a list of related items that share the ... Chronic leukemia, Leukemia). ...
B-cell chronic lymphocytic leukemia, and Castleman disease; they occur rarely in non-B cell hematological disorders such as ... and chronic lymphocytic leukemia). This involves appropriate chemotherapy regimens which may include bortezomib (promotes cell ... myelodysplastic syndromes and chronic myelogenous leukemia. Among these purely monoclonal immunoglobulin causes of ... monoclonal immunoglobulin-based cases of cryoglobulinemic disease are less commonly associated with other B-cell lymphocytic ...
"Patterns of chronic lymphocytic leukemia growth identified". dana-farber.org. May 29, 2019. Retrieved November 21, 2020. "Dana- ... "Resistance to Targeted Leukemia Drug Lurks in Cells' "Powerhouse"". cancerhealth.com. Cancer Health. December 6, 2019. ... Her research focuses on longitudinal studies of patients with chronic lymphocytic leukemia (CLL). Wu was born in New York City ... "Coupled Genetic and Functional Dissection of Chronic Lymphocytic Leukemia." Using this grant, she identified mutations in the ...
ISLN bear similarities to monoclonal B-cell lymphocytosis (MBL). MLB consists of four subtypes: chronic lymphocytic leukemia/ ... Strati P, Shanafelt TD (July 2015). "Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, ... In situ mantle cell neoplasia has also been termed in situ involvement by MCL-like cells and in situ-like B-cells of uncertain ... pre-B-cells/pro-B-cells) after which these cells circulate freely and in rare cases accumulate in the germinal centers of ...
... Associated With T Lymphocytic Hyperplasia in Bone Marrow ... Cite this: Spontaneous Remission of B-Cell Chronic Lymphocytic Leukemia Associated With T Lymphocytic Hyperplasia in Bone ... Spontaneous remissions in B-cell chronic lymphocytic leukemia (B-CLL) are rare and none of them has been studied with ... we are describing had a well-documented spontaneous remission of previously progressive B-cell chronic lymphocytic leukemia (B- ...
... allows doctors to use higher doses of chemo to kill chronic lymphocytic leukemia cells. ... and/or targeted therapy can reduce the number of leukemia cells in chronic lymphocytic leukemia (CLL) and improve symptoms. ... Chronic Lymphocytic Leukemia Treatment (PDQ®)-Patient Version. March 28, 2017. Accessed at www.cancer.gov/types/leukemia/ ... Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 5.2018 -- March 26, 2018. Accessed at www.nccn.org/ ...
Biopsy came back today as Cuteanous involvment by B cell chronic lymphocytic leukemia. ...
... proliferation and trafficking of chronic lymphocytic leukemia (CLL) cells. Inhibitors of the key kinases in this pathway, ... The B cell receptor (BCR) pathway plays a crucial role in the survival, ... Targeting the B cell receptor pathway in chronic lymphocytic leukemia Leuk Lymphoma. 2012 Dec;53(12):2362-70. doi: 10.3109/ ... proliferation and trafficking of chronic lymphocytic leukemia (CLL) cells. Inhibitors of the key kinases in this pathway, ...
... as underscored by the promising clinical results obtained in patients with chronic lymphocytic leukemia (CLL) treated with ... as underscored by the promising clinical results obtained in patients with chronic lymphocytic leukemia (CLL) treated with ... Herein, we demonstrate that the mithralog EC-7072 displays high ex vivo cytotoxic activity against leukemia cells from CLL ... Herein, we demonstrate that the mithralog EC-7072 displays high ex vivo cytotoxic activity against leukemia cells from CLL ...
B-cell Receptor Signaling in Chronic Lymphocytic Leukemia: From Pathogenesis to Targeted Therapy ... CC Grand Rounds: B-cell Receptor Signaling in Chronic Lymphocytic Leukemia: From Pathogenesis to Targeted Therapy Download ... B-cell receptor signaling in chronic lymphocytic leukemia : from pathogenesis to targeted therapy / Adrian Wiestner and ... CC Grand Rounds: B-cell Receptor Signaling in Chronic Lymphocytic Leukemia: From Pathogenesis to Targeted Therapy For more ...
Malignant B cells in chronic lymphocytic leukemia serve an essential role in the whole immune response, so their interactions ... In chronic lymphocytic leukemia (CLL), malignant B lymphocytes, similar to other tumor cells, are in constant cooperation with ... Intracellular IL‑4 and IFN‑γ expression in iNKT cells from patients with chronic lymphocytic leukemia. *Authors: *Agnieszka ... CLL, chronic lymphocytic leukemia; iNKT, invariant natural killer T cells; IL, interleukin; IFN, interferon; HV, healthy ...
This report describes a 72-year-old man with newly diagnosed chronic lymphocytic leukemia (CLL) who developed MCC of his ri … ... Increasing evidence supports an association of Merkel cell carcinoma (MCC) with immunodeficiency and neoplasia, and the ... Collision tumor of primary merkel cell carcinoma and chronic lymphocytic leukemia/small lymphocytic lymphoma, diagnosed on ... Merkel cell carcinoma after chronic lymphocytic leukemia: case report and literature review Roxana Vlad 1 , Timothy J Woodlock ...
... as single-agent treatment for B-cell chronic lymphocytic leukemia (B-CLL). Alemtuzumab was initially approved in 2001 under ... Alemtuzumab for B-cell chronic lymphocytic leukemia. Robak T. Robak T. Expert Rev Anticancer Ther. 2008 Jul;8(7):1033-51. doi: ... FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia Suzanne Demko 1 , ... FDA drug approval summary: alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia Suzanne Demko et al. ...
B-cell chronic lymphocytic leukemia with bilateral ear involvement ... Raufi A, Alsharedi M, Khelfa Y, Griswold DC, Lebowicz Y. Leukemia cutis in a patient with chronic lymphocytic leukemia ... How to cite this article: Andamoyo-Castañeda A, Godoy-Díaz DJ, Ayala-Blanca M. B-cell chronic lymphocytic leukemia with ... The findings were compatible with B-cell chronic lymphocytic leukemia (CLL-B). The myelogram done showed a lymphocyte clone ...
Chronic Lymphocytic Leukemia): learn about side effects, dosage, special precautions, and more on MedlinePlus ... Ofatumumab injection is used to treat chronic lymphocytic leukemia (CLL; a type of cancer of the white blood cells): *in ... Ofatumumab Injection (Chronic Lymphocytic Leukemia). pronounced as (o fa toom ue mab) ... for treatment of chronic lymphocytic leukemia. If you are receiving ofatumumab for multiple sclerosis, read the monograph ...
Here, we report the whole-genome sequencing of 485 chronic lymphocytic leukemia patients enrolled in clinical trials as part of ... Whole-genome sequencing of chronic lymphocytic leukemia from 485 patients identifies putative coding and noncoding drivers of ... highlight the potential of whole-genome sequencing to inform future risk stratification in chronic lymphocytic leukemia. ... Toll-like receptor 9 stimulation can induce IκBζ expression and IgM secretion in chronic lymphocytic leukemia cells. ...
Chronic Lymphocytic Leukemia: A Closer Look at Clonal Cell Subpopulations A recent study, led by a team of investigators based ... Chronic Lymphocytic Leukemia: What Families Can Tell Us Chronic lymphocytic leukemia is the most common type of leukemia in ... Monoclonal B-cell lymphocytosis (MBL) is known to predict chronic lymphocytic leukemia risk in certain individuals. But a new ... A study of 1230 individuals with chronic lymphocytic leukemia and high-count monoclonal B-cell lymphocytosis demonstrated that ...
"Angioimmunoblastic T-Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Novel Form of Composite ... Chronic Lymphocytic Leukemia. CRC Press. p. 19. ISBN 9781420068962. "Chronic Lymphocytic Leukemia Treatment". National Cancer ... untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)". Blood ... "CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia". ...
... chronic lymphoid leukemia, CLL) is a monoclonal disorder characterized by a progressive accumulation of functionally ... incompetent lymphocytes (see the image below). It is the most common form of leukemia found in adults in Western countries. ... Peripheral smear from a patient with chronic lymphocytic leukemia, large lymphocytic variety. Smudge cells are also observed; ... encoded search term (Chronic Lymphocytic Leukemia (CLL)) and Chronic Lymphocytic Leukemia (CLL) What to Read Next on Medscape ...
... a type of white blood cell. Although rare, CLL can metastasize (spread) to the brain and the fluid lining the brain in what is ... In chronic lymphocytic leukemia (CLL), a persons bone marrow makes too many lymphocytes, ... What Is Hairy Cell Leukemia? Treatment, Symptoms, and Causes. Hairy cell leukemia is considered a chronic disease because it ... What Are The Health Complications Of Chronic Lymphocytic Leukemia?. Learn about common complications of chronic lymphocytic ...
... including the blood diseases Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma ( ... Chronic Lymphocytic Leukemia News and Research. RSS Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in ... Protein markers in chronic lymphocytic leukemia may help determine patients prognoses Chronic lymphocytic leukemia (CLL) is ... T cells left in the wake of aggressive chemotherapy regimens for patients with advanced chronic lymphocytic leukemia (CLL) make ...
Genetic features of B-cell chronic lymphocytic leukemia. Rev Clin Exp Hematol 4:48-72. 11486330. . Crossref, Medline, Google ... Hamblin T (2008) Have we been wrong about ionizing radiation and chronic lymphocytic leukemia?, Leukemia Research, 10.1016/j. ... Veterans with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have a markedly increased rate of second ... in Rainwater and Its Relation to the Frequency of Hospitalization for Chronic Lymphocytic Leukemia and Chronic Myeloid Leukemia ...
high dose chlorambucil in advanced B-cell chronic lymphocytic leukemia (B-CLL): results of EORTC phase-II randomized trial ... Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic ... Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J Natl Cancer Inst. 1999; ... Comparison of fludarabine (FDB) vs CVP in untreated chronic lymphocytic leukemia (CLL). Preliminary results of a randomized ...
1.2 Diffuse Large B-Cell Lymphoma (DLBCL) 1.3 Chronic Lymphocytic Leukemia (CLL) 1.4 Limitations of Use 2 DOSAGE AND ... 14.2 Diffuse Large B-Cell Lymphoma (DLBCL) 14.3 Chronic Lymphocytic Leukemia (CLL) 14.4 Patient Experience 16 HOW SUPPLIED/ ... Chronic Lymphocytic Leukemia (CLL) Following the first cycle of treatment of rituximab, B-cells begin to deplete, with 28% of ... 2.3 Recommended Dosage for Diffuse Large B-Cell Lymphoma (DLBCL) 2.4 Recommended Dosage for Chronic Lymphocytic Leukemia (CLL) ...
... or in the groin area and whether the patient has low levels of red blood cells or platelets. The stages are called A, B, and C. ... Leukemia - Chronic Lymphocytic - CLL - Diagnosis up Leukemia - Chronic Lymphocytic - CLL - Types of Treatment › ... Leukemia - Chronic Lymphocytic - CLL: Stages. Approved by the Cancer.Net Editorial Board, 10/2017 ... Information about the leukemias stage will help the doctor recommend a specific treatment plan. The next section in this guide ...
Experts discuss findings presented at ASH 2022 regarding chronic lymphocytic leukemia, and how they can be applied to clinical ... BHAT: To understand the mechanism of action of BTK inhibitors, we must understand the CLL cell. These cells accumulate in the ... Real world treatment patterns in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma switching from first ... Chronic lymphocytic leukemia/small lymphocytic leukemia, version 2.2022. Accessed January 19, 2022. https://bit.ly/3iQT4rp ...
... SECCHIERO, Paola;TIRIBELLI M;BARBAROTTO, Elisa; ... Analysis of peripheral blood (,85% CD19+/CD5+ B) lymphocytes, obtained from 44 patients affected by B chronic lymphoid leukemia ... Analysis of peripheral blood (>85% CD19+/CD5+ B) lymphocytes, obtained from 44 patients affected by B chronic lymphoid leukemia ... significantly decreased the percentage of viable cells with respect to untreated control B-CLL cells, suggesting that surface ...
Learn about our Center for Chronic Lymphocytic Leukemia at Dana-Farber Cancer Institute today. ... Cellular therapies, including CAR T-cell therapy and stem cell/bone marrow transplant ... More Information on Chronic Lymphocytic Leukemia (CLL) ","nextArrow":". ","appendArrows":".coh-slider-container-mid","dots": ... The Center for Chronic Lymphocytic Leukemia, part of the Hematologic Oncology (Blood Cancers) Treatment Center at Dana-Farber ...
Leukemia, Prolymphocytic, B-Cell. Leukemia, Large Granular Lymphocytic. Precursor Cell Lymphoblastic Leukemia-Lymphoma. ... Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative. Leukemia, ... Leukemia, Subleukemic (index as Leukemia). Leukemia, T-Cell, HTLV-II-Associated (index as Leukemia, T-Cell) [Editors Note: The ... Leukemia, CALLA-positive (index as Precursor B-Cell Lymphoblastic Leukemia-Lymphoma). Leukemia, Null-cell (index as Precursor B ...
B-cell Surface Reactive Antibodies for the Treatment of B-Cell Chronic Lymphocytic Leukemia ... B-cell Surface Reactive Antibodies for the Treatment of B-Cell Chronic Lymphocytic Leukemia ... B-cell chronic lymphocytic leukemia (B-CLL) is a cancer characterized by a progressive accumulation of functionally incompetent ... A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic ...
... clinical trials that add a second drug to ibrutinib to eliminate the remaining leukemia or ibrutinib-resistant leukemia cells. ... however it must be given indefinitely which leads to chronic side effects and allows resistance to develop. We are conducting ... This project addresses resistance and residual disease in chronic lymphocytic leukemia (CLL) patients treated with ibrutinib ... Improving BTK Inhibitor Therapy in Chronic Lymphocytic Leukemia Through Rational Combination Strategies ...
Disseminated infection with Prototheca zopfii after unrelated stem cell transplantation for leukemia. J Clin Microbiol. 2004;42 ... In July 2007, a 79-year-old man, who had been monitored since 1993 for stage C chronic lymphocytic leukemia (5), was ... Fatal Algaemia in Patient with Chronic Lymphocytic Leukemia. Emerging Infectious Diseases. 2009;15(7):1129-1130. doi:10.3201/ ... Gram-positive spherical unicellular organisms in a blood culture from a 79-year-old man with chronic lymphocytic leukemia. ...
... chronic syndrome; recent bone marrow inflammatory transplant in adults; chronic B-cell demyelinating lymphocytic leukemia; ... Acute lymphoblastic leukemia; acute renal failure; adrenoleukodystrophy; adult HIV infection; anemia not otherwise specified ( ... pediatric HIV polyneuropathy infection Equal to other Guillain-Barre syndrome and chronic inflammatory therapy demyelinating ... NOS); asthma; bleeding disorders; neurologic disease or thrombocytopenia if NOS; Behcets syndrome; chronic fatigue syndrome; ...
Kymriah is not approved to treat multiple myeloma or chronic lymphocytic leukemia (CLL). But in some cases, the drug may be ... B-cell precursor acute lymphoblastic leukemia in children and certain adults. *large B-cell lymphoma in adults, including ... Is Kymriah used to treat multiple myeloma or chronic lymphocytic leukemia (CLL)?. ... Precursor B-cell ALL means that the cancer affects a specific type of white blood cell called precursor B cells. ...
  • The management of patients with chronic lymphocytic leukemia and mantle cell lymphoma who are treated with BTK inhibitors comes with intolerance and resistance challenges and therefore there is a continuous unmet need for novel treatments. (lls.org)
  • With that in mind, this Clinical Advances in BTK Inhibitors for Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma was created to provide a broad range of educational activities on ongoing therapeutic developments in a variety of program formats to appeal to your individual learning preferences. (lls.org)
  • This activity is developed through a collaboration between The Leukemia & Lymphoma Society and Medscape Oncology. (lls.org)
  • The Leukemia & Lymphoma Society® (LLS) is a global leader in the fight against blood cancer. (lls.org)
  • The LLS mission: Cure leukemia, lymphoma, Hodgkin disease and myeloma, and improve the quality of life of patients and their families. (lls.org)
  • The Leukemia & Lymphoma Society is a 501(c)(3) organization, and all monetary donations are tax deductible to the fullest extent allowed by tax laws. (lls.org)
  • For the gene family, see B-cell CLL/lymphoma . (wikipedia.org)
  • [9] If enlarged lymph nodes are caused by infiltrating CLL-type cells, a diagnosis of small lymphocytic lymphoma (SLL) is made. (wikipedia.org)
  • CLL can be grouped with small lymphocytic lymphoma (SLL) as one disease with two clinical presentations. (wikipedia.org)
  • Chronic lymphocytic leukemia may also develop a Richter's transformation i.e. conversion to a far more aggressive form that has the histopathology of diffuse large B cell lymphoma or Hodgkin's lymphoma. (wikipedia.org)
  • CLL has also been reported to convert into other more aggressive diseases such as lymphoblastic lymphoma, hairy cell leukemia, high grade T cell lymphomas, acute myeloid leukemia, lung cancer, brain cancer, melanoma of the eye or skin, salivary gland tumors, and Kaposi's sarcomas. (wikipedia.org)
  • 2 Bcl-2 (B-cell lymphoma-2) family of antiapoptotic (bcl-2, bcl-xl, bcl-w and mcl-1) and proapoptotic (bax, bak and bok) proteins are critical regulators of apoptosis in CLL. (haematologica.org)
  • Three years ago, I was diagnosed with chronic lymphocytic leukemia and small cell lymphoma. (biotherapy.asia)
  • Richter's syndrome, or a Richter transformation, occurs when CLL develops into an aggressive non-Hodgkin lymphoma, usually a diffuse large B-cell lymphoma (DLBCL) . (cancer.ca)
  • Approximately 5% to 10% of patients with chronic lymphocytic leukemia develop a high-grade (aggressive) form of non-Hodgkin's lymphoma called a large B-cell lymphoma . (medifocus.com)
  • Non-Hodgkin lymphoma (NHL) is a cancer of white blood cells. (medicalnewstoday.com)
  • There are many types of NHL, and only some have lymphocytosis as a characteristic, such as mantle cell lymphoma (MCL) . (medicalnewstoday.com)
  • Leukemia and Lymphoma , 61 (S1), 213-215. (edu.au)
  • [ 1 ] They found 1.2% of cases involved leukemia or lymphoma: nine chronic lymphocytic leukemia/small lymphocytic lymphomas (CLL/SLLs), three Hodgkin lymphomas, and one hairy cell leukemia. (medscape.com)
  • [ 2 ] They found that 29 (0.6%) cases demonstrated involvement by leukemia or lymphoma: 17 CLL/SLLs, three marginal-zone lymphomas, three mantle cell lymphomas, one diffuse large B-cell lymphoma (DLBCL), and four follicular lymphomas. (medscape.com)
  • Combined, these studies suggest CLL/SLL is the most common type of leukemia/lymphoma to involve the prostate in routine specimens, and it is usually seen in association with involvement at different sites, particularly the pelvic lymph nodes. (medscape.com)
  • [ 5 ] and an elderly Czech patient with mantle cell lymphoma and prostate adenocarcinoma. (medscape.com)
  • Taken as a group, primary and secondary prostatic leukemia/lymphoma most commonly presents in the seventh decade. (medscape.com)
  • Secondary prostatic leukemia/lymphoma is often discovered incidental to a diagnosis of prostatic adenocarcinoma. (medscape.com)
  • [ 1 ] Secondary prostatic leukemia/lymphoma may also present with obstructive symptoms. (medscape.com)
  • Epigenetic silencing of miR-26A1 in chronic lymphocytic leukemia and mantle cell lymphoma: Impact on EZH2 expression. (scilifelab.se)
  • We investigated miR26A1 methylation and expression levels in a well-characterized series of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). (scilifelab.se)
  • in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma . (lookfordiagnosis.com)
  • These data provide the basis for advanced approaches of resistance-preventive and biomarker -guided cellular targeting of functionally relevant lymphoma driver mutations sparing normal B cells . (bvsalud.org)
  • Of these, the type most likely to cause leukemia cutis is adult T-cell leukemia/lymphoma (ATLL). (medicalnewstoday.com)
  • Mantle cell lymphoma can have a clinical presentation very similar to that of CLL, but it is more aggressive. (medscape.com)
  • Several features aid in the distinction of mantle cell lymphoma from CLL. (medscape.com)
  • Mantle cell lymphoma expresses CD5 and CD19 but not CD23 antigen, which is expressed in CLL. (medscape.com)
  • Mantle cell lymphoma typically expresses FMC-7. (medscape.com)
  • Importantly, expression of CD20 is bright in mantle cell lymphoma, whereas it is dim in CLL. (medscape.com)
  • Farm ing and pesticide use have previously been linked to non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) and multiple myeloma (MM). We evaluated agricultur al use of specific insecticides, fungicides, and fumigants and risk of NHL and NHL-subtypes (including CLL and MM) in a U.S.-based prospective cohort of farm ers and commercial pesticide applicators. (cdc.gov)
  • In subtype analyses, terbufos and DDT were associated with small cell lymphoma/chronic lymphocytic leukemia/marginal cell lymphoma, lindane and diazinon with follicular lymphoma, and permethrin with MM. However, tests of homogeneity did not show significant differences in exposure-response among NHL-subtypes for any pesticide. (cdc.gov)
  • This enabled identification of TFs that can be uniquely associated to the tumor cells of chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), hairy cell leukemia (HCL), and mantle cell lymphoma (MCL). (lu.se)
  • The terms " acute " or " chronic " refer to the rate of progression of the disease. (medifocus.com)
  • ALL is a type of acute (sudden and fast) leukemia. (healthline.com)
  • Acute myeloid leukemia (AML). (healthline.com)
  • AML is the other main type of acute (sudden and fast) leukemia. (healthline.com)
  • Leukemia can be acute or chronic. (carle.org)
  • Acute leukemia affects cells in bone marrow before they fully develop. (carle.org)
  • People with aleukemic cutis go on to develop acute myeloid leukemia (AML) . (medicalnewstoday.com)
  • Specific AML subtypes, such as acute myelomonocytic leukemia, have a much greater risk of leukemia cutis. (medicalnewstoday.com)
  • Acute lymphocytic leukemia (ALL) involves very young cells that should develop into lymphocytes but instead become cancerous. (msdmanuals.com)
  • B19 has also been associated with fetal death (both spontaneous abortions and stillbirths), acute arthralgias and arthritis, and chronic anemia in immunodeficient patients (5-14). (cdc.gov)
  • Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells. (le.ac.uk)
  • In this study we investigated the mechanism by which bortezomib induces apoptosis in chronic lymphocytic leukemia cells. (le.ac.uk)
  • Finally bortezomib when combined with seliciclib resulted in a stronger and earlier increase in NOXA protein, caspase-3 cleavage and induction of apoptosis in chronic lymphocytic leukemia cells. (le.ac.uk)
  • Conclusions: These results highlight a critical role for NOXA in bortezomib-induced apoptosis in chronic lymphocytic leukemia cells and suggest that this drug may become more efficient for the treatment of chronic lymphocytic leukemia if combined with other agents able to interfere with the basal levels of MCL1. (le.ac.uk)
  • The effect of FK506 on transforming growth factor beta signaling and apoptosis in chronic lymphocytic leukemia B cells. (unina.it)
  • Chronic lymphocytic leukemia ( CLL ) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell ). (wikipedia.org)
  • [4] [9] CLL results in the buildup of B cell lymphocytes in the bone marrow, lymph nodes, and blood . (wikipedia.org)
  • Diagnosis is typically based on blood tests finding high numbers of mature lymphocytes and smudge cells. (wikipedia.org)
  • Most people are diagnosed as having CLL based on the result of a routine blood test that shows a high white blood cell count, specifically a large increase in the number of circulating lymphocytes . (wikipedia.org)
  • This subtype, termed chronic lymphocytic leukemia-type MBL (CLL-type MBL) is an asymptomatic, indolent, and chronic disorder in which people exhibit a mild increase in the number of circulating B-cell lymphocytes. (wikipedia.org)
  • Chronic lymphocytic leukemia (CLL) is a monoclonal disorder characterized by a progressive proliferation and accumulation of mature yet functionally incompetent lymphocytes. (medscape.com)
  • Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous disease characterized by the accumulation of CD5CD23 B-cell lymphocytes. (haematologica.org)
  • Chronic lymphocytic leukemia affects a particular type of white blood cells called B lymphocytes . (medifocus.com)
  • Lymphocytes are specialized white blood cells of the immune system that play a major role in the body's ability to fight-off infections. (medifocus.com)
  • Lymphocytes are a type of white blood cell that fights germs and prevents disease. (medicalnewstoday.com)
  • These white blood cells include B lymphocytes or B cells and T lymphocytes or T cells. (medicalnewstoday.com)
  • It begins in B cells and causes an increase in abnormal lymphocytes. (medicalnewstoday.com)
  • Leukemia mainly affects white blood cells called lymphocytes . (healthline.com)
  • When someone has leukemia, their body makes larger, abnormal cells called leukemic cells instead of lymphocytes and other necessary cells like red blood cells (to carry oxygen) and platelets (to help blood to clot). (healthline.com)
  • In CLL, the bone marrow makes abnormal lymphocytes (a type of white blood cell). (icdlist.com)
  • Chronic lymphocytic leukemia (CLL) is a type of cancer that happens when a person's bone marrow makes too many lymphocytes, one of the types of white blood cells that help your body fight infection. (everydayhealth.com)
  • These abnormal lymphocytes continue to grow and multiply, crowding out healthy cells and interfering with normal blood cell production. (everydayhealth.com)
  • Blood Tests Different lab tests are done, so your doctor can check your blood cell count and learn more about the lymphocytes involved in your cancer. (everydayhealth.com)
  • Purified human thymus-derived (T) lymphocytes were analyzed by detection of Fc receptors for either IgG or IgM in healthy controls and in patients with chronic lymphocytic leukemia (CLL). (elsevierpure.com)
  • Since chronic lymphocytic leukemia (CLL) cells cap poorly when compared with normal human lymphocytes, this study was undertaken to compare the motility of these two cell types. (ashpublications.org)
  • The decreased motility of CLL cells is the result of an intrinsic cell abnormality, but this finding cannot fully explain the decreased capping, since in human lymphocytes the latter is not prevented by an inhibitor of motility. (ashpublications.org)
  • A chronic leukemia characterized by abnormal b-lymphocytes and often generalized lymphadenopathy. (lookfordiagnosis.com)
  • abstract = "Chronic lymphocytic leukemia (CLL) is characterized by an acquired immune dysfunction, which may underlie the hampered efficacy of cellular immunotherapy. (vu.nl)
  • The primary study hypotheses are that the combination of nemtabrutinib plus venetoclax is superior to VR with respect to progression-free survival (PFS) per 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria as assessed by blinded independent central review (BICR). (msdoncologyclinicaltrials.com)
  • C91.12 is a billable diagnosis code used to specify a medical diagnosis of chronic lymphocytic leukemia of b-cell type in relapse. (icdlist.com)
  • The diagnosis of chronic lymphocytic leukemia (CLL) in asymptomatic patients has historically been based on documenting a characteristic lymphocyte clone and the presence of lymphocytosis. (elsevierpure.com)
  • There are minimal data regarding which lymphocyte parameter (absolute lymphocyte count [ALC] or B-cell count) and what threshold should be used for diagnosis. (elsevierpure.com)
  • We analyzed the relationship of ALC and B-cell count with clinical outcome in 459 patients with a clonal population of CLL phenotype to determine (1) whether the CLL diagnosis should be based on ALC or B-cell count, (2) what lymphocyte threshold should be used for diagnosis, and (3) whether any lymphocyte count has independent prognostic value after accounting for biologic/molecular prognostic markers. (elsevierpure.com)
  • 001). These analyses support basing the diagnosis of CLL on Bcell count and retaining the size of the B-cell count in the diagnostic criteria. (elsevierpure.com)
  • Lesions can appear before or after a leukemia diagnosis, but they usually develop afterward. (medicalnewstoday.com)
  • Leukemia cutis may develop before or after someone receives a leukemia diagnosis. (medicalnewstoday.com)
  • However, in 55-77% of cases, leukemia cutis develops after a leukemia diagnosis. (medicalnewstoday.com)
  • Doctors refer to leukemia cutis that occurs before a diagnosis as "aleukemic cutis. (medicalnewstoday.com)
  • Most people with leukemia cutis will already have a diagnosis of systemic leukemia, making the cause of the lesions clear. (medicalnewstoday.com)
  • However, in some cases, people develop these lesions before they receive a leukemia diagnosis. (medicalnewstoday.com)
  • Anemia secondary to bone marrow involvement with CLL, splenic sequestration of red blood cells, and autoimmune hemolytic anemia associated with a positive Coombs test are included in the differential diagnosis of a patient with anemia who has CLL. (medscape.com)
  • Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. (drugs.com)
  • Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. (drugs.com)
  • Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens. (drugs.com)
  • Presence of a heterogeneous population of cells with the possible varying degrees of resistance to chemotherapy was confirm by both methods. (cytgen.com)
  • Chemotherapy With c hemotherapy, drugs are used to kill cancer cells. (everydayhealth.com)
  • Chemotherapy Chemotherapy is a drug that destroys cancer cells. (msdmanuals.com)
  • Chemotherapy works by shutting down cell growth. (msdmanuals.com)
  • But since all cells in the body grow, chemotherapy drugs also destroy some normal cells and. (msdmanuals.com)
  • The structure of membrane Ig on CLL cells of unrelated patients can be remarkably similar. (nih.gov)
  • We identified a subset of Chronic Lymphocytic Leukemia (CLL) patients with high Signaling Lymphocytic Activation Molecule Family (SLAMF) receptor-related signaling that showed an indolent clinical course. (nature.com)
  • Indeed, our experiments showed significantly decreased degranulation capacity of primary NK cells from CLL patients expressing low levels of SLAMF1 and SLAMF7. (nature.com)
  • We employ mitochondrial single-cell assay for transposase-accessible chromatin with sequencing to profile 163,279 cells from 9 patients with chronic lymphocytic leukemia (CLL) collected across disease course and utilize mitochondrial DNA (mtDNA) mutations as natural genetic markers of cancer clones. (nih.gov)
  • This case highlights the importance of considering leukemia cutis in patients with underlying CLL presenting with unusual clinical features. (cdlib.org)
  • Although recently introduced small-molecule B-cell receptor signalling inhibitors have revolutionized CLL treatment, data for ibrutinib still point to impaired prognosis for TP53-affected patients. (muni.cz)
  • By capture of paraclinical, clinical and demographic data along with genetic and functional characterization of primary CLL cells in our laboratory, we assemble multidimensional data on patients with CLL through the PERSIMUNE platform. (rigshospitalet.dk)
  • With the B-cell receptor pathway as the core, our group has been part of a paradigm shift for treatment of CLL with novel targeted therapies developed also for patients with the most dismal outcome due to TP53 aberrations. (rigshospitalet.dk)
  • Patients with CLL typically have a higher-than-normal white blood cell count, which is determined by a complete blood count (CBC). (medscape.com)
  • Bax/bcl-2 was 1.50 or over in 263 patients (52%) with chronic lymphocytic leukemia. (haematologica.org)
  • Recently, we and others have shown that leukemia cells from CLL patients display higher CK2 expression and activity than normal B cells, leading to inhibition of PTEN and activation of PI3K signaling pathway [ 9 , 10 ], which is required for CLL cell survival [ 11 - 13 ]. (oncotarget.com)
  • Currently, with the possible exception of stem cell transplantation in younger patients, there is no know cure for chronic lymphocytic leukemia. (medifocus.com)
  • Adult patients with Chronic Lymphocytic Leukemia (CLL) ( 1.2 ). (drugs.com)
  • Here, we studied the expression of activating and inhibitory receptors on CLL-derived and healthy control (HC) NK cells, and their functional response towards several stimuli.NK cells from CLL patients have an increased maturation stage, with an expansion of NKG2C + NK cells in CMV seropositive individuals. (vu.nl)
  • Analysis of bone marrow cells chromosomal abnor-malities in relspse of 61 patients with B-cell chronic lymphocytic leukemia were performed. (cytgen.com)
  • It has been postulated that monitoring measurable residual disease (MRD) could be used as a surrogate marker of progression-free survival (PFS) in chronic lymphocytic leukemia (CLL) patients after treatment with immunochemotherapy regimens. (haematologica.org)
  • To test the hypothesis that in vivo isotype class switching occurs in IgM+ B-type CLL cells, we analyzed the PBMC of 19 CLL patients for the presence of transcripts encoding the rearranged CLL V(H)DJ(H) associated with either gamma or alpha H chains. (omicsdi.org)
  • The molecular data indicate that approximately 50% of B-CLL patients have amplifications of IgM+ B cells that undergo an isotype class switch. (omicsdi.org)
  • Furthermore, B cells expressing IgG and IgA of the same idiotype or V(H) family and the same CDR3 length as those of the CLL IgM+ clone can be identified in the blood of patients studied using multiparameter immunofluorescence analyses. (omicsdi.org)
  • There was a significant and persistent increase in the numbers of T cells bearing receptors for IgG (Fcγ) in CLL patients in comparison to the controls. (elsevierpure.com)
  • After an in vitro culture period, there was a significantly decreased appearance of cells with IgM receptors (Fcμ) in CLL patients in comparison to the control group. (elsevierpure.com)
  • These results indicate an imbalance in circulating T-cell subpopulations for CLL patients. (elsevierpure.com)
  • The relative motility of individual CLL patients' cells correlated best with the proportion of abnormal cells present as determined by surface receptor assays. (ashpublications.org)
  • However MEACs stimulated CLL cells from all types of patients not distinguishing between U-CLL and M-CLL and not showing an IGHV stereotype preference. (ecologicalsgardens.com)
  • We develop murine and humanized CAR constructs expressed in T cells from healthy donors and CLL patients that eradicate IGLV3-21R110 expressing cell lines and primary CLL cells , but neither cells expressing the non-pathogenic IGLV3-21G110 light chain nor polyclonal healthy B cells . (bvsalud.org)
  • Since its discovery, B19 has been shown to be the causative agent of erythema infectiosum (EI) (also known as fifth disease) and is the primary etiologic agent of TAC in patients with chronic hemolytic anemias (2-4). (cdc.gov)
  • B19 is the primary etiologic agent causing TAC in patients with chronic hemolytic anemias (e.g., sickle cell disease, hemoglobin SC disease, hereditary spherocytosis, alpha-thalassemia, and autoimmune hemolytic anemia) (22,23). (cdc.gov)
  • Investigating the targets of MIR-15a and MIR-16-1 in patients with chronic lymphocytic leukemia (CLL). (medscape.com)
  • Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973-2003 in Sweden. (medscape.com)
  • [18] CLLs are, in virtually all cases, preceded by a particular subtype of monoclonal B-cell lymphocytosis (MBL). (wikipedia.org)
  • CLLs are, in virtually all cases, preceded by a particular subtype of monoclonal B-cell lymphocytosis (MBL). (wikipedia.org)
  • Lymphocytosis is when there are too many white blood cells. (medicalnewstoday.com)
  • Using clinically relevant criteria to distinguish between monoclonal B-cell lymphocytosis (MBL) and CLL could minimize patient distress caused by labeling asymptomatic people at low risk for adverse clinical consequences as having CLL. (elsevierpure.com)
  • Design and Methods: Using western blot analysis, we monitored the regulation of BCL2 family members, proteins of the unfolded protein response (endoplasmic reticulum stress response) and activation of caspases in relation to induction of apoptosis (measured by annexin-propidium iodide staining and loss of mitochondrial membrane potential) by bortezomib in chronic lymphocytic leukemia cells. (le.ac.uk)
  • A loss of mitochondrial membrane potential preceded caspase activation and cell death. (unina.it)
  • Chronic lymphocytic leukemia (CLL) remains an incurable malignancy, urging for the identification of new molecular targets for therapeutic intervention. (oncotarget.com)
  • Andreieva S.V., Korets K.V., Skorokhod I.M., Ruzhinska O.E. Cytogenetic and molecular cytogenetic investigations in relapse of B-cells chronic lymphocytic leukemia, Tsitol Genet. (cytgen.com)
  • Molecular characterization of IgA- and/or IgG-switched chronic lymphocytic leukemia B cells. (omicsdi.org)
  • What causes chronic lymphocytic leukemia (CLL)? (icdlist.com)
  • It is an indolent disease characterized by the accumulation of mature monoclonal B cells in the blood and bone marrow, often also involving the spleen, liver, and lymph nodes. (cdlib.org)
  • These B-cells are abnormal: they are monoclonal, i.e. produced by a single ancestral B-cell, and have some of the same cell marker proteins, chromosome abnormalities, and gene mutations found in CLL. (wikipedia.org)
  • The terms " myelogenous " and " lymphocytic " denote the different types of white blood cells involved. (medifocus.com)
  • Since the SLAMF low signature was strongly associated with an unmutated CLL immunoglobulin heavy chain (IGHV) status in large datasets, we investigated the impact of SLAMF1 and SLAMF7 on the B cell receptor (BCR) signaling axis. (nature.com)
  • B cell receptor (BCR) signaling plays a critical role in driving proliferation and survival of the malignant clone in chronic lymphocytic leukemia (CLL), supported by the clinical activity of inhibitors targeted toward BCR-associated kinases [ 1 ]. (nature.com)
  • A critical component in CLL pathogenesis is the activation of the B-cell receptor signalling taking place in lymph nodes, and in the context of other microenvironmental interactions (such as CLL-T cell interaction). (europa.eu)
  • The obtained data led us to hypothesize on the mechanisms of regulation of signalling propensity of two pathways that are responsible for proliferation and survival of CLL cells, namely B Cell Receptor (BCR) signalling and signals from T-cells mediated by CD40/IL4. (europa.eu)
  • The cytotoxicity receptor NKG2D is downregulated, and the killing capacity through this receptor was markedly reduced in CLL-derived NK cells. (vu.nl)
  • These B cells appear to be blocked at the antigen receptor-expressing stage of B cell differentiation and are thought not to undergo an isotype class switch to IgG or IgA production. (omicsdi.org)
  • In addition, an in vitro defect in CLL T-cell membrane receptor appearance is present. (elsevierpure.com)
  • FKBP12 release activated the receptor-kinase activity as suggested by the enhanced levels of phospho-Smad found in cells depleted of FKBP12. (unina.it)
  • The degree of chronic lymphocytic leukemia (CLL) B-cell antigen receptor (BCR) binding to myosin exposed apoptotic cells (MEACs) correlates with worse patient outcomes suggesting a link to disease activity. (ecologicalsgardens.com)
  • Since the rise in E 2 -receptor display paralleled a large increase in the proliferative activity of the cells as well as a change in their maturation status the question was raised as to whether the E 2 -receptor should be considered as a physiological marker of growth rate or of cellular differentiation. (elsevierpure.com)
  • This suggests the association of E 2 -receptor expression with control of growth rather than cell maturation. (elsevierpure.com)
  • Here, we use a BCR light chain neoepitope defined by a characteristic point mutation (IGLV3-21R110) for selective targeting of a poor- risk subset of chronic lymphocytic leukemia (CLL) with chimeric antigen receptor ( CAR ) T cells . (bvsalud.org)
  • [17] Less commonly, the disease comes to light only after the cancerous cells overwhelm the bone marrow, resulting in low red blood cells, neutrophils, or platelets. (wikipedia.org)
  • [18] Whereas, with CLL, diseased cells propagate from within the bone marrow, in SLL they propagate from within the lymphatic tissue. (wikipedia.org)
  • Whereas, with CLL, diseased cells propagate from within the bone marrow, in SLL they propagate from within the lymphatic tissue. (wikipedia.org)
  • Abnormal blood cells (called leukemia cells) can form different patterns in the bone marrow. (cancer.ca)
  • Leukemia is a cancer of the white blood cells that arises from the bone marrow and circulates in the blood. (medifocus.com)
  • Although leukemia starts in the bone marrow, it can spread to the blood, lymph nodes, spleen, liver, central nervous system (CNS) and other organs. (medifocus.com)
  • Although the exact cause of chronic lymphocytic leukemia is currently not known, researchers have recently discovered that certain mutations (genetic alterations or errors) that occur in the DNA of normal bone marrow cells can cause these cells to transform into leukemic cells. (medifocus.com)
  • Leukemia is a type of blood cancer that begins in the bone marrow where many blood cells are made. (healthline.com)
  • This cancer can also cause abnormal blood cells to form, crowding out other healthy blood cells in the bone marrow and spilling into the bloodstream. (healthline.com)
  • Leukemia starts in blood-forming tissues such as the bone marrow. (icdlist.com)
  • Your bone marrow makes the cells which will develop into white blood cells, red blood cells, and platelets. (icdlist.com)
  • When you have leukemia, your bone marrow makes large numbers of abnormal cells. (icdlist.com)
  • These abnormal cells build up in your bone marrow and blood. (icdlist.com)
  • CLL happens when there are changes in the genetic material (DNA) in bone marrow cells. (icdlist.com)
  • The possibility that decreased cell motility in CLL was a reflection of enrichment by a "bone marrow-derived" (B cell) population was eliminated by the finding that normal B cells purified by gradient separation of rosetted cells migrated faster than normal T cells and considerably faster than CLL cells. (ashpublications.org)
  • CLL cells are characterized by their universal dependency on pro-survival and pro-proliferative signals from immune niches. (europa.eu)
  • People with chronic lymphocytic leukemia (CLL) may have questions about their prognosis and survival. (cancer.ca)
  • Learn about survival statistics for chronic lymphocytic leukemia including median survival and questions to ask your doctor about CLL. (cancer.ca)
  • Our studies suggest lipid metabolism may be a critical survival mechanism of CLL cells and recent data demonstrates upregulation of key proteins involved in this [Thurgood et al. (edu.au)
  • IL-4-dependent Jagged1 expression/processing is associated with survival of chronic lymphocytic leukemia cells but not with Notch activation. (unipg.it)
  • Notably, anti-Jagged1 antibodies partially prevented the IL-4-induced increase in Jagged1 processing and cell viability, suggesting that Jagged1 processing is one of the events contributing to IL-4-induced CLL cell survival. (unipg.it)
  • Consistent with this, Jagged1 silencing by small interfering RNA partially counteracted the capacity of IL-4 to promote CLL cell survival. (unipg.it)
  • B-cell count and ALC had similar value for predicting treatment-free survival (TFS) and overall survival as continuous variables, but as binary factors, a B-cell threshold of 11 × 10 9 /L best predicted survival. (elsevierpure.com)
  • CLL cells rely on overexpression and hyperactivation of the ubiquitous serine/threonine protein kinase CK2 for their viability in vitro. (oncotarget.com)
  • Exposure of the patient's blast cells to E 2 in vitro resulted in cessation of cell growth following at least one mitosis after addition of the inducer as seen from the replacement of the large blasts by small CLL-like cells without definite signs of alteration of the differentiation status. (elsevierpure.com)
  • Consistent with this result A66 or AG490 inhibitors did not prevent MEACs from increasing CLL cell viability (Figure 6e-f = 0.0006 and = 0.0002 respectively). (ecologicalsgardens.com)
  • Thus inhibitors of BTK or PI3Kδ but not PI3Kα or JAKs block MEAC-induced increase in CLL cell viability supporting the hypothesis that BCR signaling molecules are involved in Isradipine this effect. (ecologicalsgardens.com)
  • Peripheral smear from a patient with chronic lymphocytic leukemia, small lymphocytic variety. (medscape.com)
  • We describe a fatal case of P. wickerhamii algaemia in a patient with chronic lymphocytic leukemia. (cdc.gov)
  • In the early stages of the disease, clinical symptoms of chronic lymphocytic leukemia may not be obvious or may be overlooked by the patient. (medifocus.com)
  • This is why leukemia can cause symptoms like fatigue or excessive bleeding and bruising. (healthline.com)
  • What are the symptoms of chronic lymphocytic leukemia (CLL)? (icdlist.com)
  • Some people may have additional leukemia symptoms alongside leukemia cutis. (medicalnewstoday.com)
  • However, some forms of leukemia do not cause symptoms at first. (medicalnewstoday.com)
  • Whether a person experiences other symptoms can depend on the type of leukemia they have and the speed of its growth. (medicalnewstoday.com)
  • A doctor who thinks a person has leukemia cutis will look at the lesions and ask about the person's symptoms. (medicalnewstoday.com)
  • When the leukemia cells are more spread out (called a diffuse pattern) it is a less favourable prognostic factor. (cancer.ca)
  • CIGB-300 demonstrated a dose-dependent antiproliferative and proapoptotic effect in a variety of tumor cells [ 20 ]. (oncotarget.com)
  • We suggest that SA-MIP can be used for screening of different tumor cells of various stages, including CLL cells. (lu.se)
  • In this study, global GEP analyses were performed on highly purified, flow-cytometry sorted tumor-cells from eight subgroups of BCLs. (lu.se)
  • By overexpression of miR26A1 in CLL and MCL cell lines, reduced EZH2 protein levels were observed using both Western blot and flow cytometry. (scilifelab.se)
  • Here, we have performed an extended screening of SA expression by using SA-MIP and included four different chronic lymphocytic leukemia (CLL) cell lines, conveniently analyzed by flow cytometry and fluorescence microscopy. (lu.se)
  • Still, this information is not used for classification of B-cell lymphomas (BCLs). (lu.se)
  • Single-cell multi-omic profiling of CLL reveals the utility of somatic mtDNA mutations as in vivo barcodes, which mark subclones that can evolve over time along with changes in accessible chromatin and gene expression profiles to capture dynamics of disease evolution. (nih.gov)
  • The immunoglobulin (Ig) variable region (V) genes expressed by IgM chronic lymphocytic leukemia (CLL) B cells display little or no somatic mutations. (omicsdi.org)
  • The concept of precision cell therapy targeting tumor -specific mutations is appealing but requires surface-exposed neoepitopes, which is a rarity in cancer . (bvsalud.org)
  • B cell receptors (BCR) of mature lymphoid malignancies are exceptional in that they harbor tumor -specific-stereotyped sequences in the form of point mutations that drive self -engagement of the BCR and autologous signaling. (bvsalud.org)
  • The abnormal cells in AML are white blood cells called myeloblasts. (healthline.com)
  • When the abnormal cells crowd out the healthy cells, it can lead to infection, anemia, and easy bleeding. (icdlist.com)
  • The abnormal cells can also spread outside the blood to other parts of the body. (icdlist.com)
  • This includes analysis of CLL samples at various times during the disease course, during microenvironment-targeting therapies, and comparison of CLL cells in lymph nodes and peripheral blood. (europa.eu)
  • We aim to reveal how the malignant B cells change the propensity of their signalling pathways in response to the different microenvironments such as peripheral blood vs lymph node to obtain the proliferative signals. (europa.eu)
  • In chronic lymphocytic leukemia the balance between the pro-apoptotic and anti-apoptotic members of the bcl-2 family is involved in the pathogenesis, chemorefractoriness and clinical outcome. (haematologica.org)
  • In conclusion, we defined the prognostic power of bax/bcl-2 ratio, as determined by a flow cytometric approach, and highlighted a correlation with chemoresistance and outcome in chronic lymphocytic leukemia. (haematologica.org)
  • Despite significant improvements in treatment outcome in recent years [ 1 , 2 ], chronic lymphocytic leukemia (CLL) - the most common leukemia in the Western world - remains incurable [ 3 , 4 ]. (oncotarget.com)
  • Sequencing of daughter cell pairs derived from micronucleated mother cells demonstrated that complex rearrangements are indeed a common outcome of micronucleus formation. (nature.com)
  • Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. (medscape.com)
  • Since SLAMF receptors play a role in NK cell biology, we reasoned that these receptors may impact NK cell-mediated CLL immunity. (nature.com)
  • Overexpression of SLAMF1 or SLAMF7 in IGHV mutated CLL cell models resulted in reduced proliferation and impaired responses to BCR ligation, whereas the knockout of both receptors showed opposing effects and increased sensitivity toward inhibition of components of the BCR pathway. (nature.com)
  • Together, our data indicate that SLAMF receptors are important modulators of the BCR signaling axis and may improve immune control in CLL by interference with NK cells. (nature.com)
  • Signaling Lymphocytic Activation Molecule Family (SLAMF) receptors are a group of nine type I transmembrane receptors that are mainly expressed on a variety of immune cells. (nature.com)
  • In B cells, this class of receptors has been shown to be expressed in distinct patterns associated with development and activation [ 11 ]. (nature.com)
  • A previous study demonstrated that SLAMF1, SLAMF2, and SLAMF7 receptors are rather downregulated on CLL cells as compared to their normal B cell counterpart [ 12 ], suggesting that high expression of these molecules may have detrimental (e.g., antiproliferative) effects in the CLL context. (nature.com)
  • Rather they supply a large number Fam162a of other autoantigens that the apoptotic process makes available to immune receptors.4 6 42 Surface membrane exposed myosin is primarily serving as an indicator of the type of cell involved in the process. (ecologicalsgardens.com)
  • Since natural IgM Abs can recognize MEACs (Figure 4) this is consistent with the rationale of apoptotic cell removal.39 It is also consistent with at least some CLL clones deriving from B cells that produce natural autoreactive Abs that are used as their surface receptors and Isradipine potentially as their secreted effector molecules. (ecologicalsgardens.com)
  • SA plays an important role for regulation of the innate immunity, function as markers of the cells and can be recognized by a variety of receptors. (lu.se)
  • These findings indicate that NK cells in CLL are not intrinsically defect and still perform effector functions upon adequate activating signaling. (vu.nl)
  • These findings warrant future studies on NK cell mediated immunotherapeutic strategies in CLL. (vu.nl)
  • These findings suggest that IgA- and/or IgG-expressing CLLs represent, in their VH gene structure, transformants of B cells at different stages of ontogeny. (omicsdi.org)
  • Extended analysis using pyrosequencing confirmed our findings and real-time quantitative PCR verified low miR26A1 expression in both CLL (n = 70) and MCL (n = 38) compared to normal B-cells. (scilifelab.se)
  • Hello, and welcome to this OncLive® Peer Exchange titled "Evolving Therapies in Chronic Lymphocytic Leukemia. (onclive.com)
  • Today we're going to discuss a number of topics pertaining to first-line therapy for CLL [chronic lymphocytic leukemia] as well as second line and therapies for relapsed/refractory CLL. (onclive.com)
  • TP53 gene defects represent the most unfavorable prognostic factor in chronic lymphocytic leukemia (CLL). (muni.cz)
  • Leukemia cells that are in small clumps (called a nodular pattern) or leukemia cells between normal cells (called an interstitial pattern) are more favourable prognostic factors. (cancer.ca)
  • This has important therapeutic implication since CD20 is used as a therapeutic target for 20 years (rituximab), but its function in CLL/normal B cells is unknown. (europa.eu)
  • Klepfish A, Gilles L, Ioannis K, Eliezer R, Ami S. Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL. (medscape.com)
  • Possible sources of these Abs could be B-1 cells which express CD5 in mice and in ~75% of human B-1 cells (CD20+ CD27+ CD43+) marginal zone B cells transitional B cells or antigen-experienced mature CD5+ B cells as have been proposed.30 43 Just as apoptotic cell infusions into mice stimulate natural Ab producing B cells 46 MEACs Isradipine may stimulate CLL cells in a similar manner. (ecologicalsgardens.com)
  • Elter T, Hallek M, Engert A. Fludarabine in chronic lymphocytic leukaemia. (medscape.com)
  • Blood cells form and develop in marrow and then move into the bloodstream. (carle.org)
  • If these cells become cancerous, they start growing out of control and can spread around the body via the bloodstream. (medicalnewstoday.com)
  • CIGB-300 is a cell-permeable selective CK2 inhibitor peptide undergoing clinical trials for several cancers. (oncotarget.com)
  • Chronic lymphocytic leukemia (CLL) represents approximately 33% of all leukemias and occurs most frequently in the elderly population. (medifocus.com)
  • The most common chronic leukemia in adults, CLL occurs more frequently in men than women. (healthline.com)
  • Leukemia cutis occurs when leukemia cells affect the skin, forming clusters within the layers of tissue. (medicalnewstoday.com)
  • If you are diagnosed with leukemia, you may need regular physical exams and blood tests, so your doctor can watch for signs of disease progression or remission. (healthline.com)
  • CLL cells with a changed, or mutated, gene for IGHV (immunoglobulin heavy chain variable region) have a more favourable prognosis. (cancer.ca)
  • Functionally co-culture of MEACs with CLL cells regardless of immunoglobulin heavy chain variable region gene mutation status improved leukemic cell viability. (ecologicalsgardens.com)
  • This monograph only gives information about ofatumumab injection (Arzerra) for treatment of chronic lymphocytic leukemia. (medlineplus.gov)
  • Borthakur G, O'Brien S . Treatment of chronic lymphocytic leukemia and related disorders. (cancer.ca)
  • Because CLL is a chronic disease, it is often monitored for several years without the need for any treatment intervention. (medifocus.com)
  • Clinical relevance of this finding was shown by treatment with novel nanobody-Fc constructs, which induced cytotoxic responses in both CLL- and HC-derived NK cells via CD16. (vu.nl)
  • How are blood counts used to monitor leukemia during treatment? (healthline.com)
  • Bortezomib has been successfully used in the treatment of multiple myeloma and has been proposed as a potential treatment for chronic lymphocytic leukemia. (le.ac.uk)
  • The health care provider will suggest seeing a hematologist, a specialist in leukemia treatment. (carle.org)
  • Within the B-cell and T-cell categories, two subdivisions are recognized: precursor neoplasms, which correspond to the earliest stages of differentiation, and more mature differentiated neoplasms. (medscape.com)
  • It works by killing cancer cells. (medlineplus.gov)
  • The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. (oncotarget.com)
  • Leukemia is cancer of the white blood cells. (carle.org)
  • However, in most cases, these patterns of chromothripsis differed from those in cancer genomes as the rearrangements were largely restricted to a single daughter cell and lacked the canonical oscillations in DNA copy-number states 2 . (nature.com)
  • Mitotic clustering drives the unequal inheritance of acentric fragments by a single daughter cell, providing an explanation for the origins of distinct patterns of chromothripsis found across diverse cancer types and congenital disorders. (nature.com)
  • Light micrograph of cells from a patient suffering from lymphocytic leukemia, a type of blood cancer. (everydayhealth.com)
  • If, on these tests, the CLL cells have low levels of the proteins ZAP-70 and CD38, the cancer tends to be of the more slow-growing variety, though there are always exceptions to this rule. (everydayhealth.com)
  • The Department of Health and Human Services (HHS) is proposing to treat chronic lymphocytic leukemia (CLL) as a radiogenic cancer under the Energy Employees Occupational Illness Compensation Program Act of 2000 (EEOICPA). (cdc.gov)
  • Relationship of leukemia risk to radiation dose following cancer of the uterine corpus. (cdc.gov)
  • Overview of Cancer Cancer is the out-of-control growth of cells in your body. (msdmanuals.com)
  • Interestingly, the level of SA expression is increased on metastatic cancer cells. (lu.se)
  • SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. (medscape.com)
  • If you have leukemia, your blood cells count will likely show higher than usual levels of white blood cells, which include leukemic cells. (healthline.com)
  • They also suggest that Ag may play a role in the clonal selection of some of these isotype-switched leukemic cells, but bcl-1 and bcl-2 oncogene rearrangements and p53 tumor suppressor gene mutation are not associated with the pathogenesis of isotype-switched CLLs. (omicsdi.org)
  • In accordance, CIGB-300 decreases the viability and proliferation of CLL cell lines, promotes apoptosis of primary leukemia cells and displays antitumor efficacy in a xenograft mouse model of human CLL. (oncotarget.com)
  • If you have higher than normal levels of white blood cells and low counts of red blood cells and platelets, the doctor will order additional tests atto get more information. (healthline.com)
  • Despite increasing knowledge of the impact of Notch alterations on CLL biology and pathogenesis, the role of Jagged1 expressed in CLL cells remains undefined. (unipg.it)
  • Overall, this study provides new insights into the Notch-ligand system in CLL cells and suggests that targeting this system may be exploited as a novel/additional therapy approach for CLL. (unipg.it)
  • [2] [9] Enlargement of the spleen and low red blood cells ( anemia ) may also occur. (wikipedia.org)
  • [4] These cells do not function well and crowd out healthy blood cells . (wikipedia.org)
  • When I went to the hospital for my regular checkup, the results after Bioqrâ„¢ therapy proved to be good, because the white blood cell count decreased for approximately 2500. (biotherapy.asia)
  • It is characterized by uncontrolled growth of white blood cells. (medifocus.com)
  • Leukemia is a disease of the blood cells and does not usually form a solid tumor. (medifocus.com)
  • Most bacterial infections cause a high count of neutrophils , another type of white blood cell. (medicalnewstoday.com)
  • What Do Leukemia Blood Counts Mean? (healthline.com)
  • The results of a blood count can help diagnose or manage leukemia. (healthline.com)
  • If you have leukemia, you may not make enough of some kinds of blood cells. (healthline.com)
  • Getting tested to find out your specific blood counts is important for diagnosing and managing leukemia. (healthline.com)
  • How does leukemia affect blood counts? (healthline.com)
  • For example, too many white blood cells and too few red blood cells or platelet cells may mean that you have leukemia or that your leukemia is not well-controlled. (healthline.com)
  • Different kinds of leukemia affect blood cell counts in different ways. (healthline.com)
  • Typical blood cell counts vary by age and gender. (healthline.com)
  • You may also have lower than usual red blood cell and platelet cell counts. (healthline.com)
  • Leukemia blood cell counts also help to show whether you need additional treatments. (healthline.com)
  • Leukemia is a term for cancers of the blood cells. (icdlist.com)
  • This problem most often happens with white blood cells. (icdlist.com)
  • They crowd out the healthy blood cells and make it hard for your cells and blood to do their work. (icdlist.com)
  • Gram-positive spherical unicellular organisms in a blood culture from a 79-year-old man with chronic lymphocytic leukemia. (cdc.gov)
  • Chronic lymphocytic leukemia (CLL) causes too many white blood cells to be produced. (carle.org)
  • People may also have nosebleeds, easy bruising, or other bleeding problems, and weakness from anemia (low red blood cell count) or thrombocytopenia (low platelet count). (carle.org)
  • These people have too many white blood cells, swollen glands, or enlarged spleen (the spleen makes and stores blood cells). (carle.org)
  • These are cells that will go on to become a type of blood cell, such as a red blood cell, white blood cell, or platelet. (medicalnewstoday.com)
  • of white blood cells. (msdmanuals.com)
  • With leukemia, you have a very high white blood cell count. (msdmanuals.com)
  • However, the cancerous white blood cells don't work properly, so you're likely to get infections. (msdmanuals.com)
  • Overview of Anemia Anemia is not having enough red blood cells or hemoglobin. (msdmanuals.com)
  • Red blood cells carry oxygen from your lungs to all of your other organs. (msdmanuals.com)
  • Hemoglobin is the substance inside your red blood cells that. (msdmanuals.com)
  • It can also cause TAC in other conditions in which increased red cell production is necessary to maintain stable red cell indices, as may occur in anemia due to blood loss. (cdc.gov)
  • This is of major relevance for CLL, but also transferable to the biology of some other B cell malignancies and/or normal B cells. (europa.eu)
  • We also show that subset-defining sequence patterns in CLL differ from those underlying BCR stereotypy in other B-cell malignancies. (unisr.it)